

Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	0323U	Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites, or fungi	07/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0326U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	07/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0326U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	08/01/2022			Circulating Tumor Cell and DNA Assays for Cancer Management (Company)
Commercial/ASO, OHP, PEBB	A4459	Manual pump-operated enema system, includes balloon, catheter and all accessories, reusable, any type	03/01/2024			Fecal Incontinence Treatments (Company)
Medicare	0003U	Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0004M	Scoliosis, DNA analysis of 53 single nucleotide polymorphisms (SNPs), using saliva, prognostic algorithm reported as a risk score	01/01/2022			Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	0005U	Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score	05/01/2022			Prostate: Protein Biomarkers and Genetic Testing (Medicare)
Medicare	0006M	Oncology (hepatic), mRNA expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha- fetoprotein level, algorithm reported as a risk classifier	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0007M	Oncology (gastrointestinal neuroendocrine tumors), real-time PCR expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0009U	Oncology (breast cancer), ERBB2 (HER2) copy number by FISH, tumor cells from formalin- fixed paraffin-embedded tissue isolated using image-based dielectrophoresis (DEP) sorting, reported as ERBB2 gene amplified or non- amplified	08/01/2018			Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Company)
Medicare	0009U	Oncology (breast cancer), ERBB2 (HER2) copy number by FISH, tumor cells from formalin- fixed paraffin-embedded tissue isolated using image-based dielectrophoresis (DEP) sorting, reported as ERBB2 gene amplified or non- amplified	08/01/2018	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0012M	Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm reported as a risk score for having urothelial carcinoma	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0013M	Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5,	01/01/2022			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 2/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		and CXCR2), utilizing urine, algorithm reported as a risk score for having recurrent urothelial carcinoma				
Medicare	0015M	Adrenal cortical tumor, biochemical assay of 25 steroid markers, utilizing 24-hour urine specimen and clinical parameters, prognostic algorithm reported as a clinical risk and integrated clinical steroid risk for adrenal cortical carcinoma, adenoma, or other adrenal malignancy	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0016M	Oncology (bladder), mRNA, microarray gene expression profiling of 209 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as molecular subtype (luminal, luminal infiltrated, basal, basal claudin-low, neuroendocrine-like)	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0017M	Oncology (diffuse large B-cell lymphoma [DLBCL]), mRNA, gene expression profiling by fluorescent probe hybridization of 20 genes, formalin-fixed paraffinembedded tissue, algorithm reported as cell of origin	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0017U	Oncology (hematolymphoid neoplasia), JAK2 mutation, DNA, PCR amplification of exons 12- 14 and sequence analysis, blood or bone marrow, report of JAK2 mutation not detected or detected	03/01/2018			Genetic Testing: Myeloproliferative Diseases (Company); Genetic Testing: Myeloproliferative Diseases (Medicare)
Medicare	0018U	Oncology (thyroid), microRNA profiling by RT- PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy	01/01/2019			Genetic Testing for Thyroid Nodules (Medicare); Genetic Testing: Thyroid Nodules (Company)
Medicare	0019U	Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed	01/01/2022			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 3/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		paraffin-embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents				
Medicare	0022U	Targeted genomic sequence analysis panel, cholangiocarcinoma and non-small cell lung neoplasia, DNA and RNA analysis, 1-23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapy(ies) to consider	08/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, PEBB	0022U	Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence/ or absence of variants and associated therapy(ies) to consider	11/01/2022			Next Generation Sequencing for Cancer (Company)
Medicare	0023U	Oncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.I836, using mononuclear cells, reported as detection or non-detection of FLT3 mutation and indication for or against the use of midostaurin	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0026U	Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result (";Positive, high probability of malignancy"; or ";Negative, low probability of malignancy";)	01/01/2019			Genetic Testing for Thyroid Nodules (Medicare); Genetic Testing: Thyroid Nodules (Company)
Commercial/ASO, OHP, PEBB	0026U	Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result (";Positive, high probability of malignancy"; or ";Negative, low probability of malignancy";)	02/01/2024			Genetic Testing for Thyroid Nodules (Medicare); Genetic Testing: Thyroid Nodules (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 4/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0027U	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15	08/01/2019			Genetic Testing: Myeloproliferative Diseases (Company); Genetic Testing: Myeloproliferative Diseases (Medicare)
Medicare	0029U	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12777823)	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0030U	Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823)	09/01/2021			Genetic and Molecular Testing (Medicare)
Medicare	0031U	CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0032U	COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0033U	HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0034U	TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15) (eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5)	01/01/2022			Genetic and Molecular Testing (Medicare); Inflammatory Bowel Disease: Serologic Testing and Therapeutic Monitoring (Medicare)
Medicare	0036U	Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor	01/01/2022			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 5/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		tissue and normal specimen, sequence analyses				
Medicare	0037U	Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	09/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0037U	Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	11/01/2022			Next Generation Sequencing for Cancer (Company)
Commercial/ASO, Medicare, OHP, PEBB	0042T	Cerebral perfusion analysis using computed tomography with contrast administration, including post-processing of parametric maps with determination of cerebral blood flow, cerebral blood volume, and mean transit time	06/11/2022		Commercial/ASO,Medicare,OHP,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	0045U	Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score	10/01/2018	12/31/2019		Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Medicare)
Medicare	0046U	FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0047U	Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score	10/01/2018			Prostate: Protein Biomarkers and Genetic Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, PEBB	0047U	Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score	06/01/2022			Prostate: Protein Biomarkers and Genetic Testing (Company)
Medicare	0048U	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin- embedded tumor tissue, report of clinically significant mutation(s)	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0048U	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin- embedded tumor tissue, report of clinically significant mutation(s)	11/01/2022			Next Generation Sequencing for Cancer (Company)
Commercial/ASO, OHP, PEBB	0049U	NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative	01/01/2022			Genetic Testing: Myeloproliferative Diseases (Company)
Medicare	0049U	NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0050U	Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare); Genetic Testing: Myeloproliferative Diseases (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0052T	Replacement/repair of thoracic unit of a total replacement heart system (artificial heart)	07/01/2012	12/31/2016	Medicare - In-plan only, no opt-out benefit	Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	0053T	Replacement/repair of implantable component(s)of total replacement heart system (artificial heart) excl thoracic unit	07/01/2012	12/31/2016	Medicare - In-plan only, no opt-out benefit	Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Medicare	0055U	Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0056U	Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)	01/01/2022	09/30/2022	Code termed 9/30/2022	Genetic and Molecular Testing (Medicare)
Medicare	0057U	Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank	01/01/2022	07/30/2019	Code termed 7/30/2019	Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0058T	Cryopreservation; Reproductive Tissue, Ovarian	01/01/2009	12/31/2019	Commercial/ASO,Medicare,OHP,PEBB - Coverage is subject to plan benefits, prior authorization required	
Medicare	0067U	Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin- fixed paraffin-embedded precancerous breast	01/01/2022			Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		tissue, algorithm reported as carcinoma risk score				
Commercial/ASO, Medicare, OHP, PEBB	0070U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xN)	09/01/2021			Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)
Commercial/ASO, Medicare, OHP, PEBB	0071U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)	09/01/2021			Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)
Commercial/ASO, Medicare, OHP, PEBB	0072U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)	09/01/2021			Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)
Medicare	00731	Anesthesia for upper gastrointestinal endoscopic procedures, endoscope introduced proximal to duodenum; not otherwise specified	01/01/2018	05/31/2023	Authorization is not required for location code 20 ,21, 22 or 23	Anesthesia Care with Diagnostic Endoscopy
Commercial/ASO, OHP, PEBB	00731	Anesthesia for upper gastrointestinal endoscopic procedures, endoscope introduced proximal to duodenum; not otherwise specified	01/01/2018	05/31/2023	Authorization is not required for location code 20, 21, 22 or 23	Anesthesia Care with Diagnostic Endoscopy
Medicare	00732	Anesthesia for upper gastrointestinal endoscopic procedures, endoscope introduced proximal to duodenum; endoscopic retrograde cholangiopancreatography (ERCP)	01/01/2018	05/31/2023	Authorization is not required for location code 20 ,21, 22 or 23	Anesthesia Care with Diagnostic Endoscopy
Commercial/ASO, OHP, PEBB	00732	Anesthesia for upper gastrointestinal endoscopic procedures, endoscopic introduced	01/01/2018	05/31/2023	Authorization is not required for location code 20, 21, 22 or 23	Anesthesia Care with Diagnostic Endoscopy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 9/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		proximal to duodenum; endoscopic retrograde cholangiopancreatography (ERCP)				
Commercial/ASO, Medicare, OHP, PEBB	0073U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)	09/01/2021			Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)
Commercial/ASO, Medicare, OHP, PEBB	00740	Anes Upper Gastrointestinal Endoscopic P	11/01/2012	12/31/2017		Anesthesia Care with Diagnostic Endoscopy
Commercial/ASO, Medicare, OHP, PEBB	0074U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non- duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)	09/01/2021			Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)
Commercial/ASO, Medicare, OHP, PEBB	0075U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5' gene duplication/multiplication) (List separately in addition to code for primary procedure)	09/01/2021			Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)
Commercial/ASO, Medicare, OHP, PEBB	0076U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3' gene duplication/ multiplication) (List separately in addition to code for primary procedure)	09/01/2021			Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)
Medicare	0078U	Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 10/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorde				
Commercial/ASO, Medicare, OHP, PEBB	00810	Anes Intestinal Endoscopic Procedures	11/01/2012	12/31/2017		Anesthesia Care with Diagnostic Endoscopy
Medicare	00811	Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum; not otherwise specified	01/01/2018	05/31/2023	Authorization is not required for location code 20 ,21, 22 or 23 - termed 5/31/23	Anesthesia Care with Diagnostic Endoscopy
Commercial/ASO, OHP, PEBB	00811	Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum; not otherwise specified	01/01/2018	05/31/2023	Authorization is not required for location code 20, 21, 22 or 23 - termed 5/31/23	Anesthesia Care with Diagnostic Endoscopy
Commercial/ASO, Medicare, OHP, PEBB	00813	Anesthesia for combined upper and lower gastrointestinal endoscopic procedures, endoscope introduced both proximal to and distal to the duodenum	01/01/2018	03/31/2020		Anesthesia Care with Diagnostic Endoscopy
Commercial/ASO, Medicare, OHP, PEBB	0081U	Oncology (uveal melanoma), mRNA, gene- expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping genes), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis	06/01/2019	12/31/2019		Gene Expression Profile Testing for Melanoma (Company); Gene Expression Profile Testing for Melanoma (Medicare); Genetic and Molecular Testing (Company)
Medicare	0087U	Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0087U	Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	0088U	Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0089U	Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es)	07/01/2020			Gene Expression Profile Testing for Melanoma (Medicare)
Medicare	0090U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)	06/02/2019			Gene Expression Profile Testing for Melanoma (Medicare)
Medicare	0094U	Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0095T	Removal of total disc arthroplasty, anterior approach; each additional interspace	09/01/2017		No additional PA requirements	Artificial Intervertebral Discs (Company); Artificial Intervertebral Discs (Medicare)
Commercial/ASO, OHP, PEBB	0098T	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure)	09/01/2017			Artificial Intervertebral Discs (Company)
Medicare	0098T	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure)	07/01/2020			Artificial Intervertebral Discs (Medicare)
Medicare	0101U	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis	01/01/2022			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 12/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])				
Medicare	0102U	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0103U	Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], EPCAM [deletion/duplication only])	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0106T	Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation	12/01/2021	06/30/2022		Nerve Conduction Studies (Medicare)
Medicare	0107T	Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation	12/01/2021	06/30/2022		Nerve Conduction Studies (Medicare)
Medicare	0108T	Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling	12/01/2021	06/30/2022		Nerve Conduction Studies (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 13/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		stimuli to assess small nerve fiber sensation and hyperalgesia				
Medicare	0108U	Gastroenterology (Barrett's esophagus), whole slide–digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0109T	Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia	12/01/2021	06/30/2022		Nerve Conduction Studies (Medicare)
Medicare	0110T	Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation	12/01/2021	06/30/2022		Nerve Conduction Studies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0111U	Oncology (colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis utilizing formalin- fixed paraffin-embedded tissue	10/01/2019			Genetic and Molecular Testing (Medicare)
Medicare	0118U	Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell- free DNA in the total cell-free DNA	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0120U	Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary	01/01/2022			Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter				
Commercial/ASO, Medicare, OHP, PEBB	0124U	Fetal congenital abnormalities, biochemical assays of 3 analytes (free beta-hCG, PAPP-A, AFP), time-resolved fluorescence immunoassay, maternal dried-blood spot, algorithm reported as risk scores for fetal trisomies 13/18 and 21	10/01/2019	06/30/2020	Commercial/ASO,Medicare,OHP,PEBB - Code no longer valid effective 7/1/2020	Genetic and Molecular Testing (Medicare); Non-Covered Genetic Panel Tests (Company)
Commercial/ASO, Medicare, OHP, PEBB	0129U	Hereditary breast cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and eletion/duplication analysis panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53)	10/01/2019			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Medicare	0136U	ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure)	06/01/2021	12/31/2022		New and Emerging Technologies and Other Non-Covered Services (Medicare)
Commercial/ASO, OHP, PEBB	0137U	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)	10/01/2019			Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Medicare	0137U	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)	10/01/2019	12/31/2021		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0138U	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)	10/01/2019			Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 15/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	0138U	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)	10/01/2019	12/31/2021		Genetic and Molecular Testing (Medicare)
Medicare	0153U	Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin- embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement	01/01/2022	03/31/2023		Genetic and Molecular Testing (Medicare); Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Medicare)
Medicare	0154U	FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3- TACC3v3)	01/01/2020			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0154U	FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3- TACC3v3)	01/01/2020	08/31/2021		
Commercial/ASO, Medicare, OHP, PEBB	0155U	FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3- TACC3v3)	01/01/2020			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Commercial/ASO, OHP, PEBB	0157U	APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)	01/01/2020			Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	0157U	APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP])	01/01/2020	12/31/2021		Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 16/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		mRNA sequence analysis (List separately in addition to code for primary procedure)				
Commercial/ASO, OHP, PEBB	0158U	MLH1 (mutL homolog 1) (eg, hereditary non- polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	01/01/2020			Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	0158U	MLH1 (mutL homolog 1) (eg, hereditary non- polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	01/01/2020	12/31/2021		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0159U	MSH2 (mutS homolog 2) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	01/01/2020			Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	0159U	MSH2 (mutS homolog 2) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	01/01/2020	12/31/2021		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0160U	MSH6 (mutS homolog 6) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	01/01/2020			Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	0160U	MSH6 (mutS homolog 6) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	01/01/2020	12/31/2021		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0161U	PMS2 (PMS1 homolog 2, mismatch repair system component) (eg, hereditary non- polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	01/01/2020			Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	0161U	PMS2 (PMS1 homolog 2, mismatch repair system component) (eg, hereditary non- polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	01/01/2020	12/31/2021		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0162U	Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure)	01/01/2020			Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	0162U	Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure)	01/01/2020	12/31/2021		Genetic and Molecular Testing (Medicare)
Medicare	0163T	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), each additional interspace, lumbar (List separately in addition to code for primary procedure)	07/01/2020	06/30/2021		Artificial Intervertebral Discs (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0164T	Removal of total disc arthroplasty, (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)	09/01/2019			Artificial Intervertebral Discs (Company); Artificial Intervertebral Discs (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0168U	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma without fetal fraction cutoff, algorithm reported as a risk score for each trisomy	04/01/2020	09/30/2021	This code is no longer valid effective 10/1/2021	Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	0169T	Stereotactic placement of infusion catheter(s) in the brain for delivery of therapeutic agent(s), including computerized stereotactic planning and burr hole(s).	02/01/2016	12/31/2016		



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	0169U	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants	01/01/2022			Genetic and Molecular Testing (Medicare); Inflammatory Bowel Disease: Serologic Markers and Therapeutic Monitoring (Company); Inflammatory Bowel Disease: Serologic Testing and Therapeutic Monitoring (Medicare)
Commercial/ASO, OHP, PEBB	0171U	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence	04/01/2020			Genetic Testing: Myeloproliferative Diseases (Company); Next Generation Sequencing for Minimal Residual Disease Detection (Company)
Medicare	0171U	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence	04/01/2020	05/31/2022		Genetic and Molecular Testing (Medicare); Genetic Testing: Myeloproliferative Diseases (Medicare)
Medicare	0172U	Oncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) and analysis of homologous recombination deficiency pathways, DNA, formalin-fixed paraffin- embedded tissue, algorithm quantifying tumor genomic instability score	07/01/2020			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Medicare)
Commercial/ASO, OHP, PEBB	0172U	Oncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) and analysis of homologous recombination deficiency pathways, DNA, formalin-fixed paraffin-	07/01/2020	08/31/2021		Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 19/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		embedded tissue, algorithm quantifying tumor genomic instability score				
Medicare	0173U	Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0174U	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin- embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0175U	Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 15 genes	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0177U	Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3- kinase catalytic subunit alpha) gene analysis of 11 gene variants utilizing plasma, reported as PIK3CA gene mutation status	07/01/2020			Circulating Tumor Cell and DNA Assays for Cancer Management (Company); Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Medicare	0179U	Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s)	07/01/2020	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0179U	Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s)	08/01/2022			Circulating Tumor Cell and DNA Assays for Cancer Management (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0182T	HDR Electronic Brachytherhapy Per Fraction	01/01/2007			
Medicare	0193T	Transurethral, Radiofrequency Micro- Remodeling of the Female Bladder Neck and Proximal Urethra	10/01/2009	12/31/2010		
Commercial/ASO, OHP, PEBB	0195U	KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13)	07/01/2020			Genetic and Molecular Testing (Company)
Medicare	0195U	KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13)	07/01/2020	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0203U	Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness	01/01/2022	02/28/2023		Inflammatory Bowel Disease: Serologic Testing and Therapeutic Monitoring (Medicare)
Medicare	0204U	Oncology (thyroid), mRNA, gene expression analysis of 593 genes (including BRAF, RAS, RET, PAX8, and NTRK) for sequence variants and rearrangements, utilizing fine needle aspirate, reported as detected or not detected	10/01/2020	11/30/2022		Genetic Testing for Thyroid Nodules (Medicare)
Medicare	0205U	Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0208T	Pure tone audiometry (threshold), automated (includes use of computer-assisted device); air only	01/01/2010	12/31/2015		Hearing Aids (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	0208U	Oncology (medullary thyroid carcinoma), mRNA, gene expression analysis of 108 genes, utilizing fine needle aspirate, algorithm reported as positive or negative for medullary thyroid carcinoma	10/01/2020	12/31/2021	Code no longer valid effective 1/1/2022	Genetic Testing for Thyroid Nodules (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0209T	Pure tone audiometry (threshold), automated (includes use of computer-assisted device); air and bone	01/01/2010	12/31/2015		Hearing Aids (Company)
Medicare	0209U	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0209U	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities	11/01/2022			Next Generation Sequencing for Cancer (Company)
Commercial/ASO, Medicare, OHP, PEBB	0210T	Speech audiometry threshold, automated (includes use of computer-assisted device);	01/01/2010	12/31/2015		Hearing Aids (Company)
Commercial/ASO, Medicare, OHP, PEBB	0211T	Speech audiometry threshold, automated (includes use of computer-assisted device); with speech recognition	01/01/2010	12/31/2015		Hearing Aids (Company)
Medicare	0211U	Oncology (pan-tumor), DNA and RNA by next- generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0211U	Oncology (pan-tumor), DNA and RNA by next- generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy	11/01/2022			Next Generation Sequencing for Cancer (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 22/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		number alterations, tumor mutational burden, and microsatellite instability, with therapy association				
Commercial/ASO, Medicare, OHP, PEBB	0212T	Comprehensive audiometry threshold evaluation and speech recognition (0209T, 0211T combined), automated (includes use of	01/01/2010	12/31/2015		Hearing Aids (Company)
Medicare	0212U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0213U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent, sibling)	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0214U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0215U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 23/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling)				
Medicare	0216U	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0217U	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0218U	Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or saliva, identification and characterization of genetic variants	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0223T	Acoustic cardiography, including automated analysis of combined acoustic and electrical intervals; single, with interp	07/01/2010	06/30/2015		
Commercial/ASO, Medicare, OHP, PEBB	0224T	Acoustic cardiography, including automated analysis of combined acoustic and electrical intervals; multiple, AV or W del	07/01/2010	06/30/2015		

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 24/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	0228T	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance, cervical or thoracic;	06/01/2015	09/30/2015		Epidural Steroid Injections (Company)
Medicare	0228T	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance, cervical or thoracic;	06/01/2015	09/30/2015		Epidural Steroid Injections (Company)
Medicare	0228U	Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0229U	BCAT1 (Branched chain amino acid transaminase 1) or IKZF1 (IKAROS family zinc finger 1) (eg, colorectal cancer) promoter methylation analysis	06/01/2021			Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0230T	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance, lumbar or sacral; sing	06/01/2015	09/30/2015		Epidural Steroid Injections (Company)
Medicare	0230T	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance, lumbar or sacral; sing	06/01/2015	09/30/2015		Epidural Steroid Injections (Company)
Medicare	0230U	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), full sequence analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions	01/01/2022	12/31/2022		Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0231U	CACNA1A (calcium voltage-gated channel subunit alpha 1A) (eg, spinocerebellar ataxia), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) gene expansions, mobile element insertions, and variants in non-uniquely mappable regions	01/01/2021			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	0232U	CSTB (cystatin B) (eg, progressive myoclonic epilepsy type 1A, Unverricht-Lundborg disease), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions	01/01/2021			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	0233U	FXN (frataxin) (eg, Friedreich ataxia), gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions	01/01/2021			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	0233U	FXN (frataxin) (eg, Friedreich ataxia), gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions	01/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0234U	MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non- uniquely mappable regions	01/01/2021			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 26/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	0234U	MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non- uniquely mappable regions	01/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0235U	PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non- uniquely mappable regions	01/01/2021			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0236U	SMN1 (survival of motor neuron 1, telomeric) and SMN2 (survival of motor neuron 2, centromeric) (eg, spinal muscular atrophy) full gene analysis, including small sequence changes in exonic and intronic regions, duplications and deletions, and mobile element insertions	01/01/2021			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	0236U	SMN1 (survival of motor neuron 1, telomeric) and SMN2 (survival of motor neuron 2, centromeric) (eg, spinal muscular atrophy) full gene analysis, including small sequence changes in exonic and intronic regions, duplications and deletions, and mobile element insertions	01/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0237U	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia), genomic sequence analysis panel including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A, including small sequence changes	01/01/2021			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 27/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions				
Medicare	0237U	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia), genomic sequence analysis panel including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions	01/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0238U	Oncology (Lynch syndrome), genomic DNA sequence analysis of MLH1, MSH2, MSH6, PMS2, and EPCAM, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions	01/01/2021			Genetic and Molecular Testing (Company); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	0238U	Oncology (Lynch syndrome), genomic DNA sequence analysis of MLH1, MSH2, MSH6, PMS2, and EPCAM, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions	01/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0239T	Bioimpedance spectroscopy (BIS), measuring 100 frequencies or greater, direct measurement of extracellular fluid differe	01/01/2011			
Medicare	0239U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions,	01/01/2021			Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 28/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		insertions, deletions, select rearrangements, and copy number variations				
Commercial/ASO, OHP, PEBB	0239U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations	08/01/2022			Circulating Tumor Cell and DNA Assays for Cancer Management (Company)
Commercial/ASO, Medicare, OHP, PEBB	0240T	Esophageal motility study with interpretation and report; with 3-dimensional high resolution esophageal pressure topogr	01/01/2011			
Commercial/ASO, Medicare, OHP, PEBB	0241T	Esophageal motility study with interpretation and report; with stimulation or perfusion during 3-dimensional high resolu	01/01/2011			
Medicare	0242U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 55-74 genes, interrogation for sequence variants, gene copy number amplifications, and gene rearrangements	04/01/2021			Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)
Commercial/ASO, OHP, PEBB	0242U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 55-74 genes, interrogation for sequence variants, gene copy number amplifications, and gene rearrangements	08/01/2022			
Medicare	0244U	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite instability, utilizing formalin-fixed paraffin-embedded tumor tissue	04/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 29/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	0244U	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite instability, utilizing formalin-fixed paraffin-embedded tumor tissue	11/01/2022			Next Generation Sequencing for Cancer (Company)
Medicare	0245U	Oncology (thyroid), mutation analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers using next-generation sequencing, fine needle aspirate, report includes associated risk of malignancy expressed as a percentage	04/01/2021			Genetic Testing for Thyroid Nodules (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0249T	Ligation, hemorrhoidal vascular bundle(s), including ultrasound guidance	01/01/2011			
Medicare	0249U	Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection, with algorithmic analysis and interpretative report	12/01/2021	03/31/2022		Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0250T	Airway sizing and insertion of bronchial valve(s), each lobe (List separately in addition to code for primary procedure)	01/01/2011			
Medicare	0250U	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden	12/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare); Non-Small Cell Lung Cancer: Molecular Testing for Targeted Therapy (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	0250U	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden	11/01/2022			Next Generation Sequencing for Cancer (Company); Next Generation Sequencing for Minimal Residual Disease Detection (Company)
Commercial/ASO, Medicare, OHP, PEBB	0251T	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of bronchial valve(s), in	01/01/2011			
Commercial/ASO, Medicare, OHP, PEBB	0252T	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of bronchial valve(s), ea	01/01/2011			
Medicare	0254U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using embryonic DNA genomic sequence analysis for aneuploidy, and a mitochondrial DNA score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy, per embryo tested	01/01/2022	06/30/2022		Genetic and Molecular Testing (Medicare)
Medicare	0258U	Autoimmune (psoriasis), mRNA, next- generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0260U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	0264U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0265U	Rare constitutional and other heritable disorders, whole genome and mitochondrial DNA sequence analysis, blood, frozen and formalin-fixed paraffin-embedded (FFPE) tissue, saliva, buccal swabs or cell lines, identification of single nucleotide and copy number variants	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare); Whole Exome, Whole Genome, and Proteogenomic Genetic Testing (Company)
Medicare	0266U	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole-transcriptome and next- generation sequencing, blood, formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0267U	Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0268U	Hematology (atypical hemolytic uremic syndrome [aHUS]), genomic sequence analysis of 15 genes, blood, buccal swab, or amniotic fluid	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0268U	Hematology (atypical hemolytic uremic syndrome [aHUS]), genomic sequence analysis of 15 genes, blood, buccal swab, or amniotic fluid	11/01/2022			Next Generation Sequencing for Cancer (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 32/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0269U	Hematology (autosomal dominant congenital thrombocytopenia), genomic sequence analysis of 22 genes, blood, buccal swab, or amniotic fluid	10/01/2021			Genetic and Molecular Testing (Medicare); Next Generation Sequencing for Cancer (Company)
Medicare	0270U	Hematology (congenital coagulation disorders), genomic sequence analysis of 20 genes, blood, buccal swab, or amniotic fluid	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0270U	Hematology (congenital coagulation disorders), genomic sequence analysis of 20 genes, blood, buccal swab, or amniotic fluid	11/01/2022			Next Generation Sequencing for Cancer (Company)
Medicare	0271U	Hematology (congenital neutropenia), genomic sequence analysis of 23 genes, blood, buccal swab, or amniotic fluid	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	0272U	Hematology (genetic bleeding disorders), genomic sequence analysis of 51 genes, blood, buccal swab, or amniotic fluid, comprehensive	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0272U	Hematology (genetic bleeding disorders), genomic sequence analysis of 60 genes and duplication/deletion of PLAU, blood, buccal swab, or amniotic fluid, comprehensive	11/01/2022			Next Generation Sequencing for Cancer (Company)
Medicare	0273U	Hematology (genetic hyperfibrinolysis, delayed bleeding), genomic sequence analysis of 8 genes (F13A1, F13B, FGA, FGB, FGG, SERPINA1, SERPINE1, SERPINF2, PLAU), blood, buccal swab, or amniotic fluid	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0273U	Hematology (genetic hyperfibrinolysis, delayed bleeding), genomic sequence analysis of 9 8 genes (F13A1, F13B, FGA, FGB, FGG, SERPINA1, SERPINE1, SERPINF2 by next- generation sequencing , and PLAU by array comparative genomic hybridization ), blood, buccal swab, or amniotic fluid	11/01/2022			Next Generation Sequencing for Cancer (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 33/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	0274U	Hematology (genetic platelet disorders), genomic sequence analysis of 43 genes, blood, buccal swab, or amniotic fluid	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0274U	Hematology (genetic platelet disorders), genomic sequence analysis of 62 genes and duplication/deletion of PLAU, blood, buccal swab, or amniotic fluid	11/01/2022			Next Generation Sequencing for Cancer (Company); Non-Covered Genetic Panel Tests (Company)
Medicare	0276U	Hematology (inherited thrombocytopenia), genomic sequence analysis of 23 genes, blood, buccal swab, or amniotic fluid	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0276U	Hematology (inherited thrombocytopenia), genomic sequence analysis of 23 genes, blood, buccal swab, or amniotic fluid	11/01/2022			Next Generation Sequencing for Cancer (Company)
Medicare	0277U	Hematology (genetic platelet function disorder), genomic sequence analysis of 31 genes, blood, buccal swab, or amniotic fluid	10/01/2021	12/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0277U	Hematology (genetic platelet function disorder), genomic sequence analysis of 40 genes and duplication/deletion of PLAU, blood, buccal swab, or amniotic fluid	11/01/2022			Next Generation Sequencing for Cancer (Company)
Medicare	0278U	Hematology (genetic thrombosis), genomic sequence analysis of 12 genes, blood, buccal swab, or amniotic fluid	10/01/2021	04/30/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0278U	Hematology (genetic thrombosis), genomic sequence analysis of 14 genes, blood, buccal swab, or amniotic fluid	11/01/2022			Next Generation Sequencing for Cancer (Company); Next Generation Sequencing for Minimal Residual Disease Detection (Company)
Medicare	0281T	Percutaneous transcatheter closure of the left atrial appendage with implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial	02/08/2016			Cardiac: Left Atrial Appendage Devices (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 34/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		appendage angiography, radiological supervision and interpretation				
Commercial/ASO, Medicare, OHP, PEBB	0282T	Percutaneous Or Open Implantation Of Neurostimulator Electrode Array(s), Subcutaneous; For Trial	01/01/2012	12/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	0284T	Revision Or Removal Of Pulse Generator Or Electrodes Including Addition Of New Electrodes, When Performed	01/01/2012	12/31/2016		Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Medicare	0287U	Oncology (thyroid), DNA and mRNA, next- generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin- embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high)	01/01/2022	07/31/2023		Genetic Testing for Thyroid Nodules (Medicare)
Medicare	0288U	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score	07/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0291T	Intravascular optical coherence tomography (coronary native vessel or graft) during diagnostic evaluation and/or therapeutic intervention, including imaging supervision, inter	01/01/2012			
PEBB	0292T	Intravascular optical coherence tomography (coronary native vessel or graft) during diagnostic evaluation and/or therapeutic intervention, including imaging supervision, inter	01/01/2010			



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP	0292T	Intravascular optical coherence tomography (coronary native vessel or graft) during diagnostic evaluation and/or therapeutic intervention, including imaging supervision, inter	01/01/2012			
Commercial/ASO, Medicare, OHP, PEBB	0295T	External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, rev	01/01/2012	04/30/2019		Cardiac: External Ambulatory Electrocardiography (Company); Cardiac: External Ambulatory Electrocardiography (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0296T	External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)	01/01/2012	04/30/2019		Cardiac: External Ambulatory Electrocardiography (Company); Cardiac: External Ambulatory Electrocardiography (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0297T	External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; scanning analysis with report	01/01/2012	04/30/2019		Cardiac: External Ambulatory Electrocardiography (Company); Cardiac: External Ambulatory Electrocardiography (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0298T	External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation	01/01/2012	04/30/2019		Cardiac: External Ambulatory Electrocardiography (Company); Cardiac: External Ambulatory Electrocardiography (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0309T	Arthrodesis, Pre-Sacral Interbody Technique, W Posterior Instrumentation, Lumbar, L4-L5 Interspace	01/01/2013	12/31/2017		
Commercial/ASO, Medicare, OHP, PEBB	0310T	Motor Function Mapping Using Non-Invasive Navigated Transcranial Magnetic Stimulation (Ntms), Upper And Lower Extremity	01/01/2013	02/28/2017		
Commercial/ASO, Medicare, OHP, PEBB	0311T	Non-Invasive Calculation And Analysis Of Central Arterial Pressure Waveforms With Interpretation And Report	01/01/2013	12/31/2015		

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 36/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	0313U	Oncology (pancreas), DNA and mRNA next- generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia)	11/01/2022			Next Generation Sequencing for Cancer (Company)
Medicare	0314U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)	08/06/2023			Gene Expression Profile Testing for Melanoma (Company); Gene Expression Profile Testing for Melanoma (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0318T	Implantation Of Catheter-Delivered Prosthetic Aortic Heart Valve, Open Thoracic Approach	01/01/2013	12/31/2013		
Commercial/ASO, Medicare, OHP, PEBB	0319T	Insertion Or Replacement Of Subcutaneous Implantable Defibrillator System With Subcutaneous Electrode	01/01/2013	12/31/2014		
Commercial/ASO, Medicare, OHP, PEBB	0320T	Insertion Of Subcutaneous Defibrillator Electrode	01/01/2013	12/31/2014		
Commercial/ASO, Medicare, OHP, PEBB	0321T	Insertion Of Subcutaneous Implantable Defibrillator Pulse Generator Only With Existing Subcutaneous Electrode	01/01/2013	12/31/2014		
Commercial/ASO, Medicare, OHP, PEBB	0322T	Removal Of Subcutaneous Implantable Defibrillator Pulse Generator Only	01/01/2013	12/31/2014		
Commercial/ASO, Medicare, OHP, PEBB	0323T	Removal Of Subcutaneous Implantable Defibrillator Pulse Generator With Replacement Of Generator Only	01/01/2013	12/31/2014		
Commercial/ASO, Medicare, OHP, PEBB	0324T	Removal Of Subcutaneous Defibrillator Electrode	01/01/2013	12/31/2014		



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0325T	Repositioning Of Subcutaneous Implantable Defibrillator Electrode And/Or Pulse Generator	01/01/2013	12/31/2014	In-plan only, no opt-out benefit	
Commercial/ASO, Medicare, OHP, PEBB	0326T	Electrophysiologic Evaluation Of Subcutaneous Implantable Defibrillator	01/01/2013	12/31/2014		
Commercial/ASO, Medicare, OHP, PEBB	0327T	Interrogation Device Eval (In Person) W Analysis, Review And Report; Implantable Subcutaneous Lead Defibrillator System	01/01/2013	12/31/2014		
Medicare	0327u	Fetal aneuploidy (trisomy 13, 18, and 21), DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy, includes sex reporting, if performed	07/01/2022		Medicare -	Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0327U	Fetal aneuploidy (trisomy 13, 18, and 21), DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy, includes sex reporting, if performed	07/01/2022			Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	0328T	Programming Device Evaluation (In Person) With Iterative Adjustment; Implantable Subcutaneous Lead Defibrillator System	01/01/2013	12/31/2014		
Medicare	0329U	Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations	07/01/2022			Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	0329U	Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations	08/01/2023			Next Generation Sequencing for Cancer (Company); Whole Exome, Whole Genome, and Proteogenomic Genetic Testing (Company)
Commercial/ASO, OHP, PEBB	0330T	Tear film imaging, unilateral or bilateral, with interpretation and report	10/01/2017	12/31/2023		Eye: Automated Evacuation of Meibomian Glands (Company)
Commercial/ASO, OHP, PEBB	0332T	Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; with tomographic SPECT	10/01/2017	01/01/2023		
Commercial/ASO, OHP, PEBB	0333T	Visual evoked potential, screening of visual acuity, automated, with report	10/01/2017			
Commercial/ASO, OHP, PEBB	0334U	Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin- embedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	10/01/2022			Genetic and Molecular Testing (Company); Next Generation Sequencing for Cancer (Company)
Medicare	0339U	Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT- PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer	01/01/2024			Prostate: Protein Biomarkers and Genetic Testing (Medicare)
Medicare	0340U	Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the	10/01/2022			Next Generation Sequencing for Minimal Residual Disease Detection (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 39/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		patient's tumor and germline DNA, reported as absence or presence of MRD, with disease- burden correlation, if appropriate				
Medicare	0345U	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6	10/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	0355T	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), colon, with interpretation and report	04/01/2021	12/31/2021	This code is no longer valid effective 1/1/2022	Wireless Capsule Endoscopy (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0357T	Cryopreservation; immature oocyte(s)	01/01/2015	12/31/2016	Commercial/ASO - Coverage is subject to plan benefits, prior authorization required	
Commercial/ASO, OHP, PEBB	0358T	Bioelectrical impedance analysis whole body composition assessment, with interpretation and report	10/01/2017			
Commercial/ASO, Medicare, OHP, PEBB	0359T	Behavior identification assessment, by the physician or other qualified health care professional, face-to-face with patient and caregiver(s), includes administration of standardized and non-standardized tests, detailed behavioral history, patient observation and caregiver interview, interpretation of test results, discussion of findings and recommendations with the primary guardian(s)/caregiver(s), and preparation of report	06/01/2016	03/31/2017		Autism Spectrum Disorders Assessment and Treatment ARCHIVED 4/1/17
Commercial/ASO, OHP, PEBB	0359U	Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer	01/01/2023			Prostate: Protein Biomarkers and Genetic Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 40/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0360T	Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; first 30 minutes of technician time, face-to-face with the patient	06/01/2016	03/31/2017		Autism Spectrum Disorders Assessment and Treatment ARCHIVED 4/1/17
Commercial/ASO, Medicare, OHP, PEBB	0361T	Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; each additional 30 minutes of technician time, face-to-face with the patient	06/01/2016	03/31/2017		Autism Spectrum Disorders Assessment and Treatment ARCHIVED 4/1/17
Commercial/ASO	0362T	Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient	04/01/2021		Prior authorization Excludes Providence St Joseph Health Except St. Joseph Health Northern California. Prior authorization excludes Intel	Applied Behavior Analysis (Company)
Medicare	0362T	Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient	04/01/2021	02/28/2023	Medicare was removed from this policy 3/1/2023	Applied Behavior Analysis (Company)
PEBB	0362T	Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the	04/01/2021	06/30/2023	PEBB was removed from this policy 7/1/2023	Applied Behavior Analysis (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 41/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient				
Commercial/ASO, Medicare, OHP, PEBB	0363T	Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient	06/01/2016	03/31/2017		Autism Spectrum Disorders Assessment and Treatment ARCHIVED 4/1/17
Medicare	0364U	Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate	04/01/2023	11/30/2023		Next Generation Sequencing for Minimal Residual Disease Detection (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0365T	Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; each additional 30 minutes of technician time	06/01/2016	03/31/2017		Autism Spectrum Disorders Assessment and Treatment ARCHIVED 4/1/17
Commercial/ASO, Medicare, OHP, PEBB	0367T	Group adaptive behavior treatment by protocol, administered by technician, face-to- face with two or more patients; each additional 30 minutes of technician time	06/01/2016	03/31/2017		Autism Spectrum Disorders Assessment and Treatment ARCHIVED 4/1/17
Commercial/ASO, Medicare, OHP, PEBB	0368T	Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; first 30 minutes of patient face- to-face time	06/01/2016	03/31/2017		Autism Spectrum Disorders Assessment and Treatment ARCHIVED 4/1/17

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0369T	Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time	06/01/2016	03/31/2017		Autism Spectrum Disorders Assessment and Treatment ARCHIVED 4/1/17
Commercial/ASO, Medicare, OHP, PEBB	0371T	Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present)	06/01/2016	03/31/2017		Autism Spectrum Disorders Assessment and Treatment ARCHIVED 4/1/17
Commercial/ASO, Medicare, OHP, PEBB	0372T	Adaptive behavior treatment social skills group, administered by physician or other qualified health care professional face-to-face with multiple patients	06/01/2016	03/31/2017		Autism Spectrum Disorders Assessment and Treatment ARCHIVED 4/1/17
Commercial/ASO	0373T	Adaptive behavior treatment with protocol modification, each 15 minutes of technicians' time face-to-face with a patient, requiring the following components: administration by the physician or other qualified health care professional who is on site; with the assistance of two or more technicians; for a patient who exhibits destructive behavior; completion in an environment that is customized to the patient's behavior.	01/01/2021		PA required by Optum for Providence St Joseph Health (PSJH), except St. Joseph Health Northern California. PA required by PHP and PPP for commercial/ASO, and St. Joseph Health Northern California. Prior authorization excludes Intel	Applied Behavior Analysis (Company)
Medicare	0373T	Adaptive behavior treatment with protocol modification, each 15 minutes of technicians' time face-to-face with a patient, requiring the following components: administration by the physician or other qualified health care professional who is on site; with the assistance of two or more technicians; for a patient who exhibits destructive behavior; completion in an environment that is customized to the patient's behavior.	01/01/2021	02/28/2023	Medicare was removed from this policy 3/1/2023	Applied Behavior Analysis (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
PEBB	0373T	Adaptive behavior treatment with protocol modification, each 15 minutes of technicians' time face-to-face with a patient, requiring the following components: administration by the physician or other qualified health care professional who is on site; with the assistance of two or more technicians; for a patient who exhibits destructive behavior; completion in an environment that is customized to the patient's behavior.	01/01/2021	06/30/2023	PEBB was removed from this policy 7/1/2023	Applied Behavior Analysis (Company)
Commercial/ASO, Medicare, OHP, PEBB	0374T	Exposure adaptive behavior treatment with protocol modification requiring two or more technicians for severe maladaptive behavior(s); each additional 30 minutes of technicians' time face-to-face with patient (List separately in addition to code for primary procedure)	06/01/2016	03/31/2017		Autism Spectrum Disorders Assessment and Treatment ARCHIVED 4/1/17
Commercial/ASO, Medicare, OHP, PEBB	0377T	Anoscopy with directed submucosal injection of bulking agent for fecal incontinence	01/01/2015	02/28/2017		Drug: Solesta (Dextranomer in Stabilized Sodium Hyaluronate) for Fecal Incontinence
Medicare	0379U	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden	04/01/2023			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	0379U	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden	04/01/2023			Next Generation Sequencing for Cancer (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 44/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	0380U	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis, 20 gene variants and CYP2D6 deletion or duplication analysis with reported genotype and phenotype	01/01/2024			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0388U	Oncology (non-small cell lung cancer), next- generation sequencing with identification of single nucleotide variants, copy number variants, insertions and deletions, and structural variants in 37 cancer-related genes, plasma, with report for alteration detection	07/01/2023			Circulating Tumor Cell and DNA Assays for Cancer Management (Company); Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)
Commercial/ASO, OHP, PEBB	0391U	Oncology (solid tumor), DNA and RNA by next- generation sequencing, utilizing formalin-fixed paraffin-embedded (FFPE) tissue, 437 genes, interpretive report for single nucleotide variants, splice site variants, insertions/deletions, copy number alterations, gene fusions, tumor mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy response score	07/01/2023			Next Generation Sequencing for Cancer (Company)
Commercial/ASO, Medicare, OHP, PEBB	0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed	01/01/2016	12/31/2017		Liver Tumor Treatment (Company); New and Emerging Technologies and Other Non- Covered Services (Company)
Commercial/ASO, Medicare, OHP, PEBB	0397U	Oncology (non-small cell lung cancer), cell-free DNA from plasma, targeted sequence analysis of at least 109 genes, including sequence variants, substitutions, insertions, deletions, select rearrangements, and copy number variations	07/01/2023	10/01/2023		Circulating Tumor Cell and DNA Assays for Cancer Management (Company); Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)
Medicare	0398T	Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation lesion, intracranial for movement disorder including stereotactic	11/01/2022			Magnetic Resonance-Guided Focused Ultrasound Surgery (MRgFUS) (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 45/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		navigation and frame placement when performed				
Commercial/ASO, OHP, PEBB	0398T	Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation lesion, intracranial for movement disorder including stereotactic navigation and frame placement when performed	11/01/2022			Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) (Company)
Commercial/ASO, OHP, PEBB	0400U	Obstetrics (expanded carrier screening), 145 genes by nextgeneration sequencing, fragment analysis and multiplex ligationdependent probe amplification, DNA, reported as carrier positive or negative	07/01/2023			Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	0402T	Collagen cross-linking of cornea (including removal of the corneal epithelium and intraoperative pachymetry when performed)	11/01/2018			Eye: Corneal Collagen Cross-Linking (Company) ; New and Emerging Technologies and Other Non-Covered Services (Company)
Commercial/ASO, Medicare, OHP, PEBB	0409U	Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, and fusions, report showing identified mutations with clinical actionability	10/01/2023			Circulating Tumor Cell and DNA Assays for Cancer Management (Company); Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)
Medicare	0411U	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6	10/01/2023			Genetic and Molecular Testing (Company)
Commercial/ASO, OHP, PEBB	0417U	Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear encoded mitochondrial gene analysis of 335 nuclear	10/01/2023			Whole Exome, Whole Genome, and Proteogenomic Genetic Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 46/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder– associated genetic variants				
Commercial/ASO, OHP, PEBB	0421T	Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed)	11/01/2022			Benign Prostatic Hyperplasia Treatments (Company)
Medicare	0422U	Oncology (pan-solid tumor), analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre- treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate	01/01/2024			Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)
Commercial/ASO, OHP, PEBB	0422U	Oncology (pan-solid tumor), analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre- treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate	01/01/2024			Circulating Tumor Cell and DNA Assays for Cancer Management (Company)
Medicare	0428U	Oncology (breast), targeted hybrid-capture genomic sequence analysis panel, circulating tumor DNA (ctDNA) analysis of 56 or more genes, interrogation for sequence variants,	01/01/2024			Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 47/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutation burden				
Commercial/ASO, OHP, PEBB	0439T	Myocardial contrast perfusion echocardiography, at rest or with stress, for assessment of myocardial ischemia or viability (List separately in addition to code for primary procedure)	01/01/2018			
Commercial/ASO, OHP, PEBB	0440T	Ablation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve	10/01/2017			
Commercial/ASO, OHP, PEBB	0442T	Ablation, percutaneous, cryoablation, includes imaging guidance; nerve plexus or other truncal nerve (eg, brachial plexus, pudendal nerve)	10/01/2017			
Commercial/ASO, Medicare, OHP, PEBB	0444U	Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue, report of clinically significant variant(s)	04/01/2024			Genetic and Molecular Testing (Medicare); Next Generation Sequencing for Cancer (Company)
Medicare	0446T	Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training	11/01/2020			Advanced Diabetes Management Technology (Medicare)
Medicare	0447T	Removal of implantable interstitial glucose sensor from subcutaneous pocket via incision	11/01/2020			Advanced Diabetes Management Technology (Medicare)
Medicare	0448T	Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new	11/01/2020			Advanced Diabetes Management Technology (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		implantable sensor, including system activation				
Commercial/ASO, Medicare, OHP, PEBB	0448U	Oncology (lung and colon cancer), DNA, qualitative, next-generation sequencing detection of single-nucleotide variants and deletions in EGFR and KRAS genes, formalin- fixed paraffin-embedded (FFPE) solid tumor samples, reported as presence or absence of targeted mutation(s), with recommended therapeutic options	04/01/2024			Genetic and Molecular Testing (Medicare); Next Generation Sequencing for Cancer (Company)
Commercial/ASO, OHP, PEBB	0449U	Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia), regardless of race or self-identified ancestry, genomic sequence analysis panel, must include analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2)	04/01/2024			Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	0451T	Insertion or replacement of a permanently implantable aortic counterpulsation ventricular assist system, endovascular approach, and programming of sensing and therapeutic parameters; complete system (counterpulsation device, vascular graft, implantable vascular hemostatic seal, mechano-electrical skin interface and subcutaneous electrodes)	01/01/2017	04/30/2020		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	0452T	Insertion or replacement of a permanently implantable aortic counterpulsation ventricular assist system, endovascular approach, and programming of sensing and therapeutic parameters; aortic counterpulsation device and vascular hemostatic seal	01/01/2017	04/30/2020		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 49/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0453T	Insertion or replacement of a permanently implantable aortic counterpulsation ventricular assist system, endovascular approach, and programming of sensing and therapeutic parameters; mechano-electrical skin interface	01/01/2017	04/30/2020		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	0454T	Insertion or replacement of a permanently implantable aortic counterpulsation ventricular assist system, endovascular approach, and programming of sensing and therapeutic parameters; subcutaneous electrode	01/01/2017	04/30/2020		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	0462T	Programming device evaluation (in person) with iterative adjustment of the implantable mechano-electrical skin interface and/or external driver to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable aortic counterpulsation ventricular assist system, per day	01/01/2017	04/30/2020		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	0463T	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable aortic counterpulsation ventricular assist system, per day	01/01/2017	04/30/2020		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, OHP, PEBB	0466T	Insertion of chest wall respiratory sensor electrode or electrode array, including connection to pulse generator (List separately in addition to code for primary procedure)	12/01/2019	12/31/2021	This code is no longer valid effective 1/1/2022	Sleep Disorder Surgery (Company); Vagus Nerve Stimulation (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	0466T	Insertion of chest wall respiratory sensor electrode or electrode array, including connection to pulse generator (List separately in addition to code for primary procedure)	03/01/2020	12/31/2021	This code is no longer valid effective 1/1/2022	Sleep Disorder Surgery (Medicare); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, OHP, PEBB	0467T	Revision or replacement of chest wall respiratory sensor electrode or electrode array, including connection to existing pulse generator	12/01/2019	12/31/2021	This code is no longer valid effective 1/1/2022	Sleep Disorder Surgery (Company); Vagus Nerve Stimulation (Company)
Medicare	0467T	Revision or replacement of chest wall respiratory sensor electrode or electrode array, including connection to existing pulse generator	03/01/2020	12/31/2021	This code is no longer valid effective 1/1/2022	Sleep Disorder Surgery (Medicare); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, OHP, PEBB	0468T	Removal of chest wall respiratory sensor electrode or electrode array	12/01/2019	12/31/2021	This code is no longer valid effective 1/1/2022	Sleep Disorder Surgery (Company); Vagus Nerve Stimulation (Company)
Medicare	0468T	Removal of chest wall respiratory sensor electrode or electrode array	03/01/2020	12/31/2021	This code is no longer valid effective 1/1/2022	Sleep Disorder Surgery (Medicare); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	0494T	Surgical preparation and cannulation of marginal (extended) cadaver donor lung(s) to ex vivo organ perfusion system, including decannulation, separation from the perfusion system, and cold preservation of the allograft prior to implantation, when performed	01/01/2018		Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0495T	Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas	01/01/2018		Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		analysis), including bronchoscopy and X ray when performed; first two hours in sterile field				
Commercial/ASO, Medicare, OHP, PEBB	0496T	Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; each additional hour (List separately in addition to code for primary procedure)	01/01/2018		Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0497T	External patient-activated, physician- or other qualified health care professional-prescribed, electrocardiographic rhythm derived event recorder without 24 hour attended monitoring; in-office connection	01/01/2018	01/01/2023		Cardiac: External Ambulatory Electrocardiography (Company); Cardiac: External Ambulatory Electrocardiography (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0498T	External patient-activated, physician- or other qualified health care professional-prescribed, electrocardiographic rhythm derived event recorder without 24 hour attended monitoring; review and interpretation by a physician or other qualified health care professional per 30 days with at least one patient-generated triggered event	01/01/2018	01/01/2023		Cardiac: External Ambulatory Electrocardiography (Company); Cardiac: External Ambulatory Electrocardiography (Medicare)
Medicare	0499T	Cystourethroscopy, with mechanical dilation and urethral therapeutic drug delivery for urethral stricture or stenosis, including fluoroscopy, when performed	01/01/2018	12/31/2022		



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0501T	Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; data preparation and transmission, analysis of fluid dynamics and simulated maximal coronary hyperemia, generation of estimated FFR model, with anatomical data review in comparison with estimated FFR model to reconcile discordant data, interpretation and report	09/01/2018			General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	0502T	Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; data preparation and transmission	09/01/2018			General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	0503T	Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; analysis of fluid dynamics and simulated maximal coronary hyperemia, and generation of estimated FFR model	09/01/2018			General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	0504T	Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery	09/01/2018			General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 53/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		disease; anatomical data review in comparison with estimated FFR model to reconcile discordant data, interpretation and report				
Medicare	0524T	Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring	01/01/2019	02/29/2024		Varicose Veins (Medicare)
Commercial/ASO, OHP, PEBB	0587T	Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	01/01/2020			Urinary Incontinence Treatments (Company)
Medicare	0587T	Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	01/01/2020	06/30/2022		Urinary Incontinence Treatments (Medicare)
Commercial/ASO, OHP, PEBB	0588T	Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	01/01/2020			Urinary Incontinence Treatments (Company)
Medicare	0588T	Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	01/01/2020	06/30/2022		Urinary Incontinence Treatments (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 54/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	0589T	Electronic analysis with simple programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters	01/01/2020			Urinary Incontinence Treatments (Company)
Medicare	0589T	Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters	01/01/2020	06/30/2022		Urinary Incontinence Treatments (Medicare)
Commercial/ASO, OHP, PEBB	0590T	Electronic analysis with complex programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care	01/01/2020			Urinary Incontinence Treatments (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		professional, posterior tibial nerve, 4 or more parameters				
Medicare	0590T	Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters	01/01/2020	06/30/2022		Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0633T	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast material	06/11/2022		Commercial/ASO,Medicare,OHP,PEBB - Carelon Prior Authorization Required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	0634T	Computed tomography, breast, including 3D rendering, when performed, unilateral; with contrast material(s)	06/11/2022		Commercial/ASO,Medicare,OHP,PEBB - Carelon Prior Authorization Required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	0635T	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast, followed by contrast material(s)	06/11/2022		Commercial/ASO,Medicare,OHP,PEBB - Carelon Prior Authorization Required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	0636T	Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast material(s)	06/11/2022		Commercial/ASO,Medicare,OHP,PEBB - Carelon Prior Authorization Required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	0637T	Computed tomography, breast, including 3D rendering, when performed, bilateral; with contrast material(s)	06/11/2022		Commercial/ASO,Medicare,OHP,PEBB - Carelon Prior Authorization Required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0638T	Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast, followed by contrast material(s)	06/11/2022		Commercial/ASO,Medicare,OHP,PEBB - Carelon Prior Authorization Required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	0648T	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session ; single organ	06/11/2022		Carelon Prior Authorization Required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	0649T	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure ); ) single organ (List separately in addition to code for primary procedure)	06/11/2022		Carelon Prior Authorization Required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	0784T	Insertion or replacement of percutaneous electrode array, spinal, with integrated neurostimulator, including imaging guidance, when performed	01/01/2024			Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	0785T	Revision or removal of neurostimulator electrode array, spinal, with integrated neurostimulator	01/01/2024			Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0786T	Insertion or replacement of percutaneous electrode array, sacral, with integrated neurostimulator, including imaging guidance, when performed	01/01/2024			Fecal Incontinence Treatments (Company); Fecal Incontinence Treatments (Medicare); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0787T	Revision or removal of neurostimulator electrode array, sacral, with integrated neurostimulator	01/01/2024			Fecal Incontinence Treatments (Company); Fecal Incontinence Treatments (Medicare); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0816T	Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subcutaneous	01/01/2024			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0817T	Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subfascial	01/01/2024			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0818T	Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subcutaneous	01/01/2024			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	0819T	Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subfascial	01/01/2024			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	0858T	Externally applied transcranial magnetic stimulation with concomitant measurement of evoked cortical potentials with automated report	01/01/2024			Transcranial Magnetic Stimulation (Company); Transcranial Magnetic Stimulation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	11920	Tattoo/Color Defect to 6.0 Sq Cm	09/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	11921	Tattooing 6-20 Sq Cm	09/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	11922	Tattoo/Color Defect Ea Add 20 Sq Cm	09/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 59/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	11980	Subcutaneous hormone pellet implantation (implantation of estradiol and/or testosterone pellets beneath the skin)	08/01/2023			Hormone Replacement Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	15002	Surgical Preparation or Creation of Recipient Site, T/A/L; 1st 100 Sq Cm or 1% of Body Area of Infants and Children	10/01/2007	05/31/2018		Skin and Tissue Substitutes (Company)
Commercial/ASO, Medicare, OHP, PEBB	15003	Surgical Preparation or Creation of Recipient Site, T/A/L; Ea Addl 100 Sq Cm or Ea Addl 1% of Body Area Infant / Child	10/01/2007	05/31/2018		Skin and Tissue Substitutes (Company)
Commercial/ASO, Medicare, OHP, PEBB	15004	Surgical Preparation or Creation of Recipient Site, F/S/E/M/N/E/O/G/H/F/D; 1st 100 Sq Cm or 1% of Body Area Infant/Child	10/01/2007	05/31/2018		Skin and Tissue Substitutes (Company)
Commercial/ASO, Medicare, OHP, PEBB	15005	Surg Preparation or Creation of Recipient Site, F/S/E/M/N/E/O/G/H/F/D; Ea Addl 100 Sq Cm or 1% Of Body Area Infant/Child	10/01/2007	05/31/2018		Skin and Tissue Substitutes (Company)
Commercial/ASO, Medicare, OHP, PEBB	15271	Skin Subst Graft To Trunk, Arms, Legs, Area Up To 100 Sq Cm; First 25 Sq Cm Or Less Wound Surface Area	01/01/2012		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15272	Skin Subst Graft To Trunk, Arms, Legs, Area Up To 100 Sq Cm; Ea Additional 25 Sq Cm Wound Surface Area, Or Part Thereof	01/01/2012		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15273	Skin Subst Graft To Trunk, Arms, Legs, Area >/= 100 Sq Cm; 1St 100 Sq Cm Or 1% Of Body Area Of Infants And Children	01/01/2012		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15274	Skin Subst Graft To Trunk, Arms, Legs, Area >/= 100 Sq Cm; Ea Addl 100 Sq Cm Or Ea Adl 1% Of Body Area Of Inf&Children	01/01/2012		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15275	Skin Subst Graft To F/S/E/M/N/E/O/G/H/F/D, Area Up To 100 Sq Cm; 1St 25 Sq Cm Or Less Wound Surface Area	01/01/2012		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 60/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	15276	Skin Subst Graft To F/S/E/M/N/E/O/G/H/F/D, Area Up To 100 Sq Cm; Ea Addl 25 Sq Cm Wound Surface Area, Or Part Thereof	01/01/2012		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15277	Skin Subst Graft To F/S/E/M/N/E/O/G/H/F/D, Area >/= 100 Sq Cm; 1St 100 Sq Cm Or 1% Of Body Area Of Infants And Children	01/01/2012		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15278	Skin Subst Graft To F/S/E/M/N/E/O/G/H/F/D, Area >/= 100 Sq Cm; Ea Addl 100 Sq Cm Or 1% Of Body Area Of Inf And Children	01/01/2012		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15769	Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)	01/01/2020	05/31/2022		Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	15771	Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate	01/01/2020	05/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	15772	Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)	01/01/2020	05/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	15777	Implantation of biologic implant (eg, acellular dermal matrix) for soft tissue reinforcement (ie, breast, trunk) (List separately in addition to code for primary procedure)	06/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Medicare	15788	Chemical peel, facial; epidermal	05/01/2022			Cosmetic and Reconstructive Surgery (Medicare)
Medicare	15789	Chemical peel, facial; dermal	05/01/2022			Cosmetic and Reconstructive Surgery (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	15792	Chemical peel, nonfacial; epidermal	05/01/2022			Cosmetic and Reconstructive Surgery (Medicare)
Medicare	15793	Chemical peel, nonfacial; dermal	05/01/2022			Cosmetic and Reconstructive Surgery (Medicare)
Commercial/ASO, OHP, PEBB	15820	Blepharoplasty Lower Eyelids	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company); Gender Affirming Surgical Interventions (Company)
Commercial/ASO, OHP, PEBB	15821	Blepharoplasty W Extensive Fat Pads	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company); Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	15822	Blepharoplasty Upper Eyelid	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15823	Rhytidectomy W Excess Skin On Lids	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Medicare	15824	Rhytidectomy; forehead	05/01/2022			Cosmetic and Reconstructive Surgery (Medicare)
Medicare	15825	Rhytidectomy; neck with platysmal tightening (platysmal flap, P-flap)	05/01/2022			Cosmetic and Reconstructive Surgery (Medicare)
Medicare	15826	Rhytidectomy; glabellar frown lines	05/01/2022			Cosmetic and Reconstructive Surgery (Medicare)
Medicare	15828	Rhytidectomy; cheek, chin, and neck	05/01/2022		Code pays if paired with one of the following: F64.0, F64.1, F64.8, F64.9	Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	15829	Rhytidectomy; superficial musculoaponeurotic system (SMAS) flap	05/01/2022		Code PAs. If billed with F64.0, F64.1, F64.8,or F64.9 then code will pay	Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15830	Excision, Excessive Skin and Subcutaneous Tissue (Includes Lipectomy); Abdomen, Infraumbilical Panniculectomy	01/01/2007			Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15832	Exc Excess Skin Subq Tiss Thigh	05/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Liposuction for Lipedema (Company); Liposuction for Lipedema (Medicare); Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare); Surgical Treatments for Lymphedema (Company); Surgical Treatments for Lymphedema (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15833	Exc Excess Skin Leg	05/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Liposuction for Lipedema (Company); Liposuction for Lipedema (Medicare); Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare); Surgical Treatments for Lymphedema (Company); Surgical Treatments for Lymphedema (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	15834	Exc Excess Skin Subq Tiss Hip	05/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Liposuction for Lipedema (Company); Liposuction for Lipedema (Medicare); Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare); Surgical Treatments for Lymphedema (Company); Surgical Treatments for Lymphedema (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15835	Exc Excess Skin Buttock	05/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Liposuction for Lipedema (Company); Liposuction for Lipedema (Medicare); Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare); Surgical Treatments for Lymphedema (Company); Surgical Treatments for Lymphedema (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	15836	Exc Excess Skin Subq Tiss Arm	05/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Liposuction for Lipedema (Company); Liposuction for Lipedema (Medicare); Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare); Surgical Treatments for Lymphedema (Company); Surgical Treatments for Lymphedema (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15837	Exc Excess Skin Forearm	05/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Liposuction for Lipedema (Company); Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare); Surgical Treatments for Lymphedema (Company); Surgical Treatments for Lymphedema (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15838	Exc Excess Skin Subq Tiss Fat Pad	05/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Liposuction for Lipedema (Company); Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare); Surgical Treatments for Lymphedema (Company); Surgical Treatments for Lymphedema (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	15839	Exc Excess Skin Other Area	05/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Liposuction for Lipedema (Company); Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare); Surgical Treatments for Lymphedema (Company); Surgical Treatments for Lymphedema (Medicare)
Commercial/ASO, OHP, PEBB	15847	Excision, Excessive Skin and Subcutaneous Tissue (Includes Lipectomy), Abdomen	01/01/2007		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Gender Affirming Surgical Interventions (Company); Surgical Treatment for Skin Redundancy (Company)
Medicare	15847	Excision, Excessive Skin and Subcutaneous Tissue (Includes Lipectomy), Abdomen	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Medicare); Surgical Treatment for Skin Redundancy (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15876	Suction assisted lipectomy; head and neck	06/01/2017		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Liposuction for Lipedema (Company); Liposuction for Lipedema (Medicare); Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare); Surgical Treatments for Lymphedema (Company); Surgical Treatments for Lymphedema (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	15877	Suction assisted lipectomy; trunk	06/01/2017		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Liposuction for Lipedema (Company); Liposuction for Lipedema (Medicare); Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare); Surgical Treatments for Lymphedema (Company); Surgical Treatments for Lymphedema (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	15878	Suction assisted lipectomy; upper extremity	06/01/2017		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Liposuction for Lipedema (Company); Liposuction for Lipedema (Medicare); Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare); Surgical Treatments for Lymphedema (Company); Surgical Treatments for Lymphedema (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	15879	Suction assisted lipectomy; lower extremity	06/01/2017		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Liposuction for Lipedema (Company); Liposuction for Lipedema (Medicare); Surgical Treatment for Skin Redundancy (Company); Surgical Treatment for Skin Redundancy (Medicare); Surgical Treatments for Lymphedema (Company); Surgical Treatments for Lymphedema (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	17106	Dest Cut Vasc Proliferative Les to 10 Sq	09/01/2003			Hemangioma and Vascular Malformation Laser Treatment (Company); Hemangioma and Vascular Malformation Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	17107	Dest Cut Vasc Prolif Les 10-50 Sqcm	09/01/2003			Hemangioma and Vascular Malformation Laser Treatment (Company); Hemangioma and Vascular Malformation Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	17108	Dest Cut Vasc Proliferative Les Over 50.	09/01/2003			Hemangioma and Vascular Malformation Laser Treatment (Company); Hemangioma and Vascular Malformation Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	17380	Electrolysis epilation, each 30 minutes	01/01/2018	07/31/2021	Commercial/ASO,Medicare,OHP,PEBB - This code is covered when billed with one of the following diagnosis codes F64.0, F64.1, F64.8, or F64.9	Cosmetic and Reconstructive Surgery (Company)
Medicare	17380	Electrolysis epilation, each 30 minutes	08/01/2021	04/30/2022	Medicare - This code may pay based on billed diagnosis code	Cosmetic and Reconstructive Surgery (Company); Gender Affirming Surgical Interventions (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP	19300	Mastectomy for gynecomastia	01/01/2007		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty (All Lines of Business Except Medicare) ARCHIVE 7.1.22; Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19316	Mastopexy	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Cosmetic and Reconstructive Surgery (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19318	Mammoplasty Reduction	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9.	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19324	Mammaplasty Augment Wo/Prosthetic Implan	09/01/2003	12/31/2020		Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Cosmetic and Reconstructive Surgery (Company); Gender Affirming Surgical Interventions (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	19325	Mammoplasty Augmentation W Implant	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Cosmetic and Reconstructive Surgery (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19328	Removal of intact breast implant	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19330	Removal of ruptured breast implant, including implant contents (eg, saline, silicone gel)	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19340	Insertion of breast implant on same day of mastectomy (ie, immediate)	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Cosmetic and Reconstructive Surgery (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	19342	Insertion or replacement of breast implant on separate day from mastectomy	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Cosmetic and Reconstructive Surgery (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19350	Reconstruct Nipple/Areolar Unil	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19355	Correction Inverted Nipple(S)	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19357	Tissue expander placement in breast reconstruction, including subsequent expansion(s)	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	19361	Breast reconstruction with latissimus dorsi flap	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19364	Breast reconstruction; with free flap (eg, fTRAM, DIEP, SIEA, GAP flap)	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19366	Reconstruction Breast Other Method	09/01/2003	12/31/2020		Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company)
Commercial/ASO, Medicare, OHP, PEBB	19367	Breast reconstruction; with single-pedicled transverse rectus abdominis myocutaneous flap (TRAM) flap, single pedicle, including closure of donor site	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	19368	Breast reconstruction; with single-pedicled transverse rectus abdominis myocutaneous flap (TRAM) flap, single pedicle, including closure of donor site; with requiring separate microvascular anastomosis (supercharging)	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19369	Breast reconstruction; with bipedicled transverse rectus abdominis myocutaneous flap (TRAM) flap	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19370	Revision of Open peri-implant capsule, breast, includingprosthetic capsulotomy, and /or partial capsulectomy breast	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19371	Periprosthetic Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	19380	Revision of reconstructed breast (eg, significant removal of tissue, re-advancement and/or re-inset of flaps in autologous reconstruction or significant capsular revision combined with soft tissue excision in implant- based reconstruction)	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	19396	Preparation Moulage Breast Implant	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery and Implant Management (Medicare); Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	20939	Bone marrow aspiration for bone grafting, spine surgery only, through separate skin or fascial incision (List separately in addition to code for primary procedure)	02/01/2019			Stem Cell Therapy for Orthopedic Applications (Company); Stem Cell Therapy for Orthopedic Applications (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	20974	Electrical stimulation to aid bone healing; noninvasive (nonoperative)	09/01/2003			Bone Growth Stimulators (Company); Bone Growth Stimulators (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	20975	Electrical stimulation to aid bone healing; invasive (operative)	09/01/2003			Bone Growth Stimulators (Company); Bone Growth Stimulators (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	20979	Low intensity ultrasound stimulation to aid bone healing, noninvasive (nonoperative)	09/01/2003			Bone Growth Stimulators (Company); Bone Growth Stimulators (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	20982	Ablation therapy for reduction or eradication of 1 or more bone tumors (eg, metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; radiofrequency	04/01/2023			Radiofrequency Ablation for Tumors Outside the Liver (Company); Radiofrequency Ablation of Tumors Outside the Liver (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 74/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	21010	Arthrotomy Temporomandibular Unil	01/01/2008	01/31/2016	PEBB - Contract exclusion with TMJ diagnosis	
Medicare	21010	Arthrotomy Temporomandibular Unil	09/01/2003	01/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	21031	Exc Torus Mandibularis	09/01/2003	01/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	21032	Excision Maxillary Torus Palatinus	09/01/2003	01/31/2016		
Commercial/ASO, OHP, PEBB	21060	Meniscectomy Temporomandibular	01/01/2008	01/31/2016		
Medicare	21060	Meniscectomy Temporomandibular	12/01/2015	01/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	21070	Coronoidectomy Unilateral	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21076	Impression and Custom Preparation; Surgical Obturator Prosthesis	09/01/2003	01/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	21077	Impression and Custom Preparation; Orbital Prosthesis	09/01/2003	02/28/2022		
Commercial/ASO, Medicare, OHP, PEBB	21079	Impress/Prep Interim Obturator	09/01/2003	01/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	21080	Impress Custom Prep Definitive Obturator	09/01/2003	01/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	21081	Impress/Prep Mandibular Resection	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21082	Impress Custom Prep Palatal Augmentation	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 75/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	21083	Impress/Prep Palatal Lift Prosth	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21084	Impress Custom Prep Speech Aid Prosth	09/01/2003	01/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	21085	Impress/Prep Oral Surgical Splint	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare); Sleep Disorder Treatment with Oral and Sleep Position Appliances (Company); Sleep Disorder Treatment: Oral and Sleep Position Appliances (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21086	Impression and custom preparation; auricular prosthesis	09/01/2003	02/28/2022		
Commercial/ASO, Medicare, OHP, PEBB	21087	Impression and custom preparation; nasal prosthesis	09/01/2003	02/28/2022		
Commercial/ASO, Medicare, OHP, PEBB	21088	Impression and custom preparation; facial prosthesis	09/01/2003	02/28/2022		
Commercial/ASO, Medicare, OHP, PEBB	21110	Apply Interdental Fixation Other	12/01/2012			Sleep Apnea: Surgical Treatments; Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21116	Inj Proc Temporomandibular Joint Arthrog	09/01/2003	01/31/2016		Orthognathic Surgery (Company)
Commercial/ASO, Medicare, OHP, PEBB	21121	Genioplasty Sliding Osteotomy Single Pie	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Sleep Disorder Surgery (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	21122	Genioplasty Slide Osteotomy 2+	04/01/2007		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare); Sleep Disorder Surgery (Company)
Commercial/ASO, Medicare, OHP, PEBB	21123	Genioplasty; sliding, augmentation with interpositional bone grafts (includes obtaining autografts)	04/01/2007		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21141	Reconstruction Midface, Single Piece	04/01/2007			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare); Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21142	Reconstruction Midface, Two Pieces	01/01/2008			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare); Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21143	Reconstruction Midface, Three or More Pieces	01/01/2008			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare); Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21145	Recon Midface Lefort I Single Graft	04/01/2007			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare); Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21146	Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted unilateral alveolar cleft)	01/01/2008			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare); Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	21147	Recon Midface Lefort I 3+ Pcs Graft	01/01/2008			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare); Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21150	Recon Midface Lefort II Anterior Intrusi	01/01/2008			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21151	Recon Midface Lefort II W/Bone Grft	01/01/2008			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21154	Recon Midface Lefort III Wo/Lefort I	01/01/2008			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21155	Recon Midface Lefort III W/Lefrt I	01/01/2008			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21159	Recon Midface Lefort III W/Graft Wo/Lefo	01/01/2008			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21160	Recon Midface Lefort III W/Grft/L I	01/01/2008			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, OHP, PEBB	21196	Recon Mand Ramus Sag Split W/Rigid Rix	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Gender Affirming Surgical Interventions (Company); Orthognathic Surgery (Company); Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Medicare	21196	Recon Mand Ramus Sag Split W/Rigid Rix	09/01/2003		Code requires PA. If billed with F64.0, F64.1, F64.8,or F64.9 then code will pay without PA	Gender Affirming Surgical Interventions (Medicare); Orthognathic Surgery (Medicare); Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21198	Osteotomy Mandible Segmental	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare); Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	21199	Osteotomy, Mandible, Segmental; with Genioglossus Advancement	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare); Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21206	Osteotomy Maxilla Segmental	09/01/2003			Orthognathic Surgery (Medicare); Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, OHP, PEBB	21208	Osteoplasty Facial Bone Augment	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Gender Affirming Surgical Interventions (Company); Orthognathic Surgery (Company)
Medicare	21208	Osteoplasty Facial Bone Augment	09/01/2003		Code requires PA. If billed with F64.0, F64.1, F64.8,or F64.9 then code will pay without PA	Gender Affirming Surgical Interventions (Medicare); Orthognathic Surgery (Medicare)
Commercial/ASO, OHP, PEBB	21209	Osteoplasty Facial Reduction	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Gender Affirming Surgical Interventions (Company); Orthognathic Surgery (Company)
Medicare	21209	Osteoplasty Facial Reduction	09/01/2003		Code requires PA. If billed with F64.0, F64.1, F64.8,or F64.9 then code will pay without PA	Gender Affirming Surgical Interventions (Medicare); Orthognathic Surgery (Medicare)
Commercial/ASO, OHP, PEBB	21210	Graft Bone Nasal Maxilla Malar Area	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Gender Affirming Surgical Interventions (Company); Orthognathic Surgery (Company)
Medicare	21210	Graft Bone Nasal Maxilla Malar Area	09/01/2003		Code requires PA. If billed with F64.0, F64.1, F64.8,or F64.9 then code will pay without PA	Gender Affirming Surgical Interventions (Medicare); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21215	Graft Bone Mandible	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21230	Grft Rib Cart to Face Chin Nose Ear	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21235	Graft Cartilage Ear to Nose/Ear	01/01/2008	01/31/2016		Orthognathic Surgery (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	21240	Arthroplasty Temporomandib Unil	01/01/2008	01/31/2016	PEBB - Contract exclusion with TMJ diagnosis	Orthognathic Surgery (Company)
Medicare	21240	Arthroplasty Temporomandib Unil	09/01/2003	01/31/2016		Orthognathic Surgery (Company)
Commercial/ASO, OHP, PEBB	21242	Arthroplasty Tmj Alloplastic Agent	01/01/2008	01/31/2016	PEBB - Contract exclusion with TMJ diagnosis	Orthognathic Surgery (Company)
Medicare	21242	Arthroplasty Tmj Alloplastic Agent	09/01/2003	01/31/2016		Orthognathic Surgery (Company)
Commercial/ASO, OHP, PEBB	21243	Arthroplasty Tmj W/Pros Jnt Replace	01/01/2008	01/31/2016	PEBB - Contract exclusion with TMJ diagnosis	Orthognathic Surgery (Company)
Medicare	21243	Arthroplasty Tmj W/Pros Jnt Replace	09/01/2003	01/31/2016		Orthognathic Surgery (Company)
Commercial/ASO, Medicare, OHP, PEBB	21244	Reconstruct Mandible W Bone Plate	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21245	Recon Mand Max Subperiosteal Part	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21246	Repair Jaw W Subperiost Implnt Tot	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, OHP, PEBB	21247	Recon Mand Condyle Bone Cart Auto	01/01/2008			Orthognathic Surgery (Company)
Medicare	21247	Recon Mand Condyle Bone Cart Auto	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21248	Recon Mandible Maxilla Endosteal Implant	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21249	Repair Jaw W Endosteal ImpInt Tot	09/01/2003			Orthognathic Surgery (Company); Orthognathic Surgery (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 80/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	21255	Recon Zygomatic Arch/Glenoid Fossa W/Aut	09/01/2003	01/31/2016		Orthognathic Surgery (Company)
Commercial/ASO, Medicare, OHP, PEBB	21256	Reconstruction of orbit with osteotomies (extracranial) and with bone grafts (includes obtaining autografts) (eg, micro-ophthalmia)	09/01/2003	02/28/2022		
Commercial/ASO, Medicare, OHP, PEBB	21260	Periorbital osteotomies for orbital hypertelorism, with bone grafts; extracranial approach	09/01/2003	02/28/2022		
Commercial/ASO, Medicare, OHP, PEBB	21261	Periorbital osteotomies for orbital hypertelorism, with bone grafts; combined intra- and extracranial approach	09/01/2003	02/28/2022		
Commercial/ASO, Medicare, OHP, PEBB	21267	Orbital repositioning, periorbital osteotomies, unilateral, with bone grafts; extracranial approach	09/01/2003	02/28/2022		
Commercial/ASO, Medicare, OHP, PEBB	21268	Orbital repositioning, periorbital osteotomies, unilateral, with bone grafts; combined intra- and extracranial approach	09/01/2003	02/28/2022		
Commercial/ASO, Medicare, OHP, PEBB	21275	Secondary revision of orbitocraniofacial reconstruction	09/01/2003	02/28/2022		
Commercial/ASO, Medicare, OHP, PEBB	21685	Hyoid Myotomy and Suspension	04/01/2007			Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21740	Recon Rep Pectus Excava/Carinatum	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	21742	Reconstructive Repair of Pectus Excavatum or Carinatum; Minimally Invasive Approach (Nuss Procedure), Wo Thoracoscopy	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	21743	Reconstructive Repair of Pectus Excavatum or Carinatum; Minimally Invasive Approach (Nuss Procedure), w Thoracoscopy	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22100	Resect Vertebra Part Cervical	07/01/2012	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	22102	Partial excision of posterior vertebral component (eg, spinous process, lamina or facet) for intrinsic bony lesion, single vertebral segment; lumbar	07/01/2012	11/30/2019		Back: Lumbar Spine Surgery Archived 12/1/19
Commercial/ASO, Medicare, OHP, PEBB	22103	Partial excision of posterior vertebral component (eg, spinous process, lamina or facet) for intrinsic bony lesion, single vertebral segment; each additional segment (List separately in addition to code for primary procedure)	07/01/2012	11/30/2019		Back: Lumbar Spine Surgery Archived 12/1/19; Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	22110	Exc Vertebra Part Cervical	12/01/2012	09/30/2021		
Commercial/ASO, Medicare, OHP, PEBB	22116	Partial Excision of Vertebral Body for each additional Vertebral Segme	01/01/2013	09/30/2021		
ОНР	22510	Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; cervicothoracic	01/01/2015	10/31/2019		



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
ОНР	22515	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 verteb	01/01/2015	10/31/2019		
Medicare	22526	Percutaneous Intradiscal Electrothermal Annuloplasty, Unilateral or Bilateral including Fluoroscopic Guidance; Sgl Level	01/01/2007	06/30/2016		Back: Intradiscal Procedures for Low Back Pain (Company); Back: Intradiscal Procedures for Low Back Pain (Medicare)
Medicare	22527	Percutaneous Intradiscal Electrothermal Annuloplasty, Unilateral or Bilateral; One or More Additional Levels	09/01/2003	06/30/2016		Back: Intradiscal Procedures for Low Back Pain (Company); Back: Intradiscal Procedures for Low Back Pain (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22532	Arthrodesis, Lateral Extracavitary Technique, Including Minimal Diskectomy To Prepare Interspace; Thoracic	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22533	Arthrodesis, lateral extracavitary technique, including minimal discectomy to prepare interspace (other than for decompression); lumbar	10/01/2009			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22534	Arthrodesis, Lateral Extracavitary Technique, Including Minimal Diskectomy; Thoracic or Lumbar, Each Additional Segment	04/01/2007			Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22548	Arthrodes, Txs/Extraoral, Clivus-C1-2	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22551	Arthrodesis, Anterior Interbody; Cervical Below C2	01/01/2011			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 83/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	22552	Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below C2, each add	01/01/2011			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22554	Arthrodesis Ant Interbody-C2 Below	09/01/2003			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22556	Arthrodesis Ant Interbody-Thoracic	09/01/2003			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22558	Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); lumbar	09/01/2003			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22585	Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); each additional interspace (List separately in addition to code for primary procedure)	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22586	Arthrodesis, pre-sacral interbody technique, including disc space preparation, discectomy, with posterior instrumentation, with image guidance, includes bone graft when performed, L5-S1 interspace	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22595	Arthrodesis, Poster. Tech, Atlas-Axis, C1-C2	01/01/2007	12/31/2020		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	22610	Arthrodesis Post-Thoracic	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 84/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	22612	Arthrodesis, posterior or posterolateral technique, single level; lumbar (with lateral transverse technique, when performed)	09/01/2003			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22614	Arthrodesis, posterior or posterolateral technique, single level; each additional vertebral segment (List separately in addition to code for primary procedure)	05/01/2012			Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22630	Arthrodesis, posterior interbody technique, including laminectomy and/or discectomy to prepare interspace (other than for decompression), single interspace; lumbar	09/01/2003			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22632	Arthrodesis, posterior interbody technique, including laminectomy and/or discectomy to prepare interspace (other than for decompression), single interspace; each additional interspace (List separately in addition to code for primary procedure)	09/01/2003			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22633	Arthrodesis, combined posterior or posterolateral technique with posterior interbody technique including laminectomy and/or discectomy sufficient to prepare interspace (other than for decompression), single interspace and segment; lumbar	01/01/2012			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	22634	Arthrodesis, combined posterior or posterolateral technique with posterior interbody technique including laminectomy and/or discectomy sufficient to prepare interspace (other than for decompression), single interspace and segment; each additional interspace and segment (List separately in addition to code for primary procedure)	01/01/2012			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22800	Arthrodesis, posterior, for spinal deformity, with or without cast; up to 6 vertebral segments	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22802	Arthrodesis, posterior, for spinal deformity, with or without cast; 7 to 12 vertebral segments	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22804	Arthrodesis, posterior, for spinal deformity, with or without cast; 13 or more vertebral segments	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22808	Arthrodesis, anterior, for spinal deformity, with or without cast; 2 to 3 vertebral segments	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22810	Arthrodesis, anterior, for spinal deformity, with or without cast; 4 to 7 vertebral segments	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22812	Arthrodesis, anterior, for spinal deformity, with or without cast; 8 or more vertebral segments	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22818	Kyphectomy, circumferential exposure of spine and resection of vertebral segment(s) (including body and posterior elements); single or 2 segments	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	22819	Kyphectomy, circumferential exposure of spine and resection of vertebral segment(s) (including body and posterior elements); 3 or more segments	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22840	Posterior non-segmental instrumentation (eg, Harrington rod technique, pedicle fixation across 1 interspace, atlantoaxial transarticular screw fixation, sublaminar wiring at C1, facet screw fixation) (List separately in addition to code for primary procedure)	07/01/2007			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Medicare	22841	Internal Spinal Fixation by Wiring of Spinous Processes	01/01/2007			Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, OHP, PEBB	22841	Internal Spinal Fixation by Wiring of Spinous Processes	01/01/2007	12/31/2022		Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	22842	Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and sublaminar wires); 3 to 6 vertebral segments (List separately in addition to code for primary procedure)	07/01/2006			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22843	Posterior Segmental Instrumentation, 7 To 12 Vertebral Segments	09/01/2003			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	22844	Posterior Segmental Instrumentation, 13 or More Vertebral Segments	09/01/2003			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22845	Anterior instrumentation; 2 to 3 vertebral segments (List separately in addition to code for primary procedure)	01/01/2007			Back: Stabilization Devices and Interspinous Spacers (Company); Back: Stabilization Devices and Interspinous Spacers (Medicare); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22846	Anterior Instrumentation, 4 To 7 Vertebral Segments	01/01/2007			Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22847	Anterior Instrumentation, 8 or More Vertebral Segments	01/01/2007			Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22848	Pelvic fixation (attachment of caudal end of instrumentation to pelvic bony structures) other than sacrum (List separately in addition to code for primary procedure)	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22849	Reinsertion of spinal fixation device	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22851	Application of Intervertebral Biomechanic Device	01/01/2007	12/31/2016		



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	22852	Removal of posterior segmental instrumentation	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22853	Insertion of interbody biomechanical device(s) (eg, synthetic cage, mesh) with integral anterior instrumentation for device anchoring (eg, screws, flanges), when performed, to intervertebral disc space in conjunction with interbody arthrodesis, each interspace (List separately in addition to code for primary procedure)	01/01/2017			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22854	Insertion of intervertebral biomechanical device(s) (eg, synthetic cage, mesh) with integral anterior instrumentation for device anchoring (eg, screws, flanges), when performed, to vertebral corpectomy(ies) (vertebral body resection, partial or complete) defect, in conjunction with interbody arthrodesis, each contiguous defect (List separately in addition to code for primary procedure)	01/01/2017			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22855	Removal of anterior instrumentation	12/01/2019			Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	22856	Total Disc Arthroplasty, Anterior Approach, Including Discectomy with End Plate Preparation, Single Interspace, Cervical	04/01/2009			Artificial Intervertebral Discs (Company); Artificial Intervertebral Discs (Medicare)
Commercial/ASO, OHP, PEBB	22857	Total Disc Arthroplasty (Artificial Disc), Anterior Approach, Including Discectomy, Lumbar, Single Interspace	09/01/2017			Artificial Intervertebral Discs (Company)
Medicare	22857	Total Disc Arthroplasty (Artificial Disc), Anterior Approach, Including Discectomy, Lumbar, Single Interspace	07/01/2020			Artificial Intervertebral Discs (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	22858	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompres	09/01/2017			Artificial Intervertebral Discs (Company); Artificial Intervertebral Discs (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22859	Insertion of intervertebral biomechanical device(s) (eg, synthetic cage, mesh, methylmethacrylate) to intervertebral disc space or vertebral body defect without interbody arthrodesis, each contiguous defect (List separately in addition to code for primary procedure)	01/01/2017			Back: Lumbar Spine Surgery Archived 12/1/19; Back: Stabilization Devices and Interspinous Spacers (Company); Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	22861	Revision Including Replacement of Total Disc Arthroplasty (Artificial Disc), Anterior Approach, Single Interspace; Cerv	04/01/2009			Artificial Intervertebral Discs (Company); Artificial Intervertebral Discs (Medicare)
Commercial/ASO, OHP, PEBB	22862	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; lumbar	09/01/2017			Artificial Intervertebral Discs (Company)
Medicare	22862	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; lumbar	07/01/2020			Artificial Intervertebral Discs (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22864	Removal of Total Disc Arthroplasty (Artificial Disc), Anterior Approach, Single Interspace; Cervical	04/01/2009			Artificial Intervertebral Discs (Company); Artificial Intervertebral Discs (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	22865	Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace; lumbar	09/01/2017			Artificial Intervertebral Discs (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	27130	Arthroplasty, acetabular and proximal femoral prosthetic replacement (total hip arthroplasty), with or without autograft or allograft	01/01/2018			Hip: Total Joint Arthroplasty (Company); Hip: Total Joint Arthroplasty (Medicare); Surgical Site of Service (Company); Surgical Site of Service (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	27132	Conversion of previous hip surgery to total hip arthroplasty, with or without autograft or allograft	01/01/2018			Hip: Total Joint Arthroplasty (Company); Hip: Total Joint Arthroplasty (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	27134	Revision of total hip arthroplasty; both components, with or without autograft or allograft	01/01/2018			Hip: Total Joint Arthroplasty (Company); Hip: Total Joint Arthroplasty (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	27137	Revision of total hip arthroplasty; acetabular component only, with or without autograft or allograft	01/01/2018			Hip: Total Joint Arthroplasty (Company); Hip: Total Joint Arthroplasty (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	27138	Revision of total hip arthroplasty; femoral component only, with or without allograft	01/01/2018			Hip: Total Joint Arthroplasty (Company); Hip: Total Joint Arthroplasty (Medicare)
Medicare	27279	Arthrodesis, sacroiliac joint, percutaneous or minimally invasive (indirect visualization), with image guidance, includes obtaining bone graft when performed, and placement of	01/01/2015			Sacroiliac Joint Fusion or Stabilization (Medicare)
Commercial/ASO, OHP, PEBB	27279	Arthrodesis, sacroiliac joint, percutaneous or minimally invasive (indirect visualization), with image guidance, includes obtaining bone graft when performed, and placement of transfixing device	12/01/2019			Sacroiliac Joint Fusion or Stabilization (Company)
Commercial/ASO, Medicare, OHP, PEBB	27280	Arthrodesis, open, sacroiliac joint, including obtaining bone graft, including instrumentation, when performed	10/01/2014			Sacroiliac Joint Fusion or Stabilization (Company); Sacroiliac Joint Fusion or Stabilization (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	27332	Arthrotomy, with excision of semilunar cartilage (meniscectomy) knee; medial OR lateral	01/01/2016	03/31/2019		Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company)
Commercial/ASO, OHP	27333	Exc Semilunar Cartilage Med + Lat	01/01/2012	03/31/2019		Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	27333	Exc Semilunar Cartilage Med + Lat	01/01/2016	03/31/2019		Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company)
Commercial/ASO, Medicare, OHP, PEBB	27412	Autologous Chondrocyte Implantation, Knee	09/01/2010			Autologous Chondrocyte Implantation (ACI); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Medicare); Balloon Dilation of the Sinuses or Eustachian Tubes (Medicare); Knee: Cartilagenous Defects of the knee
Commercial/ASO, Medicare, OHP, PEBB	27415	Rep Ligaments Knee+pes Anserin Tran	09/01/2010			Autologous Chondrocyte Implantation (ACI); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Medicare); Balloon Dilation of the Sinuses or Eustachian Tubes (Medicare); Knee: Cartilagenous Defects of the knee; Osteochondral Allografts and Autografts for Cartilaginous Defects (Company); Osteochondral Allografts and Autografts for Cartilaginous Defects (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	27416	Osteochondral autograft(s), knee, open (eg, mosaicplasty) (includes harvesting of autograft[s])Advancement Pes Anserinus	09/01/2010			Autologous Chondrocyte Implantation (ACI); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Medicare); Balloon Dilation of the Sinuses or Eustachian Tubes (Medicare); Knee: Cartilagenous Defects of the knee; Osteochondral Allografts and Autografts for Cartilaginous Defects (Company); Osteochondral Allografts and Autografts for Cartilaginous Defects (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 92/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	27445	Arthroplasty, knee, hinge prosthesis (eg, Walldius type)	01/01/2018		Commercial/ASO,OHP,PEBB - Effective 7/1/2020 This code only requires a prior authorization when done in an inpatient setting.	Knee: Total Joint Arthroplasty (All Lines of Business Except Medicare) ARCHIVED 5/1/2020; Knee: Total Joint Arthroplasty (Medicare only) ARCHIVED 5/1/2020; Surgical Site of Service (Company)
Medicare	27445	Arthroplasty, knee, hinge prosthesis (eg, Walldius type)	01/01/2018	12/31/2021	Commercial/ASO,Medicare,OHP,PEBB - Effective 7/1/2020 This code only requires a prior authorization when done in an inpatient setting.	Surgical Site of Service (Company)
Commercial/ASO, Medicare, OHP, PEBB	27446	Arthroplasty, knee, condyle and plateau; medial OR lateral compartment	01/01/2023		This code only requires PA when billed with facility code 21 (inpatient hospital)	Surgical Site of Service (Company); Surgical Site of Service (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	27447	Arthroplasty, knee, condyle and plateau; medial AND lateral compartments with or without patella resurfacing (total knee arthroplasty)	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Effective 7/1/2020 This code only requires a prior authorization when done in an inpatient setting.	Surgical Site of Service (Company); Surgical Site of Service (Medicare)
Medicare	27486	Revision of total knee arthroplasty, with or withor without allograft; 1 component	01/01/2018	12/31/2021		Surgical Site of Service (Company)
Commercial/ASO, OHP, PEBB	27486	Revision of total knee arthroplasty, with or without allograft; 1 component	01/01/2018	03/31/2022		Surgical Site of Service (Company)
Medicare	27487	Revision of total knee arthroplasty, with or without allograft; femoral and entire tibial component	01/01/2018	12/31/2021		Surgical Site of Service (Company)
Commercial/ASO, OHP, PEBB	27487	Revision of total knee arthroplasty, with or without allograft; femoral and entire tibial component	01/01/2018	03/31/2022		Surgical Site of Service (Company)
Commercial/ASO, Medicare, OHP, PEBB	27702	Arthroplasty,Ankle; with Implant (Total	04/01/2007	02/28/2017		Ankle Joint Replacement
Commercial/ASO, Medicare, OHP, PEBB	27703	Arthroplasty Ankle Second Reconstr	04/01/2007	02/28/2017		Ankle Joint Replacement

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 93/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	27704	Removal of Ankle Implant	04/01/2007	02/28/2017		Ankle Joint Replacement
Commercial/ASO, Medicare, OHP, PEBB	28291	Hallux rigidus correction with cheilectomy, debridement and capsular release of the first metatarsophalangeal joint; with implant	01/01/2017	02/28/2017		Definition: Experimental/Investigational
Commercial/ASO, Medicare, OHP, PEBB	29850	Arthroscopically aided treatment of intercondylar spine and/or tuberosity fracture(s) of the knee, with or without manipulation; without internal or external fixation (includes arthroscopy)	10/01/2015	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29851	Arthroscopically aided treatment of intercondylar spine and/or tuberosity fracture(s) of the knee, with or without manipulation; with internal or external fixation (includes arthroscopy)	10/01/2015	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29855	Arthroscopically aided treatment of tibial plateau fracture	01/01/2012	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29856	Arthscp Tx Tib Fx Bicondy W/Wo Fix	01/01/2012	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29861	Arthroscopy, Hip, Surgical; With Removal Of Loose Body Or Foreign Body	12/01/2012	05/31/2016		Hip Arthroscopy Policy archived 3/1/2020
Commercial/ASO, Medicare, OHP, PEBB	29862	Arthroscopy, Hip, Surg; W Chondroplsty, Arthroplsty, &/ Labrum Resectn	12/01/2012	05/31/2016		Hip Arthroscopy Policy archived 3/1/2020
Commercial/ASO, Medicare, OHP, PEBB	29863	Arthroscopy, Hip, Surgical; With Synovectomy	12/01/2012	05/31/2016		Hip Arthroscopy Policy archived 3/1/2020



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	29866	Arthroscopy, Knee, Surgical; Osteochondral Autograft(S) (Eg, Mosaicplasty) (Includes Harvesting Of The Autograft)	09/01/2010			Autologous Chondrocyte Implantation (ACI); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Medicare); Balloon Dilation of the Sinuses or Eustachian Tubes (Medicare); Knee: Cartilagenous Defects of the knee; Osteochondral Allografts and Autografts for Cartilaginous Defects (Company); Osteochondral Allografts and Autografts for Cartilaginous Defects (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	29867	Arthroscopy, Knee, Surgical; Osteochondral Allograft (Eg, Mosaicplasty)	09/01/2010			Autologous Chondrocyte Implantation (ACI); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Medicare); Balloon Dilation of the Sinuses or Eustachian Tubes (Medicare); Knee: Cartilagenous Defects of the knee; Osteochondral Allografts and Autografts for Cartilaginous Defects (Company); Osteochondral Allografts and Autografts for Cartilaginous Defects (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	29868	Arthroscopy, Knee, Surgical; Meniscal Transplantation (Includes Arthrotomy For Meniscal Insertion), Medial Or Lateral	07/01/2010	03/31/2019		Autologous Chondrocyte Implantation (ACI); Knee: Cartilagenous Defects of the knee; Meniscal Allograft Transplant and Other Meniscal Implants (Company); Osteochondral Allografts and Autografts for Cartilaginous Defects (Company)
Commercial/ASO, Medicare, OHP, PEBB	29870	Arthroscopy,Knee,Dx,W/Wo Syn.Bx	01/01/2012	08/31/2016		Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	29871	Arthroscopy,Knee,Surg;for Infection,Lava	01/01/2012	08/31/2016		Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company)
Commercial/ASO, Medicare, OHP, PEBB	29873	Arthroscopy, Knee, Surgical; with Lateral Release	01/01/2012	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29874	Arthroscopy, knee surgical for removal of loose body or foreign body	01/01/2012	08/31/2016		Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company)
Commercial/ASO, Medicare, OHP, PEBB	29875	Arthroscopy, knee surgical with synovectomy, limited	01/01/2012	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29876	Arthroscopy, knee surgical with synovectomy, major	01/01/2012	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29877	Arthroscopy, knee surgical with debridement/shaving of articular cartilage (chondroplasty)	01/01/2012	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29879	Arthroscopy Knee	01/01/2012	03/31/2019		Autologous Chondrocyte Implantation (ACI); Osteochondral Allografts and Autografts for Cartilaginous Defects (Company)
Commercial/ASO, Medicare, OHP, PEBB	29881	Arthroscop Knee W Partial Meniscect	01/01/2012	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29883	Arthroscop Knee W Tot Meniscus Rep	01/01/2012	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29884	Arthroscopy, knee surgical with meniscectomy (medial AND lateral) with lysis of adhesions, with or without manipulation (separate procedure)	10/01/2015	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29885	Arthroscop Knee W Drilling + Graft	01/01/2012	08/31/2016		



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	29886	Arthrosc,Knee,Surg;drill-Intact Ost.Diss	01/01/2012	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29887	Arthroscop Knee W Drilling+int Fix	01/01/2012	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29888	Arthroscopically Aided Anter, Cruciate Li	01/01/2012	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29889	Arthroscop Knee W Post Lig Rep	01/01/2012	08/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	29892	Arthroscopically aided repair of large osteochondritis dissecans lesion, talar dome fracture, or tibial plafond fracture, with or without internal fixation (includes arthroscopy)	01/01/2023			Osteochondral Allografts and Autografts for Cartilaginous Defects (Company); Osteochondral Allografts and Autografts for Cartilaginous Defects (Medicare)
Commercial/ASO, OHP, PEBB	30400	Rhinoplasty Primary Partial	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Rhinoplasty and Other Nasal Surgeries (Company)
Medicare	30400	Rhinoplasty Primary Partial	07/01/2020		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Gender Affirming Surgical Interventions (Medicare); Rhinoplasty and Other Nasal Surgeries (Medicare)
Commercial/ASO, OHP, PEBB	30410	Rhinoplas, Prim; complet, Extern. Parts	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Rhinoplasty and Other Nasal Surgeries (Company)
Medicare	30410	Rhinoplas, Prim; complet, Extern. Parts	07/01/2020		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Gender Affirming Surgical Interventions (Medicare); Rhinoplasty and Other Nasal Surgeries (Medicare)
Commercial/ASO, OHP, PEBB	30420	Rhinoplasty Primary Maj Septal Rep	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Rhinoplasty and Other Nasal Surgeries (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	30420	Rhinoplasty Primary Maj Septal Rep	07/01/2020		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Gender Affirming Surgical Interventions (Medicare); Rhinoplasty and Other Nasal Surgeries (Medicare)
Commercial/ASO, OHP, PEBB	30430	Rhinoplasty,2ndary;minor Revision	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Rhinoplasty and Other Nasal Surgeries (Company)
Medicare	30430	Rhinoplasty,2ndary;minor Revision	07/01/2020		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Gender Affirming Surgical Interventions (Medicare); Rhinoplasty and Other Nasal Surgeries (Medicare)
Commercial/ASO, OHP, PEBB	30435	Rhinoplasty,Intermed Revis-Bony Work W O	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Rhinoplasty and Other Nasal Surgeries (Company)
Medicare	30435	Rhinoplasty,Intermed Revis-Bony Work W O	07/01/2020		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Gender Affirming Surgical Interventions (Medicare); Rhinoplasty and Other Nasal Surgeries (Medicare)
Commercial/ASO, OHP, PEBB	30450	Rhinoplasty, secondary; major revision (nasal tip work and osteotomies)	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Rhinoplasty and Other Nasal Surgeries (Company)
Medicare	30450	Rhinoplasty, secondary; major revision (nasal tip work and osteotomies)	07/01/2020		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Gender Affirming Surgical Interventions (Medicare); Rhinoplasty and Other Nasal Surgeries (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	30460	Rhinoplsty For Deform Tip Only	09/01/2003	10/31/2019		Rhinoplasty and Other Nasal Surgeries (Company); Rhinoplasty and Other Nasal Surgeries (Medicare)
Medicare	30460	Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip only	07/01/2020			Rhinoplasty and Other Nasal Surgeries (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	30462	Rhinoplsty For Deform Tip/Sept/Oste	09/01/2003	10/31/2019		Rhinoplasty and Other Nasal Surgeries (Company); Rhinoplasty and Other Nasal Surgeries (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 98/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	30462	Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip, septum, osteotomies	07/01/2020			Rhinoplasty and Other Nasal Surgeries (Medicare)
Medicare	30801	Ablation, soft tissue of inferior turbinates, unilateral or bilateral, any method (eg, electrocautery, radiofrequency ablation, or tissue volume reduction); superficial	12/01/2020	11/30/2022		Sleep Disorder Surgery (Medicare)
Medicare	30802	Ablation, soft tissue of inferior turbinates, unilateral or bilateral, any method (eg, electrocautery, radiofrequency ablation, or tissue volume reduction); intramural (ie, submucosal)	12/01/2019	11/30/2022		Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	31295	Nasal/sinus endoscopy, surgical; with dilation of maxillary sinus ostium (e.g. balloon dilation), transnasal or via canine fossa	12/01/2015			Balloon Dilation of the Sinuses or Eustachian Tubes; Balloon Dilation of the Sinuses or Eustachian Tubes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	31296	Nasal/sinus endoscopy, surgical; with dilation of frontal sinus ostium (e.g. balloon dilation)	12/01/2015			Balloon Dilation of the Sinuses or Eustachian Tubes; Balloon Dilation of the Sinuses or Eustachian Tubes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	31297	Nasal/sinus endoscopy, surgical; with dilation of sphenoid sinus ostium (e.g. Balloon dilation)	12/01/2015			Balloon Dilation of the Sinuses or Eustachian Tubes; Balloon Dilation of the Sinuses or Eustachian Tubes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	31298	Nasal/sinus endoscopy, surgical; with dilation of frontal and sphenoid sinus ostia (eg, balloon dilation)	01/01/2018			Balloon Dilation of the Sinuses or Eustachian Tubes; Balloon Dilation of the Sinuses or Eustachian Tubes (Medicare)
Commercial/ASO, Medicare, PEBB	31513	Laryngoscopy, indirect; with vocal cord injection	09/01/2019			Neuromuscular Drugs: Botulinum Toxin
Commercial/ASO, Medicare, PEBB	31570	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic	09/01/2019			Botulinum Therapies (Company); Botulinum Therapies (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	31641	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with destruction of tumor or relief of stenosis by any method other than excision (eg, laser therapy, cryotherapy)	04/01/2023			Radiofrequency Ablation for Tumors Outside the Liver (Company); Radiofrequency Ablation of Tumors Outside the Liver (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	32664	Thoracoscopy, Surgical; with Thoracic Sympathectomy	09/01/2003	02/28/2017		Hyperhidrosis Surgical Treatment Iontophoresis
Commercial/ASO, Medicare, OHP, PEBB	32850	Donor Pneumonectomy(ies) W Prep and Maintenance of Allograft (Cadaver)	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	32851	Lung Transplant, Single; Without Cardiopulmonary Bypass	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	32852	Lung Transplant, Single, with Cardiopulmonary Bypass	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	32853	Lung Transplant, Double (Sequential or En Bloc); Without Cardpulm Bypa	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	32854	Lung Transplant, Double (Sequential or En Bloc); with CardPulm Bypass	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 100/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	32855	Backbench Standard Preparation Of Cadaver Donor Lung Allograft; Unilateral	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	32856	Backbench Standard Preparation Of Cadaver Donor Lung Allograft; Bilateral	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	32998	Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; radiofrequency	04/01/2023			Radiofrequency Ablation for Tumors Outside the Liver (Company); Radiofrequency Ablation of Tumors Outside the Liver (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	33270	Insertion or replacement of permanent subcutaneous implantable defibrillator system, with subcutaneous electrode, including defibrillation threshold evaluation, induction of a	01/01/2015	01/01/2015		Automatic External Defibrillators (AED) (archived 6/1/2021)
Commercial/ASO, Medicare, OHP, PEBB	33271	Insertion of subcutaneous implantable defibrillator electrode	01/01/2015	01/01/2015		Automatic External Defibrillators (AED) (archived 6/1/2021)
Commercial/ASO, Medicare, OHP, PEBB	33272	Removal of subcutaneous implantable defibrillator electrode	01/01/2015	01/01/2015		Automatic External Defibrillators (AED) (archived 6/1/2021)
Commercial/ASO, Medicare, OHP, PEBB	33273	Repositioning of previously implanted subcutaneous implantable defibrillator electrode	01/01/2015	01/01/2015		Automatic External Defibrillators (AED) (archived 6/1/2021)
Commercial/ASO, Medicare, OHP, PEBB	33282	Implantation of patient-activated cardiac event recorder	10/01/2014	12/31/2018		Cardiac: Implantable Loop Recorders (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 101/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	33285	Insertion, subcutaneous cardiac rhythm monitor, including programming	01/01/2019			Cardiac: Implantable Loop Recorders (Company); Cardiac: Implantable Loop Recorders (Medicare)
Commercial/ASO, OHP, PEBB	33340	Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation	08/01/2018			Cardiac: Left Atrial Appendage Devices (Company)
Medicare	33340	Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation	01/01/2017	07/31/2018		Cardiac: Left Atrial Appendage Devices (Medicare)
Medicare	33361	Transcatheter Aortic Valve Replacement (TAVR/TAVI) With Prosthetic Valve; Percutaneous Femoral Artery Approach	01/01/2013	11/30/2015		Cardiac: Transcatheter Aortic Valve Replacement (Company)
Commercial/ASO, Medicare, OHP, PEBB	33362	Transcatheter Aortic Valve Replacement (TAVR/TAVI) With Prosthetic Valve; Open Femoral Artery Approach	01/01/2013	11/30/2015		Cardiac: Transcatheter Aortic Valve Replacement (Company)
Commercial/ASO, Medicare, OHP, PEBB	33363	Transcatheter Aortic Valve Replacement (TAVR/TAVI) With Prosthetic Valve; Open Axillary Artery Approach	01/01/2013	11/30/2015		Cardiac: Transcatheter Aortic Valve Replacement (Company)
Commercial/ASO, Medicare, OHP, PEBB	33364	Transcatheter Aortic Valve Replacement (TAVR/TAVI) With Prosthetic Valve; Open Iliac Artery Approach	01/01/2013	11/30/2015		Cardiac: Transcatheter Aortic Valve Replacement (Company)
Commercial/ASO, Medicare, OHP, PEBB	33365	Transcatheter Aortic Valve Replacement (TAVR/TAVI) With Prosthetic Valve; Transaortic Approach	01/01/2013	11/30/2015		Cardiac: Transcatheter Aortic Valve Replacement (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 102/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	33366	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; transapical exposure (eg, left thoracotomy)	01/01/2014	11/30/2015		Cardiac: Transcatheter Aortic Valve Replacement (Company)
Commercial/ASO, Medicare, OHP, PEBB	33927	Implantation of a total replacement heart system (artificial heart) with recipient cardiectomy	01/01/2018	04/30/2022		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33928	Removal and replacement of total replacement heart system (artificial heart)	01/01/2018	04/30/2022		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33929	Removal of a total replacement heart system (artificial heart) for heart transplantation (List separately in addition to code for primary procedure)	01/01/2018	04/30/2022		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022; Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	33930	Donr Cardiectmy-Pneum,Prep/Main.Hom	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	33933	Backbench Standard Preparation Of Cadaver Donor Heart/Lung Allograft	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	33935	Heart-Lung Transplant W Recipient Cardi/	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	33940	Donor Cardiectomy, Prep/Mainten. Homo	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant	Organ Transplantation (Company); Organ Transplantation (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 103/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
					facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	
Commercial/ASO, Medicare, OHP, PEBB	33944	Backbench Standard Preparation Of Cadaver Donor Heart Allograft	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	33945	Heart Transplant, W/Wo Recipient Cardiec	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	33975	Implantation of Ventricular Assist Device; Single Ventricle Support	09/01/2003	04/30/2022		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33977	Removal of Ventricular Assist Device; Single Ventricle Support	09/01/2003	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33978	Removal of Ventricular Assist Device; Biventricular Support	09/01/2003	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33979	Insertion Of Ventricular Assist Device, Implantable Intracorporeal, Single Ventricle	09/01/2003	04/30/2022		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33980	Removal Of Ventricular Assist Device, Implantable Intrcorporeal, Single Ventricle	09/01/2003	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33981	Replacement of Extracorporeal Ventricular Assist Device, Single or Biventricular, Pump(s), Single or Each Pump	01/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 104/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	33982	Replacement of Ventricular Assist Device Pump(s); Implantable Intracorporeal, Single Ventricl,w/o Cardiopulmonary Bypass	01/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33983	Replacement of Ventricular Assist Device Pump(s); Implantable Intracorporeal, Single Ventricle, W Cardiopulmonary Bypass	01/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33990	Insertion Of Ventricular Assist Device, Percutaneous; Arterial Access Only	01/01/2013	04/30/2022		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33991	Insertion Of Ventricular Assist Device, Percutaneous; Both Arterial And Venous Access, With Transseptal Puncture	01/01/2013	04/30/2022		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33992	Removal Of Percutaneous Ventricular Assist Device At Separate And Distinct Session From Insertion	01/01/2013	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33993	Repositioning Of Percutaneous Ventricular Assist Device With Imaging Guidance At Separate Session From Insertion	01/01/2013	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33995	Insertion of ventricular assist device, percutaneous, including radiological supervision and interpretation; right heart, venous access only	01/01/2021	04/30/2022		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	33997	Removal of percutaneous right heart ventricular assist device, venous cannula, at separate and distinct session from insertion	01/01/2021	04/30/2022		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	34841	Endovascular repair of visceral aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) by deployment of a fenestrate	10/01/2014	05/31/2017		Fenestrated Endovascular Repair



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	34842	Endovascular repair of visceral aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) by deployment of a fenestrate	10/01/2014	05/31/2017		Fenestrated Endovascular Repair
Commercial/ASO, Medicare, OHP, PEBB	34843	Endovascular repair of visceral aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) by deployment of a fenestrate	10/01/2014	05/31/2017		Fenestrated Endovascular Repair
Commercial/ASO, Medicare, OHP, PEBB	34844	Endovascular repair of visceral aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) by deployment of a fenestrate	10/01/2014	05/31/2017		Fenestrated Endovascular Repair
Commercial/ASO, Medicare, OHP, PEBB	34845	Endovascular repair of visceral aorta and infrarenal abdominal aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption	10/01/2014	05/31/2017		Fenestrated Endovascular Repair
Commercial/ASO, Medicare, OHP, PEBB	34848	Endovascular repair of visceral aorta and infrarenal abdominal aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption	10/01/2014	05/31/2017		Fenestrated Endovascular Repair
Commercial/ASO, Medicare, OHP, PEBB	36215	Intro Cath Head/Neck Artery	01/01/2013			Blood Brain Barrier Disruption and Bypass (Company); Blood Brain Barrier Disruption and Bypass (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36216	Select Cath Plcmt Art; 2nd Order Thoraci	01/01/2013			Blood Brain Barrier Disruption and Bypass (Company); Blood Brain Barrier Disruption and Bypass (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 106/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	36217	Select Cath Plcmt Art;3rd Ord Thrc	01/01/2013			Blood Brain Barrier Disruption and Bypass (Company); Blood Brain Barrier Disruption and Bypass (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36218	Select Cath Plcmt Art; Add 2nd/3rd Order	01/01/2013			Blood Brain Barrier Disruption and Bypass (Company); Blood Brain Barrier Disruption and Bypass (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36465	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; single incompetent extremity truncal vein (eg, great saphenous vein, accessory saphenous vein)	01/01/2018			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36466	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; multiple incompetent truncal veins (eg, great saphenous vein, accessory saphenous vein), same leg	01/01/2018			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP	36468	Single or multiple injections of sclerosing solutions, spider veins (telangiectasia), limb or trunk	10/01/2014	12/31/2017		Varicose Veins (Company); Varicose Veins (PEBB Only)
Commercial/ASO, Medicare, OHP, PEBB	36469	1+injec-Scler.Sol,Spider Veins;face	10/01/2014	12/31/2015		Varicose Veins (Company); Varicose Veins (PEBB Only)
Commercial/ASO, Medicare, OHP, PEBB	36470	Injection of sclerosing solution; single vein	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36471	Inject Sclerosing Agent Mult Veins	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Medicare	36473	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging	01/01/2018			Varicose Veins (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 107/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		guidance and monitoring, percutaneous, mechanochemical; first vein treated				
Medicare	36474	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)	01/01/2018			Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36475	Endovenous Ablation Therapy Of Incompetent Vein, Extremity, Percutaneous, Radiofrequency; First Vein Treated	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36476	Endovenous Ablation Therapy Incompetent Vein, Extremity, Percut, Radiofreq; 2nd & Subsequent Veins,Same Extrem,Sep Sites	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36478	Endovenous Ablation Therapy Of Incompetent Vein, Extremity, Percutaneous, Laser; First Vein Treated	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36479	Endovenous Ablation Therapy Incompetent Vein, Extremity, Percutaneous, Laser; 2nd & Subseq Veins, Same Extrem, Sep Sites	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Medicare	36482	Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; first vein treated	01/01/2018			Varicose Veins (Medicare)
Medicare	36483	Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous;	01/01/2018			Varicose Veins (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 108/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)				
Commercial/ASO, Medicare, OHP, PEBB	36511	Therapeutic apheresis; for white blood cells	11/01/2022		Commercial/ASO,Medicare,OHP,PEBB - This code will pay if billed with location code 21	Apheresis (Therapeutic Pheresis) (Company); Apheresis (Therapeutic Pheresis) (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36512	Therapeutic apheresis; for red blood cells	11/01/2022		Commercial/ASO,Medicare,OHP,PEBB - This code will pay if billed with location code 21	Apheresis (Therapeutic Pheresis) (Company); Apheresis (Therapeutic Pheresis) (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36513	Therapeutic apheresis; for platelets	11/01/2022		Commercial/ASO,Medicare,OHP,PEBB - This code will pay if billed with location code 21	Apheresis (Therapeutic Pheresis) (Company); Apheresis (Therapeutic Pheresis) (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36514	Therapeutic apheresis; for plasma pheresis	10/01/2021	10/31/2022		Apheresis (Therapeutic Pheresis) (Company); Apheresis (Therapeutic Pheresis) (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36514	Therapeutic apheresis; for plasma pheresis	11/01/2022		Commercial/ASO,Medicare,OHP,PEBB - This code will pay if billed with location code 21	Apheresis (Therapeutic Pheresis) (Company); Apheresis (Therapeutic Pheresis) (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36516	Therapeutic apheresis; with extracorporeal immunoadsorption, selective adsorption or selective filtration and plasma reinfusion	10/01/2021	10/31/2022		Apheresis (Therapeutic Pheresis) (Company); Apheresis (Therapeutic Pheresis) (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36516	Therapeutic apheresis; with extracorporeal immunoadsorption, selective adsorption or selective filtration and plasma reinfusion	11/01/2022		Commercial/ASO,Medicare,OHP,PEBB - This code will pay if billed with location code 21	Apheresis (Therapeutic Pheresis) (Company); Apheresis (Therapeutic Pheresis) (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	36522	Photopheresis, extracorporeal	11/01/2022		Commercial/ASO,Medicare,OHP,PEBB - This code will pay if billed with location code 21	Apheresis (Therapeutic Pheresis) (Company); Apheresis (Therapeutic Pheresis) (Medicare)
Commercial/ASO, Medicare, OHP	37188	Percutaneous transluminal mechanical thrombectomy, vein(s), repeat treatment on subsequent day of thrombolytic therapy	12/01/2012	10/31/2017		Varicose Veins (Company); Varicose Veins (PEBB Only)
Commercial/ASO, Medicare, OHP, PEBB	37202	Transcath Infusion Any Not Thromb	01/01/2013	12/31/2015		
Commercial/ASO, Medicare, OHP, PEBB	37243	Vascular embolization or occlusion, inclusive of all radiological supervision and	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB - This code requires a Prior Authorization when	Liver Tumor Treatment (Company); Liver Tumor Treatment (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 109/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction			billed with one of the codes below: C220 C221 C222 C223 C224 C227 C228 C229 C787 C7B03 D015	
Commercial/ASO, OHP, PEBB	37500	Vascular endoscopy, surgical, with ligation of perforator veins, subfascial (SEPS)	01/01/2018			Varicose Veins (Company)
Medicare	37500	Vascular endoscopy, surgical, with ligation of perforator veins, subfascial (SEPS)	10/01/2020			Varicose Veins (Medicare)
PEBB	37700	Lig/Div.Saph.Vein at Junc/Interrupt	01/01/2013			Varicose Veins (Company)
Commercial/ASO, Medicare, OHP	37700	Lig/Div.Saph.Vein at Junc/Interrupt	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	37718	Ligation, division, and stripping, short saphenous vein	01/01/2013			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	37722	Ligation, division, and stripping, long (greater) saphenous veins from saphenofemoral junction to knee or below	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	37735	Ligation & Strip Saphen+ulcer Unil	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	37760	Ligation Perforators Rad (Linton)	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	37761	Ligation of Perforator Vein(s), Subfascial, Open, Including Ultrasound Guidance, When Performed, 1 Leg	05/01/2012			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	37765	Stab Phlebectomy of Varicose Veins, One Extremity; 10-20 Stab Incisions	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	37766	Stab Phlebectomy of Varicose Veins, One Extremity; More Than 20 Incisions	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 110/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	37780	Ligation and division of short saphenous vein at saphenopopliteal junction (separate procedure)	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	37785	Ligation, division, and/or excision of varicose vein cluster(s), 1 leg	02/01/2006			Varicose Veins (Company); Varicose Veins (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38204	Management of Recipient Hematopoietic Progenitor Cell Donor Search and Cell Acquisition	09/01/2003	03/31/2024		Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38205	Blood-Derived Hematopoietic Progenitor Cell Harvesting for Transplantation, Per Collection; Allogenic	09/01/2003			Stem Cell Therapy for Orthopedic Applications (Company); Stem Cell Therapy for Orthopedic Applications (Medicare); Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38206	Blood-Derived Hematopoietic Progenitor Cell Harvesting for Transplantation, Per Collection; Autologous	09/01/2003			Stem Cell Therapy for Orthopedic Applications (Company); Stem Cell Therapy for Orthopedic Applications (Medicare); Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38207	Transplant Preparation of Hematopoietic Progenitor Cells; Cryopreservation and Storage	09/01/2003			Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38208	Transplant Preparation of Hematopoietic Progenitor Cells; Thawing of Previously Frozen Harvest	09/01/2003			Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38209	Transplant Preparation of Hematopoietic Progenitor Cells; Washing of Harvest	09/01/2003			Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38210	Transplant Preparation of Hematopoietic Progenitor Cells; Specific Cell Depletion Within Harvest, T-Cell Depletion	09/01/2003			Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38211	Transplant Preparation of Hematopoietic Progenitor Cells; Tumor Cell Depletion	09/01/2003			Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 111/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	38212	Transplant Preparation of Hematopoietic Progenitor Cells; Red Blood Cell Removal	09/01/2003			Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38213	Transplant Preparation of Hematopoietic Progenitor Cells; Platelet Depletion	09/01/2003			Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38214	Transplant Preparation of Hematopoietic Progenitor Cells; Plasma (Volume) Depletion	09/01/2003			Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38215	Transplant Preparation of Hematopoietic Progenitor Cells; Cell Concentration in Plasma, Mononuclear, or Buffy Coat Layer	09/01/2003			Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38230	Harvest Bone Marrow For Transplant	09/01/2003			Stem Cell Therapy for Orthopedic Applications (Company); Stem Cell Therapy for Orthopedic Applications (Medicare); Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38232	Bone Marrow Harvesting For Transplantation; Autologous	01/01/2012		Medicare - In-plan only, no opt-out benefit	Stem Cell Therapy for Orthopedic Applications (Company); Stem Cell Therapy for Orthopedic Applications (Medicare); Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38240	Bone Marrow Transplantation; Allogenic	09/01/2003		Medicare - In-plan only, no opt-out benefit	Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38241	Bone Marrow Transplant; Autologous	09/01/2003		Medicare - In-plan only, no opt-out benefit	Stem Cell Therapy for Orthopedic Applications (Company); Stem Cell Therapy for Orthopedic Applications (Medicare); Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	38242	Bone Marrow or Blood-Derived Peripheral Stem Cell Transplantation; Allogeneic Donor Lymphocyte Infusions	09/01/2003		Medicare - In-plan only, no opt-out benefit	Stem Cell Transplantation (Company); Stem Cell Transplantation (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	41120	Glossectomy; less than one-half tongue	02/01/2017	11/30/2019		Sleep Apnea: Surgical Treatments; Sleep Disorder Surgery (Company)
Medicare	41120	Glossectomy; less than one-half tongue	02/01/2017	11/30/2019		Sleep Apnea: Surgical Treatments; Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	41500	Fixation of tongue, mechanical, other than suture (eg, K-wire)	02/01/2017	12/31/2018		Sleep Apnea: Surgical Treatments
Commercial/ASO, OHP, PEBB	41530	Submucosal Ablation of the Tongue Base, Radiofrequency, One or More Sites, Per Session	05/01/2010	11/30/2019		Sleep Disorder Surgery (Company)
Commercial/ASO, Medicare, OHP, PEBB	42120	Resect Palateor Extensive Lesion	04/01/2007			Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Medicare	42140	Uvulectomy	09/01/2003		Medicare - In-plan only, no opt-out benefit	Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, OHP, PEBB	42140	Uvulectomy	09/01/2003	11/30/2022		Sleep Disorder Surgery (Company)
Commercial/ASO, Medicare, OHP, PEBB	42145	Uvuloplatopharyngoplasty	09/01/2003		Medicare - In-plan only, no opt-out benefit	Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, OHP, PEBB	42160	Destruct Lesion Palate/Uvula	09/01/2003	11/30/2019	In-plan only, no opt-out benefit	Sleep Disorder Surgery (Company)
Commercial/ASO, Medicare, OHP, PEBB	42235	Repair Anterior Palate Including Vomer F	09/01/2003			Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	42950	Pharyngoplasty	04/01/2007			Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, OHP, PEBB	42953	Repair Pharyngoesophageal	04/01/2007	11/30/2019		Sleep Disorder Surgery (Company)
Medicare	42953	Repair Pharyngoesophageal	04/01/2007	11/30/2019		Sleep Disorder Surgery (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 113/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	43192	Esophagoscopy, rigid, transoral; with directed submucosal injection(s), any substance	05/01/2018			Endoscopic Treatments for Gastroesophageal Reflux Disease (GERD) (Company); Gastroesophageal Reflux Disease: Endoscopic Treatments (Medicare)
ОНР	43201	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance	05/01/2018	12/31/2018		Endoscopic Treatments for Gastroesophageal Reflux Disease (GERD) (Company); Gastroesophageal Reflux Disease: Endoscopic Treatments (Medicare)
Commercial/ASO, Medicare, PEBB	43201	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance	05/01/2018			Endoscopic Treatments for Gastroesophageal Reflux Disease (GERD) (Company); Gastroesophageal Reflux Disease: Endoscopic Treatments (Medicare)
Medicare	43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed	05/01/2018	03/31/2022		Gastroesophageal Reflux Disease: Endoscopic Treatments (Medicare)
Commercial/ASO, OHP, PEBB	43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed	05/01/2018			Endoscopic Treatments for Gastroesophageal Reflux Disease (GERD) (Company)
ОНР	43236	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance	05/01/2018	12/31/2018		Endoscopic Treatments for Gastroesophageal Reflux Disease (GERD) (Company); Gastroesophageal Reflux Disease: Endoscopic Treatments (Medicare)
Commercial/ASO, Medicare, PEBB	43236	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance	05/01/2018			Endoscopic Treatments for Gastroesophageal Reflux Disease (GERD) (Company); Gastroesophageal Reflux Disease: Endoscopic Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	43327	Esophagogastric Fundoplasty Partial Or Complete; Laparotomy	01/01/2011	05/31/2018		Endoscopic Treatments for Gastroesophageal Reflux Disease (GERD) (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 114/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	43497	Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM])	01/01/2022			Peroral Endoscopic Myotomy (POEM) (Company); Peroral Endoscopic Myotomy (POEM) (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	43631	Gastrectomy, Partial, Distal; with Gastroduodenostomy	01/01/2003			Bariatric Surgery (Company); Bariatric Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	43644	Laparoscopy, Surg, Gastric Restrictive Procedure; W Gastric Bypass And Roux-En-Y Gastroenterostomy (Roux Limb <= 150 Cm)	09/01/2005			Bariatric Surgery (Company); Bariatric Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	43645	Laparoscopy, Surgical, Gastric Restrictive Procedure; With Gastric Bypass And Small Intestine Reconstruction	09/01/2005			Bariatric Surgery (Company); Bariatric Surgery (Intel Connected Care Only) ARCHIVED 1/1/19; Bariatric Surgery (Medicare); Bariatric Surgery (Oregon Health Plan Only) ARCHIVED 1/1/19; Bariatric Surgery (PEBB Members Only) ARCHIVED 1/1/19; Bariatric Surgery (Providence Health & Services Only) ARCHIVED 1/1/19; Bariatric Surgery (SAIF Members Only) ARCHIVED 1/1/19
Commercial/ASO, Medicare, OHP, PEBB	43647	Laparoscopy, Surgical; Implantation or Replacement of Gastric Neurostimulator Electrodes, Antrum	05/01/2010			Electrical Stimulation and Electromagnetic Therapies (Medicare); Gastric Electrical Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	43648	Laparoscopy, Surgical; Revision or Removal of Gastric Neurostimulator Electrodes, Antrum	05/01/2010			Electrical Stimulation and Electromagnetic Therapies (Medicare); Gastric Electrical Stimulation (Company)
Medicare	43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	01/01/2019			Bariatric Surgery (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	43771	Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric band component only	01/01/2006			Bariatric Surgery (Company); Bariatric Surgery (Medicare); Bariatric Surgery (Oregon Health Plan Only) ARCHIVED 1/1/19; Bariatric Surgery (PEBB Members Only) ARCHIVED 1/1/19; Bariatric Surgery (Providence Health & Services Only) ARCHIVED 1/1/19; Bariatric Surgery (SAIF Members Only) ARCHIVED 1/1/19
Commercial/ASO, Medicare, OHP, PEBB	43772	Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric band component only	01/01/2006			Bariatric Surgery (Company); Bariatric Surgery (Intel Connected Care Only) ARCHIVED 1/1/19; Bariatric Surgery (Medicare); Bariatric Surgery (Oregon Health Plan Only) ARCHIVED 1/1/19; Bariatric Surgery (PEBB Members Only) ARCHIVED 1/1/19; Bariatric Surgery (SAIF Members Only) ARCHIVED 1/1/19
Medicare	43773	Laparoscopy, surgical, gastric restrictive procedure; removal and replacement of adjustable gastric restrictive device component only	01/01/2019			Bariatric Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	43774	Laparoscopy, surg, gastric restrictive procedure; removal of adjustable gastric band and subcutaneous port components	01/01/2006			Bariatric Surgery (Company); Bariatric Surgery (Intel Connected Care Only) ARCHIVED 1/1/19; Bariatric Surgery (Medicare); Bariatric Surgery (Oregon Health Plan Only) ARCHIVED 1/1/19; Bariatric Surgery (PEBB Members Only) ARCHIVED 1/1/19; Bariatric Surgery (SAIF Members Only) ARCHIVED 1/1/19



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	43775	Laparoscopy, Surgical, Gastric Restrictive Procedure; Longitudinal Gastrectomy (ie, Sleeve Gastrectomy)	05/01/2012			Bariatric Surgery (Company); Bariatric Surgery (Intel Connected Care Only) ARCHIVED 1/1/19; Bariatric Surgery (Medicare); Bariatric Surgery (Oregon Health Plan Only) ARCHIVED 1/1/19; Bariatric Surgery (PEBB Members Only) ARCHIVED 1/1/19; Bariatric Surgery (Providence Health & Services Only) ARCHIVED 1/1/19; Bariatric Surgery (SAIF Members Only) ARCHIVED 1/1/19
Commercial/ASO, OHP, PEBB	43842	Gastroplsty Vertical-Banded Obesity	09/01/2003	12/31/2018		Bariatric Surgery (Company); Bariatric Surgery (PEBB Members Only) ARCHIVED 1/1/19; Bariatric Surgery (Providence Health & Services Only) ARCHIVED 1/1/19; Bariatric Surgery (SAIF Members Only) ARCHIVED 1/1/19; Bariatric: Revision or Repeat Surgery
Medicare	43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	09/01/2003	02/28/2017		Bariatric Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	43843	Gastroplsty Non Vert-Banded Obesity	09/01/2003			Bariatric Surgery (Company); Bariatric Surgery (Medicare); Bariatric Surgery (PEBB Members Only) ARCHIVED 1/1/19; Bariatric Surgery (Providence Health & Services Only) ARCHIVED 1/1/19; Bariatric Surgery (SAIF Members Only) ARCHIVED 1/1/19
Commercial/ASO, Medicare, OHP, PEBB	43845	Gastric Stapling Morbid Obesity	09/01/2003			Bariatric Surgery (Company); Bariatric Surgery (Medicare); Bariatric Surgery (PEBB Members Only) ARCHIVED 1/1/19; Bariatric Surgery (Providence Health & Services Only) ARCHIVED 1/1/19; Bariatric Surgery (SAIF Members Only) ARCHIVED 1/1/19



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	43846	Gastric Bypass W/Roux-En-Y-Mor.Obes	09/01/2003			Bariatric Surgery (Company); Bariatric Surgery (Intel Connected Care Only) ARCHIVED 1/1/19; Bariatric Surgery (Medicare); Bariatric Surgery (Oregon Health Plan Only) ARCHIVED 1/1/19; Bariatric Surgery (PEBB Members Only) ARCHIVED 1/1/19; Bariatric Surgery (Providence Health & Services Only) ARCHIVED 1/1/19; Bariatric Surgery (SAIF Members Only) ARCHIVED 1/1/19
Commercial/ASO, Medicare, OHP, PEBB	43847	Gstrc Restricve Prcd w Gstrc Byps F Morbid Obesty; w/Sml Bowel Rcnstn	09/01/2003			Bariatric Surgery (Company); Bariatric Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	43848	Revision of Gastrc Restrictive Prcd For Morbid Obesity (Separate Prcd)	09/01/2003			Bariatric Surgery (Company); Bariatric Surgery (Medicare)
Medicare	43850	Rev Gastroduodenostomy Wo Vagotomy	10/01/2009	12/31/2021	Code no longer valid effective 1/1/2022	Bariatric Surgery (Medicare)
Commercial/ASO, OHP, PEBB	43850	Revision of gastroduodenal anastomosis (gastroduodenostomy) with reconstruction; without vagotomy	09/01/2018	12/31/2021	Code no longer valid effective 1/1/2022	
Medicare	43855	Revis.Gastroduo.Anast,Recons;w/Vag	10/01/2009	12/31/2021	Code no longer valid effective 1/1/2022	Bariatric Surgery (Medicare)
Commercial/ASO, OHP, PEBB	43855	Revision of gastroduodenal anastomosis (gastroduodenostomy) with reconstruction; with vagotomy	09/01/2018	12/31/2021	Code no longer valid effective 1/1/2022	Bariatric Surgery (Company)
Medicare	43860	Rev Gastrojejunostomy Wo Vagotomy	10/01/2009			Bariatric Surgery (Medicare)
Commercial/ASO, OHP, PEBB	43860	Revision of gastrojejunal anastomosis (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; without vagotomy	09/01/2018			Bariatric Surgery (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 118/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	43865	Gastrojejunostomy;with Vagotomy	10/01/2009			Bariatric Surgery (Medicare)
Commercial/ASO, OHP, PEBB	43865	Revision of gastrojejunal anastomosis (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; with vagotomy	09/01/2018			Bariatric Surgery (Company)
Commercial/ASO, Medicare, OHP, PEBB	43881	Implantation or Replacement of Gastric Neurostimulator Electrodes, Antrum, Open	05/01/2010			Electrical Stimulation and Electromagnetic Therapies (Medicare); Gastric Electrical Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	43882	Revision or Removal of Gastric Neurostimulator Electrodes, Antrum, Open	05/01/2010			Electrical Stimulation and Electromagnetic Therapies (Medicare); Gastric Electrical Stimulation (Company)
Medicare	43886	Gastric restrictive procedure, open; revision of subcutaneous port component only	09/01/2018			Bariatric Surgery (Medicare)
Commercial/ASO, OHP, PEBB	43886	Gastric restrictive procedure, open; revision of subcutaneous port component only	01/01/2013			Bariatric Surgery (Company)
Medicare	43887	Gastric restrictive procedure, open; removal of subcutaneous port component only	09/01/2018			Bariatric Surgery (Medicare)
Commercial/ASO, OHP, PEBB	43887	Gastric restrictive procedure, open; removal of subcutaneous port component only	01/01/2013			Bariatric Surgery (Company)
Medicare	43888	Gastric restrictive procedure, open; removal and replacement of subcutaneous port component only	09/01/2018			Bariatric Surgery (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	43888	Gastric restrictive procedure, open; removal and replacement of subcutaneous port component only	01/01/2013			Bariatric Surgery (Company); Bariatric Surgery (Intel Connected Care Only) ARCHIVED 1/1/19; Bariatric Surgery (Oregon Health Plan Only) ARCHIVED 1/1/19; Bariatric Surgery (PEBB Members Only) ARCHIVED 1/1/19; Bariatric Surgery (Providence Health & Services Only) ARCHIVED 1/1/19; Bariatric Surgery (SAIF Members Only) ARCHIVED 1/1/19
Commercial/ASO, Medicare, OHP, PEBB	44133	Donor Enterectomy, Open, w Allograft Prep & Maintenance; Living Donor	09/01/2003		Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	44136	Intestinal Allotransplantation; From Living Donor	09/01/2003		Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, PEBB	46505	Chemodenervation of internal anal sphincter	09/01/2019			Botulinum Therapies (Company); Botulinum Therapies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47133	Donor Hepatectomy,W Prep & Maintenance-H	09/01/2003		Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47135	Transplant Liver (Recipient)	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47140	Donor Hepatectomy, with Preparation and Maintenance of Allograft, Living Donor; Left Lateral Segment Only	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	47141	Donor Hepatectomy, with Preparation and Maintenance of Allograft, Living Donor; Total Left Lobectomy	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47142	Donor Hepatectomy, with Preparation and Maintenance of Allograft, Living Donor; Total Right Lobectomy	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47143	Backbench Standard Preparation Of Cadaver Donor Whole Liver Graft; Without Trisegment Or Lobe Split	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47144	Backbench Standard Preparation Of Cadaver Donor Whole Liver Graft; W Trisegment Split Of Graft Into Two Partial Grafts	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47145	Backbench Standard Preparation Of Cadaver Donor Whole Liver Graft; With Lobe Split Of Graft Into Two Partial Grafts	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47146	Backbench Reconstruction Of Cadaver Or Living Donor Liver Graft Prior To Allotransplantation; Venous Anastomosis, Each	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47147	Backbench Reconstruction Of Cadaver Or Living Donor Liver Graft Prior To	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant	Organ Transplantation (Company); Organ Transplantation (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 121/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		Allotransplantation; Arterial Anastomosis, Each			facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	
Commercial/ASO, Medicare, OHP, PEBB	47370	Laparoscopy, Surgical, Ablation Of One Or More Liver Tumor(S); Radiofrequency	09/01/2003			Liver Tumor Treatment (Company); Liver Tumor Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47371	Laparoscopy, Surgical, Ablation Of One Or More Liver Tumor(S); Cryosurgical	09/01/2003			Liver Tumor Treatment (Company); Liver Tumor Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47380	Ablation, Open, Of One Or More Liver Tumor(S); Radiofrequency	09/01/2003			Liver Tumor Treatment (Company); Liver Tumor Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47381	Ablation, Open, Of One Or More Liver Tumor(S); Cryosurgical	09/01/2003			Liver Tumor Treatment (Company); Liver Tumor Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47382	Ablation, One Or More Liver Tumor(S), Percutaneous, Radiofrequency	09/01/2003			Liver Tumor Treatment (Company); Liver Tumor Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	47383	Ablation, 1 or more liver tumor(s), percutaneous, cryoablation	01/01/2015			Liver Tumor Treatment (Company); Liver Tumor Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	48550	Donor Pancreatectomy For Transplantation	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	48551	Backbench Standard Preparation Of Cadaver Donor Pancreas Allograft	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	48552	Backbench Reconstruction Of Cadaver Donor Pancreas Allograft Prior To Transplantation, Venous Anastomosis, Each	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 122/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	48554	Transplantation of Pancreatic Allograft	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	48556	Removal of Transplanted Pancreatic Allograft	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50300	Nephrectomy Cadaver Donor	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50320	Donor Nephrectomy;from Living Donor,Unil	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50323	Backbench Standard Preparation Of Cadaver Donor Renal Allograft	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50325	Backbench Standard Preparation Of Living Donor Renal Allograft (Open Or Laparoscopic)	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50327	Backbench Reconstruction Of Cadaver Or Living Donor Renal Allograft Prior To Transplantation; Venous Anastomosis, Each	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant	Organ Transplantation (Company); Organ Transplantation (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 123/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
					facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	
Commercial/ASO, Medicare, OHP, PEBB	50328	Backbench Reconstruction Of Cadaver Or Living Donor Renal Allograft Prior To Transplantation; Arterial Anastomosis, Each	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50329	Backbench Reconstruction Of Cadaver Or Living Donor Renal Allograft Prior To Transplantation; Ureteral Anastomosis, Each	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50340	Nephrectomy Recipient Unilateral	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50360	Transplant Renal Homograft	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50365	Renal Homotxplnt,Implnt Gft;w/Recipnt Ne	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50370	Removal of Transplanted Homograft	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	50380	Transplant Renal Autograft	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50542	Laparoscopy, surgical; ablation of renal mass lesion(s), including intraoperative ultrasound guidance and monitoring, when performed	04/01/2023			Radiofrequency Ablation for Tumors Outside the Liver (Company); Radiofrequency Ablation of Tumors Outside the Liver (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50547	Laparoscopy, surgical; donor nephrectomy from living donor	09/01/2003		Medicare - In-plan only, no opt-out benefit Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Organ Transplantation (Company); Organ Transplantation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	50592	Ablation, 1 or more renal tumor(s), percutaneous, unilateral, radiofrequency	04/01/2023			Radiofrequency Ablation for Tumors Outside the Liver (Company); Radiofrequency Ablation of Tumors Outside the Liver (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	51715	Endoscopic injection of implant material into the submucosal tissues of the urethra and/or bladder neck	07/01/2019			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
ОНР	52287	Cystourethroscopy, With Injection(s) For Chemodenervation Of The Bladder	01/01/2013	12/31/2018		Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	52287	Cystourethroscopy, With Injection(s) For Chemodenervation Of The Bladder	01/01/2013			Botulinum Therapies (Company)
Commercial/ASO, Medicare, OHP, PEBB	52327	Cystourethroscopy (including ureteral catheterization); with subureteric injection of implant material	07/01/2019			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, OHP, PEBB	52441	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant	07/01/2017			Benign Prostatic Hyperplasia Treatments (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	52441	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant	07/01/2017	01/31/2022		Prostate: Prostatic Urethral Lift ARCHIVED 2/1/2022
Commercial/ASO, OHP, PEBB	52442	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure)	07/01/2017			Benign Prostatic Hyperplasia Treatments (Company)
Medicare	52442	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure)	07/01/2017	01/31/2022		Prostate: Prostatic Urethral Lift ARCHIVED 2/1/2022
Commercial/ASO, Medicare, OHP, PEBB	53430	Urethroplasty, reconstruction of female urethra	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	53444	Insertion of tandem cuff (dual cuff)	07/01/2019			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	53445	Insertion of inflatable urethral/bladder neck sphincter, including placement of pump, reservoir, and cuff	07/01/2019			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	53446	Removal of inflatable urethral/bladder neck sphincter, including pump, reservoir, and cuff	07/01/2019			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	53447	Removal and replacement of inflatable urethral/bladder neck sphincter including pump, reservoir, and cuff at the same operative session	07/01/2019			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	53449	Repair of inflatable urethral/bladder neck sphincter, including pump, reservoir, and cuff	07/01/2019			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	53854	Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy	04/01/2021			Benign Prostatic Hyperplasia Treatments (Company)
Commercial/ASO, OHP, PEBB	53860	Transurethral Radiofrequency Micro- Remodeling Of The Female Bladder Neck And Proximal Urethra	01/01/2013	12/31/2016		Urinary Incontinence Treatments (Company)
Medicare	53860	Transurethral Radiofrequency Micro- Remodeling Of The Female Bladder Neck And Proximal Urethra	01/01/2011	06/30/2019		Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	54120	Amputation of penis; partial	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	54125	Amputation of penis; complete	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	54400	Insertion of penile prosthesis; non-inflatable (semi-rigid)	01/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	54401	Insertion of penile prosthesis; inflatable (self- contained)	01/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	54405	Insertion of multi-component, inflatable penile prosthesis, including placement of pump, cylinders, and reservoir	01/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	54410	Removal and replacement of all component(s) of a multi-component, inflatable penile prosthesis at the same operative session	02/01/2023			Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	54520	Orchiectomy, simple (including subcapsular), with or without testicular prosthesis, scrotal or inguinal approach	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	54660	Insertion of testicular prosthesis (separate procedure)	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	54690	Laparoscopy, surgical; orchiectomy	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	55150	Resection of scrotum	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	55175	Scrotoplasty; simple	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	55180	Scrotoplasty; complicated	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	55706	Biopsies, Prostate, Needle, Transperineal, Stereotactic Template Guided Saturation Sampling, Including Imaging Guidance	11/01/2012	03/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	55873	Cryosurgical Ablation of the Prostate (Incl Ultrasonic Probe Placemnt)	09/01/2003	05/31/2017		Prostate: Cryosurgical Ablation For Prostate Cancer
Commercial/ASO, OHP, PEBB	55880	Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance	10/01/2022			High Intensity Focused Ultrasound (HIFU) (Company) ; New and Emerging Technologies and Other Non-Covered Services (Company)
Commercial/ASO, OHP, PEBB	55970	Intersex Op Male to Female	01/01/2015	12/31/2022		Gender Affirming Surgical Interventions (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 128/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	55970	Intersex surgery; male to female	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, OHP, PEBB	55980	Intersex Surgery;female to Male	01/01/2015	12/31/2022	Commercial/ASO,PEBB -	Gender Affirming Surgical Interventions (Company)
Medicare	55980	Intersex surgery; female to male	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	56625	Vulvectomy simple; complete	01/01/2018	11/30/2018		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	56800	Plastic repair of introitus	01/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	56805	Clitoroplasty for intersex state	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	57106	Vaginectomy, partial removal of vaginal wall	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	57110	Vaginectomy, complete removal of vaginal wall	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	57291	Construction of artificial vagina; without graft	01/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	57292	Construction of artificial vagina; with graft	01/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	57295	Revision (including removal) of prosthetic vaginal graft; vaginal approach	01/01/2018	12/31/2019		

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	57296	Revision (including removal) of prosthetic vaginal graft; open abdominal approach	01/01/2018	12/31/2019		
Commercial/ASO, Medicare, OHP, PEBB	57335	Vaginoplasty for intersex state	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	57426	Revision (including removal) of prosthetic vaginal graft, laparoscopic approach	01/01/2018	12/31/2019		
Commercial/ASO, OHP, PEBB	58150	Total abdominal hysterectomy (corpus and cervix), with or without removal of tube(s), with or without removal of ovary(s)	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58152	Total abdominal hysterectomy (corpus and cervix), with or without removal of tube(s), with or without removal of ovary(s); with colpo-urethrocystopexy (eg, Marshall- Marchetti-Krantz, Burch)	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58180	Supracervical abdominal hysterectomy (subtotal hysterectomy), with or without removal of tube(s), with or without removal of ovary(s)	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58260	Vaginal hysterectomy, for uterus 250 g or less	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58262	Vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s), and/or ovary(s)	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9.	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58263	Vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s), and/or ovary(s), with repair of enterocele	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code	Hysterectomy for Benign Conditions (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 130/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	58267	Vaginal hysterectomy, for uterus 250 g or less; with colpo-urethrocystopexy (Marshall- Marchetti-Krantz type, Pereyra type) with or without endoscopic control	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58270	Vaginal hysterectomy, for uterus 250 g or less; with repair of enterocele	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58275	Vaginal hysterectomy, with total or partial vaginectomy	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58290	Vaginal hysterectomy, for uterus greater than 250 g	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58291	Vaginal hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58292	Vaginal hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s), with repair of enterocele	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58541	Laparoscopy, surgical, supracervical hysterectomy, for uterus 250 g or less	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58542	Laparoscopy, surgical, supracervical hysterectomy, for uterus 250 g or less; with removal of tube(s) and/or ovary(s)	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58543	Laparoscopy, surgical, supracervical hysterectomy, for uterus greater than 250 g	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This	Hysterectomy for Benign Conditions (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 131/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
					code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	
Commercial/ASO, OHP, PEBB	58544	Laparoscopy, surgical, supracervical hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58550	Laparoscopy, surgical, with vaginal hysterectomy, for uterus 250 g or less	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58552	Laparoscopy, surgical, with vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s) and/or ovary(s)	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58553	Laparoscopy, surgical, with vaginal hysterectomy, for uterus greater than 250 g	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58554	Laparoscopy, surgical, with vaginal hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58570	Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58571	Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less; with removal of tube(s) and/or ovary(s)	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	58572	Laparoscopy, surgical, with total hysterectomy, for uterus greater than 250 g	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, OHP, PEBB	58573	Laparoscopy, surgical, with total hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)	02/01/2022		Commercial/ASO,OHP,PEBB - This code may require PA depending on diagnosis code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Hysterectomy for Benign Conditions (Company)
Commercial/ASO, Medicare, OHP, PEBB	58580	Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency	01/01/2024			Radiofrequency Ablation for Tumors Outside the Liver (Company); Radiofrequency Ablation of Tumors Outside the Liver (Medicare)
Medicare	58674	Laparoscopy, surgical, ablation of uterine fibroid(s) including intraoperative ultrasound guidance and monitoring, radiofrequency	01/01/2024			Radiofrequency Ablation of Tumors Outside the Liver (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	59015	Chorionic Villus Sampling, Any Method	01/01/2012	01/31/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	61517	Implantation of Brain Intracavitary ChemoTherapy Agent	09/01/2003	04/30/2020		Stereotactic Computer Assisted Volumetric (Navigational) Procedure ARCHIVED 5/1/2020
Commercial/ASO, Medicare, OHP, PEBB	61650	Endovascular intracranial prolonged administration of pharmacologic agent(s) other than for thrombolysis, arterial, including catheter placement, diagnostic angiography, and imaging guidance; initial vascular territory	01/01/2016	06/30/2017		
Commercial/ASO, Medicare, OHP, PEBB	61651	Endovascular intracranial prolonged administration of pharmacologic agent(s) other than for thrombolysis, arterial, including catheter placement, diagnostic angiography, and imaging guidance; each additional vascular territory (List separately in addition to code for primary procedure)	01/01/2016	06/30/2017		

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 133/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	61850	Twst Drl/Brr Hole-Impl Elec;corticl	07/01/2010			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	61860	Craniec/Otmy ImpIn-Elec,Cerebr;cort	07/01/2010			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	61863	Burr Hole Craniotomy with Implantation of Subcortical Electrode Array, wo Intraop Microelectrode Recording; First Array	09/01/2003			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	61864	Burr Hole Craniotomy w Implantation of Subcortical Electrode Array, wo Intraop Microelectrode Recording; ea addl Array	09/01/2003			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	61867	Burr Hole Craniotomy with Implantation of Subcortical Electrode Array, w Intraop Microelectrode Recording; First Array	09/01/2003			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	61868	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (eg, thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), with use of intraoperative microelectrode recording; each additional array (List separately in addition to primary procedure)	09/01/2003			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	61880	Revis/Remv Intracr.Neurost.Electrod	07/01/2008			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	61885	Placement Subcutan Neurostim Receiv	07/01/2008			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	61886	Incision/subcutaneous placement of cranial neurostim pulse generator/receiver, direct or inductive coupling; >1 arrays	07/01/2008			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	61888	Rev/Rem.Cran Generatoror Receiver	07/01/2008			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	61889	Insertion of skull-mounted cranial neurostimulator pulse generator or receiver, including craniectomy or craniotomy, when performed, with direct or inductive coupling, with connection to depth and/or cortical strip electrode array(s)	01/01/2024			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	61891	Revision or replacement of skull-mounted cranial neurostimulator pulse generator or receiver with connection to depth and/or cortical strip electrode array(s)	01/01/2024			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	61892	Removal of skull-mounted cranial neurostimulator pulse generator or receiver with cranioplasty, when performed	01/01/2024			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 135/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	62287	Asp Percutaneous Diskectomy One/Mult Lev	01/01/2022	12/31/2022		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	62290	Inj Proc Diskography Ea Level; Lumb	09/01/2003	02/28/2017		Back: Discography (Company); Back: Discography (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	62291	Inject For Diskography Cervical	09/01/2003	02/28/2017		Back: Discography (Company); Back: Discography (Medicare)
Commercial/ASO, OHP, PEBB	62310	Injection, single, with or w/o contrast of diag or therapeutic substance, epidural or subarachnoid; cervical or thoracic	06/01/2015	12/31/2016		Epidural Steroid Injections (Company)
Medicare	62310	Injection, single, with or w/o contrast of diag or therapeutic substance, epidural or subarachnoid; cervical or thoracic	06/01/2015	09/30/2015		Epidural Steroid Injections (Company)
Commercial/ASO, OHP, PEBB	62311	Injection, single, with or w/o contrast of diag or therapeutic substance, epidural or subarachnoid; lumbar, sacral	06/01/2015	12/31/2016		Epidural Steroid Injections (Company)
Medicare	62311	Injection, single, with or w/o contrast of diag or therapeutic substance, epidural or subarachnoid; lumbar, sacral	06/01/2015	09/30/2015		Epidural Steroid Injections (Company)
Medicare	62320	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance	02/01/2017	07/31/2017		Back: Epidural Steroid Injections (Medicare)
Commercial/ASO, OHP, PEBB	62320	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or	01/01/2017	12/31/2020		Epidural Steroid Injections (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		subarachnoid, cervical or thoracic; without imaging guidance				
Medicare	62321	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (ie, fluoroscopy or CT	02/01/2017	07/31/2017		Back: Epidural Steroid Injections (Medicare)
Commercial/ASO, OHP, PEBB	62321	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (ie, fluoroscopy or CT)	01/01/2017			Epidural Steroid Injections (Company)
Commercial/ASO, OHP, PEBB	62322	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance	01/01/2017	12/31/2020		Epidural Steroid Injections (Company)
Commercial/ASO, OHP, PEBB	62323	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy or CT)	01/01/2017			Epidural Steroid Injections (Company)
Commercial/ASO, OHP, PEBB	62324	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or	01/01/2017	07/31/2017		Epidural Steroid Injections (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 137/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance				
Medicare	62324	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance	02/01/2017	07/31/2017		Epidural Steroid Injections (Company)
Medicare	62380	Endoscopic decompression of spinal cord, nerve root(s), including laminotomy, partial facetectomy, foraminotomy, discectomy and/or excision of herniated intervertebral disc, 1 interspace, lumbar	01/01/2022	12/31/2022		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63001	Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), 1 or 2 vertebral segments; cervical	01/01/2007			Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63003	Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), 1 or 2 vertebral segments; thoracic	01/01/2007			Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63005	Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), 1 or 2 vertebral segments; lumbar, except for spondylolisthesis	09/01/2003			Spinal Fusion and Decompression Procedures (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 138/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	63011	Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), 1 or 2 vertebral segments; sacral	09/01/2003			Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63012	Laminectomy with removal of abnormal facets and/or pars inter-articularis with decompression of cauda equina and nerve roots for spondylolisthesis, lumbar (Gill type procedure)	09/01/2003			Back: Lumbar Spine Surgery Archived 12/1/19; Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63015	Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), more than 2 vertebral segments; cervical	09/01/2003			Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63016	Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), more than 2 vertebral segments; thoracic	09/01/2003			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63017	Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), more than 2 vertebral segments; lumbar	09/01/2006			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63020	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; 1 interspace, cervical	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63030	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or	09/01/2003			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 139/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		excision of herniated intervertebral disc; 1 interspace, lumbar				
Commercial/ASO, Medicare, OHP, PEBB	63035	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; each additional interspace, cervical or lumbar (List separately in addition to code for primary procedure)	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63040	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; cervical	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63042	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; lumbar	09/01/2003			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63043	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; each additional cervical interspace (List separately in addition to code for primary procedure)	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63044	Laminotomy w Decompressn Nerve Root, Reexplor; Ea Addl Lumb Interspace	01/01/2014			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63045	Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 140/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; cervical				
Commercial/ASO, Medicare, OHP, PEBB	63046	Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; thoracic	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63047	Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; lumbar	09/01/2003			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63048	Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; each additional segment, cervical, thoracic, or lumbar (List separately in addition to code for primary procedure)	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63050	Laminoplasty, Cervical, With Decompression Of The Spinal Cord, Two Or More Vertebral Segments;	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63051	Laminoplasty, Cerv, W Decompression Of Spinal Cord, 2 Or > Verteb Segments; W Reconstruction Of Posterior Bony Elements	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63052	Laminectomy, facetectomy, or foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s] [eg, spinal or lateral recess stenosis]), during posterior interbody arthrodesis, lumbar; single vertebral segment (List separately in addition to code for primary procedure)	01/01/2022			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 141/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	63053	Laminectomy, facetectomy, or foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s] [eg, spinal or lateral recess stenosis]), during posterior interbody arthrodesis, lumbar; each additional segment (List separately in addition to code for primary procedure)	01/01/2022			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63055	Transpedicular approach with decompression of spinal cord, equina and/or nerve root(s) (eg, herniated intervertebral disc), single segment; thoracic	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63056	Transpedicular approach with decompression of spinal cord, equina and/or nerve root(s) (eg, herniated intervertebral disc), single segment; lumbar (including transfacet, or lateral extraforaminal approach) (eg, far lateral herniated intervertebral disc)	09/01/2003			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63057	Transpedicular approach with decompression of spinal cord, equina and/or nerve root(s) (eg, herniated intervertebral disc), single segment; each additional segment, thoracic or lumbar (List separately in addition to code for primary procedure)	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63064	Costovertebral approach with decompression of spinal cord or nerve root(s) (eg, herniated intervertebral disc), thoracic; single segment	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63066	Costovertebral approach with decompression of spinal cord or nerve root(s) (eg, herniated intervertebral disc), thoracic; each additional segment (List separately in addition to code for primary procedure)	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	63075	Discectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophytectomy; cervical, single interspace	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63076	Discectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophytectomy; cervical, each additional interspace (List separately in addition to code for primary procedure)	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63077	Discectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophytectomy; thoracic, single interspace	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63078	Discectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophytectomy; thoracic, each additional interspace (List separately in addition to code for primary procedure)	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63081	Vertebral corpectomy (vertebral body resection), partial or complete, anterior approach with decompression of spinal cord and/or nerve root(s); cervical, single segment	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63082	Vertebral corpectomy (vertebral body resection), partial or complete, anterior approach with decompression of spinal cord and/or nerve root(s); cervical, each additional segment (List separately in addition to code for primary procedure)	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63085	Vertebral corpectomy (vertebral body resection), partial or complete, transthoracic approach with decompression of spinal cord and/or nerve root(s); thoracic, single segment	01/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	63086	Vertebral corpectomy (vertebral body resection), partial or complete, transthoracic approach with decompression of spinal cord and/or nerve root(s); thoracic, each additional segment (List separately in addition to code for primary procedure)	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63087	Vertebral corpectomy (vertebral body resection), partial or complete, combined thoracolumbar approach with decompression of spinal cord, cauda equina or nerve root(s), lower thoracic or lumbar; single segment	09/01/2003			Back: Lumbar Spine Surgery Archived 12/1/19; Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63088	Vertebral corpectomy (vertebral body resection), partial or complete, combined thoracolumbar approach with decompression of spinal cord, cauda equina or nerve root(s), lower thoracic or lumbar; each additional segment (List separately in addition to code for primary procedure)	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63090	Vertebral corpectomy (vertebral body resection), partial or complete, transperitoneal or retroperitoneal approach with decompression of spinal cord, cauda equina or nerve root(s), lower thoracic, lumbar, or sacral; single segment	09/01/2003			Back: Lumbar Spine Surgery Archived 12/1/19; Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63091	Vertebral corpectomy (vertebral body resection), partial or complete, transperitoneal or retroperitoneal approach with decompression of spinal cord, cauda equina or nerve root(s), lower thoracic, lumbar, or sacral; each additional segment (List separately in addition to code for primary procedure)	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	63101	Vertebral corpectomy (vertebral body resection), partial or complete, lateral extracavitary approach with decompression of spinal cord and/or nerve root(s) (eg, for tumor or retropulsed bone fragments); thoracic, single segment	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63102	Vertebral corpectomy (vertebral body resection), partial or complete, lateral extracavitary approach with decompression of spinal cord and/or nerve root(s) (eg, for tumor or retropulsed bone fragments); lumbar, single segment	12/01/2019			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63103	Vertebral corpectomy (vertebral body resection), partial or complete, lateral extracavitary approach with decompression of spinal cord and/or nerve root(s) (eg, for tumor or retropulsed bone fragments); thoracic or lumbar, each additional segment (List separately in addition to code for primary procedure)	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63170	Laminectomy with myelotomy (eg, Bischof or DREZ type), cervical, thoracic, or thoracolumbar	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63180	Laminectomy and section of dentate ligaments, with or without dural graft, cervical; 1 or 2 segments	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63190	Laminectomy with rhizotomy; more than 2 segments	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63191	Laminectomy with section of spinal accessory nerve	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63194	Laminectomy with cordotomy, with section of 1 spinothalamic tract, 1 stage; cervical	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 145/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	63195	Laminectomy with cordotomy, with section of 1 spinothalamic tract, 1 stage; thoracic	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63196	Laminectomy with cordotomy, with section of both spinothalamic tracts, 1 stage; cervical	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63197	Laminectomy with cordotomy, with section of both spinothalamic tracts, 1 stage; thoracic	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63198	Laminectomy with cordotomy with section of both spinothalamic tracts, 2 stages within 14 days; cervical	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63199	Laminectomy with cordotomy with section of both spinothalamic tracts, 2 stages within 14 days; thoracic	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63200	Laminectomy, with release of tethered spinal cord, lumbar	04/01/2009	11/30/2019		Back: Lumbar Spine Surgery Archived 12/1/19; Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63265	Laminectomy for excision or evacuation of intraspinal lesion other than neoplasm, extradural; cervical	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63266	Laminectomy for excision or evacuation of intraspinal lesion other than neoplasm, extradural; thoracic	04/01/2007			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	63267	Laminectomy for excision or evacuation of intraspinal lesion other than neoplasm, extradural; lumbar	09/01/2003			Back: Lumbar Spine Surgery Archived 12/1/19; Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63270	Laminectomy for excision of intraspinal lesion other than neoplasm, intradural; cervical	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63271	Laminectomy for excision of intraspinal lesion other than neoplasm, intradural; thoracic	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 146/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	63272	Laminectomy for excision of intraspinal lesion other than neoplasm, intradural; lumbar	09/01/2003	11/30/2019		Back: Lumbar Spine Surgery Archived 12/1/19
Commercial/ASO, Medicare, OHP, PEBB	63275	Laminectomy for biopsy/excision of intraspinal neoplasm; extradural, cervical	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63276	Laminectomy for biopsy/excision of intraspinal neoplasm; extradural, thoracic	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63285	Laminectomy for biopsy/excision of intraspinal neoplasm; intradural, intramedullary, cervical	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63286	Laminectomy for biopsy/excision of intraspinal neoplasm; intradural, intramedullary, thoracic	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63287	Laminectomy for biopsy/excision of intraspinal neoplasm; intradural, intramedullary, thoracolumbar	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63295	Osteoplastic Reconstruction Of Dorsal Spinal Elements, Following Primary Intraspinal Procedure (List Sep)	09/01/2003	08/31/2020		
Commercial/ASO, Medicare, OHP, PEBB	63300	Vertebral corpectomy (vertebral body resection), partial or complete, for excision of intraspinal lesion, single segment; extradural, cervical	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63302	Vertebral corpectomy (vertebral body resection), partial or complete, for excision of intraspinal lesion, single segment; extradural, thoracic by thoracolumbar approach	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63304	Vertebral corpectomy (vertebral body resection), partial or complete, for excision of intraspinal lesion, single segment; intradural, cervical	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	63305	Vertebral corpectomy (vertebral body resection), partial or complete, for excision of intraspinal lesion, single segment; intradural, thoracic by transthoracic approach	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63306	Vertebral corpectomy (vertebral body resection), partial or complete, for excision of intraspinal lesion, single segment; intradural, thoracic by thoracolumbar approach	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63307	Vertebral corpectomy (vertebral body resection), partial or complete, for excision of intraspinal lesion, single segment; intradural, lumbar or sacral by transperitoneal or retroperitoneal approach	09/01/2003	11/30/2019		Back: Lumbar Spine Surgery Archived 12/1/19
Commercial/ASO, Medicare, OHP, PEBB	63308	Vertebral corpectomy (vertebral body resection), partial or complete, for excision of intraspinal lesion, single segment; each additional segment (List separately in addition to codes for single segment)	04/01/2007	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	63650	Percut.Impl-Neurostm.Electrod;epidu	09/01/2003			Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	63655	Lam-Impl-Neurostim.Electrod;epidurl	09/01/2003			Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	63661	Removal of Spinal Neurostimulator Electrode Percutaneous Array(s), Including Fluoroscopy, When Performed	01/01/2010			Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 148/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	63662	Removal of Spinal Neurostimulator Electrode Plate/Paddle(s) Placed Via Laminotomy or Laminectomy, inc Fluoro	01/01/2010			Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	63663	Revision including Replacement, When Performed, of Spinal Neurostimulator Electrode Percutaneous Array(s), inc Fluoro	01/01/2010			Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	63664	Revision inc Replacement, If Performed, of Spinal Neurostimr Electrode Plate/Paddles Placed Via Laminotomy/Ectomy	01/01/2010			Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver requiring pocket creation and connection between electrode array and pulse generator or receiver	09/01/2003			Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	63688	Revision or removal of implanted spinal neurostimulator pulse generator or receiver, with detachable connection to electrode array	09/01/2003			Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Medicare	64479	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with imaging guidance (fluoroscopy or CT); cervical or thoracic, single level	02/01/2017	07/31/2017		Back: Epidural Steroid Injections (Medicare)
Commercial/ASO, OHP, PEBB	64479	Injection, anes agent and/or steroid, transforaminal epidural; cervical or thoracic, sgl level	06/01/2015			Epidural Steroid Injections (Company)
Medicare	64480	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with imaging guidance (fluoroscopy or CT); cervical or	02/01/2017	07/31/2017		Back: Epidural Steroid Injections (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		thoracic, each additional level (List separately in addition to code for primary procedure)				
Commercial/ASO, OHP, PEBB	64480	Injection, anes agent and/or steroid, transforaminal epidural; cervical or thoracic, each addtl level	06/01/2015			Epidural Steroid Injections (Company)
Commercial/ASO, OHP, PEBB	64483	Injection, anes agent and/or steroid, transforaminal epidural; lumbar or sacral, sgl level	06/01/2015			Epidural Steroid Injections (Company)
Commercial/ASO, OHP, PEBB	64484	Injection, anes agent and/or steroid, transforaminal epidural; lumbar or sacral, each addtl level	06/01/2015			Epidural Steroid Injections (Company)
Commercial/ASO, OHP, PEBB	64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve	10/01/2016	01/31/2020		Electrical Stimulation: Non-Covered Therapies (Company); Vagus Nerve Stimulation (Company)
Medicare	64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve	10/01/2016	01/31/2020		Electrical Stimulation: Non-Covered Therapies (Company); Vagus Nerve Stimulation (Company)
Medicare	64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)	05/01/2018			Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company)
Commercial/ASO, OHP, PEBB	64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)	05/01/2018	12/31/2023		Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	64561	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed	03/01/2016			Fecal Incontinence Treatments (Company); Fecal Incontinence Treatments (Medicare); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	64568	Open implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator	10/01/2016			Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	64569	Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator	10/01/2016			Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Vagus Nerve Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	64570	Removal of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator	10/01/2016			Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	64575	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)	05/01/2018			Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company)
Commercial/ASO, Medicare, OHP, PEBB	64581	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement)	03/01/2016			Fecal Incontinence Treatments (Company); Fecal Incontinence Treatments (Medicare); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	64582	Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array	01/01/2022			Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	64583	Revision or replacement of hypoglossal nerve neurostimulator array and distal respiratory sensor electrode or electrode array, including connection to existing pulse generator	01/01/2022			Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	64584	Removal of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array	01/01/2022			Sleep Disorder Surgery (Company); Sleep Disorder Surgery (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 151/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	64585	Revision or removal of peripheral neurostimulator electrode array	05/01/2018			Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Fecal Incontinence Treatments (Company); Fecal Incontinence Treatments (Medicare); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, direct or inductive coupling	05/01/2010			Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Fecal Incontinence Treatments (Company); Fecal Incontinence Treatments (Medicare); Gastric Electrical Stimulation (Company); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver	05/01/2010			Electrical Stimulation and Electromagnetic Therapies (Medicare); Fecal Incontinence Treatments (Company); Fecal Incontinence Treatments (Medicare); Gastric Electrical Stimulation (Company); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Medicare	64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array	01/01/2024			Electrical Stimulation and Electromagnetic Therapies (Medicare)
Medicare	64597	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array (List separately in addition to code for primary procedure)	01/01/2024			Electrical Stimulation and Electromagnetic Therapies (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 152/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	64598	Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator	01/01/2024			Electrical Stimulation and Electromagnetic Therapies (Medicare)
Commercial/ASO, Medicare, PEBB	64611	Chemodenervation of parotid and submandibular salivary glands, bilateral	09/01/2019			Botulinum Therapies (Company); Botulinum Therapies (Medicare)
ОНР	64612	Dest Neurolytic Agent; Muscle Enervated	02/01/2014	12/31/2018		Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	64612	Dest Neurolytic Agent; Muscle Enervated	02/01/2014			Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	64615	Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)	09/01/2019			Botulinum Therapies (Company); Botulinum Therapies (Medicare)
ОНР	64616	Chemodenervation of muscle(s); neck muscle(s), excluding muscles of the larynx, unilateral (eg, for cervical dystonia, spasmodic torticollis)	02/01/2014	12/31/2018		Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	64616	Chemodenervation of muscle(s); neck muscle(s), excluding muscles of the larynx, unilateral (eg, for cervical dystonia, spasmodic torticollis)	02/01/2014			Botulinum Therapies (Company)
ОНР	64617	Chemodenervation of muscle(s); larynx, unilateral, percutaneous (eg, for spasmodic dysphonia), includes guidance by needle electromyography, when performed	02/01/2014	12/31/2018		Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	64617	Chemodenervation of muscle(s); larynx, unilateral, percutaneous (eg, for spasmodic dysphonia), includes guidance by needle electromyography, when performed	02/01/2014			Botulinum Therapies (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	64628	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral	01/01/2024			Ablative Procedures to Treat Back and Neck Pain (Company)
Medicare	64628	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral	01/01/2024			Ablative Procedures to Treat Back and Neck Pain (Medicare)
Commercial/ASO, OHP, PEBB	64629	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure)	01/01/2024			Ablative Procedures to Treat Back and Neck Pain (Company)
Medicare	64629	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure)	01/01/2024			Ablative Procedures to Treat Back and Neck Pain (Medicare)
Commercial/ASO, OHP, PEBB	64633	Destruction By Neurolytic Agt, Paraverteb Facet Jt Nrvs, W Imaging Guidance; Cervical Or Thoracic, Single Facet Joint	01/01/2012			Ablative Procedures to Treat Back and Neck Pain (Medicare); Back: Radiofrequency Ablation for Persistent Facet Pain (Company)
Medicare	64633	Destruction By Neurolytic Agt, Paraverteb Facet Jt Nrvs, W Imaging Guidance; Cervical Or Thoracic, Single Facet Joint	10/01/2015			Ablative Procedures to Treat Back and Neck Pain (Medicare)
Commercial/ASO, OHP, PEBB	64634	Destruction By Neurolytic Agt, Paraverteb Facet Joint Nrvs, W Imaging Guidance; Cervical Or Thoracic, Ea Addl Facet Jt	01/01/2012			Ablative Procedures to Treat Back and Neck Pain (Company)
Medicare	64634	Destruction By Neurolytic Agt, Paraverteb Facet Joint Nrvs, W Imaging Guidance; Cervical Or Thoracic, Ea Addl Facet Jt	10/01/2015			Ablative Procedures to Treat Back and Neck Pain (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	64635	Destruction By Neurolytic Agt, Paraverteb Facet Jt Nrvs, W Imaging Guidance; Lumbar Or Sacral, Single Facet Joint	01/01/2012			Ablative Procedures to Treat Back and Neck Pain (Company)
Medicare	64635	Destruction By Neurolytic Agt, Paraverteb Facet Jt Nrvs, W Imaging Guidance; Lumbar Or Sacral, Single Facet Joint	10/01/2015			Ablative Procedures to Treat Back and Neck Pain (Medicare)
Commercial/ASO, OHP, PEBB	64636	Destruction By Neurolytic Agt, Paraverteb Facet Joint Nrvs, W Imaging Guidance; Lumbar Or Sacral, Ea Addl Facet Jt	01/01/2012			Ablative Procedures to Treat Back and Neck Pain (Company)
Medicare	64636	Destruction By Neurolytic Agt, Paraverteb Facet Joint Nrvs, W Imaging Guidance; Lumbar Or Sacral, Ea Addl Facet Jt	10/01/2015			Ablative Procedures to Treat Back and Neck Pain (Medicare)
ОНР	64642	Chemodenervation of one extremity; 1-4 muscle(s)	02/01/2014	12/31/2018		Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	64642	Chemodenervation of one extremity; 1-4 muscle(s)	02/01/2014			Botulinum Therapies (Company)
ОНР	64643	Chemodenervation of one extremity; each additional extremity, 1-4 muscle(s) (List separately in addition to code for primary procedure)	02/01/2014	12/31/2018		Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	64643	Chemodenervation of one extremity; each additional extremity, 1-4 muscle(s) (List separately in addition to code for primary procedure)	02/01/2014			Botulinum Therapies (Company); Botulinum Therapies (Medicare)
ОНР	64644	Chemodenervation of one extremity; 5 or more muscle(s)	02/01/2014	12/31/2018		Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	64644	Chemodenervation of one extremity; 5 or more muscle(s)	02/01/2014			Botulinum Therapies (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
ОНР	64645	Chemodenervation of one extremity; each additional extremity, 5 or more muscle(s) (List separately in addition to code for primary procedure)	02/01/2014	12/31/2018		Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	64645	Chemodenervation of one extremity; each additional extremity, 5 or more muscle(s) (List separately in addition to code for primary procedure)	02/01/2014			Botulinum Therapies (Company)
ОНР	64646	Chemodenervation of trunk muscle(s); 1-5 muscle(s)	02/01/2014	12/31/2018		Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	64646	Chemodenervation of trunk muscle(s); 1-5 muscle(s)	02/01/2014			Botulinum Therapies (Company)
ОНР	64647	Chemodenervation of trunk muscle(s); 6 or more muscle(s)	02/01/2014	12/31/2018		Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	64647	Chemodenervation of trunk muscle(s); 6 or more muscle(s)	02/01/2014			Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	64650	Chemodenervation of eccrine glands; both axillae	01/01/2014			Botulinum Therapies (Company)
ОНР	64653	Chemodenervation of eccrine glands; other area(s) (eg, scalp, face, neck), per day	01/01/2006	12/31/2018		Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	64653	Chemodenervation of eccrine glands; other area(s) (eg, scalp, face, neck), per day	01/01/2006			Botulinum Therapies (Company)
Commercial/ASO, Medicare, PEBB	67345	Chemodenervation of extraocular muscle	09/01/2019			Botulinum Therapies (Company); Botulinum Therapies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	67900	Repair Brow Ptosis (Supraciliary/Mid/Cor	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 156/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	67901	Repair Blepharoptosis; Frontalis	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company); Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	67902	Rep Blepharoptosis Frontalis+sling	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	67903	Rep. Bleph;adv.;internal Appr.	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	67904	Rep Blepharoptosis Levator External	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	67906	Rep.Bleph;sup.Rectus Tech,Fasc.Slng	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	67908	Rep.Bleph;conjunct-Tarso-Lev.Resec	09/01/2003		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	67917	Repair Ectropion; Blephplsty	10/01/2015	08/31/2016		Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company)
Commercial/ASO, Medicare, OHP, PEBB	67935	Suture Recent Wound,Lid;full Thickn	01/01/2013	08/31/2016		Eye: Blepharoplasty, Blepharoptosis Repair, and Brow Lift (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	69705	Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); unilateral	12/01/2022			Balloon Dilation of the Sinuses or Eustachian Tubes; Balloon Dilation of the Sinuses or Eustachian Tubes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	69706	Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); bilateral	12/01/2022			Balloon Dilation of the Sinuses or Eustachian Tubes; Balloon Dilation of the Sinuses or Eustachian Tubes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	69714	Implantation, osseointetrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; without mastoidectomy	06/01/2016	09/30/2017		Cochlear Implants and Auditory Brainstem Implants (Company)
Commercial/ASO, Medicare, OHP, PEBB	69714	Implantation, osseointegrated implant, skull, with percutaneous attachment to external speech processor	11/01/2023			Bone-Anchored Hearing Aids (Company); Bone-Anchored Hearing Aids (Medicare)
Commercial/ASO, OHP, PEBB	69715	Implantation, osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy	10/01/2017	10/01/2017		Cochlear Implants and Auditory Brainstem Implants (Company)
Commercial/ASO, Medicare, OHP, PEBB	69716	Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or resulting in removal of less than 100 sq mm surface area of bone deep to the outer cranial cortex	11/01/2023			Bone-Anchored Hearing Aids (Company); Bone-Anchored Hearing Aids (Medicare)
Commercial/ASO, OHP, PEBB	69717	Replacement (including removal of existing device), osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; without mastoidectomy	10/01/2017	10/01/2017		Cochlear Implants and Auditory Brainstem Implants (Company)
Commercial/ASO, Medicare, OHP, PEBB	69717	Replacement (including removal of existing device), osseointegrated implant, skull; with	11/01/2023			Bone-Anchored Hearing Aids (Company); Bone-Anchored Hearing Aids (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 158/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		percutaneous attachment to external speech processor				
Commercial/ASO, OHP, PEBB	69718	Replacement (including removal of existing device), osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy	10/01/2017	10/01/2017		Cochlear Implants and Auditory Brainstem Implants (Company)
Commercial/ASO, Medicare, OHP, PEBB	69719	Replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or involving a bony defect less than 100 sq mm surface area of bone deep to the outer cranial cortex	11/01/2023			Bone-Anchored Hearing Aids (Company); Bone-Anchored Hearing Aids (Medicare)
Commercial/ASO, OHP, PEBB	69726	Removal, entire osseointegrated implant, skull; with percutaneous attachment to external speech processor	11/01/2023			Bone-Anchored Hearing Aids (Company)
Commercial/ASO, OHP, PEBB	69727	Removal, entire osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or involving a bony defect less than 100 sq mm surface area of bone deep to the outer cranial cortex	11/01/2023			Bone-Anchored Hearing Aids (Company)
Commercial/ASO, OHP, PEBB	69728	Removal, entire osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex	11/01/2023			Bone-Anchored Hearing Aids (Company)
Commercial/ASO, Medicare, OHP, PEBB	69729	Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside of the	11/01/2023			Bone-Anchored Hearing Aids (Company); Bone-Anchored Hearing Aids (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 159/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		mastoid and resulting in removal of greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex				
Commercial/ASO, Medicare, OHP, PEBB	69730	Replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex	11/01/2023			Bone-Anchored Hearing Aids (Company); Bone-Anchored Hearing Aids (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	69930	Cochlear Device Implantation, W/Wo Masto	09/01/2003			Cochlear Implants and Auditory Brainstem Implants (Company); Cochlear Implants and Auditory Brainstem Implants (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	70336	Magnetic Resonance (Eg, Proton) Imaging,	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70450	Ct,Head/Brain;w/O Contrast Material	01/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70460	C A T Heador Brain; with Contrast Mater	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70470	Ct,Head/Brain;w/O,W Contrst Mater'L	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70480	C A T Orbit,Sella/Post Fossa,Ear;w/O Con	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70481	Ct,Orbit,Sella,Fossa,Ear;w/Contrast	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	70482	C A T Orbit,Sella/P.Fossa,Ear;wo/W Contr	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70486	Ct,Maxillofac.Area;w/O Cntrst Mat'L	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70487	C A T Maxillofacial Area; W/Contrast Mat	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70488	Ct,Max-Facial Area;w/O,W Cntrst Mat	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70490	C A T Soft Tissue Neck; W/O Contrast Mat	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70491	Ct,Soft Tissue Neck;w/Contrast Mat.	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70492	C A T Soft Tissue Neck;w/O Then W/Contr.	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70496	Ct Angiography, Head, w/o Contrast then w Contrast & Further Sections	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70498	Ct Angiography, Neck, w/o Contrast then w Contrast & Further Sections	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70540	Mri; Orbit, Face, & Neck	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 161/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	70542	MRI, Orbit, Face, And Neck; with Contrast Material(S)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70543	MRI, Orbit, Face, Neck; wo Contrast then w Contrast, Further Sequences	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70544	Magnetic Resonance Angiography, Head; without Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70545	Magnetic Resonance Angiography, Head; with Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70546	Mr Angiography, Head; w/o Contrast then w Contrast & Further Sequences	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70547	Magnetic Resonance Angiography, Neck; without Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70548	Magnetic Resonance Angiography, Neck; with Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70549	Mr Angiography, Neck; w/o Contrast then w Contrast & Further Sequences	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70551	Magnetic Resonance Imag, Brain; w/O Contra	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70552	Mri, Brain; W/Contrast Material(S)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 162/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	70553	Mri Brain; W/O Contrast & W/Contrast & A	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70554	MRI, Brain, Functional; inc Test Selection and Admin of Repetitive Body Part Movement & Visual Stim, wo Phys/Psycholgst	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	70555	MRI, Brain, Functional; Requiring Physician or Psychologist Administration of Entire Neurofunctional Testing	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	71250	Ct, Thorax; W/O Contrast Material	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	71260	C A T Thorax; W/Contrast Material	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	71270	Ct, Thorax; W/O Then W/Contrast	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	71271	Computed tomography, thorax, low dose for lung cancer screening, without contrast material(s)	01/01/2021		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	71275	Ct Angiography, Chest, w/o Contrast then w Contrast & Further Sections	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	71550	Magnetic Resonance Imaging, Chest-Eval.Ly	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	71551	MRI, Chest (Eg, For Lymphadenopathy Eval); with Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 163/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	71552	MRI, Chest; w/o Contrast then with Contrast And Further Sequences	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	71555	Magnetic Resonance Angiography, Chest (exclusing myocardium) W or Wo Contrast Materials	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72125	Cat Cerv.Spine;w/O Contrst Material,18-2	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72126	Ct Cervical Spine;w/Contrast Mater.	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72127	Cat,Cerv.Spine;w/O,With Contrast Materia	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72128	Ct Thoracic Spine;w/0 Contrast Mat.	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72129	Cat, Thoracic Spine; w/Contrst Materl, 18-2	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72130	Ct Thorac.Spine;w/O,Then W/Contrast	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72131	Cat Lumbar Spine;w/O Contrst Materl,18-2	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72132	Ct Lumbar Spine;w/Contrast Material	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 164/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	72133	Computed tomography, lumbar spine; without contrast material, followed by contrast material(s) and further sections	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72141	Mri,Spin.Canal,Cerv;w/O Contrst Mat	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72142	Mri,Spinal Canal/Contents,Cerv;w/Contrst	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72146	Mri,Spin.Canal,Thor;w/O Cntrst Matl	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72147	Mri,Spinal Canal/Contents,Thorac;w/Cntrs	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72148	Mri,Spin.Canal,Lumb;w/O Cntrst Matl	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72149	Mri,Spinal Canal/Contents,Lumbar;w/Cntrs	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72156	Mri Spinal Wo & W Contrast: Cerv	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72157	Mri Spinal Canal Wo & W Contrast; Thorac	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72158	Mri Spinal Wo & W Contrast: Lumbar	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 165/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	72159	Magnetic Resonance Angiography Spine and Contents W/WO Contrast	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72191	Ct Angiography, Pelvis, w/o Contrast then w Contrast, Further Sections	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72192	Ct Pelvis; W/O Contrast Material	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72193	C A T Pelvis; with Contrast Material(S)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72194	Ct Pelvis;w/O,Then W/Contrast Mater	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72195	MRI, Pelvis; without Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72196	Magnetic Resonance (Eg, Proton) Imaging,	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72197	MRI, Pelvis; w/o Contrast then with Contrast And Further Sequences	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72198	Magnetic Resonance Angiography Pelvis W/WO Contrast	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	72285	Diskography Cervical Rad S&I	09/01/2003	02/28/2017		Back: Discography (Company); Back: Discography (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 166/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	72295	Discography, lumbar, radiological supervision and interpretation	09/01/2003	02/28/2017		Back: Discography (Company); Back: Discography (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	73200	C A T Upper Extremity; W/O Contrast Mate	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73201	Ct Upper Extremity;w/Contrast Mater	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73202	C A T Upper Extremity;w/O Then W/Contr.M	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73206	Ct Angiography, Upper Extremity, w/o then w Contrast, Further Sections	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73218	MRI, Upper Extremity, Other Than Joint; without Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73219	MRI, Upper Extremity, Other Than Joint; with Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73220	Magnetic Resonance Imag, Upper Extrem, N	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73221	Mri, Any Joint of Upper Extremity	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73222	MRI, Any Joint of Upper Extremity; with Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	73223	MRI, Any Joint, Upper Extremity; w/o then w Contrast&Further Sequences	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73225	Magnetic Resonance Angiography Upper Extremity W/WO Contrast	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73700	C A T Lower Extremity; W/O Contrast Mate	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73701	Ct,Lower Extremity;w/Contrast Mater	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73702	C A T Lower Extremity;w/O Then W/Contr.M	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73706	Ct Angiography, Lower Extremity, w/o then w Contrast&Further Sections	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73718	MRI, Lower Extremity Other Than Joint; without Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73719	MRI, Lower Extremity Other Than Joint; with Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73720	Mri Lower Extremity, Other Than Jnt	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73721	Magnetic Resonance Imaging, Any Jnt-Lowe	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 168/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	73722	MRI, Any Joint of Lower Extremity; with Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73723	MRI, Any Joint of Lower Extremity; w/o then w Contrast, More Sequences	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	73725	Magnetic Resonance Angiography LowerExtremity W/WO Contrast	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74150	Ct Abdomen; W/O Contrast Material	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74160	C A T Abdomen; with Contrast Material(S)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74170	Ct Abdomen;w/O,Then W/Contrast Mat	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74174	Computed Tomographic Angiography, Abdomen And Pelvis, With Contrast Material(s), Including Noncontrast Images	01/01/2012		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74175	Ct Angiography, Abdomen, wo Contrast then w Contrast, Further Sections	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74176	Computed Tomography, Abdomen And Pelvis; Without Contrast Material	01/01/2011		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74177	Computed Tomography, Abdomen And Pelvis; With Contrast Material(S)	01/01/2011		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 169/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	74178	Ct, Abdomen And Pelvis; W/O Contrast Material In One Or Both Body Regions, Followed By Contrst Mats And Further Sections	01/01/2011		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74181	Magnetic Resonance Imaging, Abdomen	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74182	MRI, Abdomen; with Contrast Material(s)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74183	MRI, Abdomen; w/o Contrast then with Contrast And Further Sequences	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74185	Magnetic Resonance Angiography Abdomen W/WO Contrast	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74261	Computed Tomographic (CT) Colonography, Diagnostic, Including Image Postprocessing; without Contrast Material	01/01/2010		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74262	CT Colonography, Diagnostic, including Image Postprocessing; W Contrast Materials inc Non- Contrast Images, If Performed	01/01/2010		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74263	Computed Tomographic (CT) Colonography, Screening, Including Image Postprocessing	01/01/2010		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	74712	Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; single or first gestation	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	74713	Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; each additional gestation (List separately in addition to code for primary procedure)	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	75557	Cardiac Magnetic Resonance Imaging for Morphology and Function without Contrast Material;	01/01/2008		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	75559	Cardiac Magnetic Resonance Imaging for Morphology and Function without Contrast Material; with Stress Imaging	01/01/2008		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	75561	Cardiac MRI wo Contrast Followed by Contrast and Further Sequences;	01/01/2008		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	75563	Cardiac MRI wo Contrast Followed by Contrast and Further Sequences; with Stress Imaging	01/01/2008		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	75565	Cardiac MRI for velocity flow mapping	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	75571	CT Heart w/o Contrast; quantitative eval of coronary calcium	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	75572	CT Heart w/ Contrast; eval of cardiac structure and morphology	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	75573	CT Heart w/ Contrast; eval of cardiac structure and morphology in setting of congenital heart disease	01/01/2016		Carelon prior authorization required Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	75574	CT angiography, heart, coronary arteries, and bypass grafts	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	75635	Ct Angio, Aorta&Iliofemoral, Rad Sup∬, wo, w Contrast, Addl Sectns	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	75665	Angiography, carotid, cerebral, unilateral, radiological supervision and interpretation	02/01/2016	12/31/2012		
Commercial/ASO, Medicare, OHP	75685	Angiography Vertebral Cervical Intracran	01/01/2013	12/31/2012		
PEBB	75685	Angiography Vertebral Cervical Intracran	01/01/2014	12/31/2012		
Commercial/ASO, Medicare, OHP, PEBB	76376	3D rendering w/ interpretationand reporting of CT MRI, US or other Tomographyic modality with image postprocessing under concurrent supervision	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	76377	3D rendering w/ interpretationand reporting of CT MRI, US or other Tomographyic modality requiring postprocessing on an independent workstation	01/01/2016	01/01/2016	Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	76380	CT, limited or localized follow-up study	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	76390	Magnetic Resonance Spectroscopy	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	76391	Magnetic resonance (eg, vibration) elastography	01/01/2020		Prior authorization completed by Carelon	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 172/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	77046	Magnetic resonance imaging, breast, without contrast material; unilateral	01/01/2019		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	77047	Magnetic resonance imaging, breast, without contrast material; bilateral	01/01/2019		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	77048	Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral	01/01/2019		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	77049	Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral	01/01/2019		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	77058	Magnetic Resonance Imaging, Breast, without and/or with Contrast Material(s); Unilateral	07/01/2007	12/31/2018	Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	77059	Magnetic Resonance Imaging, Breast, without and/or with Contrast Material(s); Bilateral	07/01/2007	12/31/2018	Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	77078	Computed Tomography, Bone Mineral Density Study, 1 or More Sites; Axial Skeleton (Eg, Hips, Pelvis, Spine)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	77084	Magnetic Resonance (Eg, Proton) Imaging, Bone Marrow Blood Supply	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	77520	Proton beam delivery to a sgl treatment area, sgl port, custom block	11/01/2021		This code will pay if billed with diagnosis code C61 in the primary position. Prior Authorization required for all other diagnosis codes.	Proton Beam Radiation Therapy (Company); Proton Beam Radiation Therapy (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	77522	Proton Treatment Delivery; Simple, with Compensation	09/01/2003	10/31/2021		Proton Beam Radiation Therapy (Company)
Commercial/ASO, Medicare, OHP, PEBB	77522	Proton Treatment Delivery; Simple, with Compensation	11/01/2021		This code will pay if billed with diagnosis code C61 in the primary position. Prior Authorization required for all other diagnosis codes.	Proton Beam Radiation Therapy (Company); Proton Beam Radiation Therapy (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	77523	Proton beam delivery to one or two treatment areas, two or more ports, two or more custom blocks	09/01/2003	10/31/2021		Proton Beam Radiation Therapy (Company)
Commercial/ASO, Medicare, OHP, PEBB	77523	Proton beam delivery to one or two treatment areas, two or more ports, two or more custom blocks	11/01/2021		This code will pay if billed with diagnosis code C61 in the primary position. Prior Authorization required for all other diagnosis codes.	Proton Beam Radiation Therapy (Company); Proton Beam Radiation Therapy (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	77525	Proton Treatment Delivery; Complex	09/01/2003	10/31/2021		Proton Beam Radiation Therapy (Company)
Commercial/ASO, Medicare, OHP, PEBB	77525	Proton Treatment Delivery; Complex	11/01/2021		This code will pay if billed with diagnosis code C61 in the primary position. Prior Authorization required for all other diagnosis codes.	Proton Beam Radiation Therapy (Company); Proton Beam Radiation Therapy (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel	01/01/2016	11/30/2019		Liver Tumor Treatment (Company)
Commercial/ASO, Medicare, OHP, PEBB	77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed;	01/01/2016	11/30/2019		Liver Tumor Treatment (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions				
Commercial/ASO, Medicare, OHP, PEBB	77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel	01/01/2016	11/30/2019		Liver Tumor Treatment (Company)
Commercial/ASO, Medicare, OHP, PEBB	77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels	01/01/2016	11/30/2019		Liver Tumor Treatment (Company)
Commercial/ASO, Medicare, OHP, PEBB	77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels	01/01/2016	11/30/2019		Liver Tumor Treatment (Company)
Commercial/ASO, Medicare, OHP, PEBB	78429	Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study; with concurrently acquired computed tomography transmission scan	01/01/2020		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78430	Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan	01/01/2020		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78431	Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic),	01/01/2020		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 175/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		with concurrently acquired computed tomography transmission scan				
Commercial/ASO, Medicare, OHP, PEBB	78432	Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability)	01/01/2020		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78433	Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography transmission scan	01/01/2020		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	78451	Myocardial Perfusion Imaging, Tomographic (Spect); Single Study, At Rest or Stress	01/01/2010		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	78451	Myocardial Perfusion Imaging, Tomographic (Spect); Single Study, At Rest or Stress	01/01/2010	07/31/2023	Carelon prior auth request not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	78452	Myocardial Perfusion Imaging, Tomographic (Spect); Mult Studies, At Rest &/ Stress &/ Redistribution &/ Rest Reinjection	01/01/2010		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	78452	Myocardial Perfusion Imaging, Tomographic (Spect); Mult Studies, At Rest &/ Stress &/ Redistribution &/ Rest Reinjection	01/01/2010	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	78453	Myocardial Perfusion Imaging, Planar; Single Study, At Rest or Stress (Exercise or Pharmacologic)	01/01/2010		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 176/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	78453	Myocardial Perfusion Imaging, Planar; Single Study, At Rest or Stress (Exercise or Pharmacologic)	01/01/2010	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	78454	Myocardial Perfusion Imaging, Planar; Multiple Studies, At Rest &/ Stress &/ Redistribution &/ Rest Reinjection	01/01/2010		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	78454	Myocardial Perfusion Imaging, Planar; Multiple Studies, At Rest &/ Stress &/ Redistribution &/ Rest Reinjection	01/01/2010	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78459	Myocardial Imaging	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	78466	Myocardial Imge Infarct;	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	78466	Myocardial Imge Infarct;	07/01/2007	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78468	Myocardial Img Infarct; Eject 1pass	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	78469	Myocardial Image Infarct; Spect	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	78469	Myocardial Image Infarct; Spect	07/01/2007	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	78472	Card Bld Pool Image; 1 Rest W/Motn	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 177/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	78472	Card Bld Pool Image; 1 Rest W/Motn	07/01/2007	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	78473	Cardiac Blood Pool; Mult Study Rest & St	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	78473	Cardiac Blood Pool; Mult Study Rest & St	07/01/2007	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	78481	Cardiac Blood Pool 1st Pass; Single at R	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	78481	Cardiac Blood Pool 1st Pass; Single at R	07/01/2007	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	78483	Cardiac Blood Pool 1st Pass; Mult	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	78483	Cardiac Blood Pool 1st Pass; Mult	07/01/2007	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78491	Myocardial Imaging, Pet, Perfusion; Single Study Rest/Stress	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78492	Myocardial Imaging, Pet, Perfusion;Multiple Studies Rest And/Or Stress	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	78494	Cardiac blood pool imaging gated equilib SPECT at rest wall motion study + eject fract w/wo quant process	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 178/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	78494	Cardiac blood pool imaging gated equilib SPECT at rest wall motion study + eject fract w/wo quant process	07/01/2007	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	78496	cardiac Blood Pool Imaging, single study	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	78496	cardiac Blood Pool Imaging, single study	01/01/2016	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78608	Brain Imaging Positron Emission Tomography	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78609	Brain Imaging Positron Emission Tomography Perfusion Evaluation	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78811	Tumor Imaging, Positron Emission Tomography (Pet); Limited Area (Eg, Chest, Head/Neck)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78812	Tumor Imaging, Positron Emission Tomography (Pet); Skull Base To Mid-Thigh	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78813	Tumor Imaging, Positron Emission Tomography (Pet); Whole Body	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78814	Tumor Imaging, Positron Emission Tomography (Pet) W Concurrently Acquired Ct; Limited Area (Eg, Chest, Head/Neck)	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	78815	Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 179/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	78816	Tumor Imaging, Positron Emission Tomography (Pet) W Concurrently Acquired Ct; Whole Body	07/01/2007		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	81105	Human Platelet Antigen 1 genotyping (HPA-1), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post- transfusion purpura), gene analysis, common variant, HPA-1a/b (L33P)	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81106	Human Platelet Antigen 2 genotyping (HPA-2), GP1BA (glycoprotein lb [platelet], alpha polypeptide [GPIba]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-2a/b (T145M)	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81107	Human Platelet Antigen 3 genotyping (HPA-3), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex], antigen CD41 [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-3a/b (I843S)	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81108	Human Platelet Antigen 4 genotyping (HPA-4), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post- transfusion purpura), gene analysis, common variant, HPA-4a/b (R143Q)	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81109	Human Platelet Antigen 5 genotyping (HPA-5), ITGA2 (integrin, alpha 2 [CD49B, alpha 2 subunit of VLA-2 receptor] [GPIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 180/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		analysis, common variant (eg, HPA-5a/b (K505E))				
Commercial/ASO, Medicare, OHP, PEBB	81110	Human Platelet Antigen 6 genotyping (HPA- 6w), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa, antigen CD61] [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-6a/b (R489Q)	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81111	Human Platelet Antigen 9 genotyping (HPA- 9w), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41] [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-9a/b (V837M)	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81112	Human Platelet Antigen 15 genotyping (HPA- 15), CD109 (CD109 molecule) (eg, neonatal alloimmune thrombocytopenia [NAIT], post- transfusion purpura), gene analysis, common variant, HPA-15a/b (S682Y)	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81120	IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma), common variants (eg, R132H, R132C)	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81121	IDH2 (isocitrate dehydrogenase 2 [NADP+], mitochondrial) (eg, glioma), common variants (eg, R140W, R172M)	01/01/2018			Genetic and Molecular Testing (Company)
Medicare	81121	IDH2 (isocitrate dehydrogenase 2 [NADP+], mitochondrial) (eg, glioma), common variants (eg, R140W, R172M)	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81161	DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed	07/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 181/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	81161	DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81162	BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis	01/01/2016			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Commercial/ASO, OHP, PEBB	81163	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Medicare	81163	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis	01/01/2019	08/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	81164	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)	01/01/2022	08/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81165	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Medicare	81165	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis	01/01/2019	08/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	81166	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)	01/01/2022	08/31/2022		Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	81167	BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)	01/01/2022	08/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	81168	CCND1/IGH (t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81171	AFF2 (AF4 transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81172	AFF2 (AF4 transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81173	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81174	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81175	ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene sequence	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81176	ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 183/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted sequence analysis (eg, exon 12)				
Commercial/ASO, Medicare, OHP, PEBB	81177	ATN1 (atrophin 1) (eg, dentatorubral- pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81178	ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81179	ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81180	ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81181	ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81182	ATXN8OS (ATXN8 opposite strand [non- protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81183	ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 184/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81184	CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81185	CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81186	CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81187	CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81188	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81189	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81190	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81191	NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis	01/01/2022			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 185/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	81192	NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81193	NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81194	NTRK (neurotrophic receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81200	ASPA (aspartoacylase) (eg, Canavan disease) gene analysis, common variants (eg, E285A, Y231X)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81201	APC (Adenomatous Polyposis Coli) Gene Analysis; Full Gene Sequence	01/01/2013			Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81201	APC (Adenomatous Polyposis Coli) Gene Analysis; Full Gene Sequence	01/01/2013	08/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81202	APC (Adenomatous Polyposis Coli) Gene Analysis; Known Familial Variants	01/01/2013			Genetic and Molecular Testing (Medicare); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81203	APC (Adenomatous Polyposis Coli) Gene Analysis; Duplication/Deletion Variants	01/01/2013			Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81203	APC (Adenomatous Polyposis Coli) Gene Analysis; Duplication/Deletion Variants	01/01/2013	08/31/2022		Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81204	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81205	BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease) gene analysis, common variants (eg, R183P, G278S, E422X)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81209	BLM (Bloom syndrome, RecQ helicase-like) (eg, Bloom syndrome) gene analysis, 2281del6ins7 variant	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81210	BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, V600 variant(s)	01/01/2013			Genetic and Molecular Testing (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company); Genetic Testing: Thyroid Nodules (Company); Non-Small Cell Lung Cancer: Tumor Testing for Targeted Therapy (Company)
Medicare	81210	Braf (V-Raf Murine Sarcoma Viral Oncogene Homolog B1) (Eg, Colon Cancer), Gene Analysis, V600E Variant	01/01/2013	06/30/2018		Genetic and Molecular Testing (Company); Genetic Testing for Thyroid Nodules (Medicare); Non-Small Cell Lung Cancer: Molecular Testing for Targeted Therapy (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81211	Brca1, Brca2 Gene Analysis; Full Sequence Analysis And Common Duplication/Deletion Variants In Brca1	01/01/2012	12/31/2018		Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Hereditary Breast and Ovarian Cancer (Medicare)
Commercial/ASO, OHP, PEBB	81212	Brca1, Brca2 Gene Analysis; 185Delag, 5385Insc, 6174Delt Variants	01/01/2012			Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Medicare	81212	Brca1, Brca2 Gene Analysis; 185Delag, 5385Insc, 6174Delt Variants	01/01/2012	08/31/2022		Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 187/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81213	Brca1, Brca2 Gene Analysis; Uncommon Duplication/Deletion Variants	01/01/2012	03/31/2017		Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Hereditary Breast and Ovarian Cancer (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81214	Brca1 Gene Analysis; Full Sequence Analysis And Common Duplication/Deletion Variants	01/01/2012	12/31/2018		Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Hereditary Breast and Ovarian Cancer (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81215	Brca1 (Breast Cancer 1) (Eg, Hereditary Breast And Ovarian Cancer) Gene Analysis; Known Familial Variant	01/01/2012			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Commercial/ASO, OHP, PEBB	81216	Brca2 (Breast Cancer 2) (Eg, Hereditary Breast And Ovarian Cancer) Gene Analysis; Full Sequence Analysis	01/01/2012			Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Medicare	81216	Brca2 (Breast Cancer 2) (Eg, Hereditary Breast And Ovarian Cancer) Gene Analysis; Full Sequence Analysis	01/01/2012	08/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81217	Brca2 (Breast Cancer 2) (Eg, Hereditary Breast And Ovarian Cancer) Gene Analysis; Known Familial Variant	01/01/2012			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Medicare	81218	CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81219	CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon 9	03/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Myeloproliferative Diseases (Company); Genetic Testing: Myeloproliferative Diseases (Medicare)
Medicare	81220	Cftr (Cystic Fibrosis Transmembrane Conductance Regulator) Gene Analysis; Common Variants (Eg, Acmg/Acog Guidelines)	01/01/2022			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 188/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	81221	CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; known familial variants	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81222	Cftr (Cystic Fibrosis Transmembrane Conductance Regulator) Gene Analysis; Duplication/Deletion Variants	01/01/2012	06/01/2016		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81222	CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; duplication/deletion variants	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81223	Cftr (Cystic Fibrosis Transmembrane Conductance Regulator) (Eg, Cystic Fibrosis) Gene Analysis; Full Gene Sequence	01/01/2012	01/01/2016		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81223	CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; full gene sequence	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81224	Cftr (Cystic Fibrosis Transmembrane Conductance Regulator) Gene Analysis; Intron 8 Poly-T Analysis	01/01/2012	01/01/2016		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81224	CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; intron 8 poly-T analysis (eg, male infertility)	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81225	Cyp2C19 (Cytochrome P450, Family 2, Subfamily C, Polypeptide 19), Gene Analysis, Common Variants	01/01/2012			Cardiac: Disease Risk Screening (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)
Commercial/ASO, Medicare, OHP, PEBB	81226	Cyp2D6 (Cytochrome P450, Family 2, Subfamily D, Polypeptide 6), Gene Analysis, Common Variants	01/01/2012			Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81227	Cyp2C9 (Cytochrome P450, Family 2, Subfamily C, Polypeptide 9), Gene Analysis, Common Variants (Eg, *2, *3, *5, *6)	01/01/2012			Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)
Commercial/ASO, OHP, PEBB	81228	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)	02/01/2018	04/30/2020		Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)
Commercial/ASO, OHP, PEBB	81229	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities	02/01/2018	04/30/2020		Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)
Medicare	81229	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities	07/01/2018	04/30/2020		
Commercial/ASO, Medicare, OHP, PEBB	81230	CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)	01/01/2018			Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)
Commercial/ASO, Medicare, OHP, PEBB	81231	CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)	01/01/2018			Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)
Medicare	81232	DPYD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug metabolism), gene analysis, common variant(s) (eg, *2A, *4, *5, *6)	01/01/2018			Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	81232	DPYD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug metabolism), gene analysis, common variant(s) (eg, *2A, *4, *5, *6)	01/01/2018	11/30/2021		Genetic Testing: Pharmacogenetic Testing (Company); Non-Covered Genetic Panel Tests (Company)
Commercial/ASO, Medicare, OHP, PEBB	81233	BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81234	DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81235	EGFR (Epidermal growth factor receptor)(EG, non-small cell lung cancer) gene analysis, common variants (EG, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)	01/01/2016			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Small Cell Lung Cancer: Tumor Testing for Targeted Therapy (Company)
Medicare	81235	EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)	10/01/2016	06/30/2018		Genetic and Molecular Testing (Company); Non-Small Cell Lung Cancer: Tumor Testing for Targeted Therapy (Company)
Commercial/ASO, Medicare, OHP, PEBB	81236	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81237	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81238	F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81239	DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81240	F2 (prothrombin, coagulation factor II) (eg, hereditary hypercoagulability) gene analysis, 20210G>A variant	02/01/2018			Genetic Testing: Inherited Thrombophilias (Company)
Commercial/ASO, OHP, PEBB	81241	F5 (coagulation factor V) (eg, hereditary hypercoagulability) gene analysis, Leiden variant	02/01/2018			Genetic Testing: Inherited Thrombophilias (Company)
Commercial/ASO, OHP, PEBB	81242	FANCC (Fanconi anemia, complementation group C) (eg, Fanconi anemia, type C) gene analysis, common variant (eg, IVS4+4A>T)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81243	FMR1 (Fragile X messenger ribonucleoprotein 1) (e.g., fragile x syndrome, X-linked intellectual disability [XLID]) gene analysis; evaluation to detect abnormal (e.g., expanded) alleles	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81244	FMR1 (Fragile X messenger ribonucleoprotein 1) (e.g., fragile X syndrome, X-linked intellectual disability [XLID]) gene analysis; characterization of alleles (e.g., expanded size and methylation status)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81247	G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; common variant(s) (eg, A, A-)	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81248	G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; known familial variant(s)	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81249	G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; full gene sequence	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Medicare	81250	G6PC (glucose-6-phosphatase, catalytic subunit) (eg, Glycogen storage disease, type 1a, von Gierke disease) gene analysis, common variants (eg, R83C, Q347X)	07/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81250	G6PC (glucose-6-phosphatase, catalytic subunit) (eg, Glycogen storage disease, type 1a, von Gierke disease) gene analysis, common variants (eg, R83C, Q347X)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81251	GBA (glucosidase, beta, acid) (eg, Gaucher disease) gene analysis, common variants (eg, N370S, 84GG, L444P, IVS2+1G>A)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81252	GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence	02/01/2018	03/31/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81252	GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence	01/01/2022	06/30/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81253	GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; known familial variants	02/01/2018	03/31/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)
Medicare	81253	GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; known familial variants	01/01/2022	06/30/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81254	GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (eg, nonsyndromic hearing loss) gene analysis, common variants (eg, 309kb [del(GJB6-D13S1830)] and 232kb [del(GJB6- D13S1854)])	02/01/2018	03/31/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 193/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	81254	GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (eg, nonsyndromic hearing loss) gene analysis, common variants (eg, 309kb [del(GJB6-D13S1830)] and 232kb [del(GJB6- D13S1854)])	01/01/2022	06/30/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81255	HEXA (hexosaminidase A [alpha polypeptide]) (eg, Tay-Sachs disease) gene analysis, common variants (eg, 1278insTATC, 1421+1G>C, G269S)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81256	Hfe (Hemochromatosis) (Eg, Hereditary Hemochromatosis) Gene Analysis, Common Variants (Eg, C282Y, H63D)	01/01/2013	06/30/2023		Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81257	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis, for common deletions or variant (eg, Southeast Asian, Thai, Filipino, Mediterranean, alpha3.7, alpha4.2, alpha20.5, and Constant Spring)	07/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81257	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis, for common deletions or variant (eg, Southeast Asian, Thai, Filipino, Mediterranean, alpha3.7, alpha4.2, alpha20.5, and Constant Spring)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81258	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; known familial variant	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81259	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; full gene sequence	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81260	IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex- associated protein) (eg, familial dysautonomia) gene analysis, common variants (eg, 2507+6T>C, R696P)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81265	Comparative analysis using Short Tandem Repeat Markers	02/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81265	Comparative analysis using Short Tandem Repeat Markers	02/01/2018	11/30/2022		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81266	Comparative analysis using Short Tandem Repeat (STR) markers; each additional specimen (eg, additional cord blood donor, additional fetal samples from different cultures, or additional zygosity in multiple birth pregnancies) (List separately in addition to code for primary procedure)	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81267	Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline analyses; without cell selection	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81268	Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline analyses; with cell selection (eg, CD3, CD33), each cell type	01/01/2022			Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81269	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; duplication/deletion variants	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81270	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant	03/01/2018			Genetic and Molecular Testing (Medicare); Genetic Testing: Myeloproliferative Diseases (Company); Genetic Testing: Myeloproliferative Diseases (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81271	HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81274	HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81275	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; variants in exon 2 (eg, codons 12 and 13)	10/01/2014			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Small Cell Lung Cancer: Tumor Testing for Targeted Therapy (Company)
Medicare	81275	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; variants in exon 2 (eg, codons 12 and 13)	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81276	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)	10/01/2016			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Small Cell Lung Cancer: Tumor Testing for Targeted Therapy (Company)
Medicare	81276	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)	01/01/2022			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 196/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	81277	GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (eg, nonsyndromic hearing loss) gene analysis, common variants (eg, 309kb [del(GJB6-D13S1830)] and 232kb [del(GJB6- D13S1854)])	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81279	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13)	01/01/2021			Genetic and Molecular Testing (Medicare); Genetic Testing: Myeloproliferative Diseases (Company); Genetic Testing: Myeloproliferative Diseases (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81280	Long Qt Syndrome Gene Analyses; Full Sequence Analysis	01/01/2013	12/31/2016	This code is no longer valid effective 1/1/2017	Genetic and Molecular Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81281	Long Qt Syndrome Gene Analyses; Known Familial Sequence Variant	01/01/2013	12/31/2016	This code is no longer valid effective 1/1/2017	Genetic and Molecular Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81282	Long Qt Syndrome Gene Analyses; Duplication/Deletion Variants	01/01/2013	12/31/2016	This code is no longer valid effective 1/1/2017	Genetic and Molecular Testing (Company)
Medicare	81283	IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant	01/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81283	IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant	01/01/2018	11/30/2021		Genetic Testing: Pharmacogenetic Testing (Company); Non-Covered Genetic Panel Tests (Company)
Commercial/ASO, Medicare, OHP, PEBB	81284	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81285	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81286	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81287	MGMT, methylation analysis	01/01/2015			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81287	MGMT, methylation analysis	01/01/2015	11/30/2021		Genetic Testing: Pharmacogenetic Testing (Company); Non-Covered Genetic Panel Tests (Company)
Commercial/ASO, Medicare, OHP, PEBB	81288	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non- polyposis colorectal cancer, Lynch syndrome) gene analysis; promoter methylation analysis	01/01/2015			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Commercial/ASO, Medicare, OHP, PEBB	81289	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81290	MCOLN1 (mucolipin 1) (eg, Mucolipidosis, type IV) gene analysis, common variants (eg, IVS3- 2A>G, del6.4kb)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81292	Mlh1 (Mutl Homolog 1, Colon Cancer, Nonpolyposis Type 2) Gene Analysis; Full Sequence Analysis	01/01/2012			Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	81292	Mlh1 (Mutl Homolog 1, Colon Cancer, Nonpolyposis Type 2) Gene Analysis; Full Sequence Analysis	01/01/2012	08/31/2022		Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81293	Mlh1 (Mutl Homolog 1, Colon Cancer, Nonpolyposis Type 2) Gene Analysis; Known Familial Variants	01/01/2012			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Commercial/ASO, OHP, PEBB	81294	Mlh1 (Mutl Homolog 1, Colon Cancer, Nonpolyposis Type 2) Gene Analysis; Duplication/Deletion Variants	01/01/2012			Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	81294	Mlh1 (Mutl Homolog 1, Colon Cancer, Nonpolyposis Type 2) Gene Analysis; Duplication/Deletion Variants	01/01/2012	08/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81295	Msh2 (Muts Homolog 2, Colon Cancer, Nonpolyposis Type 1) Gene Analysis; Full Sequence Analysis	01/01/2012			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	81295	Msh2 (Muts Homolog 2, Colon Cancer, Nonpolyposis Type 1) Gene Analysis; Full Sequence Analysis	01/01/2012	08/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81296	Msh2 (Muts Homolog 2, Colon Cancer, Nonpolyposis Type 1) Gene Analysis; Known Familial Variants	01/01/2012			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Commercial/ASO, OHP, PEBB	81297	Msh2 (Muts Homolog 2, Colon Cancer, Nonpolyposis Type 1) Gene Analysis; Duplication/Deletion Variants	01/01/2012			Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	81297	Msh2 (Muts Homolog 2, Colon Cancer, Nonpolyposis Type 1) Gene Analysis; Duplication/Deletion Variants	01/01/2012	08/31/2022		Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 199/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	81298	MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis	01/01/2012			Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	81298	MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis	01/01/2012	08/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81299	Msh6 (Muts Homolog 6 [E. Coli]) Gene Analysis; Known Familial Variants	01/01/2012			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Commercial/ASO, OHP, PEBB	81300	Msh6 (Muts Homolog 6 [E. Coli]) Gene Analysis; Duplication/Deletion Variants	01/01/2012			Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	81300	Msh6 (Muts Homolog 6 [E. Coli]) Gene Analysis; Duplication/Deletion Variants	01/01/2012	08/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81301	Microsatellite Instability Analysis Of Markers For Mismatch Repair Deficiency	01/01/2012	07/31/2016		
Commercial/ASO, OHP, PEBB	81302	MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; full sequence analysis	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81303	MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; known familial variant	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81304	MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; duplication/deletion variants	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 200/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81305	MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81306	NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)	12/01/2021			Inflammatory Bowel Disease (IBD) Serologic Testing and Therapeutic Monitoring
Medicare	81306	NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)	12/01/2021			Genetic and Molecular Testing (Medicare); Inflammatory Bowel Disease: Serologic Markers and Therapeutic Monitoring (Company); Inflammatory Bowel Disease: Serologic Testing and Therapeutic Monitoring (Medicare)
Commercial/ASO, OHP, PEBB	81307	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence	01/01/2020			Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Medicare	81307	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence	01/01/2020	08/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81308	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; known familial variant	01/01/2020			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Commercial/ASO, Medicare, OHP, PEBB	81309	PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20)	01/01/2020			Circulating Tumor Cell and DNA Assays for Cancer Management (Company); Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare); Genetic and Molecular Testing (Medicare)
Medicare	81310	NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants	01/01/2022			Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81311	NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61)	01/01/2016			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing for Thyroid Nodules (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Genetic Testing: Thyroid Nodules (Company)
Commercial/ASO, Medicare, OHP, PEBB	81312	PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81313	PCA3/KLK3 (prostate cancer antigen 3 {non- protein coding}/ kallikrein-related peptidase 3 {prostate specific antigen} ratio (eg prostate cancer)	10/01/2015			Prostate Cancer: Biomarkers and Genetic Testing Medicare
Medicare	81314	PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) (eg, gastrointestinal stromal tumor [GIST]), gene analysis, targeted sequence analysis (eg, exons 12, 18)	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81315	Promyelocytic Leukemia/Retinoic Acid Receptor Alpha, (T(15;17)), Translocation Analysis; Common Breakpoints, Qual/Quant	10/01/2014			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81316	Promyelocytic Leukemia/Retinoic Acid Receptor Alpha, (T(15;17)), Translocation Analysis; Single Breakpoint, Qual/Quant	10/01/2014			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81317	Pms2 (Postmeiotic Segregation Increased 2 [S. Cerevisiae]) Gene Analysis; Full Sequence Analysis	01/01/2012			Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	81317	Pms2 (Postmeiotic Segregation Increased 2 [S. Cerevisiae]) Gene Analysis; Full Sequence Analysis	01/01/2012	08/31/2022		Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 202/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81318	Pms2 (Postmeiotic Segregation Increased 2 [S. Cerevisiae]) Gene Analysis; Known Familial Variants	01/01/2012			Genetic and Molecular Testing (Medicare); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Commercial/ASO, OHP, PEBB	81319	Pms2 (Postmeiotic Segregation Increased 2 [S. Cerevisiae]) Gene Analysis; Duplication/Deletion Variants	01/01/2012			Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Medicare	81319	Pms2 (Postmeiotic Segregation Increased 2 [S. Cerevisiae]) Gene Analysis; Duplication/Deletion Variants	01/01/2012	08/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	81320	PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81320	PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)	01/01/2022	03/31/2023		Non-Covered Genetic Panel Tests (Company)
Commercial/ASO, OHP, PEBB	81321	PTEN (Phosphatase And Tensin Homolog) Gene Analysis; Full Sequence Analysis	01/01/2013			Genetic and Molecular Testing (Company); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Medicare	81321	PTEN (Phosphatase And Tensin Homolog) Gene Analysis; Full Sequence Analysis	01/01/2013	08/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81322	PTEN (Phosphatase And Tensin Homolog) Gene Analysis; Known Familial Variant	01/01/2013			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Commercial/ASO, OHP, PEBB	81323	PTEN (Phosphatase And Tensin Homolog) Gene Analysis; Duplication/Deletion Variant	01/01/2013			Genetic and Molecular Testing (Medicare)
Medicare	81323	PTEN (Phosphatase And Tensin Homolog) Gene Analysis; Duplication/Deletion Variant	01/01/2013	08/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	81324	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy	07/01/2018			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 203/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		with liability to pressure palsies) gene analysis; duplication/deletion analysis				
Commercial/ASO, OHP, PEBB	81324	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81325	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence analysis	07/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81325	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence analysis	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81326	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant	07/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81326	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81327	SEPT9 (Septin9) (eg, colorectal cancer) methylation analysis	01/01/2017			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81328	SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug reaction), gene analysis, common variant(s) (eg, *5)	11/01/2018	11/30/2021		Genetic Testing: Pharmacogenetic Testing (Company); Non-Covered Genetic Panel Tests (Company)
Medicare	81328	SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse	01/01/2022			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 204/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		drug reaction), gene analysis, common variant(s) (eg, *5)				
Commercial/ASO, Medicare, OHP, PEBB	81329	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81330	SMPD1(sphingomyelin phosphodiesterase 1, acid lysosomal) (eg, Niemann-Pick disease, Type A) gene analysis, common variants (eg, R496L, L302P, fsP330)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (eg, Prader-Willi syndrome and/or Angelman syndrome), methylation analysis	07/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (eg, Prader-Willi syndrome and/or Angelman syndrome), methylation analysis	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81332	Serpina1 (Serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1), Gene Analysis,Common Vars	01/01/2012			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81333	TGFBI (transforming growth factor beta- induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81334	RUNX1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy),	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 205/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		gene analysis, targeted sequence analysis (eg, exons 3-8)				
Commercial/ASO, Medicare, OHP, PEBB	81335	TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3)	01/01/2018			Genetic and Molecular Testing (Medicare); Inflammatory Bowel Disease (IBD) Serologic Testing and Therapeutic Monitoring; Inflammatory Bowel Disease: Serologic Testing and Therapeutic Monitoring (Medicare); Non- Covered Genetic Panel Tests (Company)
Commercial/ASO, Medicare, OHP, PEBB	81336	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81337	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81338	MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R)	01/01/2021			Genetic and Molecular Testing (Medicare); Genetic Testing: Myeloproliferative Diseases (Company); Genetic Testing: Myeloproliferative Diseases (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81339	MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10	01/01/2021			Genetic and Molecular Testing (Medicare); Genetic Testing: Myeloproliferative Diseases (Company); Genetic Testing: Myeloproliferative Diseases (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81343	PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81344	TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 206/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81345	TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81346	TYMS (thymidylate synthetase) (eg, 5- fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)	01/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81346	TYMS (thymidylate synthetase) (eg, 5- fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)	01/01/2018	11/30/2021		Genetic Testing: Pharmacogenetic Testing (Company); Non-Covered Genetic Panel Tests (Company)
Commercial/ASO, Medicare, OHP, PEBB	81347	SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L)	01/01/2021			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81348	SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L)	01/01/2021			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Medicare	81349	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysis	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81350	UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, irinotecan metabolism), gene analysis, common variants (eg, *28, *36, *37)	02/01/2018			Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81350	UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, drug metabolism , ), hereditary unconjugated hyperbilirubinemia	01/01/2022			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 207/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		[Gilbert syndrome]) gene analysis, common variants (eg, *28, *36, *37)				
Medicare	81351	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence	01/01/2022	08/31/2022		Genetic and Molecular Testing (Medicare)
Medicare	81352	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology)	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81353	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81355	Vkorc1 (Vitamin K Epoxide Reductase Complex, Subunit 1) (Eg, Warfarin Metabolism), Gene Analysis, Common Variants	01/01/2012			Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company)
Commercial/ASO, Medicare, OHP, PEBB	81357	U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P)	01/01/2021			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81360	ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)	01/01/2021			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81361	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); common variant(s) (eg, HbS, HbC, HbE)	04/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81362	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); known familial variant(s)	04/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 208/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	81363	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); duplication/deletion variant(s)	04/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81364	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); full gene sequence	04/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81382	HLA class II typing, high resolutionn (ie, alleles or allele groups); one locus (eg, HLA-DRB1, - DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	08/01/2016	08/01/2022		
Medicare	81382	HLA class II typing, high resolutionn (ie, alleles or allele groups); one locus (eg, HLA-DRB1, - DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	08/01/2016	08/31/2022		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81400	Molecular Pathology Procedure Level 1	01/01/2012			Cardiac: Disease Risk Screening (Company); Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Inherited Thrombophilias (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	81401	Molecular Pathology Procedure Level 2	01/01/2012			Cardiac: Disease Risk Screening (Company); Gene Expression Profile Testing for Melanoma (Company); Genetic and Molecular Testing (Company); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Genetic Testing: Thyroid Nodules (Company); Inflammatory Bowel Disease: Serologic Markers and Therapeutic Monitoring (Company); Non-Covered Genetic Panel Tests (Company); Non-Small Cell Lung Cancer: Tumor Testing for Targeted Therapy (Company)
Medicare	81401	Molecular Pathology Procedure Level 2	01/01/2012	10/31/2022		Cardiac: Disease Risk Screening (Medicare); Gene Expression Profile Testing for Melanoma (Medicare); Genetic and Molecular Testing (Medicare); Genetic Testing for Thyroid Nodules (Medicare); Inflammatory Bowel Disease: Serologic Testing and Therapeutic Monitoring (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81402	Molecular Pathology Procedure Level 3	01/01/2012			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company); Genetic Testing: Myeloproliferative Diseases (Company); Genetic Testing: Myeloproliferative Diseases (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81403	Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons	01/01/2012			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing for Thyroid Nodules (Medicare); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company); Genetic Testing: Myeloproliferative Diseases (Company); Genetic Testing: Myeloproliferative Diseases (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Genetic Testing: Thyroid Nodules (Company); Non-Covered Genetic Panel Tests (Company); Non-Small Cell Lung Cancer: Tumor Testing for Targeted Therapy (Company)
Commercial/ASO, Medicare, OHP, PEBB	81404	Molecular Pathology Procedure Level 5	01/01/2012			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing for Thyroid Nodules (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Maturity-Onset Diabetes of the Young (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Genetic Testing: Thyroid Nodules (Company); Non-Covered Genetic Panel Tests (Company); Non-Small Cell Lung Cancer: Tumor Testing for Targeted Therapy (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81405	Molecular Pathology Procedure Level 6	01/01/2012			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing for Thyroid Nodules (Medicare); Genetic Testing: Cytochrome P450 and VKORC1 Polymorphisms (Company); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Maturity-Onset Diabetes of the Young (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Genetic Testing: Thyroid Nodules (Company); Non-Covered Genetic Panel Tests (Company); Non-Small Cell Lung Cancer: Tumor Testing for Targeted Therapy (Company)
Commercial/ASO, Medicare, OHP, PEBB	81406	Molecular Pathology Procedure Level 7	01/01/2012			Cardiac: Disease Risk Screening (Company); Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing for Thyroid Nodules (Medicare); Genetic Testing: CADASIL Disease; Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company); Genetic Testing: Maturity-Onset Diabetes of the Young (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Genetic Testing: Thyroid Nodules (Company); Non-Covered Genetic Panel Tests (Company); Non-Small Cell Lung Cancer: Tumor Testing for Targeted Therapy (Company)
Commercial/ASO, Medicare, OHP, PEBB	81407	Molecular Pathology Procedure Level 8	01/01/2012			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 212/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81408	Molecular Pathology Procedure Level 9	01/01/2012			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)
Medicare	81410	Aortic dysfunction or dilation (eg, Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); genomic sequence analysis panel, must include sequencing of at least 9 genes, including FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, and MYLK	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81411	Aortic dysfunction or dilation (eg, Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); duplication/deletion analysis panel, must include analyses for TGFBR1, TGFBR2, MYH11, and COL3A1	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81412	Ashkenazi Jewish associated disorders (eg, Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)
Medicare	81413	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A	07/01/2018			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 213/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	81413	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)
Medicare	81414	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); duplication/deletion gene analysis panel, must include analysis of at least 2 genes, including KCNH2 and KCNQ1	07/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81414	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); duplication/deletion gene analysis panel, must include analysis of at least 2 genes, including KCNH2 and KCNQ1	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)
Medicare	81415	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis	07/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81415	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company); Whole Exome, Whole Genome, and Proteogenomic Genetic Testing (Company)
Medicare	81416	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents,	07/01/2018			Genetic and Molecular Testing (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		siblings) (List separately in addition to code for primary procedure)				
Commercial/ASO, OHP, PEBB	81416	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) (List separately in addition to code for primary procedure)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company); Whole Exome, Whole Genome, and Proteogenomic Genetic Testing (Company)
Medicare	81417	Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome)	07/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81417	Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome)	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company); Whole Exome, Whole Genome, and Proteogenomic Genetic Testing (Company)
Medicare	81418	Drug metabolism (eg, pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplication/deletion analysis	01/01/2023			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81419	Epilepsy genomic sequence analysis panel, must include analyses for ALDH7A1, CACNA1A, CDKL5, CHD2, GABRG2, GRIN2A, KCNQ2, MECP2, PCDH19, POLG, PRRT2, SCN1A, SCN1B, SCN2A, SCN8A, SLC2A1, SLC9A6, STXBP1, SYNGAP1, TCF4, TPP1, TSC1, TSC2, and ZEB2	01/01/2021			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Medicare	81420	Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in	07/01/2018			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 215/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		maternal blood, must include analysis of chromosomes 13, 18, and 21				
Commercial/ASO, OHP, PEBB	81420	Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21	02/01/2018	12/31/2021		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81422	Fetal chromosomal microdeletion(s) genomic sequence analysis (eg, DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood	07/01/2018			Genetic and Molecular Testing (Medicare)
Medicare	81425	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81426	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (eg, parents, siblings) (List separately in addition to code for primary procedure)	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81427	Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)	02/01/2018	05/31/2019		Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Whole Exome, Whole Genome, and Proteogenomic Genetic Testing (Company)
Medicare	81427	Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81430	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); genomic sequence analysis panel, must	04/01/2018	04/30/2022		Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 216/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		include sequencing of at least 60 genes, including CDH23, CLRN1, GJB2, GPR98, MTRNR1, MYO7A, MYO15A, PCDH15, OTOF, SLC26A4, TMC1, TMPRSS3, USH1C, USH1G, USH2A, and WFS1				
Commercial/ASO, OHP, PEBB	81430	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); genomic sequence analysis panel, must include sequencing of at least 60 genes, including CDH23, CLRN1, GJB2, GPR98, MTRNR1, MYO7A, MYO15A, PCDH15, OTOF, SLC26A4, TMC1, TMPRSS3, USH1C, USH1G, USH2A, and WFS1	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81431	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); duplication/deletion analysis panel, must include copy number analyses for STRC and DFNB1 deletions in GJB2 and GJB6 genes	04/01/2018	04/30/2022		Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81431	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); duplication/deletion analysis panel, must include copy number analyses for STRC and DFNB1 deletions in GJB2 and GJB6 genes	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81432	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 14 genes, including ATM, BRCA1, BRCA2, BRIP1, CDH1, MLH1, MSH2, MSH6, NBN, PALB2, PTEN, RAD51C, STK11, and TP53	01/01/2016			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)
Commercial/ASO, Medicare, OHP, PEBB	81433	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer);	01/01/2016			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 217/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11				
Medicare	81434	Hereditary retinal disorders (eg, retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy), genomic sequence analysis panel, must include sequencing of at least 15 genes, including ABCA4, CNGA1, CRB1, EYS, PDE6A, PDE6B, PRPF31, PRPH2, RDH12, RHO, RP1, RP2, RPE65, RPGR, and USH2A	07/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81434	Hereditary retinal disorders (eg, retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy), genomic sequence analysis panel, must include sequencing of at least 15 genes, including ABCA4, CNGA1, CRB1, EYS, PDE6A, PDE6B, PRPF31, PRPH2, RDH12, RHO, RP1, RP2, RPE65, RPGR, and USH2A	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)
Commercial/ASO, Medicare, OHP, PEBB	81435	Hereditary colon cancer syndromes (eg, Lynch syndrome, familial adenomatosis polyposis); genomic sequence analysis panel, must include analysis of at least 7 genes, including	01/01/2015			Genetic and Molecular Testing (Medicare); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Commercial/ASO, Medicare, OHP, PEBB	81436	Hereditary colon cancer syndromes (eg, Lynch syndrome, familial adenomatosis polyposis); duplication/deletion gene analysis panel, must include analysis of at least 8 genes, i	01/01/2015			Genetic and Molecular Testing (Medicare); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company)
Commercial/ASO, Medicare, OHP, PEBB	81437	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); genomic sequence analysis panel, must include sequencing of at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127, and VHL	01/01/2016			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Non-Covered Genetic Panel Tests (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 218/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81438	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL	01/01/2016			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Non-Covered Genetic Panel Tests (Company)
Medicare	81439	Inherited cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy) genomic sequence analysis panel, must include sequencing of at least 5 genes, including DSG2, MYBPC3, MYH7, PKP2, and TTN	07/01/2018			Cardiac: Disease Risk Screening (Medicare); Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81439	Inherited cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy) genomic sequence analysis panel, must include sequencing of at least 5 genes, including DSG2, MYBPC3, MYH7, PKP2, and TTN	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)
Medicare	81440	Nuclear encoded mitochondrial genes (eg, neurologic or myopathic phenotypes), genomic sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2, COQ2, COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP	07/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81440	Nuclear encoded mitochondrial genes (eg, neurologic or myopathic phenotypes), genomic sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2, COQ2, COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1,	02/01/2018			Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Whole Exome, Whole Genome, and Proteogenomic Genetic Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 219/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		SCO2, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP				
Commercial/ASO, OHP, PEBB	81441	Inherited bone marrow failure syndromes (IBMFS) (eg, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome, congenital amegakaryocytic thrombocytopenia) sequence analysis panel, must include sequencing of at least 30 genes, including BRCA2, BRIP1, DKC1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, GATA1, GATA2, MPL, NHP2, NOP10, PALB2, RAD51C, RPL11, RPL35A, RPL5, RPS10, RPS19, RPS24, RPS26, RPS7, SBDS, TERT, and TINF2	01/01/2023		Commercial/ASO,OHP,PEBB -	Genetic and Molecular Testing (Company)
Medicare	81441	Inherited bone marrow failure syndromes (IBMFS) (eg, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome, congenital amegakaryocytic thrombocytopenia) sequence analysis panel, must include sequencing of at least 30 genes, including BRCA2, BRIP1, DKC1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, GATA1, GATA2, MPL, NHP2, NOP10, PALB2, RAD51C, RPL11, RPL35A, RPL5, RPS10, RPS19, RPS24, RPS26, RPS7, SBDS, TERT, and TINF2	01/01/2023			Genetic and Molecular Testing (Medicare)
Medicare	81442	Noonan spectrum disorders (eg, Noonan syndrome, cardio-facio-cutaneous syndrome, Costello syndrome, LEOPARD syndrome, Noonan-like syndrome), genomic sequence analysis panel, must include sequencing of at least 12 genes, including BRAF, CBL, HRAS,	07/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 220/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1				
Commercial/ASO, OHP, PEBB	81442	Noonan spectrum disorders (eg, Noonan syndrome, cardio-facio-cutaneous syndrome, Costello syndrome, LEOPARD syndrome, Noonan-like syndrome), genomic sequence analysis panel, must include sequencing of at least 12 genes, including BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1	02/01/2018			Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)
Commercial/ASO, Medicare, OHP, PEBB	81443	Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish- associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay- Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)	01/01/2019			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Covered Genetic Panel Tests (Company)
Commercial/ASO, Medicare, OHP, PEBB	81445	Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis	01/01/2015			Genetic and Molecular Testing (Medicare); Genetic Testing for Thyroid Nodules (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company); Genetic Testing: Thyroid Nodules (Company); Next Generation Sequencing for Cancer (Company)
Commercial/ASO, Medicare, OHP, PEBB	81448	Hereditary peripheral neuropathies (eg, Charcot-Marie-Tooth, spastic paraplegia), genomic sequence analysis panel, must include sequencing of at least 5 peripheral	01/01/2018			Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare); Non-Covered Genetic Panel Tests (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 221/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		neuropathy-related genes (eg, BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, SPTLC1)				
Commercial/ASO, OHP, PEBB	81449	Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; RNA analysis	01/01/2023			Next Generation Sequencing for Cancer (Company)
Medicare	81449	Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; RNA analysis	01/01/2023			Genetic and Molecular Testing (Medicare); Genetic Testing for Thyroid Nodules (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81450	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed	01/01/2015			Genetic and Molecular Testing (Medicare); Genetic Testing: Myeloproliferative Diseases (Company); Genetic Testing: Myeloproliferative Diseases (Medicare)
Commercial/ASO, OHP, PEBB	81451	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis	01/01/2023			Next Generation Sequencing for Cancer (Company)
Medicare	81451	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis	01/01/2023			Genetic and Molecular Testing (Medicare); Genetic Testing: Myeloproliferative Diseases (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81455	Solid organ or hematolymphoid neoplasm, genomic sequence analysis panel, 51 or greater genes, interrogation for sequence variants and copy number variants or rearrangements, if performed	01/01/2015			Genetic and Molecular Testing (Medicare); Genetic Testing: Hereditary Breast and Ovarian Cancer (Company); Genetic Testing: Inherited Susceptibility to Colorectal Cancer (Company); Genetic Testing: Myeloproliferative Diseases (Company); Genetic Testing: Myeloproliferative Diseases (Medicare); Next Generation Sequencing for Cancer (Company)
Commercial/ASO, OHP, PEBB	81456	Solid organ or hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 51 or greater genes, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis	01/01/2023			Next Generation Sequencing for Cancer (Company)
Medicare	81456	Solid organ or hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 51 or greater genes, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis	01/01/2023			Genetic and Molecular Testing (Medicare); Genetic Testing: Myeloproliferative Diseases (Medicare)
Medicare	81457	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, microsatellite instability	01/01/2024			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81457	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, microsatellite instability	01/01/2024			Next Generation Sequencing for Cancer (Company)
Medicare	81458	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence	01/01/2024			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 223/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		variants; DNA analysis, copy number variants and microsatellite instability				
Commercial/ASO, OHP, PEBB	81458	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, copy number variants and microsatellite instability	01/01/2024			Next Generation Sequencing for Cancer (Company)
Medicare	81459	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements	01/01/2024			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81459	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements	01/01/2024			Next Generation Sequencing for Cancer (Company)
Commercial/ASO, Medicare, OHP, PEBB	81460	Whole mitochondrial genome (eg, Leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with ragged-red fibers [	01/01/2015	06/30/2021		Whole Exome, Whole Genome, and Proteogenomic Genetic Testing (Company)
Medicare	81460	Whole mitochondrial genome (eg, Leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with ragged-red fibers [	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81460	Whole mitochondrial genome (eg, Leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with ragged-red fibers [MERFF], neuropathy, ataxia, and	11/01/2023			Whole Exome, Whole Genome, and Proteogenomic Genetic Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 224/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		retinitis pigmentosa [NARP], Leber hereditary optic neuropathy [LHON]), genomic sequence, must include sequence analysis of entire mitochondrial genome with heteroplasmy detection				
Commercial/ASO, Medicare, OHP, PEBB	81462	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants and rearrangements	01/01/2024			Circulating Tumor Cell and DNA Assays for Cancer Management (Company); Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81463	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis, copy number variants, and microsatellite instability	01/01/2024			Circulating Tumor Cell and DNA Assays for Cancer Management (Company); Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81464	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements	01/01/2024			Circulating Tumor Cell and DNA Assays for Cancer Management (Company); Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81465	Whole mitochondrial genome large deletion analysis panel (eg, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia), including heteroplasmy detection, if perfor	01/01/2015	06/30/2021		Whole Exome, Whole Genome, and Proteogenomic Genetic Testing (Company)
Medicare	81465	Whole mitochondrial genome large deletion analysis panel (eg, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia), including heteroplasmy detection, if perfor	01/01/2022			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 225/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	81470	X-linked intellectual disability (XLID) (eg, syndromic and non-syndromic XLID); genomic sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2	07/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81470	X-linked intellectual disability (XLID) (eg, syndromic and non-syndromic XLID); genomic sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2	02/01/2018			Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81471	X-linked intellectual disability (XLID) (eg, syndromic and non-syndromic XLID); duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2	07/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81471	X-linked intellectual disability (XLID) (eg, syndromic and non-syndromic XLID); duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2	02/01/2018			Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81500	Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score	01/01/2022			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 226/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	81503	Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81504	Quantitative carotid intima media thickness and carotid atheroma evaluation, bilateral	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy	07/01/2018			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy	02/01/2018	03/31/2021	This code may pay based on member's age	Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, OHP, PEBB	81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy	04/01/2021			Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	81508	Fetal congenital abnormalities, biochemical assays of 2 proteins	04/01/2016	06/30/2017		Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81508	Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81509	Fetal congenital abnormalities, biochemical assays of 3 proteins	04/01/2016	06/30/2017		Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81509	Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any	01/01/2022			Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 227/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		form], DIA), utilizing maternal serum, algorithm reported as a risk score				
Commercial/ASO, Medicare, OHP, PEBB	81510	Fetal congenital abnormalities, biochemical assays of three analytes	04/01/2016	06/30/2017		Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81510	Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81511	Fetal congenital abnormalities, biochemical assays of 4 analytes	04/01/2016	06/30/2017		Genetic and Molecular Testing (Medicare); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Medicare	81511	Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81512	Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal serum, algorithm reported as a risk score	01/01/2022			Genetic and Molecular Testing (Medicare)
Commercial/ASO, OHP, PEBB	81518	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy	01/01/2019			Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Company)
Medicare	81518	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing	01/01/2019	12/31/2019		Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 228/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy				
Commercial/ASO, OHP, PEBB	81519	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score	09/01/2017			Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Company)
Medicare	81519	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score	09/01/2017	12/31/2019		Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Medicare)
Commercial/ASO, OHP, PEBB	81520	Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence risk score	03/01/2018			Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Company)
Medicare	81520	Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence risk score	01/01/2018	12/31/2019		Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Medicare)
Commercial/ASO, OHP, PEBB	81521	Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis	03/01/2019		Both 81521 and 81523 may not be billed together for testing on the same tumor. If one test was billed, the other will be considered not medically necessary and not covered.	Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Company)
Medicare	81521	Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue,	01/01/2018	12/31/2019		Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 229/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		algorithm reported as index related to risk of distant metastasis				
Commercial/ASO, OHP, PEBB	81522	Oncology (breast), mRNA, gene expression profiling by RT-PCR of 12 genes (8 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk score	01/01/2020			Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Company); Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Medicare)
Commercial/ASO, OHP, PEBB	81523	Oncology (breast), mRNA, next-generation sequencing gene expression profiling of 70 content genes and 31 housekeeping genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk to distant metastasis	01/01/2022		Both 81521 and 81523 may not be billed together for testing on the same tumor. If one test was billed, the other will be considered not medically necessary and not covered.	Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Company)
Medicare	81525	Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81529	Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis	01/01/2021			Gene Expression Profile Testing for Melanoma (Medicare)
Medicare	81538	Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival	01/01/2022			Genetic and Molecular Testing (Medicare)
Medicare	81539	Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2	05/01/2022			Prostate Cancer: Biomarkers and Genetic Testing Medicare

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 230/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		[hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score				
Commercial/ASO, OHP, PEBB	81540	Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin- embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype	01/01/2016	06/30/2018		Non-Covered Genetic Panel Tests (Company)
Medicare	81541	Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score	01/01/2018			Prostate: Protein Biomarkers and Genetic Testing (Medicare)
Commercial/ASO, PEBB	81541	Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score	06/01/2022			Prostate: Protein Biomarkers and Genetic Testing (Company)
Medicare	81542	Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score	01/01/2020			Prostate: Protein Biomarkers and Genetic Testing (Medicare)
Commercial/ASO, OHP, PEBB	81542	Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score	06/01/2022			Prostate: Protein Biomarkers and Genetic Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 231/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	81545	Oncology (thyroid), gene expression analysis of 142 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious)	01/01/2016	12/31/2020	This code is no longer valid effective 1/1/2021	Genetic Testing for Thyroid Nodules (Medicare); Genetic Testing: Thyroid Nodules (Company)
Commercial/ASO, Medicare, OHP, PEBB	81546	Oncology (thyroid), mRNA, gene expression analysis of 10,196 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious)	01/01/2021			Genetic and Molecular Testing (Company); Genetic Testing for Thyroid Nodules (Medicare)
Medicare	81551	Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin- embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy	01/01/2018			Prostate: Protein Biomarkers and Genetic Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81552	Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis	01/01/2020			Gene Expression Profile Testing for Melanoma (Company); Gene Expression Profile Testing for Melanoma (Medicare)
Medicare	81554	Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (eg, positive or negative for high probability of usual interstitial pneumonia [UIP])	01/01/2021			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	81595	Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score	01/01/2016		Medicaid – As of 12/1/23 PA is no longer required for OHP for contracted transplant facilities. Refer to guideline note 42 in OHA's prioritized list for additional billing guidelines.	Genetic and Molecular Testing (Company); Genetic and Molecular Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 232/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	82106	Alpha-fetoprotein; amniotic fluid	08/01/2016	05/30/2017		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	83020	Hemoglobulin frantionation and quantitation, electrophoresis	04/01/2016	06/30/2017		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	83021	Hemoglobin fractionation and quantitation, chromatography	04/01/2016	06/30/2017		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	83921	Organic acid, single, quantitative	01/01/2016	12/31/2022		Cardiac: Disease Risk Screening (Company); Organic Acid Testing (Company) ; Organic Acid Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	84433	Thiopurine S-methyltransferase (TPMT)	01/01/2023			Inflammatory Bowel Disease: Serologic Markers and Therapeutic Monitoring (Company); Inflammatory Bowel Disease: Serologic Testing and Therapeutic Monitoring (Medicare)
Medicare	86001	Allergen Specific Igg Quantitative or Semiquantitative, Each Allergen	09/01/2003	10/31/2017		Allergy Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	86003	Allergen Specific IGE each Panel	09/01/2003	06/30/2019		Allergy Testing (Company); Allergy Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	86008	Allergen specific lgE; quantitative or semiquantitative, recombinant or purified component, each	05/01/2018	06/30/2019		Allergy Testing (Company); Allergy Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	86152	Cell Enumeration Using Immunologic Selection And Identification In Fluid Specimen	01/01/2013	02/28/2017		Circulating Tumor Cell and DNA Assays for Cancer Management (Company)
Medicare	86152	Cell Enumeration Using Immunologic Selection And Identification In Fluid Specimen	06/01/2021			Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	86153	Cell Enumeration Using Immunologic Selection And Identification In Fluid Specimen; Physician Interp And Report	01/01/2013	02/28/2017		Circulating Tumor Cell and DNA Assays for Cancer Management (Company); Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 233/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	86153	Cell Enumeration Using Immunologic Selection And Identification In Fluid Specimen; Physician Interp And Report	06/01/2021			Circulating Tumor Cell and DNA Assays for Cancer Management (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	87900	Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics	01/01/2006	07/31/2017		
Commercial/ASO, Medicare, OHP, PEBB	88235	tissue culture for non-neoplastic disorders; amniotic fluid or chorionic villus cells	04/01/2016	12/31/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	88240	cryopreservation, freezing and storage of cells, each cell line	12/01/2015	10/31/2017		Umbilical Cord Blood Banking
Commercial/ASO, Medicare, OHP, PEBB	88241	Thawing and expansion of frozen cells each aliquot	09/01/2003	06/30/2018		
Commercial/ASO, Medicare, OHP, PEBB	88245	Chrom.An-Break.Syn;25cls,Ct 5,1kary	09/01/2003	06/30/2018		
Commercial/ASO, Medicare, OHP, PEBB	88248	Chrom.An-Brk.Syn;100cls,Ct.20,2kary	09/01/2003	06/30/2018		
Commercial/ASO, Medicare, OHP, PEBB	88249	Chromosome analysis for breakage syndromes score 100 cells clastogen stress	09/01/2003	06/30/2018		
Commercial/ASO, Medicare, OHP, PEBB	88263	Chrom.Anal;ct.45 Clls-Mosaic,2 Kary	09/01/2003	06/30/2018		
Commercial/ASO, Medicare, OHP, PEBB	88267	Chromosome analysis, amniotic fluid or chorionic villus, count 15 cells, 1 karyotype, with banding	04/01/2016	12/31/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	88269	Chromosome analysis, in situ for amniotic fluid cells, count cells from 6/12 colonies, 1 kayotype, with banding	08/01/2016	12/31/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	88271	Molecular cytogenetics DNA probe each	09/01/2003	06/30/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Small Cell Lung Cancer: Tumor Testing for Targeted Therapy (Company)
Commercial/ASO, Medicare, OHP, PEBB	88272	Molecular cytogenetics chromosomal in situ hybridization analyze 3-5 cells	09/01/2003	06/30/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	88273	Molecular cypogenetics; chromosomal in situ hybridization, analyze 10-30 cells ( eg for microdeletions)	08/01/2016	06/30/2018		Genetic and Molecular Testing (Company); Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	88274	Molecular cytogenetics interphase in situ hybridization analyze 25-99 cells	09/01/2003	06/30/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company); Non-Small Cell Lung Cancer: Tumor Testing for Targeted Therapy (Company)
Commercial/ASO, Medicare, OHP, PEBB	88275	Molecular cytogenetics interphase in situ hybridization analyze 100-300 cells	09/01/2003	06/30/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	88283	Chromosome Analy; Add. Specialized Bandi	09/01/2003	06/30/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	88285	Chrom.Anal;add.Cell Counted,Ea Stdy	09/01/2003	06/30/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	88289	Chrom.Anal;addtl High Resolutn Stdy	09/01/2003	06/30/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	88291	Cytogenetics and molecular cytogenetics interpretation and report	09/01/2003	06/30/2018		Genetic Testing: Reproductive Planning and Prenatal Testing (Company)
Commercial/ASO	90867	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management	02/01/2018		Commercial/ASO - PA required by Optum for Providence St Joseph Health (PSJH), except St. Joseph Health Northern California PA required by PHP and PPP for commercial/ASO, and St. Joseph Health Northern California	Transcranial Magnetic Stimulation (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	90867	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management	01/01/2021			Transcranial Magnetic Stimulation (Medicare)
PEBB	90867	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management	02/01/2018	06/30/2023	PEBB was removed from this policy 7/1/2023	Transcranial Magnetic Stimulation (Company)
Commercial/ASO	90868	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session	02/01/2018		Commercial/ASO - PA required by Optum for Providence St Joseph Health (PSJH), except St. Joseph Health Northern California PA required by PHP and PPP for commercial/ASO, and St. Joseph Health Northern California	Transcranial Magnetic Stimulation (Company)
Medicare	90868	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session	01/01/2021			Transcranial Magnetic Stimulation (Medicare)
PEBB	90868	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session	02/01/2018	06/30/2023	PEBB was removed from this policy 7/1/2023	Transcranial Magnetic Stimulation (Company)
Commercial/ASO	90869	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management	02/01/2018		Commercial/ASO - PA required by Optum for Providence St Joseph Health (PSJH), except St. Joseph Health Northern California PA required by PHP and PPP for commercial/ASO, and St. Joseph Health Northern California	Transcranial Magnetic Stimulation (Company)
Medicare	90869	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management	01/01/2021			Transcranial Magnetic Stimulation (Medicare)
PEBB	90869	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management	02/01/2018	06/30/2023	PEBB was removed from this policy 7/1/2023	Transcranial Magnetic Stimulation (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 236/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, PEBB	90901	Biofeedback training by any modality	06/01/2019	12/31/2020	Commercial/ASO - Commercial Only (excluding ASO groups) – Evicore prior authorization required	Biofeedback and Neurofeedback (Company); Biofeedback and Neurofeedback (Medicare)
Medicare	91065	Breath hydrogen or methane test (eg, for detection of lactase deficiency, fructose intolerance, bacterial overgrowth, or oro-cecal gastrointestinal transit)	10/01/2016			Exhaled Breath Tests (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	91110	Gastrointestinal Tract Imaging, Intraluminal (Eg, Capsule Endoscopy), Esophagus Through Ileum, w Phys Interp and Report	09/01/2003			Wireless Capsule Endoscopy (Company); Wireless Capsule Endoscopy (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	91111	Gastrointestinal Tract Imaging, Intraluminal (Eg, Capsule Endoscopy), Esophagus with Physician Interpretation and Report	01/01/2007	06/30/2020		Wireless Capsule Endoscopy (Company); Wireless Capsule Endoscopy (Medicare)
Commercial/ASO, OHP, PEBB	91111	Gastrointestinal Tract Imaging, Intraluminal (Eg, Capsule Endoscopy), Esophagus with Physician Interpretation and Report	06/01/2021			Wireless Capsule Endoscopy (Company)
Medicare	91111	Gastrointestinal Tract Imaging, Intraluminal (Eg, Capsule Endoscopy), Esophagus with Physician Interpretation and Report	04/01/2021			Wireless Capsule Endoscopy (Medicare)
Medicare	91113	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), colon, with interpretation and report	01/01/2022			Wireless Capsule Endoscopy (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	92597	Evaluation for use of Voice Prosthetic	01/01/2013	06/30/2017		Habilitation Services
Commercial/ASO, Medicare, OHP, PEBB	92618	Eval For Rx Non-Speech-Generating Augmentative And Alternative Communication Device, Face-To-Face W Pt; Ea Addl 30 Min	01/01/2012	12/31/2014		Speech Generating Devices (Company)
Commercial/ASO, Medicare, OHP, PEBB	92640	Diagnostic analysis with programming of auditory brainstem implant, per hour	10/01/2017			Cochlear Implants and Auditory Brainstem Implants (Company); Cochlear Implants and Auditory Brainstem Implants (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 237/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	93228	Wearable Mobile Cardiovascular Telemetry with Events Transmitted To Center for up to 30 Days; Physician Review W Report	10/01/2009			Cardiac: External Ambulatory Electrocardiography (Company); Cardiac: External Ambulatory Electrocardiography (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	93229	Wearable Mobile Cardiovascular Telemetry with Events Transmitted To Center for up to 30 Days; Technical Support	10/01/2009			Cardiac: External Ambulatory Electrocardiography (Company); Cardiac: External Ambulatory Electrocardiography (Medicare)
Commercial/ASO, OHP, PEBB	93303	Transthoracic Echo cardiac anomalies	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	93303	Transthoracic Echo cardiac anomalies	01/01/2016	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	93304	Transthoracic Echo cardiac anomalies, limited	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	93304	Transthoracic Echo cardiac anomalies, limited	01/01/2016	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	93306	Transthoracic Echo complete w color & spectral	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	93306	Transthoracic Echo complete w color & spectral	01/01/2016	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	93307	Transthoracic Echo complete wo color & spectral	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	93307	Transthoracic Echo complete wo color & spectral	01/01/2016	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	93308	Transthoracic Echo limited	01/01/2016		Carelon prior authorization required	
Medicare	93308	Transthoracic Echo limited	01/01/2016	07/31/2023	Carelon prior authorization not required	
Commercial/ASO, OHP, PEBB	93312	Transesophageal Echo	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	93312	Transesophageal Echo	01/01/2016	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	93313	Transesophageal Echo probe only	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	93313	Transesophageal Echo probe only	01/01/2016	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	93314	Transesophageal Echo interpretation	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	93314	Transesophageal Echo interpretation	01/01/2016	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	93315	Transesophageal Echo congenital	01/01/2016		Carelon prior authorization required	
Medicare	93315	Transesophageal Echo congenital	01/01/2016	07/31/2023	Carelon prior authorization not required	

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 239/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	93316	Transesophageal Echo congenital, probe only	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	93316	Transesophageal Echo congenital, probe only	01/01/2016	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	93317	Transesophageal Echo congenital interpretation	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	93317	Transesophageal Echo congenital interpretation	01/01/2016	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	93350	Transthoracic Stress Echo, complete	01/01/2016		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	93350	Transthoracic Stress Echo, complete	01/01/2016	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	93351	Transthoracic Stress Echo, complete w cont EKG	01/01/2016		Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Medicare	93351	Transthoracic Stress Echo, complete w cont EKG	01/01/2016	07/31/2023	Carelon prior authorization not required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	93568	Injection Procedure During Cardiac Cath; For Pulmonary Angiography	10/01/2014	12/31/2015		CardioMems Heart Failure System
Commercial/ASO, Medicare, OHP, PEBB	93590	Percutaneous transcatheter closure of paravalvular leak; initial occlusion device, mitral valve	01/01/2017	02/28/2022		New and Emerging Technologies and Other Non-Covered Services (Company); New and Emerging Technologies and Other Non- Covered Services (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 240/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	93591	Percutaneous transcatheter closure of paravalvular leak; initial occlusion device, aortic valve	01/01/2017	02/28/2022		New and Emerging Technologies and Other Non-Covered Services (Company)
Commercial/ASO, Medicare, OHP, PEBB	93784	Ambulatory blood pressure monitoring, utilizing a system such as magnetic tape and/or computer disk, for 24 hours or longer; including recording, scanning analysis, interpretation and report	09/01/2003	09/30/2016		
Commercial/ASO, Medicare, OHP, PEBB	93786	Ambulatory blood pressure monitoring, utilizing a system such as magnetic tape and/or computer disk, for 24 hours or longer; recording only	09/01/2003	09/30/2016		
Commercial/ASO, Medicare, OHP, PEBB	93788	Ambulatory blood pressure monitoring, utilizing a system such as magnetic tape and/or computer disk, for 24 hours or longer; scanning analysis with report	09/01/2003	09/30/2016		
Commercial/ASO, Medicare, OHP, PEBB	93790	Ambulatory blood pressure monitoring, utilizing a system such as magnetic tape and/or computer disk, for 24 hours or longer; review with interpretation and report	09/01/2003	09/30/2016		
Commercial/ASO, Medicare, OHP, PEBB	94669	Mechanical chest wall oscillation to facilitate lung function, per session	01/01/2014	12/31/2016		High Frequency Chest Wall Oscillation Devices
Commercial/ASO, Medicare, OHP, PEBB	95782	Polysomnography; Pt < 6 Yrs, Sleep Staging With 4 Or More Additional Parameters Of Sleep	01/01/2013	07/31/2016		Sleep Disorder Testing (Company)
Commercial/ASO, Medicare, OHP, PEBB	95783	Polysomnography; Pt < 6 Yrs, Sleep Staging With 4 Or More Additional Parameters Of Sleep, W Cpap Or Bi-Level Ventilation	01/01/2013	07/31/2016		Sleep Disorder Testing (Company)
Medicare	95805	Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation of physiological measurements	01/01/2009	03/31/2018		Sleep Disorder Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 241/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		of sleep during multiple trials to assess sleepiness				
Commercial/ASO, OHP, PEBB	95805	Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation of physiological measurements of sleep during multiple trials to assess sleepiness	01/01/2009		No prior authorization required for ages 17 and under	Sleep Disorder Testing (Company)
Medicare	95807	Sleep Study, 3 or More Parameters Other Than Staging	01/01/2009	03/31/2018		Sleep Disorder Testing (Medicare)
Commercial/ASO, OHP, PEBB	95807	Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist	01/01/2009		No prior authorization required for ages 17 and under	Sleep Disorder Testing (Company)
Medicare	95808	Polysomnography; Sleep Staging with 1 to 3 Additional Parameters	01/01/2009	03/31/2018		Sleep Disorder Testing (Company)
Commercial/ASO, OHP, PEBB	95808	Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist	01/01/2009		No prior authorization required for ages 17 and under	Sleep Disorder Testing (Company)
Commercial/ASO, OHP, PEBB	95810	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist	01/01/2009		Commercial/ASO,OHP,PEBB - No prior authorization required for ages 17 and under, effective 8/1/16	Sleep Disorder Testing (Company)
Medicare	95810	Polysomnography; Sleep Staging with 4 or More Parameters	01/01/2009	03/31/2018		Sleep Disorder Testing (Company)
Commercial/ASO, OHP, PEBB	95811	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist	01/01/2009		Commercial/ASO,OHP,PEBB - No prior authorization required for ages 17 and under, effective 8/1/16	Sleep Disorder Testing (Company)
Medicare	95811	Polysomnography; Sleep Staging With >3 Addit Parameters, W Cpap,Attend	01/01/2009	03/31/2018		Sleep Disorder Testing (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 242/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	95836	Electrocorticogram from an implanted brain neurostimulator pulse generator/transmitter, including recording, with interpretation and written report, up to 30 days	01/01/2019			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company)
Commercial/ASO, Medicare, PEBB	95873	Electrical stimulation for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)	09/01/2019			Botulinum Therapies (Company); Botulinum Therapies (Medicare)
Commercial/ASO, Medicare, PEBB	95874	Needle electromyography for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)	09/01/2019			Botulinum Therapies (Company); Botulinum Therapies (Medicare)
Commercial/ASO, OHP, PEBB	95940	Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List separately in addition to code for primary procedure)	01/01/2022		Commercial/ASO,OHP,PEBB - This code may pay based on billed diagnosis code	Intraoperative Monitoring (Company)
Medicare	95940	Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List separately in addition to code for primary procedure)	01/01/2022		Medicare - This code may pay based on billed diagnosis code	Intraoperative Monitoring (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	95951	Monit/Lateraliz Seiz EEG & Video 24	07/01/2006	11/30/2017		Long-Term Video-EEG Monitoring



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	95970	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple or complex brain, spinal cord, or peripheral (ie, cranial nerve, peripheral nerve, sacral nerve, neuromuscular) neurostimulator pulse generator/transmitter, without reprogramming	10/01/2016	03/31/2018		Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation: Non-Covered Therapies (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Occipital Nerve Stimulation and Ablation (Company); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	95974	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour	10/01/2016	06/30/2018		Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	95975	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)	10/01/2016	06/30/2018		Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 244/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	95976	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional	01/01/2019	12/31/2019		Deep Brain and Responsive Cortical Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	95977	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional	01/01/2019	12/31/2019		Deep Brain and Responsive Cortical Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	95978	Electronic Analysis Implanted Neurostimulator Pulse Generator System, Complex Deep Brain System, W Programming; First Hr	07/01/2010	12/31/2018		Deep Brain and Responsive Cortical Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	95979	Electronic Analysis Implanted Neurostim Pulse Generator System, Complex Deep Brain System, W Programming; Ea Addl 30 Min	07/01/2010	12/31/2018		Deep Brain and Responsive Cortical Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	95983	Electronic analysis of implanted neurostimulator pulse generator/transmitter	01/01/2019	12/31/2019		Deep Brain and Responsive Cortical Stimulation (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 245/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		(eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional				
Commercial/ASO, Medicare, OHP, PEBB	95984	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)	01/01/2019	12/31/2019		Deep Brain and Responsive Cortical Stimulation (Company)
Commercial/ASO	95992	Canalith repositioning procedure(s) (eg, Epley maneuver, Semont maneuver), per day	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO, Medicare, OHP, PEBB	96040	Medical Genetics and Genetic Counseling Services, Each 30 Minutes Face-To-Face with Patient/Family	01/01/2007	12/31/2015		Breast Cancer: Genetic Counseling and Testing; Genetic Testing: Reproductive Planning and Prenatal Testing (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 246/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO	97010	Application of a modality to 1 or more areas; hot or cold packs	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97012	Application of a modality to 1 or more areas; traction, mechanical	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97014	Application of a modality to 1 or more areas; electrical stimulation (unattended)	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	Electrical Stimulation: Non-Covered Therapies (Company)
Commercial/ASO	97016	Application of a modality to 1 or more areas; vasopneumatic devices	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97018	Application of a modality to 1 or more areas; paraffin bath	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97022	Application of a modality to 1 or more areas; whirlpool	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97024	Application of a modality to 1 or more areas; diathermy (eg, microwave)	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA	

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 247/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
					General Requirements pages for specific ASO plans.	
Commercial/ASO	97026	Application of a modality to 1 or more areas; infrared	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97028	Application of a modality to 1 or more areas; ultraviolet	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97032	Application of a modality to 1 or more areas; electrical stimulation (manual), each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	Electrical Stimulation: Non-Covered Therapies (Company)
Commercial/ASO	97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97034	Application of a modality to 1 or more areas; contrast baths, each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97035	Application of a modality to 1 or more areas; ultrasound, each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO	97036	Application of a modality to 1 or more areas; Hubbard tank, each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97039	Unlisted modality (specify type and time if constant attendance)	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	Complementary and Alternative Medicine (CAM) Treatments (Company)
Commercial/ASO	97110	Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97112	Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97113	Therapeutic procedure, 1 or more areas, each 15 minutes; aquatic therapy with therapeutic exercises	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97116	Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Medicare	97127	Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem	06/01/2019	12/31/2019	Commercial/ASO - Commercial Only (excluding ASO groups) – Evicore prior authorization	

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 249/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing and sequencing tasks), direct (one-on-one) patient contact			required This code is no longer valid effective 1/1/2020	
Commercial/ASO	97129	Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; initial 15 minutes	01/01/2020		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97130	Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; each additional 15 minutes (List separately in addition to code for primary procedure)	01/01/2020		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97139	Unlisted therapeutic procedure (specify)	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97140	Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage,	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA	Complementary and Alternative Medicine (CAM) Treatments (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 250/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		manual traction), 1 or more regions, each 15 minutes			General Requirements pages for specific ASO plans.	
Commercial/ASO	97150	Therapeutic procedure(s), group (2 or more individuals)	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97151	Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan	01/01/2021		PA required by Optum for Providence St Joseph Health (PSJH), except St. Joseph Health Northern California. PA required by PHP and PPP for commercial/ASO, and St. Joseph Health Northern California. Prior authorization excludes Intel	Applied Behavior Analysis (Company)
Medicare	97151	Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan	01/01/2021	02/28/2023	Medicare was removed from this policy 3/1/2023	Applied Behavior Analysis (Company)
PEBB	97151	Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient	01/01/2021	06/30/2023	PEBB was removed from this policy 7/1/2023	Applied Behavior Analysis (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 251/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan				
Commercial/ASO	97152	Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes	01/01/2021		PA required by Optum for Providence St Joseph Health (PSJH), except St. Joseph Health Northern California. PA required by PHP and PPP for commercial/ASO, and St. Joseph Health Northern California. Prior authorization excludes Intel	Applied Behavior Analysis (Company)
Medicare	97152	Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes	01/01/2021	02/28/2023	Medicare was removed from this policy 3/1/2023	Applied Behavior Analysis (Company)
PEBB	97152	Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes	01/01/2021	06/30/2023	PEBB was removed from this policy 7/1/2023	Applied Behavior Analysis (Company)
Commercial/ASO	97153	Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes	01/01/2021		PA required by Optum for Providence St Joseph Health (PSJH), except St. Joseph Health Northern California PA required by PHP and PPP for commercial/ASO, and St. Joseph Health Northern California. Prior authorization excludes Intel	Applied Behavior Analysis (Company)
Medicare	97153	Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes	01/01/2021	02/28/2023	Medicare was removed from this policy 3/1/2023	Applied Behavior Analysis (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 252/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
PEBB	97153	Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes	01/01/2021	06/30/2023	PEBB was removed from this policy 7/1/2023	Applied Behavior Analysis (Company)
Commercial/ASO	97154	Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes	01/01/2021		PA required by Optum for Providence St Joseph Health (PSJH), except St. Joseph Health Northern California. PA required by PHP and PPP for commercial/ASO, and St. Joseph Health Northern California. Prior authorization excludes Intel	Applied Behavior Analysis (Company)
Medicare	97154	Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes	01/01/2021	02/28/2023	Medicare was removed from this policy 3/1/2023	Applied Behavior Analysis (Company)
PEBB	97154	Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes	01/01/2021	06/30/2023	PEBB was removed from this policy 7/1/2023	Applied Behavior Analysis (Company)
Commercial/ASO	97155	Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes	01/01/2021		PA required by Optum for Providence St Joseph Health (PSJH), except St. Joseph Health Northern California. PA required by PHP and PPP for commercial/ASO, and St. Joseph Health Northern California. Prior authorization excludes Intel	Applied Behavior Analysis (Company)
Medicare	97155	Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes	01/01/2021	02/28/2023	Medicare was removed from this policy 3/1/2023	Applied Behavior Analysis (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 253/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
PEBB	97155	Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes	01/01/2021	06/30/2023	PEBB was removed from this policy 7/1/2023	Applied Behavior Analysis (Company)
Commercial/ASO	97156	Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes	01/01/2021		PA required by Optum for Providence St Joseph Health (PSJH), except St. Joseph Health Northern California. PA required by PHP and PPP for commercial/ASO, and St. Joseph Health Northern California. Prior authorization excludes Intel	Applied Behavior Analysis (Company)
Medicare	97156	Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes	01/01/2021	02/28/2023	Medicare was removed from this policy 3/1/2023	Applied Behavior Analysis (Company)
PEBB	97156	Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes	01/01/2021	06/30/2023	PEBB was removed from this policy 7/1/2023	Applied Behavior Analysis (Company)
Commercial/ASO	97157	Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes	01/01/2021		PA required by Optum for Providence St Joseph Health (PSJH), except St. Joseph Health Northern California. PA required by PHP and PPP for commercial/ASO, and St. Joseph Health Northern California. Prior authorization excludes Intel	Applied Behavior Analysis (Company)
Medicare	97157	Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present),	01/01/2021	02/28/2023	Medicare was removed from this policy 3/1/2023	Applied Behavior Analysis (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 254/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		face-to-face with multiple sets of guardians/caregivers, each 15 minutes				
PEBB	97157	Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes	01/01/2021	06/30/2023	PEBB was removed from this policy 7/1/2023	Applied Behavior Analysis (Company)
Commercial/ASO	97158	Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes	01/01/2021		PA required by Optum for Providence St Joseph Health (PSJH), except St. Joseph Health Northern California. PA required by PHP and PPP for commercial/ASO, and St. Joseph Health Northern California. Prior authorization excludes Intel	Applied Behavior Analysis (Company)
Medicare	97158	Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes	01/01/2021	02/28/2023	Medicare was removed from this policy 3/1/2023	Applied Behavior Analysis (Company)
PEBB	97158	Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes	01/01/2021	06/30/2023	PEBB was removed from this policy 7/1/2023	Applied Behavior Analysis (Company)
Commercial/ASO	97161	Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements from any of the following: body structures and functions, activity limitations, and/or participation restrictions; A clinical presentation with stable	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 255/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		and/or uncomplicated characteristics; and Clinical decision making of low complexity using standardized patient assessment instrument and/or measurable assessment of functional outcome. Typically, 20 minutes are spent face-to-face with the patient and/or family.				
Commercial/ASO	97162	Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in addressing a total of 3 or more elements from any of the following: body structures and functions, activity limitations, and/or participation restrictions; An evolving clinical presentation with changing characteristics; and Clinical decision making of moderate complexity using standardized patient assessment instrument and/or measurable assessment of functional outcome. Typically, 30 minutes are spent face-to-face with the patient and/or family	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97163	Physical therapy evaluation: high complexity, requiring these components: A history of present problem with 3 or more personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures addressing a total of 4 or more elements from any of the following: body structures and functions, activity limitations, and/or participation restrictions; A clinical presentation with unstable and unpredictable characteristics; and Clinical decision making of	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 256/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		high complexity using standardized patient assessment instrument and/or measurable assessment of functional outcome. Typically, 45 minutes are spent face-to-face with the patient and/or family				
Commercial/ASO	97164	Re-evaluation of physical therapy established plan of care, requiring these components: An examination including a review of history and use of standardized tests and measures is required; and Revised plan of care using a standardized patient assessment instrument and/or measurable assessment of functional outcome Typically, 20 minutes are spent face- to-face with the patient and/or family.	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97165	Occupational therapy evaluation, low complexity, requiring these components: An occupational profile and medical and therapy history, which includes a brief history including review of medical and/or therapy records relating to the presenting problem; An assessment(s) that identifies 1-3 performance deficits (ie, relating to physical, cognitive, or psychosocial skills) that result in activity limitations and/or participation restrictions; and Clinical decision making of low complexity, which includes an analysis of the occupational profile, analysis of data from problem-focused assessment(s), and consideration of a limited number of treatment options. Patient presents with no comorbidities that affect occupational performance. Modification of tasks or assistance (eg, physical or verbal) with assessment(s) is not necessary to enable completion of evaluation component.	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		Typically, 30 minutes are spent face-to-face with the patient and/or family.				
Commercial/ASO	97166	Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or psychosocial history related to current functional performance; An assessment(s) that identifies 3-5 performance deficits (ie, relating to physical, cognitive, or psychosocial skills) that result in activity limitations and/or participation restrictions; and Clinical decision making of moderate analytic complexity, which includes an analysis of the occupational profile, analysis of data from detailed assessment(s), and consideration of several treatment options. Patient may present with comorbidities that affect occupational performance. Minimal to moderate modification of tasks or assistance (eg, physical or verbal) with assessment(s) is necessary to enable patient to complete evaluation component. Typically, 45 minutes are spent face-to-face with the patient and/or family.	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97167	Occupational therapy evaluation, high complexity, requiring these components: An occupational profile and medical and therapy history, which includes review of medical and/or therapy records and extensive additional review of physical, cognitive, or psychosocial history related to current functional performance; An assessment(s) that	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 258/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		identifies 5 or more performance deficits (ie, relating to physical, cognitive, or psychosocial skills) that result in activity limitations and/or participation restrictions; and Clinical decision making of high analytic complexity, which includes an analysis of the patient profile, analysis of data from comprehensive assessment(s), and consideration of multiple treatment options. Patient presents with comorbidities that affect occupational performance. Significant modification of tasks or assistance (eg, physical or verbal) with assessment(s) is necessary to enable patient to complete evaluation component. Typically, 60 minutes are spent face-to-face with the patient and/or family				
Commercial/ASO	97168	Re-evaluation of occupational therapy established plan of care, requiring these components: An assessment of changes in patient functional or medical status with revised plan of care; An update to the initial occupational profile to reflect changes in condition or environment that affect future interventions and/or goals; and A revised plan of care. A formal reevaluation is performed when there is a documented change in functional status or a significant change to the plan of care is required. Typically, 30 minutes are spent face-to-face with the patient and/or family.	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97530	Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO	97535	Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97537	Community/work reintegration training (eg, shopping, transportation, money management, avocational activities and/or work environment/modification analysis, work task analysis, use of assistive technology device/adaptive equipment), direct one-on- one contact, each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	Outpatient Physical Therapy (Company)
Commercial/ASO	97542	Wheelchair management (eg, assessment, fitting, training), each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97545	Work hardening/conditioning; initial 2 hours	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97546	Work hardening/conditioning; each additional hour (List separately in addition to code for primary procedure)	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO, Medicare, OHP, PEBB	97605	Negative Pressure Wound Therapy, Per Session; Total Area	09/01/2003	12/31/2023		Negative Pressure Wound Therapy (Company); Negative Pressure Wound Therapy (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	97606	Negative Pressure Wound Therapy, Per Session; Total Area > 50 Sq Cm	09/01/2003	12/31/2023		Negative Pressure Wound Therapy (Company); Negative Pressure Wound Therapy (Medicare)
Medicare	97607	Negative pressure wound therapy, (eg, vacuum assisted drainage collection), utilizing disposable, non-durable medical equipment including provision of exudate management colle	10/01/2022	12/31/2023		Negative Pressure Wound Therapy (Medicare)
Medicare	97608	Negative pressure wound therapy, (eg, vacuum assisted drainage collection), utilizing disposable, non-durable medical equipment including provision of exudate management colle	10/01/2022	12/31/2023		Negative Pressure Wound Therapy (Medicare)
Medicare	97610	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day	06/01/2019	05/31/2021		Non-Contact Wound Therapy (Medicare Only) (archived 6/1/2021)
Commercial/ASO	97750	Physical performance test or measurement (eg, musculoskeletal, functional capacity), with written report, each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97755	Assistive technology assessment (eg, to restore, augment or compensate for existing function, optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact, with written report, each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97760	Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(ies), lower extremity(ies) and/or trunk, initial orthotic(s) encounter, each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO	97761	Prosthetic(s) training, upper and/or lower extremity(ies), initial prosthetic(s) encounter, each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97763	Orthotic(s)/prosthetic(s) management and/or training, upper extremity(ies), lower extremity(ies), and/or trunk, subsequent orthotic(s)/prosthetic(s) encounter, each 15 minutes	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO	97799	Unlisted physical medicine/rehabilitation service or procedure	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	
Commercial/ASO, Medicare, OHP, PEBB	99183	Physician Attendance and Supervision of Hyperbaric Oxygen Therapy; Per Session	01/01/2008			Hyperbaric Oxygen Therapy (Company); Hyperbaric Oxygen Therapy (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	A4100	Skin substitute, fda cleared as a device, not otherwise specified	04/01/2022		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	A4290	Sacral nerve stimulation test lead, each	03/01/2016			Fecal Incontinence Treatments (Company); Fecal Incontinence Treatments (Medicare); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Medicare	A4341	Indwelling intraurethral drainage device with valve, patient inserted, replacement only, each	04/01/2023			Urinary Incontinence Treatments (Medicare)
Medicare	A4342	Accessories for patient inserted indwelling intraurethral drainage device with valve, replacement only, each	04/01/2023			Urinary Incontinence Treatments (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	A4467	Belt, strap, sleeve, garment, or covering, any type	01/01/2017	03/31/2019		Ankle-Foot/Knee-Ankle-Foot Orthoses (Medicare); Knee Braces (Functional) (Company); Knee Braces (Functional) (Medicare)
Medicare	A4542	Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist	04/01/2024			Electrical Stimulation and Electromagnetic Therapies (Medicare)
Commercial/ASO, OHP, PEBB	A4555	Electrode/transducer for use with electrical stimulation device used for cancer treatment, replacement only	03/01/2017			Tumor Treatment Field Therapy for Glioblastoma (Company)
Medicare	A4555	Electrode/transducer for use with electrical stimulation device used for cancer treatment, replacement only	09/01/2019			Tumor Treatment Field Therapy for Glioblastoma (Company); Tumor Treatment Field Therapy for Glioblastoma (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	A4660	Sphygmomanometer/blood pressure apparatus with cuff and stethoscope	12/01/2015	09/30/2016	Commercial/ASO,Medicare,PEBB - Coverage is subject to plan benefits, prior authorization required	
Commercial/ASO, Medicare, OHP, PEBB	A4663	Blood pressure cuff only	12/01/2015	09/30/2016		
Commercial/ASO, Medicare, OHP, PEBB	A4670	Automatic blood pressure monitor	12/01/2015	09/30/2016	Commercial/ASO - Covered for OHP only	
Commercial/ASO, Medicare, OHP, PEBB	A7025	High Frequency Chest Wall Oscillation System Vest, Replacement For Use	09/01/2003	10/31/2017		High Frequency Chest Wall Oscillation Devices
Commercial/ASO, Medicare, OHP, PEBB	A7026	High Frequency Chest Wall Oscillation System Hose, Replacement For Use	09/01/2003	10/31/2017		High Frequency Chest Wall Oscillation Devices
Commercial/ASO, Medicare, OHP, PEBB	A9156	A9156 - Oral muco adhesive, any type (liquid, gel, paste, etc.), per 1 ml	10/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Mugard Oral Wound Rinse	Oral Rinses - Pharmacy Policy
Commercial/ASO, OHP, PEBB	A9272	Wound suction, disposable, includes dressing, all accessories and components, any type, each	01/01/2012	09/30/2022		Negative Pressure Wound Therapy (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 263/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	A9272	Wound suction, disposable, includes dressing, all accessories and components, any type, each	01/01/2012	08/31/2021		Negative Pressure Wound Therapy (Medicare)
Commercial/ASO, OHP, PEBB	A9274	External ambulatory insulin delivery system, disposable, each, includes all supplies and accessories	05/01/2020	01/31/2021	Commercial/ASO,OHP,PEBB - This code requires a prior authorization when requested as part of an integrated insulin pump and glucose monitoring system, or when requested as an insulin pump alone for type 2 diabetics with one of the following diagnosis codes: • E11 • E11.0 • E11.1 • E11.2 • E11.3 • E11.4 • E11.5 • E11.6 • E11.8 • E11.9	Advanced Diabetes Management Technology (Company); Diabetes: Insulin Infusion Pumps (External and Implanted) Archived 2/1/2021; Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (All Lines of Business Except Medicare) Archived 2/1/2021
Commercial/ASO, OHP, PEBB	A9276	Sensor; invasive (e.g., subcutaneous), disposable, for use with interstitial continuous glucose monitoring system, one unit = 1 day supply	09/01/2017			Advanced Diabetes Management Technology (Company); Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (All Lines of Business Except Medicare) Archived 2/1/2021
Medicare	A9276	Sensor; invasive (e.g., subcutaneous), disposable, for use with interstitial continuous glucose monitoring system, one unit = 1 day supply	01/01/2018	12/31/2019	Medicare -	Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (Medicare Only) Archived 2/1/2021
Commercial/ASO, OHP, PEBB	A9277	Transmitter; external, for use with interstitial continuous glucose monitoring system	09/01/2017			Advanced Diabetes Management Technology (Company); Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (All Lines of Business Except Medicare) Archived 2/1/2021
Medicare	A9277	Transmitter; external, for use with interstitial continuous glucose monitoring system	01/01/2018	12/31/2019		Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (Medicare Only) Archived 2/1/2021
Commercial/ASO, OHP, PEBB	A9278	Receiver (monitor); external, for use with interstitial continuous glucose monitoring system	09/01/2017			Advanced Diabetes Management Technology (Company); Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (All Lines of Business Except Medicare) Archived 2/1/2021

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 264/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	A9278	Receiver (monitor); external, for use with interstitial continuous glucose monitoring system	01/01/2018	12/31/2019		Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (Medicare Only) Archived 2/1/2021
Commercial/ASO, Medicare, OHP, PEBB	A9513	Lutetium lu 177, dotatate, therapeutic, 1 millicurie	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Lutathera	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	A9590	lodine i-131, iobenguane, 1 millicurie	01/01/2020		Commercial/ASO,Medicare,OHP,PEBB - AZEDRA	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	A9606	Radium Ra-223 dichloride, therapeutic, per microcurie	01/01/2015		Commercial/ASO,Medicare,OHP,PEBB - Xofigo®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	A9607	Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie	10/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Pluvicto	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4100	Food thickener, administered orally, per ounce	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4102	Enteral formula, for adults, used to replace fluids and electrolytes (e.g., clear liquids), 500 ml = 1 unit	01/01/2013		Commercial/ASO,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4103	Enteral formula, for pediatrics, used to replace fluids and electrolytes (e.g., clear liquids), 500 mL = 1 unit	01/01/2013		Commercial/ASO,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	B4104	Additive for enteral formula (e.g., fiber)	01/01/2013		Commercial/ASO,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4105	In-line cartridge containing digestive enzyme(s) for enteral feeding, each	06/01/2023	12/31/2999	Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4149	Enteral formula, manufactured blenderized natural foods with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4150	Enteral formula, nutritionally complete with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4152	Enteral formula, nutritionally complete, calorically dense (equal to or greater than 1.5 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4153	Enteral formula, nutritionally complete, hydrolyzed proteins (amino acids and peptide chain), includes fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	B4154	Enteral formula, nutritionally complete, for special metabolic needs, excludes inherited disease of metabolism, includes altered composition of proteins, fats, carbohydrates, vitamins and/or minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4155	Enteral formula, nutritionally incomplete/modular nutrients, includes specific nutrients, carbohydrates (e.g., glucose polymers), proteins/amino acids (e.g., glutamine, arginine), fat (e.g., medium chain triglycerides) or combination, administered through an enteral feeding tube, 100 calories = 1 unit	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4157	Enteral formula, nutritionally complete, for special metabolic needs for inherited disease of metabolism, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4158	Enteral formula, for pediatrics, nutritionally complete with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber and/or iron, administered through an enteral feeding tube, 100 calories = 1 unit	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4159	Enteral formula, for pediatrics, nutritionally complete soy based with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber and/or iron, administered through an enteral feeding tube, 100 calories = 1 unit	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 267/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	B4160	Enteral formula, for pediatrics, nutritionally complete calorically dense (equal to or greater than 0.7 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4161	Enteral formula, for pediatrics, hydrolyzed/amino acids and peptide chain proteins, includes fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4162	Enteral formula, for pediatrics, special metabolic needs for inherited disease of metabolism, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4164	Parenteral nutrition solution: carbohydrates (dextrose), 50% or less (500 ml = 1 unit) - home mix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4168	Parenteral nutrition solution; amino acid, 3.5%, (500 ml = 1 unit) - home mix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4172	Parenteral nutrition solution; amino acid, 5.5% through 7%, (500 ml = 1 unit) - home mix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	B4176	Parenteral nutrition solution; amino acid, 7% through 8.5%, (500 ml = 1 unit) - home mix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4178	Parenteral nutrition solution: amino acid, greater than 8.5% (500 ml = 1 unit) - home mix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4180	Parenteral nutrition solution; carbohydrates (dextrose), greater than 50% (500 ml = 1 unit) - home mix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4185	Parenteral nutrition solution, per 10 grams lipids	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4187	Omegaven, 10 grams lipids	01/01/2020		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4189	Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, 10 to 51 grams of protein - premix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4193	Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, 52 to 73 grams of protein - premix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	B4197	Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements and vitamins, including preparation, any strength, 74 to 100 grams of protein - premix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4199	Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements and vitamins, including preparation, any strength, over 100 grams of protein - premix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4216	Parenteral nutrition; additives (vitamins, trace elements, heparin, electrolytes), home mix, per day	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4220	Parenteral nutrition supply kit; premix, per day	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4222	Parenteral nutrition supply kit; home mix, per day	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B4224	Parenteral nutrition administration kit, per day	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B5000	Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, renal- aminosyn-rf, nephramine, renamine-premix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 270/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	B5100	Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic, hepatamine-premix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	B5200	Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, stress- branch chain amino acids-freamine-hbc- premix	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB -	Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
ОНР	C1754	Catheter, intradiscal	03/01/2010			OHP Prioritized List of Health Services and Oregon Administrative Rules
ОНР	C1755	Catheter, intraspinal	03/01/2010			OHP Prioritized List of Health Services and Oregon Administrative Rules
Commercial/ASO, Medicare, OHP, PEBB	C1764	Event recorder, cardiac (implantable)	09/01/2017			Cardiac: Implantable Loop Recorders (Company); Cardiac: Implantable Loop Recorders (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	C1767	Generator, neurostimulator (implantable), non-rechargeable	02/01/2016			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Fecal Incontinence Treatments (Company); Fecal Incontinence Treatments (Medicare); Gastric Electrical Stimulation (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare); Vagus Nerve Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	C1776	Joint device (implantable)	12/01/2018	07/31/2022		



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	C1778	Lead, neurostimulator (implantable)	02/01/2016			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Fecal Incontinence Treatments (Company); Fecal Incontinence Treatments (Medicare); Gastric Electrical Stimulation (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, OHP, PEBB	C1787	Patient programmer, neurostimulator	11/01/2017			Electrical Stimulation and Electromagnetic Therapies (Medicare); Fecal Incontinence Treatments (Company); Fecal Incontinence Treatments (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Medicare	C1787	Patient programmer, neurostimulator	05/01/2018			Electrical Stimulation and Electromagnetic Therapies (Medicare); Fecal Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	C1813	Prosthesis, penile, inflatable	01/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	C1815	Prosthesis, urinary sphincter (implantable)	07/01/2019			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	C1816	Receiver and/or transmitter, neurostimulator (implantable)	02/01/2016			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	C1820	Generator, neurostimulator (implantable), with rechargeable battery and charging system	11/01/2017			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Medicare	C1821	Interspinous implant	10/01/2009	11/30/2015		Back: Stabilization Devices and Interspinous Spacers (Company)
Commercial/ASO, Medicare, OHP, PEBB	C1822	Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system	10/01/2017			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Gastric Electrical Stimulation (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	C1823	Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads	01/01/2019			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Fecal Incontinence Treatments (Company); Gastric Electrical Stimulation (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO	C1826	Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system	01/01/2023			Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Commercial/ASO, OHP, PEBB	C1827	Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller	01/01/2023			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation: Non-Covered Therapies (Company); Fecal Incontinence Treatments (Company); Gastric Electrical Stimulation (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Vagus Nerve Stimulation (Company)
Medicare	C1827	Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller	01/01/2023			Electrical Stimulation and Electromagnetic Therapies (Medicare); Fecal Incontinence Treatments (Medicare)
Medicare	C1831	Personalized, anterior and lateral interbody cage (implantable)	10/01/2021	12/31/2022		Spinal Fusion and Decompression Procedures (Company)
Commercial/ASO, Medicare, OHP, PEBB	C1849	Skin substitute, synthetic, resorbable, per square centimeter	07/01/2020	01/01/2023		Skin and Tissue Substitutes (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	C1883	Adapter/extension, pacing lead or neurostimulator lead (implantable)	02/01/2016			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Gastric Electrical Stimulation (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	C1888	Catheter, Ablation, Non-Cardiac, Endovascular (Implantable)	03/01/2010	10/31/2015		
Commercial/ASO, Medicare, OHP, PEBB	C1889	Implantable/insertable device for device intensive procedure, not otherwise classified	01/01/2017	04/30/2023		
Commercial/ASO, Medicare, OHP, PEBB	C1897	Lead, neurostimulator test kit (implantable)	10/01/2017			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Fecal Incontinence Treatments (Company); Gastric Electrical Stimulation (Company); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, OHP, PEBB	C2596	Probe, image-guided, robotic, waterjet ablation	11/01/2022			Benign Prostatic Hyperplasia Treatments (Company)
Commercial/ASO, Medicare, OHP, PEBB	C2614	Probe, Percutaneous Lumbar Discectomy	03/01/2010	11/30/2019		Spinal Fusion and Decompression Procedures (Company)
Medicare	C2614	Probe, Percutaneous Lumbar Discectomy	01/01/2022	12/31/2022		Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, OHP, PEBB	C2616	Brachytherapy seed, yttrium-90	10/01/2008			Liver Tumor Treatment (Company)
Medicare	C2616	Brachytherapy seed, yttrium-90	10/01/2008	12/31/2020		Liver Tumor Treatment (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 275/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	C2616	Brachytherapy seed, yttrium-90	01/01/2022			Liver Tumor Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	C2622	Prosthesis, penile, non-inflatable	01/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Cosmetic and Reconstructive Surgery (Company); Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Company); Gender Affirming Surgical Interventions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	C2698	Brachytherapy source, stranded, not otherwise specified, per source	07/01/2012			Liver Tumor Treatment (Company); Liver Tumor Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	C2699	Brachytherapy source, non-stranded, not otherwise specified, per source	07/01/2012			Liver Tumor Treatment (Company); Liver Tumor Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	C8900	Magnetic resonance angiography with contrast, abdomen	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8901	Magnetic resonance angiography without contrast, abdomen	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8902	Magnetic resonance angiography without contrast followed by with contrast, abdomen	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8903	Magnetic resonance imaging with contrast, breast; unilateral	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8904	Magnetic resonance imaging without contrast, breast; unilateral	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8905	Magnetic resonance imaging without contrast followed by with contrast, breast; unilateral	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	C8906	Magnetic resonance imaging with contrast, breast; bilateral	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8907	Magnetic resonance imaging without contrast, breast; bilateral	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8908	Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8909	Magnetic resonance angiography with contrast, chest (excluding myocardium)	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8910	Magnetic resonance angiography without contrast, chest (excluding myocardium)	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8911	Magnetic resonance angiography without contrast followed by with contrast, chest (excluding myocardium)	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8912	Magnetic resonance angiography with contrast, lower extremity	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8913	Magnetic resonance angiography without contrast, lower extremity	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8914	Magnetic resonance angiography without contrast followed by with contrast, lower extremity	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8918	Magnetic resonance angiography with contrast, pelvis	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 277/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	C8919	Magnetic resonance angiography without contrast, pelvis	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C8920	Magnetic resonance angiography without contrast followed by with contrast,	01/01/2012		Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, Medicare, OHP, PEBB	C9047	Injection, caplacizumab-yhdp, 1 mg	07/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Cablivi®	Cablivi <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9090	Injection, plasminogen, human-tvmh, 1 mg	04/01/2022	06/30/2022	Commercial/ASO,Medicare,OHP,PEBB - Ryplazim (New code effective 7/1/2022 see J2998)	Ryplazim - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9091	Injection, sirolimus protein-bound particles, 1 mg	04/01/2022	06/30/2022	Commercial/ASO,Medicare,OHP,PEBB - Fyarro (New code effective 7/1/2022 see J9331)	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9093	Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg	04/01/2022	06/30/2022	(New code effective 7/1/2022 see J2998)	Medicare Part B Step Therapy - Pharmacy Policy; Ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitors - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9094	Inj, sutimlimab-jome, 10 mg	07/01/2022	09/30/2022	Commercial/ASO,Medicare,OHP,PEBB - Enjaymo <sup>®</sup> (New code effective 10/1/2022 see J1302)	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9095	Inj, tebentafusp-tebn, 1 mcg	07/01/2022	09/30/2022	Commercial/ASO,Medicare,OHP,PEBB - Kimmtrak <sup>®</sup> (New code effective 10/1/2022 see J9274)	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9097	Inj, faricimab-svoa, 0.1 mg	07/01/2022	09/30/2022	Commercial/ASO,Medicare,OHP,PEBB - Vabysmo <sup>®</sup> (New code effective 10/1/2022 see J2777)	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9098	Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including	07/01/2022	09/30/2022	Commercial/ASO,Medicare,OHP,PEBB - Carvykti® (New code effective 10/1/2022 see Q2056)	New Drug/Indication Awaiting P&T Review - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 278/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		leukapheresis and dose preparation procedures, per therapeutic dose				
Commercial/ASO, Medicare, OHP, PEBB	C9142	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	10/01/2022	12/31/2022	Commercial/ASO,Medicare,OHP,PEBB - C9412 replaced by Q5126 effective 1/1/2023	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9146	Injection, mirvetuximab soravtansine-gynx, 1 mg	04/01/2023	06/30/2028	Commercial/ASO,Medicare,OHP,PEBB - Elahere (New code effective 7/1/2023)	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9147	Injection, tremelimumab-actl, 1 mg	04/01/2023	06/30/2023	Commercial/ASO,Medicare,OHP,PEBB - Imjudo (new code eff 7/1/2023)	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9148	Injection, teclistamab-cqyv, 0.5 mg	04/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Tecvayli	T-Cell Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9149	Injection, teplizumab-mzwv, 5 mcg	04/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Tzeild	Tzield - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9151	Injection, pegcetacoplan, 1 mg	07/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Syfovre®	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9155	C9155 - Injection, epcoritamab-bysp, 0.16 mg	10/01/2023		Commercial/ASO,Medicare,OHP,PEBB -	Injectable ANTI-Cancer Medications - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9157	C9157 - Injection, tofersen, 1 mg	10/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Qalsody	Qalsody-Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9160	Injection, daxibotulinumtoxina-lanm, 1 unit	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - Daxxify	
Commercial/ASO, Medicare, OHP, PEBB	C9162	Injection, avacincaptad pegol, 0.1 mg	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - IZERVAY	Izervay - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP	C9163	Injection, talquetamab-tgvs, 0.25 mg	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - TALVEY	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9164	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - CANTHARIDIN	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9165	Injection, elranatamab-bcmm, 1 mg	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - ELREXFIO	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9166	C9166 Injection, secukinumab, intravenous, 1 mg	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - COSENTYX	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9167	C9167 Injection, apadamtase alfa, 10 units	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - ADZYNMA	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9168	C9168 Injection, mirikizumab-mrkz, 1 mg	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - OMVOH	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9254	Injection, lacosamide, 1 mg	08/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Vimpat <sup>®</sup>	Aptiom <sup>®</sup> and Vimpat <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	C9354	Veritas collagen matrix, cm2	03/01/2010		Code PAs. If billed with F64.0, F64.1, F64.8,or F64.9 then code will pay	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	C9356	Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (tenoglide tendon protector sheet), per square centimeter	06/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	C9363	Integra Meshed Bil Wound Mat	03/01/2010		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	C9399	Unclassified drugs or biologicals (Hospital Outpatient Use ONLY)	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB -	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, OHP, PEBB	C9734	Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic resonance (mr) guidance	01/01/2018			Liver Tumor Treatment (Company); Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) (Company); MRI Guided Focused Ultrasound for Palliative Treatment of Bone Metastases
Medicare	C9734	Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic resonance (mr) guidance	01/01/2021			Liver Tumor Treatment (Medicare); Magnetic Resonance-Guided Focused Ultrasound Surgery (MRgFUS) (Medicare)
Commercial/ASO, OHP, PEBB	C9739	Cystourethroscopy, with insertion of transprostatic implant; 1 to 3 implants	09/01/2017			Benign Prostatic Hyperplasia Treatments (Company)
Medicare	C9739	Cystourethroscopy, with insertion of transprostatic implant; 1 to 3 implants	09/01/2017	01/31/2022		Prostate: Prostatic Urethral Lift ARCHIVED 2/1/2022
Commercial/ASO, OHP, PEBB	C9740	Cystourethroscopy, with insertion of transprostatic implant; 4 or more implants	09/01/2017			Benign Prostatic Hyperplasia Treatments (Company)
Medicare	C9740	Cystourethroscopy, with insertion of transprostatic implant; 4 or more implants	09/01/2017	01/31/2022		Prostate: Prostatic Urethral Lift ARCHIVED 2/1/2022
	C9745	Nasal endoscopy, surgical; balloon dilation of eustachian tube	09/01/2016	09/01/2016		Balloon Dilation of the Sinuses or Eustachian Tubes
Medicare	C9747	Ablation of prostate, transrectal, high intensity focused ultrasound (hifu), including imaging guidance	11/01/2018	04/30/2020		Prostate: High Intensity Focused Ultrasound (HIFU) (Medicare Only) ARCHIVED 5/1/2020
Commercial/ASO, Medicare, OHP, PEBB	C9757	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and excision of herniated intervertebral disc, and repair of annular defect with implantation of bone anchored annular closure device, including annular defect measurement,	01/01/2020			Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 281/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		alignment and sizing assessment, and image guidance; 1 interspace, lumbar				
Commercial/ASO, C979 Medicare, OHP, PEBB	C9797	Vascular embolization or occlusion procedure with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction	04/01/2024		This code requires a Prior Authorization when billed with one of the codes below: C220, C221, C222, C223, C224, C227, C228, C229, C787, C7B03, D015	Liver Tumor Treatment (Company); Liver Tumor Treatment (Medicare)
	E0118	Crutch substitute, lower leg platform, with or without wheels	04/01/2016	04/01/2016		
Commercial/ASO, Medicare, OHP, PEBB	E0170	Commode chair with integrated seat lift mechanism, electric, any type	01/01/2019			Seat Lift Mechanism (Company) ; Seat Lift Mechanism (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E0171	Commode chair with integrated seat lift mechanism, non-electric, any type	01/01/2019			Seat Lift Mechanism (Company) ; Seat Lift Mechanism (Medicare)
Commercial/ASO, OHP, PEBB	E0470	respiratory assis device, bi-level pressure capability, without back-up rate feature, used with non-invasive interface, eg, nasal or facial mask(intermittent assist device with continous positive airway pressure device	01/01/2009		No prior authorization required for ages 17 and under, effective 11/1/18	Sleep Disorder Treatment with Positive Airway Pressure (Company)
Medicare	E0470	respiratory assis device, bi-level pressure capability, without back-up rate feature, used with non-invasive interface, eg, nasal or facial mask(intermittent assist device with continous positive airway pressure device	01/01/2009	04/30/2022		Sleep Disorder Treatment: Positive Airway Pressure (Medicare)
Commercial/ASO, OHP, PEBB	E0471	Respiratory assist device, bi-level pressure capability, with back-up rate feature, used with non-invasive interface, EG nasal or facial mask (intermittent assist device with continuous positive pressure device)	01/01/2009		No prior authorization required for ages 17 and under, effective 11/1/18	Sleep Disorder Treatment with Positive Airway Pressure (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	E0471	Respiratory assist device, bi-level pressure capability, with back-up rate feature, used with non-invasive interface, EG nasal or facial mask (intermittent assist device with continuous positive pressure device)	01/01/2009	04/30/2022		Sleep Disorder Treatment: Positive Airway Pressure (Medicare)
Commercial/ASO, OHP, PEBB	E0472	Respiratory assist device, bi-level pressure capability, with backup rate feature, used with invasive interface, e.g., tracheostomy tube (intermittent assist device with continuous positive airway pressure device)	04/01/2018		No prior authorization required for ages 17 and under, effective 11/1/18	Sleep Disorder Treatment with Positive Airway Pressure (Company)
Medicare	E0472	Respiratory assist device, bi-level pressure capability, with backup rate feature, used with invasive interface, e.g., tracheostomy tube (intermittent assist device with continuous positive airway pressure device)	04/01/2018	04/30/2022		Sleep Disorder Treatment: Positive Airway Pressure (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E0483	High frequency chest wall oscillation air-pulse generator system, (includes hoses and vest), each	09/01/2003	10/31/2017		High Frequency Chest Wall Oscillation Devices
Commercial/ASO, OHP, PEBB	E0486	Oral device/appliance used to reduce upper airway collapsibility, adjustable or non- adjustable, custom fabricated,	04/01/2007			Sleep Disorder Treatment with Oral and Sleep Position Appliances (Company)
Medicare	E0486	Oral device/appliance used to reduce upper airway collapsibility, adjustable or non- adjustable, custom fabricated,	07/01/2023			Sleep Disorder Treatment: Oral and Sleep Position Appliances (Medicare)
Commercial/ASO, OHP, PEBB	E0601	Continuous positive airway pressure (CPAP) device	01/01/2009		No prior authorization required for ages 17 and under, effective 11/1/18	Sleep Disorder Treatment with Positive Airway Pressure (Company)
Medicare	E0601	Continuous positive airway pressure (CPAP) device	01/01/2009	04/30/2022		Sleep Disorder Treatment: Positive Airway Pressure (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E0616	Implantable cardiac event recorder with memory, activator and programmer	10/01/2014			Cardiac: Implantable Loop Recorders (Company); Cardiac: Implantable Loop Recorders (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 283/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	E0617	External defibrillator with integrated electrocardiogram analysis	01/01/2009	08/31/2020		Automatic External Defibrillators (AED) (archived 6/1/2021)
Commercial/ASO, Medicare, OHP, PEBB	E0627	Seat lift mechanism incorporated into a combination lift-chair mechanism	10/01/2007			Seat Lift Mechanism (Company) ; Seat Lift Mechanism (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E0628	Separate seat lift mechanism for use with patient owned furniture - electric	10/01/2007	12/31/2016		Seat Lift Mechanism (Company)
Commercial/ASO, Medicare, OHP, PEBB	E0629	Separate seat lift mechanism for use with patient owned furniture - non-electric	10/01/2007			Seat Lift Mechanism (Company) ; Seat Lift Mechanism (Medicare)
Commercial/ASO, OHP, PEBB	E0636	Multipositional patient support system, with integrated lift, patient accessible controls	01/01/2019			Standing Systems (Company)
Medicare	E0636	Multipositional patient support system, with integrated lift, patient accessible controls	08/01/2022			Standing Systems (Medicare)
Commercial/ASO, OHP, PEBB	E0638	Standing frame /table system, one position (e.g ., . upright, supine or prone stander), any size including pediatric, with or without wheels	01/01/2019			Standing Systems (Company)
Commercial/ASO, OHP, PEBB	E0641	Standing frame /table system, multi-position (e.g ., . three-way stander), any size including pediatric, with or without wheels	01/01/2019			Standing Systems (Company)
Commercial/ASO, OHP, PEBB	E0642	Standing frame /table system, mobile (dynamic stander), any size including pediatric	01/01/2019			Standing Systems (Company)
Commercial/ASO, Medicare, OHP, PEBB	E0675	Pneumatic compression device, high pressure, rapid inflation/deflation cycle	10/01/2015	12/31/2018		Compression (Pneumatic) Devices & Compression Garments; Compression: Outpatient Pneumatic Devices (Company); Compression: Outpatient Pneumatic Devices (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E0676	Intermittent limb compression device (includes all accessories), not otherwise specified	04/01/2014	12/31/2018		Compression: Outpatient Pneumatic Devices (Company); Compression: Outpatient Pneumatic Devices (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 284/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	E0734	External upper limb tremor stimulator of the peripheral nerves of the wrist	04/01/2024			Electrical Stimulation and Electromagnetic Therapies (Medicare)
Medicare	E0740	Non-implanted pelvic floor electrical stimulator, complete system	07/01/2022			Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E0745	Neuromuscular stimulator, electronic shock unit	07/01/2019	04/30/2021		Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E0747	Osteogenesis stimulator, electrical, non- invasive, other than spinal applications	09/01/2003			Bone Growth Stimulators (Company); Bone Growth Stimulators (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E0748	Osteogenesis stimulator, electrical, non- invasive, spinal applications	09/01/2003			Bone Growth Stimulators (Company); Bone Growth Stimulators (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E0749	Osteogenesis stimulator, electrical, surgically implanted	09/01/2003			Bone Growth Stimulators (Company); Bone Growth Stimulators (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E0760	Osteogenesis stimulator, low intensity ultrasound, non-invasive	09/01/2003			Bone Growth Stimulators (Company); Bone Growth Stimulators (Medicare)
Commercial/ASO, OHP, PEBB	E0764	Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program	09/01/2022			Electrical Stimulation and Electromagnetic Therapies (Medicare); Functional Electrical Stimulation (All Lines of Business Except Medicare)
Medicare	E0764	Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program	09/01/2022			Electrical Stimulation and Electromagnetic Therapies (Medicare)
ОНР, РЕВВ	E0765	FDA approved nerve stimulator, with replaceable batteries, for treatment of nausea and vomiting	07/01/2008			Electrical Stimulation and Electromagnetic Therapies (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 285/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO	E0765	FDA approved nerve stimulator, with replaceable batteries, for treatment of nausea and vomiting	07/01/2008	09/30/2023		Gastric Electrical Stimulation (Company)
Medicare	E0765	FDA approved nerve stimulator, with replaceable batteries, for treatment of nausea and vomiting	07/01/2008	09/30/2023		Electrical Stimulation and Electromagnetic Therapies (Medicare)
Commercial/ASO, OHP, PEBB	E0766	Electrical stimulation device used for cancer treatment, includes all accessories, any type	03/01/2017			Tumor Treatment Field Therapy for Glioblastoma (Company)
Medicare	E0766	Electrical stimulation device used for cancer treatment, includes all accessories, any type	09/01/2019			Tumor Treatment Field Therapy for Glioblastoma (Company); Tumor Treatment Field Therapy for Glioblastoma (Medicare)
Commercial/ASO, OHP, PEBB	E0770	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified	09/01/2022			Electrical Stimulation and Electromagnetic Therapies (Medicare); Functional Electrical Stimulation (All Lines of Business Except Medicare)
Medicare	E0770	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified	09/01/2022			Electrical Stimulation and Electromagnetic Therapies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E0784	External ambulatory infusion pump, insulin	05/01/2020	01/31/2021	Commercial/ASO,Medicare,OHP,PEBB - Requires prior authorization when requested as part of an integrated insulin pump and glucose monitoring system, or when requested as an insulin pump alone for type 2 diabetics with one of the following diagnosis codes: • E11 • E11.0 • E11.1 • E11.2 • E11.3 • E11.4 • E11.5 • E11.6 • E11.8 • E11.9	Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (All Lines of Business Except Medicare) Archived 2/1/2021; Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (Medicare Only) Archived 2/1/2021
Commercial/ASO, Medicare, OHP, PEBB	E0787	External ambulatory infusion pump, insulin, dosage rate adjustment using therapeutic continuous glucose sensing	01/01/2020	01/31/2021		Advanced Diabetes Management Technology (Company); Advanced Diabetes Management Technology (Medicare)

03/29/2024 286/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	E0985	Wheelchair accessory, seat lift mechanism	06/01/2021			Seat Lift Mechanism (Company) ; Seat Lift Mechanism (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E0988	Manual Wheelchair Accessory, Lever- Activated, Wheel Drive, Pair	07/01/2013	06/30/2020		Wheelchair and Power Vehicles (Company)
Commercial/ASO, Medicare, OHP, PEBB	E1012	Wheelchair accessory, addition to power seating system, center mount power elevating leg rest/platform, complete system, any type, each	01/01/2016	06/30/2020		Wheelchair and Power Vehicles (Company)
Commercial/ASO, Medicare, OHP, PEBB	E1230	Power operated vehicle (three or four wheel nonhighway) specify brand name and model number	07/01/2020			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E1800	Dynamic adjustable elbow extension/flexion device, includes soft interface material	03/01/2010	06/30/2018		Mechanical Stretching Devices for Joints of the Extremities (Company) ARCHIVED 3/1/24
Commercial/ASO, Medicare, OHP, PEBB	E1802	Dynamic Adjustable Forearm Pronation/Supination Device, Inc Soft Inter	03/01/2010	06/30/2018		Mechanical Stretching Devices for Joints of the Extremities (Company) ARCHIVED 3/1/24
Commercial/ASO, Medicare, OHP, PEBB	E1805	Dynamic adjustable wrist extension/flexion device, includes soft interface material	03/01/2010	06/30/2018		Mechanical Stretching Devices for Joints of the Extremities (Company) ARCHIVED 3/1/24
Commercial/ASO, Medicare, OHP, PEBB	E1810	Dynamic adjustable knee extension/flexion device, includes soft interface material	03/01/2010	06/30/2018		Mechanical Stretching Devices for Joints of the Extremities (Company) ARCHIVED 3/1/24
Commercial/ASO, Medicare, OHP, PEBB	E1812	Dynamic knee, extension/flexion device with active resistance control	03/01/2010	06/30/2018		Mechanical Stretching Devices for Joints of the Extremities (Company) ARCHIVED 3/1/24
Commercial/ASO, Medicare, OHP, PEBB	E1820	Replacement soft interface material, dynamic adjustable extension/flexion device	03/01/2010	06/30/2018		Mechanical Stretching Devices for Joints of the Extremities (Company) ARCHIVED 3/1/24
Commercial/ASO, Medicare, OHP, PEBB	E1825	Dynamic adjustable finger extension/flexion device, includes soft interface material	03/01/2010	06/30/2018		Mechanical Stretching Devices for Joints of the Extremities (Company) ARCHIVED 3/1/24
Commercial/ASO, OHP, PEBB	E2102	Adjunctive continuous glucose monitor or receiver	04/01/2022			Advanced Diabetes Management Technology (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 287/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	E2102	Adjunctive continuous glucose monitor or receiver	07/01/2023			Advanced Diabetes Management Technology (Medicare)
Commercial/ASO, OHP, PEBB	E2103	Non-adjunctive, non-implanted continuous glucose monitor or receiver	01/01/2023			Advanced Diabetes Management Technology (Company)
Medicare	E2103	Non-adjunctive, non-implanted continuous glucose monitor or receiver	07/01/2023			Advanced Diabetes Management Technology (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2298	Complex rehabilitative power wheelchair accessory, power seat elevation system, any type	04/01/2024			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2300	Wheelchair accessory, power seat elevation system, any type	07/01/2023	03/31/2024		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2331	Power wheelchair accessory, attendant control, proportional, including all related electronics and fixed mounting hardware	07/01/2020			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2358	Power Wheelchair Accessory, Group 34 Non- Sealed Lead Acid Battery, Each	07/01/2020			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2359	Power Wheelchair Accessory, Group 34 Sealed Lead Acid Battery, Each (E.G. Gel Cell, Absorbed Glassmat)	01/01/2012	08/31/2019	Commercial/ASO,Medicare,OHP,PEBB -	Wheelchair and Power Vehicles (Company)
Commercial/ASO, Medicare, OHP, PEBB	E2360	Power wheelchair accessory, 22nf non-sealed lead acid battery, each	07/01/2020			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2362	Power wheelchair accessory, group 24 non- sealed lead acid battery, each	07/01/2020			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2364	Power wheelchair accessory, U-1 non-sealed lead acid battery, each	07/01/2020			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2372	Power wheelchair accessory, Group 27 non- sealed lead acid battery, each	07/01/2020			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 288/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	E2378	Pw actuator replacement	07/01/2013	11/30/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2402	Negative pressure wound therapy electrical pump, stationary or portable	09/01/2003			Negative Pressure Wound Therapy (Company); Negative Pressure Wound Therapy (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2500	Speech generating device, digitized speech, using pre-recorded messages, 8 min. or less	01/01/2006	03/31/2019		Speech Generating Devices (Company); Speech Generating Devices (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2502	Speech generating device, digitized speech, using pre-recorded messages, 8-20 min.	01/01/2006	03/31/2019		Speech Generating Devices (Company); Speech Generating Devices (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2504	Speech generating device, digitized speech, using pre-recorded messages, 20-40 min.	01/01/2006	03/31/2019		Speech Generating Devices (Company); Speech Generating Devices (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2506	Speech generating device, digitized speech, using pre-recorded messages, over 40 min.	01/01/2006	03/31/2019		Speech Generating Devices (Company); Speech Generating Devices (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2508	Speech generating device, synthesized speech, requiring message formulation by spelling	01/01/2006	03/31/2019		Speech Generating Devices (Company); Speech Generating Devices (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2510	Speech generating device, synthesized speech, permitting multiple methods	01/01/2006	03/31/2019		Speech Generating Devices (Company); Speech Generating Devices (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2511	Speech generating software program, for personal computer or personal digital assistant	01/01/2006	03/31/2019		Speech Generating Devices (Company); Speech Generating Devices (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2512	Accessory for speech generating device, mounting system	01/01/2006	03/31/2019		Speech Generating Devices (Company); Speech Generating Devices (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	E2599	Accessory for speech generating device, not otherwise classified	03/01/2016			Speech Generating Devices (Company); Speech Generating Devices (Medicare)
Medicare	E2610	Wheelchair seat cushion, powered	07/01/2020			Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, OHP, PEBB	E2610	Wheelchair seat cushion, powered	07/01/2020	09/30/2022		Wheelchair and Power Vehicles (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	E2622	Adj skin pro w/c cus wd<22in	07/01/2013	06/30/2020		Wheelchair and Power Vehicles (Company)
Commercial/ASO, Medicare, OHP, PEBB	E2623	Adj skin pro wc cus wd>=22in	07/01/2013	06/30/2020		Wheelchair and Power Vehicles (Company)
Commercial/ASO, Medicare, OHP, PEBB	E2624	Adj skin pro/pos cus<22in	07/01/2013	06/30/2020		Wheelchair and Power Vehicles (Company)
Commercial/ASO, Medicare, OHP, PEBB	E2625	Adj skin pro/pos wc cus>=22	07/01/2013	06/30/2020		Wheelchair and Power Vehicles (Company)
Commercial/ASO, Medicare, OHP, PEBB	G0068	Professional services for the administration of anti-infective, pain management, chelation, pulmonary hypertension, and/or inotropic infusion drug(s) for each infusion drug administration calendar day in the individual's home, each 15 minutes	01/01/2019	12/31/2020		Chelation Therapy for Non-overload Conditions (Company); Chelation Therapy for Non-Overload Conditions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	G0138	G0138 Intravenous infusion of cipaglucosidase alfa-atga, including provider/supplier acquisition and clinical supervision of oral administration of miglustat in preparation of receipt of cipaglucosidase alfa-atga	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - Administration Code for Pombiliti	Enzyme Replacement Therapy - Pharmacy Policy; Enzyme Replacement Therapy, Medicare Part B -Pharmacy Policy
Medicare	G0143	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision	01/01/2013	11/30/2015		
Commercial/ASO, Medicare, OHP, PEBB	G0237	Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minut	10/01/2008	03/31/2017		Rehabilitation: Pulmonary
Commercial/ASO, Medicare, OHP, PEBB	G0238	Therapeutic procedures to improve respiratory function , other than described by G0237, one on one, face to face, per	10/01/2008	03/31/2017		Rehabilitation: Pulmonary

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 290/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	G0239	Therapeutic procedures to improve respiratory function , other than services described by G0237, two or more (includes m	10/01/2008	03/31/2017		Rehabilitation: Pulmonary
Medicare	G0248	Demonstration, prior to initiation of home INR monitoring, for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria, under the direction of a physician; includes: face- to-face demonstration of use and care of the INR monitor, obtaining at least one blood sample, provision of instructions for reporting home INR test results, and documentation of patient's ability to perform testing and report results	10/01/2014	09/30/2017		Prothrombin Time Self-Testing (Medicare)
Medicare	G0249	Provision Of Test Materials And Equipment For Home Inr Monitoring To P	02/01/2014	09/30/2017		Prothrombin Time Self-Testing (Medicare)
Medicare	G0250	Physician Review, Interpretation And Patient Management Of Home Inr Te	02/01/2014	09/30/2017		Prothrombin Time Self-Testing (Medicare)
Medicare	G0255	Current perception threshold/sensory nerve conduction threshold test SNCT), per limb, any nerve	12/01/2021	06/30/2022		Nerve Conduction Studies (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	G0277	Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval	01/01/2015			Hyperbaric Oxygen Therapy (Company); Hyperbaric Oxygen Therapy (Medicare)
Commercial/ASO	G0283	Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care	06/01/2019		Commercial/ASO - Commercial - Evicore prior authorization required. Select ASO groups - EviCore prior authorization required. See PA General Requirements pages for specific ASO plans.	Electrical Stimulation: Non-Covered Therapies (Company)
Commercial/ASO, Medicare, OHP, PEBB	G0297	Low Dose CT scan (LDCT) for lung cancer screening	07/01/2007	12/31/2020	Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 291/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	G0302	Pre-operative pulmonary surgery services for preparation for lvrs, complete	10/01/2008	12/31/2015		Rehabilitation: Pulmonary
Commercial/ASO, Medicare, OHP, PEBB	G0303	Pre-operative pulmonary surgery services for preparation for lvrs, 10 to 15	10/01/2008	12/31/2015		Rehabilitation: Pulmonary
Commercial/ASO, Medicare, OHP, PEBB	G0304	Pre-operative pulmonary surgery services for preparation for lvrs, 1 to 9 days	10/01/2008	12/31/2015		Rehabilitation: Pulmonary
Commercial/ASO, Medicare, OHP, PEBB	G0305	Post-discharge pulmonary surgery services after lvrs, minimum of 6 days	10/01/2008	12/31/2015		Rehabilitation: Pulmonary
Medicare	G0308	Creation of subcutaneous pocket with insertion of 180 day implantable interstitial glucose sensor, including system activation and patient training	12/01/2022	01/01/2023		Advanced Diabetes Management Technology (Medicare)
Medicare	G0309	Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new 180 day implantable sensor, including system activation	12/01/2022	01/01/2023		Advanced Diabetes Management Technology (Medicare)
Medicare	G0327	Oncology (brain), spheroid cell culture in a 3D microenvironment, 12 drug panel, tumor- response prediction for each drug	12/01/2021			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	G0343	Laparotomy islet cell transp	09/01/2003	12/31/2019		
Commercial/ASO, OHP, PEBB	G0416	Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method, 10-20 specimens	10/01/2015	03/31/2016		
Commercial/ASO, Medicare, OHP, PEBB	G0424	Pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day	01/01/2010	03/31/2017		Rehabilitation: Pulmonary



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	G0429	Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (LDS) (e.g., as a result of highly active antiretroviral therapy)	01/01/2013			Cosmetic and Reconstructive Surgery (Medicare); Gender Affirming Surgical Interventions (Medicare)
Medicare	G0453	Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure)	01/01/2022		Medicare - this code may pay based on billed diagnosis code	Intraoperative Monitoring (Medicare)
Commercial/ASO, OHP, PEBB	G0453	Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure)	01/01/2022		Commercial/ASO,OHP,PEBB - this code may pay based on billed diagnosis code	Intraoperative Monitoring (Company)
Commercial/ASO, Medicare, OHP, PEBB	G0455	Fecal microbiota prep instil	07/01/2013	07/01/2022		Fecal Microbiota Transplantation - Archived 7/1/22
Commercial/ASO, Medicare, OHP, PEBB	G0500	Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra- service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate)	01/01/2017	02/27/2017		Anesthesia Care with Diagnostic Endoscopy
Commercial/ASO	G0515	Development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact, each 15 minutes	06/01/2019	12/31/2019	Commercial/ASO - Commercial Only (excluding ASO groups) – Evicore prior authorization required This code is no longer valid effective 1/1/2020	
Commercial/ASO, Medicare, PEBB	G2082	Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a	01/01/2020		Commercial/ASO,Medicare,OHP,PEBB -	SPRAVATO <sup>®</sup> - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 293/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation				
Commercial/ASO, Medicare, PEBB	G2083	Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation	01/01/2020		Commercial/ASO,Medicare,OHP,PEBB -	SPRAVATO <sup>®</sup> - Pharmacy Policy
Medicare	G9143	Warfarin respon genetic test	09/01/2010			Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	G9708	Women who had a bilateral mastectomy or who have a history of a bilateral mastectomy or for whom there is evidence of a right and a left unilateral mastectomy	01/01/2017	05/31/2018		Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company)
	G9843	Kras gene mutation	01/01/2017	01/01/2017		
Medicare, OHP	J0129	Abatacept injection	01/01/2007		Medicare,OHP - Orencia®	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, PEBB	J0129	Abatacept injection	01/01/2007		Commercial/ASO,PEBB - Orencia®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medically Infused Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy; Self- Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
ОНР	J0135	Injection, adalimumab, 20 mg	04/01/2017		OHP - Humira®	Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Commercial/ASO, PEBB	J0135	Injection, adalimumab, 20 mg	01/01/2018		Commercial/ASO,PEBB - Humira®	Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0172	Injection, aducanumab-avwa, 2 mg	01/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Aduhelm®	Anti-Amyloid Monoclonal Antibodies - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0174	Injection, lecanemab-irmb, 1 mg	07/06/2023		Commercial/ASO,Medicare,OHP,PEBB - Leqembi	Anti-Amyloid Monoclonal Antibodies - Pharmacy Policy; Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0178	Injection, aflibercept, 1 mg	05/01/2018	07/31/2022	Commercial/ASO,Medicare,OHP,PEBB - Eylea®	Medicare Part B Step Therapy - Pharmacy Policy; Ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitors - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0179	Injection, brolucizumab-dbll, 1 mg	01/01/2020		Commercial/ASO,Medicare,OHP,PEBB - Beovu	Medicare Part B Step Therapy - Pharmacy Policy; Ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitors - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0180	Injection, agalsidase beta, 1 mg	02/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Fabrazyme	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, PEBB	J0180	Injection, agalsidase beta, 1 mg	08/01/2022			Infusion Therapy Site of Care -Commercial- Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 295/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J0202	Injection, alemtuzumab, 1 mg	01/01/2016		Commercial/ASO,Medicare,OHP,PEBB - Lemtrada®	Lemtrada <sup>®</sup> - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0208	Injection, sodium thiosulfate, 100 mg	04/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Pedmark	
Commercial/ASO, Medicare, OHP, PEBB	J0217	Injection, velmanase alfa-tycv, 1 mg	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - LAMZEDE	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0218	Injection, olipudase alfa-rpcp, 1 mg	04/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Xenpozyme	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0219	Injection, avalglucosidase alfa-ngpt, 4 mg	04/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Nexviazyme®	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0221	Injection, alglucosidase alfa, (lumizyme), 10 mg	01/01/2012		Commercial/ASO,Medicare,OHP,PEBB - Lumizyme®	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, PEBB	J0221	Injection, alglucosidase alfa, (lumizyme), 10 mg	08/01/2022			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0222	Injection, Patisiran, 0.1 mg	10/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Onpattro®	Transthyretin (TTR) Lowering Agents Pharmacy Policy
Commercial/ASO, PEBB	J0222	Injection, patisiran, 0.1 mg	08/01/2022			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0223	Injection, givosiran, 0.5 mg	07/01/2020			Givlaari <sup>®</sup> - Pharmacy Policy; Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0224	Injection, lumasiran, 0.5 mg	07/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Oxlumo® (Lumasiran)	Medicare Part B Step Therapy - Pharmacy Policy; OXLUMO <sup>®</sup> - PHARMACY POLICY
Commercial/ASO, Medicare, OHP, PEBB	J0225	Injection, vutrisiran, 1 mg	01/01/2023		Commercial/ASO,Medicare,OHP,PEBB - AMVUTTRA	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; TRANSTHYRETIN (TTR) LOWERING AGENTS - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0256	Alpha 1 Proteinase Inhibitor	01/01/2007		Commercial/ASO,Medicare,OHP,PEBB - Aralast NP®, Prolastin®-C, Zemaira®	Aralast NP®, Glassia® Prolastin®-C, Zemaira® - Pharmacy Policy; Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 296/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, PEBB	J0256	Injection, alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg	08/01/2022			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0257	Injection, alpha 1 proteinase inhibitor (human), (glassia), 10 mg	01/01/2012		Commercial/ASO,Medicare,OHP,PEBB - Glassia®	Aralast NP®, Glassia® Prolastin®-C, Zemaira® - Pharmacy Policy; Pharmacy Policy
Commercial/ASO, PEBB	J0257	Injection, alpha 1 proteinase inhibitor (human), (glassia), 10 mg	01/01/2023		Commercial/ASO,PEBB - Glassia	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0349	J0349 - Injection, rezafungin, 1 mg	10/01/2023	12/31/2023	Commercial/ASO,Medicare,OHP,PEBB - REZZAYO	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO	J0485	Injection, belatacept, 1mg	01/01/2024		Commercial/ASO - Nulojix <sup>®</sup> ***Commercial and ASO members MAY require prior authorization for Site of Care location***	
Medicare, OHP	J0490	Injection, belimumab, 10 mg	01/01/2012		Medicare,OHP - Benlysta®	Benlysta® - Pharmacy Policy; Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, PEBB	J0490	Injection, belimumab, 10 mg	01/01/2012		Commercial/ASO,PEBB - Benlysta®	Benlysta® - Pharmacy Policy; Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0491	Injection, anifrolumab-fnia, 1 mg	04/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Saphnelo®	Saphnelo - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0517	Injection, benralizumab, 1 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Fasenra®	IL-5 Inhibitors - Pharmacy Policy; Self- Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0565	Injection, bezlotoxumab, 10 mg	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Zinplava®	Zinplava® - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0567	Injection, cerliponase alfa, 1 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Brineura®	Brineura <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0584	Injection, burosumab-twza 1 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Crysvita®	Crysvita <sup>®</sup> - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 297/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, PEBB	J0584	Injection, burosumab-twza 1 mg	09/01/2020		Commercial/ASO,PEBB - Crysvita®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, PEBB	J0585	Botulinum Toxin A Per Unit	10/01/2009		Commercial/ASO,Medicare,PEBB - Prior authorization requests for this code must include the associated procedure code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8, and F64.9.	Botulinum Therapies (Company); Botulinum Toxin - Medicare Part B - Pharmacy Policy
Commercial/ASO, Medicare, PEBB	J0586	AbobotulinumtoxinA	07/01/2010		Commercial/ASO,Medicare,PEBB - Prior authorization requests for this code must include the associated procedure code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8, and F64.9.	Botulinum Therapies (Company); Botulinum Toxin - Medicare Part B - Pharmacy Policy
Commercial/ASO, Medicare, PEBB	J0587	Botulinum toxin type b, per 100 units	10/01/2009		Commercial/ASO,Medicare,PEBB - Prior authorization requests for this code must include the associated procedure code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8, and F64.9.	Botulinum Therapies (Company); Botulinum Toxin - Medicare Part B - Pharmacy Policy
Commercial/ASO, Medicare, PEBB	J0588	Injection, incobotulinumtoxin A, 1 unit	01/01/2012		Prior authorization requests for this code must include the associated procedure code. This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8, and F64.9.	Botulinum Therapies (Company); Botulinum Toxin - Medicare Part B - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0589	J0589 Injection, daxibotulinumtoxina-lanm, 1 unit	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - DAXXIFY	Botoxulinum therapy - Pharmacy Policy; Botulinum Toxin - Medicare Part B - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0593	Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)	10/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Takhzyro®	Hereditary Prophylactic Angioedema Therapy - Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0596	Injection, c1 esterase inhibitor (recombinant), ruconest, 10 units	01/01/2016		Commercial/ASO,Medicare,OHP,PEBB - Ruconest®	Hereditary Angioedema - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 298/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J0597	C-1 esterase, berinert	01/01/2011		Commercial/ASO,Medicare,OHP,PEBB - Berinert®	Hereditary Angioedema - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy; Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0598	C1 esterase inhibitor inj	01/01/2010		Commercial/ASO,Medicare,OHP,PEBB - Cinryze®	Hereditary Prophylactic Angioedema Therapy - Medicare Part B ; Hereditary Prophylactic Angioedema Therapy - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0599	Injection, c-1 esterase inhibitor (human), (haegarda), 10 units	01/01/2019			Hereditary Prophylactic Angioedema Therapy - Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, OHP, PEBB	J0630	Injection, calcitonin salmon, up to 400 units	03/01/2018	06/01/2022	Commercial/ASO,OHP,PEBB - Miacalcin <sup>®</sup> - Covered under the pharmacy benefit for self- administration.	
Commercial/ASO, Medicare, OHP, PEBB	J0638	Canakinumab injection	01/01/2011		Commercial/ASO,Medicare,OHP,PEBB - Ilaris®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Interleukin – 1 Inhibitors - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administer	01/01/2014		Commercial/ASO,Medicare,OHP,PEBB - Cimzia®	Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0725	Chorionic Gonadotropin/1000u	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Pregnyl® , Novarel®	Infertility and Related Medications - Pharmacy Policy; Pharmacy Policy
Commercial/ASO, OHP, PEBB	J0741	Injection, cabotegravir and rilpivirine, 2mg/3mg	10/01/2021		Commercial/ASO,OHP,PEBB - Cabenuva	Cabenuva <sup>®</sup> - Pharmacy Policy; Infusion Therapy Site of Care -Commercial- Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 299/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	J0741	Injection, cabotegravir and rilpivirine, 2mg/3mg	10/01/2021	12/31/2023	Medicare - Cabenuva	Cabenuva <sup>®</sup> - Pharmacy Policy
Commercial/ASO, OHP, PEBB	J0751	Emtricitabine 200mg and tenofovir alafenamide 25mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	01/01/2024		Commercial/ASO,OHP,PEBB - Descovy	Descovy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0775	Injection, collagenase, clostridium histolyticum, 0.01 mg	07/01/2020		Commercial/ASO,Medicare,OHP,PEBB - Xiaflex	Xiaflex <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0791	Injection, crizanlizumab-tmca, 5 mg	07/01/2020			Adakveo <sup>®</sup> - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, PEBB	J0791	Injection, crizanlizumab-tmca, 5 mg	01/01/2023		Commercial/ASO,PEBB - Adakveo	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, OHP, PEBB	J0800	Corticotropin Injection	11/01/2008		Commercial/ASO,OHP,PEBB - H. P. Acthar Gel®	H. P. Acthar Gel <sup>®</sup> - Pharmacy Policy; Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0801	J0801 - Injection, corticotropin (acthar gel), up to 40 units	10/01/2023		Commercial/ASO,Medicare,OHP,PEBB -	H. P. Acthar Gel <sup>®</sup> - Pharmacy Policy; Self- Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0802	J0802 - Injection, corticotropin (ani), up to 40 units	10/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Ani	H. P. Acthar Gel <sup>®</sup> - Pharmacy Policy; Self- Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0879	J0879: Injection, difelikefalin, 0.1 microgram, (for esrd on dialysis)	10/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Korsuva®	Korsuva <sup>®</sup> - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0881	Darbepoetin alfa, non-esrd	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Aranesp®	Aranesp <sup>®</sup> , Epogen <sup>®</sup> , Procrit <sup>®</sup> , Retacrit <sup>®</sup> - Pharmacy Policy; Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0885	Epoetin alfa, non-esrd	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Epogen®, Procrit®	Aranesp <sup>®</sup> , Epogen <sup>®</sup> , Procrit <sup>®</sup> , Retacrit <sup>®</sup> - Pharmacy Policy; Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 300/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J0888	Injection, epoetin beta, 1 microgram (for non- ESRD use)	01/01/2015		Commercial/ASO,Medicare,OHP,PEBB - Mircera®	Mircera <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0893	Injection, decitabine (sun pharma) not therapeutically equivalent to j0894, 1 mg	01/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Decitabine manufacturer specific, use J0893 for Sun Pharma only	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0894	Decitabine injection	01/01/2007		Commercial/ASO,Medicare,OHP,PEBB - Dacogen®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J0896	Injection, luspatercept-aamt, 0.25 mg	07/01/2020			Reblozyl <sup>®</sup> - Pharmacy Policy
Commercial/ASO, PEBB	J0897	Injection, denosumab, 1 mg	08/01/2022		Prolia <sup>®</sup> , Xgeva <sup>®</sup> ***MAY require prior authorization for Site of Care location only***	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1202	J1202 Miglustat, oral, 65 mg	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - Opfolda	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1203	J1203 Injection, cipaglucosidase alfa-atga, 5 mg	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - Pombiliti	Enzyme Replacement Therapy - Pharmacy Policy; Enzyme Replacement Therapy, Medicare Part B -Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1203	J1203 Injection, cipaglucosidase alfa-atga, 5 mg	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - Pombiliti	Enzyme Replacement Therapy - Pharmacy Policy; Enzyme Replacement Therapy, Medicare Part B -Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1290	Ecallantide injection	01/01/2011		Commercial/ASO,Medicare,OHP,PEBB - Kalbitor®	Hereditary Angioedema - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy; Pharmacy Policy
Medicare, OHP	J1300	Eculizumab injection	01/01/2008		Medicare,OHP - Soliris®	Medicare Part B Step Therapy - Pharmacy Policy; Soliris <sup>®</sup> - Pharmacy Policy
Commercial/ASO, PEBB	J1300	Eculizumab injection	01/01/2008		Commercial/ASO,PEBB - Soliris®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Soliris <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1301	Injection, edaravone, 1 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Radicava®	Radicava <sup>®</sup> - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 301/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, PEBB	J1301	Injection, edaravone, 1 mg	08/01/2022			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1302	Injection, sutimlimab-jome, 10 mg	10/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Enjaymo	Enjaymo - Pharmacy Policy
Medicare, OHP	J1303	Injection, ravulizumab-cwvz, 10 mg	10/01/2019		Medicare,OHP - Ultomiris®	Ultomiris <sup>®</sup> - Pharmacy Policy
Commercial/ASO, PEBB	J1303	Injection, ravulizumab-cwvz, 10 mg	10/01/2019		Commercial/ASO,PEBB - Ultomiris®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Ultomiris® - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1304	Injection, tofersen, 1 mg	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - QALSODY	Qalsody-Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1305	Injection, evinacumab-dgnb, 5mg	10/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Evkeeza	HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (FH) AGENTS - Pharmacy Policy; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) AGENTS - MEDICARE PART B
Commercial/ASO, Medicare, OHP, PEBB	J1306	Injection, inclisiran, 1 mg	07/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Leqvio®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; PCSK9 Inhibitors- Commercial - Pharmacy Policy; PCSK9 Inhibitors - Medicaid - Pharmacy Policy; PCSK9 Inhibitors - Medicare Part B - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1322	Injection, elosulfase alfa, 1mg	01/01/2015		Commercial/ASO,Medicare,OHP,PEBB - Vimizim®	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, PEBB	J1322	Injection, elosulfase alfa, 1mg	08/01/2022			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1323	J1323 Injection, elranatamab-bcmm, 1 mg	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - Elrexfio	T-Cell Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1325	Epoprostenol Injection	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Flolan®, Veletri®	Pharmacy Policy; Pulmonary Arterial Hypertension - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 302/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J1411	Injection, etranacogene dezaparvovec-drlb, per therapeutic dose	04/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Hemgenix	Hemgenix - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1412	Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2 x 10^13 vector genomes	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - ROCTAVIAN	Gene Therapy for Hemophilia Policy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1413	Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose	01/01/2024		ELEVIDYS	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1426	Injection, casimersen, 10 mg	10/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Amondys 45	Exon-Skipping Therapies for Duchenne Muscular Dystrophy Policy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1427	Injection, viltolarsen, 10 mg	04/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Viltepso	Exon-Skipping Therapies for Duchenne Muscular Dystrophy Policy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1428	Injection, eteplirsen, 10 mg	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Exondys 51®	Exon-Skipping Therapies for Duchenne Muscular Dystrophy Policy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1429	Injection, golodirsen, 10 mg	07/01/2020		Commercial/ASO,Medicare,OHP,PEBB - Vyondys-53®	Exon-Skipping Therapies for Duchenne Muscular Dystrophy Policy - Pharmacy Policy
ОНР	J1438	Injection, etanercept, 25 mg	04/01/2017		OHP - Enbrel®	Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Commercial/ASO, PEBB	J1438	Injection, etanercept, 25 mg	01/01/2018		Commercial/ASO,PEBB - Enbrel®	Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1440	Fecal microbiota, live - jslm, 1 ml	07/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Rebyota®	Rebyota - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1448	Injection, trilaciclib, 1mg	10/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Cosela	Injectable ANTI-Cancer Medications - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 303/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J1458	Galsulfase injection	01/01/2007		Commercial/ASO,Medicare,OHP,PEBB - Naglazyme®	Enzyme Replacement Therapy - Pharmacy Policy; Pharmacy Policy
Commercial/ASO, PEBB	J1458	Galsulfase injection	09/01/2020		Commercial/ASO,PEBB - Naglazyme®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1459	Injection, immune globulin (Privigen), intravenous, non-lyophilized (e.g. liquid), 500 mg	01/01/2009		Commercial/ASO,Medicare,OHP,PEBB - Privigen®	IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy; Pharmacy Policy
Commercial/ASO, PEBB	J1459	Injection, immune globulin (Privigen), intravenous, non-lyophilized (e.g. liquid), 500 mg	09/01/2020			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1551	Injection, immune globulin (cutaquig), 100 mg	07/01/2022			IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1554	Injection, immune globulin (asceniv), 500 mg	04/01/2021			IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy; Infusion Therapy Site of Care - Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1555	Injection, immune globulin (cuvitru), 100 mg	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Cuvitru®	IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy
Commercial/ASO, PEBB	J1555	Injection, immune globulin (cuvitru), 100 mg	09/01/2020			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1556	Injection, immune globulin (Bivigam), 500 mg	01/01/2014		Commercial/ASO,Medicare,OHP,PEBB - Bivigam®	IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy; Infusion Therapy Site of Care - Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1557	Injection, immune globulin, (Gammaplex), intravenous, non-lyophilized (e.g. liquid), 500 mg	01/01/2012		Commercial/ASO,Medicare,OHP,PEBB - Gammaplex®	IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy; Pharmacy Policy
Commercial/ASO, PEBB	J1557	Injection, immune globulin, (Gammaplex), intravenous, non-lyophilized (e.g. liquid), 500 mg	09/01/2020		Commercial/ASO,PEBB - Gammaplex®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J1558	Injection, immune globulin (xembify), 100 mg	07/01/2020			IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy
Commercial/ASO, PEBB	J1558	Injection, immune globulin (xembify), 100 mg	09/01/2020			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1559	Hizentra injection	01/01/2011		Commercial/ASO,Medicare,OHP,PEBB - Hizentra®, Part D vs. Part B (CMS Self- Administered Drug List)	IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy
Commercial/ASO, PEBB	J1559	Hizentra injection	09/01/2020			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1561	Immune Globulin 500 Mg	01/01/2008		Commercial/ASO,Medicare,OHP,PEBB - Gamunex-C <sup>®</sup> , Gammaked <sup>®</sup>	IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy; Pharmacy Policy
Commercial/ASO, PEBB	J1561	Immune Globulin 500 Mg	09/01/2020		Commercial/ASO,PEBB - Gamunex-C <sup>®</sup> , Gammaked <sup>®</sup>	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1566	Immune globulin, powder	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Gammagard S/D <sup>®</sup> , Carimune Nanofiltered <sup>®</sup>	IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy; Pharmacy Policy
Commercial/ASO, PEBB	J1566	Immune globulin, powder	09/01/2020		Commercial/ASO,PEBB - Gammagard S/D <sup>®</sup> , Carimune Nanofiltered <sup>®</sup>	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1568	Octagam injection	01/01/2008		Commercial/ASO,Medicare,OHP,PEBB - Octagam®	IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy
Commercial/ASO, PEBB	J1568	Octagam injection	09/01/2020		Commercial/ASO,PEBB - Octagam®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1569	Gammagard liquid injection	01/01/2008		Commercial/ASO,Medicare,OHP,PEBB - Gammagard Liquid®	IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy
Commercial/ASO, PEBB	J1569	Gammagard liquid injection	09/01/2020		Commercial/ASO,PEBB - Gammagard Liquid®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1572	Flebogamma injection	01/01/2008		Commercial/ASO,Medicare,OHP,PEBB - Flebogamma Dif®	IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 305/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, PEBB	J1572	Flebogamma injection	09/01/2020		Commercial/ASO,PEBB - Flebogamma Dif®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	01/01/2016		Commercial/ASO,Medicare,OHP,PEBB - Hyqvia®	IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy
Commercial/ASO, PEBB	J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immune globulin	08/01/2022			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	07/01/2023			IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1599	lvig non-lyophilized, NOS	01/01/2011		Commercial/ASO,Medicare,OHP,PEBB - Panzyga® (Immune globulin, gamma (IGG)- IFAS HUMAN/GLYCINE)	IMMUNE GAMMA GLOBULIN(IgG) - Pharmacy Policy
Commercial/ASO, PEBB	J1599	Injection, immune globulin, intravenous, non- lyophilized (e.g., liquid), not otherwise specified, 500 mg	08/01/2022			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
ОНР	J1602	Injection, golimumab, 1 mg, for intravenous use	04/01/2017		OHP - Simponi Aria®	Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Commercial/ASO, PEBB	J1602	Injection, golimumab, 1 mg, for intravenous use	01/01/2018		Commercial/ASO,PEBB - Simponi Aria®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medically Infused Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy
Medicare	J1602	Injection, golimumab, 1 mg, for intravenous use	09/01/2020		Medicare - Simponi Aria®	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	J1628	Injection, guselkumab, 1 mg	01/01/2019		Commercial/ASO,OHP,PEBB - Tremfya®	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Medicare	J1628	Injection, guselkumab, 1 mg	01/01/2019	05/15/2021	Medicare - Tremfya <sup>®</sup> (CMS Self-administered drug, Part B exclusion effective 5/15/2021)	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1632	Injection, brexanolone, 1 mg	10/01/2020			Zulresso <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1743	Injection, idursulfase, 1 mg	10/01/2017		Commercial/ASO,Medicare,OHP,PEBB - Elaprase®	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, PEBB	J1743	Injection, idursulfase, 1 mg	08/01/2022			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, OHP, PEBB	J1744	Icatibant injection	01/01/2013		Commercial/ASO,OHP,PEBB - Firazyr®	Hereditary Angioedema - Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
ОНР	J1745	Injection, infliximab, excludes biosimilar, 10 mg	04/01/2017		OHP - Remicade®	Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Commercial/ASO, PEBB	J1745	Injection, infliximab, excludes biosimilar, 10 mg	01/01/2018		Commercial/ASO,PEBB - Remicade®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medically Infused Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 307/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	J1745	Injection, infliximab, excludes biosimilar, 10 mg	09/01/2020		Medicare - Remicade®	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1746	Injection, ibalizumab-uiyk, 10 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Trogarzo®	Trogarzo <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1747	Injection, spesolimab-sbzo, 1 mg	04/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Spevigo	Spevigo - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1786	Injection, imiglucerase, 10 units	07/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Cerezyme®	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, PEBB	J1786	Injection, imiglucerase, 10 units	09/01/2020		Commercial/ASO,PEBB - Cerezyme®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1823	Injection, inebilizumab-cdon, 1 mg	01/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Uplinza®	Medicare Part B Step Therapy - Pharmacy Policy; Uplinza <sup>®</sup> - Pharmacy Policy
Commercial/ASO, OHP, PEBB	J1830	Interferon Beta-1b / .25 Mg	08/01/2009		Commercial/ASO,OHP,PEBB - Extavia®	Extavia <sup>®</sup> - Pharmacy Policy ; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1930	Injection, lanreotide, 1 mg	09/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Somatuline Depot	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy; Pituitary Disorder Therapies (Commercial/Medicaid) - Pharmacy Policy; Somatostatin Analogs Medicare Part B - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1931	Injection, laronidase, 0.1 mg	10/01/2017		Commercial/ASO,Medicare,OHP,PEBB - Aldurazyme®	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, PEBB	J1931	Injection, laronidase, 0.1 mg	08/01/2022			Infusion Therapy Site of Care -Commercial- Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J1932	Injection, lanreotide, (cipla), 1 mg	10/01/2022			Pituitary Disorder Therapies (Commercial/Medicaid) - Pharmacy Policy; Somatostatin Analogs Medicare Part B - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1950	Leuprolide Acetate /3.75 Mg	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Eligard <sup>®</sup> , Lupron <sup>®</sup>	Gonadotropin Releasing Hormone Agonist - Pharmacy Policy; Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1951	Injection, leuprolide acetate for depot suspension (fensolvi), 0.25 mg	07/01/2021			Gonadotropin Releasing Hormone Agonist - Pharmacy Policy; Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1952	Leuprolide injectable, camcevi, 1 mg	01/01/2022			Gonadotropin Releasing Hormone Agonist - Pharmacy Policy; Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J1954	Injection, leuprolide acetate for depot suspension (lutrate), 7.5 mg	01/01/2023		Commercial/ASO,Medicare,OHP,PEBB - J1954 is specific for manufacturer, Lutrate	Gonadotropin Releasing Hormone Agonist - Pharmacy Policy; Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, OHP, PEBB	J1961	Injection, lenacapavir, 1 mg	07/01/2023		Commercial/ASO,OHP,PEBB - Sunlenca®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Sunlenca - Pharmacy Policy
Commercial/ASO, OHP, PEBB	J2170	Injection, mecasermin, 1 mg	06/01/2018		Commercial/ASO,OHP,PEBB - Increlex®	Increlex <sup>®</sup> - Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2182	Injection, mepolizumab, 1 mg	01/01/2017		Commercial/ASO,Medicare,OHP,PEBB - Nucala®	IL-5 Inhibitors - Pharmacy Policy; Self- Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, OHP, PEBB	J2212	Methylnaltrexone injection	01/01/2013		Commercial/ASO,OHP,PEBB - Relistor®	Relistor <sup>®</sup> - Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2277	J2277 Injection, motixafortide, 0.25 mg	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - Aphexda	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 309/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J2323	Natalizumab injection	01/01/2008		Commercial/ASO,Medicare,OHP,PEBB - Tysabri®	Medicare Part B Step Therapy - Pharmacy Policy; Tysabri <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2326	Injection, nusinersen, 0.1 mg	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Spinraza®	Spinraza <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2327	Injection, risankizumab-rzaa, intravenous, 1 mg	01/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Skyrizi IV only.	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Medically Infused Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2329	Injection, ublituximab-xiiy, 1mg	11/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Briumvi	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medically Administered Multiple Sclerosis Agents Prior Authorization - Pharmacy Policy; Medically Administered Multiple Sclerosis Agents Prior Authorization and Step Therapy Policy – Medicare Part B
Commercial/ASO, PEBB	J2350	Injection, Ocrelizumab	03/02/2020		Commercial/ASO,PEBB - Ocrevus <sup>®</sup> ***MAY require prior authorization for Site of Care location only***	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2350	Injection, Ocrelizumab	11/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Ocrevus <sup>®</sup> ***Commercial and ASO members MAY require prior authorization for Site of Care location also***	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medically Administered Multiple Sclerosis Agents Prior Authorization - Pharmacy Policy; Medically Administered Multiple Sclerosis Agents Prior Authorization and Step Therapy Policy – Medicare Part B
Medicare	J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	07/05/2005		Medicare - Sandostatin <sup>®</sup> LAR Depot	Medicare Part B Step Therapy - Pharmacy Policy; Part D versus Part B (Medicare Only) - Pharmacy Policy; Somatostatin Analogs Medicare Part B - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	11/01/2008		Commercial/ASO,OHP,PEBB - Sandostatin® LAR Depot	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Pituitary Disorder Therapies (Commercial/Medicaid) - Pharmacy Policy
Commercial/ASO, OHP, PEBB	J2354	Injection, octreotide, non-depot form for subcutaneous or intravenous	11/01/2008	08/31/2021	Commercial/ASO,OHP,PEBB - Sandostatin®, CMS Self-Administered Drug List	Pituitary Disorder Therapies (Commercial/Medicaid) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2356	Injection, tezepelumab-ekko, 1 mg	07/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Tezspire®	Medicare Part B Step Therapy - Pharmacy Policy; Tezspire - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2357	Omalizumab injection	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Xolair®	Medicare Part B Step Therapy - Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy; Xolair® - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2502	Injection, pasireotide long acting, 1 mg	01/01/2016		Commercial/ASO,Medicare,OHP,PEBB - Signifor LAR®	Medicare Part B Step Therapy - Pharmacy Policy; Signifor LAR <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2503	Injection, pegaptanib sodium, 0.3 mg	05/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Macugen®	Medicare Part B Step Therapy - Pharmacy Policy; Ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitors - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2507	Injection, pegloticase, 1 mg	01/01/2012		Commercial/ASO,Medicare,OHP,PEBB - Krystexxa®	Krystexxa <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2508	Injection, pegunigalsidase alfa-iwxj, 1 mg	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - ELFABRIO	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2777	Injection, faricimab-svoa, 0.1 mg	10/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Vabysmo	Medicare Part B Step Therapy - Pharmacy Policy; Ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitors - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2778	Injection, ranibizumab, 0.1 mg	05/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Lucentis®	Medicare Part B Step Therapy - Pharmacy Policy; Ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitors - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 311/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J2779	Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg	07/01/2022			Medicare Part B Step Therapy - Pharmacy Policy; Ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitors - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2781	J2781 - Injection, pegcetacoplan, intravitreal, 1 mg	10/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Syfovre	Syfovre-Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2782	J2782 Injection, avacincaptad pegol, 0.1 mg	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - Izervay	Izervay - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2786	Injection, reslizumab, 1 mg	01/01/2017		Commercial/ASO,Medicare,OHP,PEBB - Cinqair®	IL-5 Inhibitors - Pharmacy Policy
Commercial/ASO, OHP, PEBB	J2787	Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL	01/01/2019			Eye: Corneal Collagen Cross-Linking (Company)
Commercial/ASO, Medicare, OHP, PEBB	J2793	Rilonacept injection	01/01/2010		Commercial/ASO,Medicare,OHP,PEBB - Arcalyst <sup>®</sup>	Interleukin – 1 Inhibitors - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2796	Romiplostim injection	01/01/2010		Commercial/ASO,Medicare,OHP,PEBB - Nplate®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy; Thrombocytopenia Medications- Medicare Part B
Commercial/ASO, Medicare, OHP, PEBB	J2840	Injection, sebelipase alfa, 1 mg	01/01/2017		Commercial/ASO,Medicare,OHP,PEBB - Kanuma®	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, PEBB	J2840	Injection, sebelipase alfa, 1 mg	09/01/2020		Commercial/ASO,PEBB - Kanuma®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2860	Injection, siltuximab, 10 mg	01/01/2016		Commercial/ASO,Medicare,OHP,PEBB - Sylvant <sup>®</sup>	Sylvant <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J2941	Injection, somatropin, 1 mg	01/01/2007		Commercial/ASO,Medicare,OHP,PEBB - Flexpro®, Genotropin®, Humatrope®, Norditropin®, Norditropin Nordiflex®, Nutropin AQ®, Omnitrope®, Saizen®, Serostim®, Zomacton®, Zorbtive®	Human Growth Hormones for Adults - Pharmacy Policy; Human Growth Hormones for Pediatrics - Pharmacy Policy; Self- Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 312/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J2998	Injection, plasminogen, human-tvmh, 1 mg	07/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Ryplazim®	Ryplazim - Pharmacy Policy
Commercial/ASO, OHP, PEBB	J3031	Injection, fremanezumab-vfrm, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self- administered)	10/01/2019		Commercial/ASO,OHP,PEBB - Ajovy®	Calcitonin Gene-Related Peptide Receptor (CGRP) Agonists Pharmacy Policy; Self- Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3032	Injection, eptinezumab-jjmr, 1 mg	10/01/2020		Commercial/ASO,Medicare,OHP,PEBB - Vyepti®	Calcitonin Gene-Related Peptide Receptor (CGRP) Agonists Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, PEBB	J3032	Injection, eptinezumab-jjmr, 1 mg	01/01/2023		Commercial/ASO,PEBB - Vyepti	Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3055	J3055 Injection, talquetamab-tgvs, 0.25 mg	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - Talvey	T-Cell Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3060	Injection, taliglucerase alfa, 10 units (Elelyso)	07/01/2019			Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, PEBB	J3060	Injection, taliglucerase alfa, 10 units (Elelyso)	09/01/2020			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3110	Teriparatide injection	01/01/2007		Commercial/ASO,Medicare,OHP,PEBB - Forteo®	Osteoanabolic Medications - Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3111	Injection, romosozumab-aqqg, 1 mg	10/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Evenity <sup>®</sup>	Evenity <sup>®</sup> - Pharmacy Policy; Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3145	Injection, testosterone undecanoate, 1 mg	10/01/2015		Commercial/ASO,Medicare,OHP,PEBB - Aveed™	Hormone Replacement Therapy - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3241	Injection, teprotumumab-trbw, 10 mg	10/01/2020		Commercial/ASO,Medicare,OHP,PEBB - Tepezza	Tepezza <sup>®</sup> - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 313/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, PEBB	J3241	Injection, teprotumumab-trbw, 10 mg	08/01/2022			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3245	Injection, tildrakizumab, 1 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Ilumya®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Medically Infused Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Medicare, OHP	J3262	Tocilizumab injection	01/01/2011		Medicare,OHP - Actemra®	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Commercial/ASO, PEBB	J3262	Tocilizumab injection	01/01/2011		Commercial/ASO,PEBB - Actemra®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medically Infused Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy; Self- Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3285	Treprostinil injection	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Remodulin <sup>®</sup>	Pulmonary Arterial Hypertension - Pharmacy Policy
Commercial/ASO, OHP, PEBB	J3315	Injection, triptorelin pamoate, 3.75 mg	05/01/2021		Commercial/ASO,OHP,PEBB -	Gonadotropin Releasing Hormone Agonist - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 314/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J3316	Injection, triptorelin, extended-release, 3.75 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Triptodur	Gonadotropin Releasing Hormone Agonist - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3355	Urofollitropin, 75 iu	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Bravelle®	Infertility and Related Medications - Pharmacy Policy
ОНР	J3357	Ustekinumab, for subcutaneous injection, 1 mg	04/01/2017		OHP - Stelara®	Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Commercial/ASO, PEBB	J3357	Ustekinumab, for subcutaneous injection, 1 mg	01/01/2018		Commercial/ASO,PEBB - Stelara®	Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy
Medicare	J3357	Ustekinumab, for subcutaneous injection, 1 mg	04/01/2020	10/15/2021	Medicare - Medicare Part B exclusion effective 10/15/2021. Refer to the Noridian Self- Administered Drug (SAD) List.	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy
Commercial/ASO, OHP, PEBB	J3358	Ustekinumab, for intravenous injection, 1 mg	01/01/2018		Commercial/ASO,OHP,PEBB - Stelara® (IV)	Medically Infused Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Medicare	J3358	Ustekinumab, for intravenous injection, 1 mg	09/01/2020		Medicare - Stelara <sup>®</sup> IV	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Medicare, OHP	J3380	Injection, vedolizumab, 1 mg	01/01/2016		Medicare,OHP - Entyvio®	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, PEBB	J3380	Injection, vedolizumab, 1 mg	01/01/2016		Commercial/ASO,PEBB - Entyvio®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medically Infused Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3385	Injection, velaglucerase alfa, 100 units (VPRIV)	07/01/2019			Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, PEBB	J3385	Injection, velaglucerase alfa, 100 units (VPRIV)	09/01/2020			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3397	Injection, vestronidase alfa-vjbk, 1 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Mepsevii®	Enzyme Replacement Therapy - Pharmacy Policy
Commercial/ASO, PEBB	J3397	Injection, vestronidase alfa-vjbk, 1 mg	08/01/2022			Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3398	Injection, voretigene neparvovec-rzyl, 1 billion vector genomes	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Luxturna®	Luxturna <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3399	Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes	07/01/2020		Commercial/ASO,Medicare,OHP,PEBB - Zolgensma	Zolgensma <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3401	Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - VYJUVEK	Vyjuvek - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J3490	Unclassified drugs	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Aphexda® (Motixafortide); Cetrotide® (Cetrorelix acetate); Jeuveau® (Prabotulinumtoxina-XVFS); iDose TR® (Travoprost intracameral implant); Lupaneta® Pack (Leuprolide/Norethindrone Acetate); Nulibry® (Fosdenopterin hydrobromide); Prevymis® (letermovir); Revatio® IV (Sildenafil citrate); Qalsody® (Tofersen); Rivfloza® (Nedosiran); Testopel® (Testosterone pellet)	Botulinum Toxin - Medicare Part B - Pharmacy Policy; Gonadotropin Releasing Hormone Agonist - Pharmacy Policy; Hormone Replacement Therapy - Pharmacy Policy; Infertility and Related Medications - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy; Medications for Rare Indications - Pharmacy Policy; New Drug/Indication Awaiting P&T Review - Pharmacy Policy; Prevymis® - Pharmacy Policy; Pulmonary Arterial Hypertension - Pharmacy Policy; Qalsody-Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 316/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J3590	Unclassified biologics	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Adzynma®(ADAMTS13, recombinant- krhn); Lantidra® (Donislecel-jujn); Lyfgenia® (lovotibeglogene autotemcel); Omisirge® (Omidubicel-onlv); Pombiliti® (Cipaglucosidase alfa-atga); Rethymic® (Allogeneic processed thymus tissue-agdc); Skysona® (Elivaldogene autotemcel); Veopoz® (Pozelimab-bbfg); Zynteglo® (Betibeglogene autotemcel).	Medicare Part B Step Therapy - Pharmacy Policy; Medications for Rare Indications - Pharmacy Policy; New Drug/Indication Awaiting P&T Review - Pharmacy Policy; Omisirge - Pharmacy Policy; Ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitors - Pharmacy Policy; Rethymic - Pharmacy Policy; Skysona - Pharmacy Policy; Zynteglo - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J7170	Injection, emicizumab-kxwh, 0.5 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Hemlibra®	Hemlibra <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J7214	J7214 -Injection, factor viii/von willebrand factor complex, recombinant (altuviiio), per factor viii i.u.	10/01/2023		Commercial/ASO,Medicare,OHP,PEBB -	ALTUVIIIO - PHARMACY POLICY
Commercial/ASO, Medicare, OHP, PEBB	J7313	Injection, fluocinolone acetonide, intravitreal implant, 0.01 mg	01/01/2016	02/28/2017		Drug: Iluvien (Fluocinolone Acetonide) Intravitreal Implant for Diabetic Macular Edema
Commercial/ASO, Medicare, OHP, PEBB	J7316	Injection, ocriplasmin 0.125 mg	01/01/2014	03/31/2017		Eye: Vitreomacular Adhesion-Ocriplasmin (Jetrea®)
Commercial/ASO, OHP, PEBB	J7325	Synvisc or Synvisc-One	08/01/2014	12/31/2017		Viscosupplementation (Company)
Commercial/ASO, Medicare, OHP, PEBB	J7330	Cultured Chondrocytes Implnt	09/01/2003			Autologous Chondrocyte Implantation (ACI); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Medicare); Balloon Dilation of the Sinuses or Eustachian Tubes (Medicare); Knee: Cartilagenous Defects of the knee
Commercial/ASO, Medicare, OHP, PEBB	J7351	Injection, bimatoprost, intracameral implant, 1 microgram	10/01/2020			Durysta-Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 317/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J7352	Afamelanotide implant, 1 mg	01/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Scenesse®	Scenesse <sup>®</sup> - Pharmacy Policy
Medicare	J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	01/01/2016			Part D versus Part B (Medicare Only) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J7508	Tacrolimus Oral Per 5 Mg	01/01/2014			Part D versus Part B (Medicare Only) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J7686	Treprostinil, non-comp unit	01/01/2011		Commercial/ASO,Medicare,OHP,PEBB - Tyvaso®	Pulmonary Arterial Hypertension - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J7699	NOC drugs, inhalation solution administered through DME	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB -	New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J7799	Noc drugs, other than inhalation drugs, administered through dme	12/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Empaveli (Pegcetacoplan); Medicare prior- authorization also for Part B vs. Part D	Empaveli - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J8565	Gefitinib oral	01/01/2007		Commercial/ASO,Medicare,OHP,PEBB - Iressa®	Oral ANTI-Cancer Medications - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J8600	Melphalan Oral 2 Mg	11/01/2008		Commercial/ASO,Medicare,OHP,PEBB - Alkeran <sup>®</sup>	Oral ANTI-Cancer Medications - Pharmacy Policy
Commercial/ASO, OHP, PEBB	J8700	Temozolmide	11/01/2008		Commercial/ASO,OHP,PEBB - Temodar®	Oral ANTI-Cancer Medications - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9021	Injection, asparaginase, recombinant, (rylaze), 0.1 mg	01/01/2022			Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9022	Injection, atezolizumab, 10 mg	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Tecentriq®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9023	Injection, avelumab, 10 mg	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Bavencio®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9025	Azacitidine injection	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Vidaza®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9029	Injection, nadofaragene firadenovec-vncg, per therapeutic dose	07/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Adstiladrin®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9032	Injection, belinostat, 10 mg	01/01/2016		Commercial/ASO,Medicare,OHP,PEBB - Beleodaq®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9033	Injection, bendamustine Hcl, 1 mg	01/01/2009		Commercial/ASO,Medicare,OHP,PEBB - Treanda®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9034	Injection, bendamustine hcl (bendeka), 1 mg	01/01/2017		Commercial/ASO,Medicare,OHP,PEBB - Bendeka®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9035	injection, bevacizumab (for Chemotherapy)	10/01/2009		Commercial/ASO,Medicare,OHP,PEBB - Avastin® *J9035 PA for Oncology use only. **Ophthalmologists: Refer to Payment Policy 97.0 Compounded Drugs Administered in Physician's Office	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9036	Injection, bendamustine hydrochloride, (Belrapzo), 1 mg	07/01/2019			Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9037	Injection, belantamab mafodontin-blmf, 0.5 mg	04/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Blenrep	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	19039	Injection, blinatumomab, 1 microgram	01/01/2016		Commercial/ASO,Medicare,OHP,PEBB - Blincyto®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9041	Injection, bortezomib (velcade), 0.1 mg	03/01/2009		Commercial/ASO,Medicare,OHP,PEBB - Velcade®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9042	Injection, brentuximab vedotin, 1 mg	01/01/2013		Commercial/ASO,Medicare,OHP,PEBB - Adcetris®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9043	Injection, cabazitaxel, 1 mg	01/01/2012		Commercial/ASO,Medicare,OHP,PEBB - Jevtana®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9044	Injection, bortezomib, not otherwise specified, 0.1 mg	01/01/2019	12/31/2022	Commercial/ASO,Medicare,OHP,PEBB - J9044 replaced by new codes effective 1/1/2023: J9041, J9046, J9048, J9049	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9046	Injection, bortezomib, (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg	01/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Bortezomib J9046, specific manufacturer Dr. Reddy's only.	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 320/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9047	Injection, carfilzomib, 1 mg	01/01/2014		Commercial/ASO,Medicare,OHP,PEBB - Kyprolis®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9048	Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg	01/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Bortezomib J9048 for specific manufacturer Fresenius Kabi only.	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9049	Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg	01/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Bortezomib J9049 for specific manufacturer Hospira only.	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9051	J9051 - Injection, bortezomib (maia), not therapeutically equivalent to j9041, 0.1 mg	10/01/2023		Commercial/ASO,Medicare,OHP,PEBB -	Injectable ANTI-Cancer Medications - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9055	Cetuximab injection	07/17/2007		Commercial/ASO,Medicare,OHP,PEBB - Erbitux®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9056	Injection, bendamustine hydrochloride (vivimusta), 1 mg	07/01/2023			Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9057	Injection, copanlisib, 1 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Aliqopa <sup>®</sup>	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9058	Injection, bendamustine hydrochloride (apotex), 1 mg	07/01/2023			Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 321/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9059	Injection, bendamustine hydrochloride (baxter), 1 mg	07/01/2023			Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9061	Injection, amivantamab-vmjw, 2 mg	01/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Rybrevant	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9063	Injection, mirvetuximab soravtansine-gynx, 1 mg	07/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Elahere®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9064	J9064 - Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg	10/01/2023		Commercial/ASO,Medicare,OHP,PEBB -	Injectable ANTI-Cancer Medications - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9118	Injection, calaspargase pegol-mknl, 10 units	10/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Asparlas <sup>®</sup>	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9119	Injection, cemiplimab-rwlc, 1 mg	10/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Libtayo®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	01/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Darzalex Faspro <sup>®</sup>	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9145	Injection, daratumumab, 10 mg	01/01/2017		Commercial/ASO,Medicare,OHP,PEBB - Darzalex™	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 322/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9153	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Vyxeos®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9173	Injection, durvalumab, 10 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Imfinzi®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9176	Injection, elotuzumab, 1 mg	01/01/2017		Commercial/ASO,Medicare,OHP,PEBB - Empliciti®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9177	Injection, enfortumab vedotin-ejfv, 0.25 mg	07/01/2020		Commercial/ASO,Medicare,OHP,PEBB - Padcev®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9179	Injection, eribulin mesylate, 0.1 mg	01/01/2012		Commercial/ASO,Medicare,OHP,PEBB - Halaven®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9202	Goserelin acetate implant, per 3.6 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Zoladex®	Gonadotropin Releasing Hormone Agonist - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9203	Injection, gemtuzumab ozogamicin, 0.1 mg	01/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Mylotarg	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9204	Injection, mogamulizumab-kpkc, 1 mg	10/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Poteligeo®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 323/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9205	Injection, irinotecan liposome, 1 mg	01/01/2017		Commercial/ASO,Medicare,OHP,PEBB - Onivyde®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9207	Injection, ixabepilone, 1 mg	01/01/2009		Commercial/ASO,Medicare,OHP,PEBB - Ixempra®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9210	Injection, emapalumab-lzsg, 1 mg	10/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Gamifant®	Medications for Rare Indications - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9216	Interferon Gamma 1-B Inj	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Actimmune®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9217	Leuprolide acetate (for depot suspension), 7.5 mg	10/01/2014		Commercial/ASO,Medicare,OHP,PEBB - Eligard®, Lupron® [Prior-authorization not required for diagnosis C61- Prostate Cancer]	Gonadotropin Releasing Hormone Agonist - Pharmacy Policy; Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, OHP, PEBB	J9218	Leuprolide acetate, per 1 mg	10/01/2014		Commercial/ASO,OHP,PEBB - Eligard <sup>®</sup> , Lupron <sup>®</sup> [Prior-authorization not required for diagnosis C61-Prostate Cancer]	Gonadotropin Releasing Hormone Agonist - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; Self-Administered Drug (SAD) Exclusion - Commercial/Medicaid - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9223	Injection, lurbinectedin, 0.1 mg	01/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Zepzelca®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9225	Histrelin implant (Vantas), 50 mg	09/01/2019			Gonadotropin Releasing Hormone Agonist - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9226	Histrelin implant (Supprelin LA), 50 mg	03/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Supprelin LA®	Gonadotropin Releasing Hormone Agonist - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9227	Injection, isatuximab-irfc, 10 mg	10/01/2020			Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9228	Injection, ipilimumab, 1 mg	01/01/2012		Commercial/ASO,Medicare,OHP,PEBB - Yervoy®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9229	Injection, inotuzumab ozogamicin, 0.1 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Besponsa®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9245	Inj Melphalan Hydrochl 50 Mg	11/01/2008		Commercial/ASO,Medicare,OHP,PEBB - Alkeran®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9246	Injection, melphalan (evomela), 1 mg	07/01/2020		Commercial/ASO,Medicare,OHP,PEBB -	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9247	Injection, melphalan flufenamide, 1mg	10/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Pepaxto	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9258	Injection, paclitaxel protein-bound particles (teva) not therapeutically equivalent to j9264, 1 mg	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - Manufacturer = TEVA	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 325/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9259	Injection, paclitaxel protein-bound particles (american regent) not therapeutically equivalent to j9264, 1 mg	07/01/2023			Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9261	Nelarabine injection	01/01/2007		Commercial/ASO,Medicare,OHP,PEBB - Arranon <sup>®</sup>	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9262	Injection, omacetaxine mepesuccinate, 0.01 mg	01/01/2014		Commercial/ASO,Medicare,OHP,PEBB - Synribo®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9264	Injection, paclitaxel protein-bound particles, 1 mg	06/01/2016		Commercial/ASO,Medicare,OHP,PEBB - Abraxane®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9269	Injection, tagraxofusp-erzs, 10 micrograms	10/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Elzonris®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9271	Injection, pembrolizumab, 1 mg	01/01/2016		Commercial/ASO,Medicare,OHP,PEBB - Keytruda®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9272	Injection, dostarlimab-gxly, 10 mg	01/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Jemperli	Injectable ANTI-Cancer Medications - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9273	Injection, tisotumab vedotin-tftv, 1 mg	04/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Tivdak®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 326/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9274	Injection, tebentafusp-tebn, 1 microgram	10/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Kimmtrak	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9281	Mitomycin pyelocalyceal instillation, 1 mg	06/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Jelmyto	Injectable ANTI-Cancer Medications - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9285	Injection, olaratumab, 10 mg	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Lartruvo®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9286	Injection, glofitamab-gxbm, 2.5 mg	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - COLUMVI	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9295	Injection, necitumumab, 1 mg	01/01/2017		Commercial/ASO,Medicare,OHP,PEBB - Portrazza®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9298	Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg	10/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Opdualag	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9299	Injection, nivolumab, 1 mg	01/01/2016		Commercial/ASO,Medicare,OHP,PEBB - Opdivo®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9302	Ofatumumab injection	01/01/2011		Commercial/ASO,Medicare,OHP,PEBB - Arzerra®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9303	Panitumumab injection	01/01/2008		Commercial/ASO,Medicare,OHP,PEBB - Vectibix®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9306	Injection, pertuzumab, 1 mg	01/01/2014		Commercial/ASO,Medicare,OHP,PEBB - Perjeta®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9307	Pralatrexate injection	01/01/2011		Commercial/ASO,Medicare,OHP,PEBB - Folotyn®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9308	Injection, ramucirumab, 5 mg	01/01/2016		Commercial/ASO,Medicare,OHP,PEBB - Cyramza®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	19309	Injection, polatuzumab vedotin-piiq, 1 mg	01/01/2020		Commercial/ASO,Medicare,OHP,PEBB - Polivy	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9311	Injection, rituximab 10 mg and hyaluronidase	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Rituxan Hycela	Medicare Part B Step Therapy - Pharmacy Policy; Rituximab - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9312	Injection, rituximab, 10 mg	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Rituxan®	Medicare Part B Step Therapy - Pharmacy Policy; Rituximab - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9313	Injection, moxetumomab pasudotox-tdfk, 0.01 mg	10/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Lumoxiti®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9316	Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg	01/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Phesgo®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9317	Injection, sacituzumab govitecan-hziy, 2.5 mg	01/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Trodelvy®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9318	Injection, romidepsin, non-lyophilized, 0.1 mg	10/01/2021		Commercial/ASO,Medicare,OHP,PEBB -	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9319	Injection, romidepsin, lyophilized, 0.1 mg	10/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Istodax	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9321	Injection, epcoritamab-bysp, 0.16 mg	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - EPKINLY	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9325	Injection, talimogene laherparepvec, per 1 million plaque forming units	01/01/2017		Commercial/ASO,Medicare,OHP,PEBB - Imlygic®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9328	Temozolomide injection	01/01/2010		Commercial/ASO,Medicare,OHP,PEBB - Temodar <sup>®</sup> IV	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9330	Injection, temsirolimus, 1 mg	01/01/2009		Commercial/ASO,Medicare,OHP,PEBB - Torisel®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 329/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9331	Injection, sirolimus protein-bound particles, 1 mg	07/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Fyarro®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9332	Injection, efgartigimod alfa-fcab, 2mg	07/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Vyvgart®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy; Vyvgart - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9333	Injection, rozanolixizumab-noli, 1 mg	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - RYSTIGGO	FCRN Antagonists Policy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9334	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc	01/01/2024		Commercial/ASO,Medicare,OHP,PEBB - VYVGART HYTRULO	FCRN Antagonists Policy - Pharmacy Policy ; Infusion Therapy Site of Care -Commercial- Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9345	J9345 - Injection, retifanlimab-dlwr, 1 mg	10/01/2023		Commercial/ASO,Medicare,OHP,PEBB - ZYNYZ	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9347	Injection, tremelimumab-actl, 1 mg	07/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Imjudo®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9348	Injection, naxitamab-gqgk, 1 mg	07/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Danyelza® (Naxitamab-gqgk)	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9349	Injection, tafasitamab-cxix, 2 mg	04/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Monjuvi	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 330/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9350	Injection, mosunetuzumab-axgb, 1 mg	07/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Lunsumio®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9352	Injection, trabectedin, 0.1 mg	01/01/2017		Commercial/ASO,Medicare,OHP,PEBB - Yondelis®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9353	Injection, margetuximab-cmkb, 5 mg	07/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Margenza <sup>®</sup> (Margetuximab-cmkb)	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9354	Injection, ado-trastuzumab emtansine, 1 mg	01/01/2014		Commercial/ASO,Medicare,OHP,PEBB - Kadcyla®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Herceptin®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9356	Injection, trastuzumab, 10 mg and Hyaluronidase-oysk	07/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Herceptin Hylecta <sup>®</sup> (Trastuzumab- hyaluronidase-oysk)	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9358	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	07/01/2020		Commercial/ASO,Medicare,OHP,PEBB - Enhertu®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	J9359	Injection, loncastuximab tesirine-Ipyl, 0.075 mg	04/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Zynlonta®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9376	J9376 Injection, pozelimab-bbfg, 1 mg	04/01/2024		Commercial/ASO,Medicare,OHP,PEBB - Veopoz	Medications for Rare Indications - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9380	Injection, teclistamab-cqyv, 0.5 mg	07/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Tecvayli®	T-Cell Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9381	Injection, teplizumab-mzwv, 5 mcg	07/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Tzield®	Tzield - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	19393	Injection, fulvestrant (teva) not therapeutically equivalent to j9395, 25 mg	01/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Fulvestrant J9393 for specific manufacturer Teva only.	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9394	Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg	01/01/2023		Commercial/ASO,Medicare,OHP,PEBB - Fulvestrant J9394 for specific manufacturer Fresenius Kabi only.	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9395	Injection, fulvestrant, 25 mg	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Faslodex <sup>®</sup>	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	J9400	Injection, ziv-aflibercept, 1 mg	01/01/2014		Commercial/ASO,Medicare,OHP,PEBB - Zaltrap®	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	19999	Not otherwise classified, antineoplastic drugs	01/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Besremi® (Ropeginterferon alfa-2b-njft); Columvi® (glofitamab-gxbm); Elahere® (Mirvetuximab soravtansine-gynx); Epkinly® (Epcoritamab-bysp); Imjudo® (Tremelimumab-	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; New Drug/Indication Awaiting P&T Review - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 332/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
					actl); Loqtorzi® (Toripalimab-tpzi); Lunsumio® (Mosunetuzumab-axgb); Tecvayli® (Teclistamab-cqyv); Zynyz® (Retifanlimab-dlwr)	
Commercial/ASO, Medicare, OHP, PEBB	K0010	Stnd Wt Frame Power Whlchr	11/01/2013			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0011	Stnd Wt Pwr Whlchr W Control	11/01/2013			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0012	Ltwt Portbl Power Whlchr	11/01/2013			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0013	Custom Power Whichr Base	11/01/2013			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0014	Other Power Whichr Base	11/01/2013			Wheelchair and Power Vehicles (Company)
Commercial/ASO, OHP, PEBB	K0553	Supply allowance for therapeutic continuous glucose monitor (CGM), includes all supplies and accessories, 1 unit of service = 1 month's supply	07/01/2017	01/01/2023		Advanced Diabetes Management Technology (Company)
Medicare	K0553	Supply allowance for therapeutic continuous glucose monitor (CGM), includes all supplies and accessories, 1 unit of service = 1 month's supply	07/01/2017	04/30/2022		Advanced Diabetes Management Technology (Medicare)
Commercial/ASO, OHP, PEBB	K0554	Receiver (Monitor), dedicated, for use with therapeutic continuous glucose monitor system.	07/01/2017	01/01/2023		Advanced Diabetes Management Technology (Company)
Medicare	K0554	Receiver (Monitor), dedicated, for use with therapeutic continuous glucose monitor system.	07/01/2017	04/30/2022		Advanced Diabetes Management Technology (Medicare)
Commercial/ASO, OHP, PEBB	K0743	Suction pump, home model, portable, for use on wounds	07/01/2011	09/30/2022		Negative Pressure Wound Therapy (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 333/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	K0743	Suction pump, home model, portable, for use on wounds	07/01/2011	09/30/2022		
Commercial/ASO, OHP, PEBB	К0744	Absorptive wound dressing for use with suction pump, home model, portable, pad size 16 square inches or less	07/01/2011	09/30/2022		Negative Pressure Wound Therapy (Company)
Medicare	K0744	Absorptive wound dressing for use with suction pump, home model, portable, pad size 16 square inches or less	07/01/2011	09/30/2022		
Commercial/ASO, OHP, PEBB	К0745	Absorptive wound dressing for use with suction pump, home model, portable, pad size more than 16 square inches but less than or equal to 48 square inches	07/01/2011	09/30/2022		Negative Pressure Wound Therapy (Company)
Medicare	K0745	Absorptive wound dressing for use with suction pump, home model, portable, pad size more than 16 square inches but less than or equal to 48 square inches	07/01/2011	09/30/2022		
Commercial/ASO, OHP, PEBB	K0746	Absorptive wound dressing for use with suction pump, home model, portable, pad size greater than 48 square inches	07/01/2011	09/30/2022		Negative Pressure Wound Therapy (Company)
Medicare	K0746	Absorptive wound dressing for use with suction pump, home model, portable, pad size greater than 48 square inches	07/01/2011	09/30/2022		
Commercial/ASO, Medicare, OHP, PEBB	K0800	Power operated vehicle,grp 1 standard,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0801	Power operated vehicle,grp 1 heavy duty,patient weight cap 301-450 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0802	Power operated vehicle, grp 1 very heavy duty,patient weight cap 451-600 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, PEBB	К0806	Power operated vehicle, grp 2 standard,patient weight cap up to and incl 300 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0806	Power operated vehicle, grp 2 standard,patient weight cap up to and incl 300 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, PEBB	K0807	Power operated vehicle,grp 2 heavy duty,patient weight cap 301-450 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0807	Power operated vehicle,grp 2 heavy duty,patient weight cap 301-450 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, PEBB	K0808	Power operated vehicle,grp 2 very heavy duty,patient weight cap 451-600 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0808	Power operated vehicle,grp 2 very heavy duty,patient weight cap 451-600 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0812	Power operated vehicle, not otherwise classified	01/01/2007			Wheelchair and Power Vehicles (Company)
Commercial/ASO, Medicare, OHP, PEBB	K0813	Power wheelchair,grp 1 standard,portable,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0814	Power wheelchair,grp 1 standard,portable,captains chair,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0815	Power wheelchair,grp 1 standard,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0816	Power wheelchair,grp 1 standard,captains chair,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	K0820	Power wheelchair,grp 2 standard,portable,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0821	Power wheelchair,grp 2 standard,portable,captains chair,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0822	Power wheelchair,grp 2 standard,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0823	Power wheelchair,grp 2 stnd,captains chair,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0824	Power wheelchair,grp 2 heavy duty,sling/solid seat/back,patient weight cap 301-450 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0825	Power wheelchair,grp 2 heavy duty,captains chair,patient weight cap 301-450 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0826	Power wheelchair,grp 2 very heavy duty,sling/solid seat/back,patient weight cap 451-600 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0827	Power wheelchair,grp 2 very heavy duty,captains chair,patient weight cap 451- 600 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0828	Power wheelchair,grp 2 extra heavy duty,sling/solid seat/back,patient weight cap 601 lbs or more	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0829	Power wheelchair,grp 2 extra heavy duty,captains chair,patient weight cap 601 lbs or more	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, OHP, PEBB	K0830	Power wheelchair,grp 2 stnd,seat elevator,sling/solid seat/back,patient weight cap up to and incl 300 lbs	07/01/2020			Wheelchair and Power Vehicles (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 336/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	K0830	Power wheelchair,grp 2 stnd,seat elevator,sling/solid seat/back,patient weight cap up to and incl 300 lbs	07/01/2020	01/31/2022		Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, OHP, PEBB	K0831	Power wheelchair,grp 2 stnd,seat elevator,captains chair,patient weight cap up to and incl 300 lbs	07/01/2020			Wheelchair and Power Vehicles (Company)
Medicare	K0831	Power wheelchair,grp 2 stnd,seat elevator,captains chair,patient weight cap up to and incl 300 lbs	07/01/2020	01/31/2022		Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0835	Power wheelchair,grp 2 stnd,single power option,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0836	Power wheelchair,grp 2 stnd,single power option,captains chair,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0837	Power wheelchair,grp 2 heavy duty,single power option,sling/solid seat/back,patient weight cap 301-450 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0838	Power wheelchair,grp 2 heavy duty,single power option,captains chair,patient weight cap 301-450 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0839	Power wheelchair,grp 2 very heavy duty,single power option,sling/solid seat/back,patient weight cap 451-600 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	К0840	Power wheelchair,grp 2 extra heavy duty,single power option,sling/solid seat/back,patient weight cap up to and incl 300	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0841	Power wheelchair,grp 2 stnd,mult power option,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 337/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	K0842	Power wheelchair,grp 2 stnd,mult power option,captains chair,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0843	Power wheelchair,grp 2 heavy duty,mult power option,sling/solid seat/back,patient weight cap 301-450 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0848	Power wheelchair,grp 3 stnd,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0849	Power wheelchair,grp 3 stnd,captains chair,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0850	Power wheelchair,grp 3 heavy duty,sling/solid seat/back,patient weight cap 301-450 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0851	Power wheelchair,grp 3 heavy duty,captains chair,patient weight cap 301-450 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0852	Power wheelchair,grp 3 very heavy duty,sling/solid seat/back,patient weight cap 451-600 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0853	Power wheelchair,grp 3 very heavy duty,captains chair,patient weight cap 451- 600 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0854	Power wheelchair,grp 3 extra heavy duty,sling/solid seat/back,patient weight cap 601 lbs or more	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0855	Power wheelchair,grp 3 extra heavy duty,captains chair,patient weight cap 601 lbs or more	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0856	Power wheelchair,grp 3 stnd,single power option,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 338/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	K0857	Power wheelchair,grp 3 stnd,single power option,captains chair,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0858	Power wheelchair,grp 3 heavy duty,single power option,sling/solid seat/back,patient weight cap 301-450 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0859	Power wheelchair,grp 3 heavy duty,single power option,captains chair,patient weight cap 301-450 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0860	Power wheelchair,grp 3 very heavy duty,single power option,sling/solid seat/back,patient weight cap 451-600 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0861	Power wheelchair,grp 3 stnd,mult power option,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0862	Power wheelchair,grp 3 heavy duty,mult power option,sling/solid seat/back,patient weight cap 301-450 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0863	Power wheelchair,grp 3 very heavy duty,mult power option,sling/solid seat/back,patient weight cap 451-600 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0864	Power wheelchair,grp 3 extra heavy duty,mult power option,sling/solid seat/back,patient weight cap 601 lbs or more	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, PEBB	K0868	Power wheelchair,grp 4 stnd,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0868	Power wheelchair,grp 4 stnd,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 339/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, PEBB	K0869	Power wheelchair,grp 4 stnd,captains chair,patient weight cap up to and incl 300 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0869	Power wheelchair,grp 4 stnd,captains chair,patient weight cap up to and incl 300 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, PEBB	K0870	Power wheelchair,grp 4 heavy duty,sling/solid seat/back,patient weight cap 301-450 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0870	Power wheelchair,grp 4 heavy duty,sling/solid seat/back,patient weight cap 301-450 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, PEBB	K0871	Power wheelchair,grp 4 very heavy duty,sling/solid seat/back,patient weight cap 451-600 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0871	Power wheelchair,grp 4 very heavy duty,sling/solid seat/back,patient weight cap 451-600 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, PEBB	K0877	Power wheelchair,grp 4 stnd,single power option,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0877	Power wheelchair,grp 4 stnd,single power option,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007			Wheelchair and Power Vehicles (Company)
Commercial/ASO, Medicare, PEBB	К0878	Power wheelchair,grp 4 stnd,single power option,captains chair,patient weight cap up to and incl 300 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0878	Power wheelchair,grp 4 stnd,single power option,captains chair,patient weight cap up to and incl 300 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, PEBB	К0879	Power wheelchair,grp 4 heavy duty,single power option,sling/solid seat/back, patient weight cap 301-450 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 340/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
ОНР	K0879	Power wheelchair,grp 4 heavy duty,single power option,sling/solid seat/back, patient weight cap 301-450 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, PEBB	K0880	Power wheelchair,grp 4 very heavy duty,single power option,sling/solid seat/back,patient weight 451-600 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0880	Power wheelchair,grp 4 very heavy duty,single power option,sling/solid seat/back,patient weight 451-600 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, PEBB	K0884	Power wheelchair,grp 4 stnd,mult power potion,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0884	Power wheelchair,grp 4 stnd,mult power potion,sling/solid seat/back,patient weight cap up to and incl 300 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, PEBB	K0885	Power wheelchair,grp 4 stnd,mult power option,captains chair,weight cap up to and incl 300 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0885	Power wheelchair,grp 4 stnd,mult power option,captains chair,weight cap up to and incl 300 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, PEBB	K0886	Power wheelchair,grp 4 heavy duty,mult power option,sling/solid seat/back,patent weight cap 301-450 lbs	01/01/2007	01/31/2022		Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
ОНР	K0886	Power wheelchair,grp 4 heavy duty,mult power option,sling/solid seat/back,patent weight cap 301-450 lbs	01/01/2007		OHP -	Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0890	Power wheelchair,grp 5 ped,single power option,sling/solid seat/back,patient weight cap up to and incl 125 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 341/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	K0891	Power wheelchair,grp 5 pediatric,mult power option,sling/solid seat/back,patient weight cap up to and incl 125 lbs	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0898	Power wheelchair, not otherwise classified	01/01/2007			Wheelchair and Power Vehicles (Company) ; Wheelchair and Power Vehicles (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	K0899	Power mobility device, not coded by DME PDAC or does not meet criteria	01/01/2007	06/30/2020		Wheelchair and Power Vehicles (Company)
Commercial/ASO, Medicare, OHP, PEBB	K1022	Addition to lower extremity prosthesis, endoskeletal, knee disarticulation, above knee, hip disarticulation, positional rotation unit, any type	10/01/2021	12/31/2023		Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Medicare	K1027	Oral device/appliance used to reduce upper airway collapsibility, without fixed mechanical hinge, custom fabricated, includes fitting and adjustment	10/01/2021	04/30/2022		Sleep Disorder Treatment: Oral and Sleep Position Appliances (Medicare)
Medicare	L2006	Knee ankle foot device, any material, single or double upright, swing and/or stance phase microprocessor control with adjustability, includes all components (e.g., sensors, batteries, charger), any type activation, with or without ankle joint(s), custom fabricated	01/01/2020			Ankle-Foot/Knee-Ankle-Foot Orthoses (Company); Ankle-Foot/Knee-Ankle-Foot Orthoses (Medicare); Lower Limb Prosthesis (Company)
Commercial/ASO, OHP, PEBB	L2006	Knee ankle foot device, any material, single or double upright, swing and/or stance phase microprocessor control with adjustability, includes all components (e.g., sensors, batteries, charger), any type activation, with or without ankle joint(s), custom fabricated	01/01/2020	06/30/2023		Ankle-Foot/Knee-Ankle-Foot Orthoses (Company); Lower Limb Prosthesis (Company)
Commercial/ASO, Medicare, OHP, PEBB	L5610	Addition to lower extremity, endoskeletal system, above knee, hydracadence system	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 342/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	L5613	Addition to lower extremity, endoskeletal system, above knee - knee disarticulation, 4 bar linkage, with hydraulic swing	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5614	Addition to lower extremity, endoskeletal system, above knee - knee disarticulation, 4 bar linkage, with pneumatic swing	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5615	Addition, endoskeletal knee-shin system, 4 bar linkage or multiaxial, fluid swing and stance phase control	01/01/2024			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5722	Addition, exoskeletal knee-shin system, single axis, pneumatic swing, friction stance phase control	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5724	Addition, exoskeletal knee-shin system, single axis, fluid swing phase control	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5726	Addition, exoskeletal knee-shin system, single axis, external joints, fluid swing phase control	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5728	Addition, exoskeletal knee-shin system, single axis, fluid swing and stance phase control	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5780	Addition, exoskeletal knee-shin system, single axis, pneumatic/hydra pneumatic swing phase control	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5814	Addition, endoskeletal knee-shin system, polycentric, hydraulic swing phase control, mechanical stance phase lock	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5816	Addition, endoskeletal knee-shin system, polycentric, mechanical stance phase lock	03/01/2017			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5822	Addition, endoskeletal knee-shin system, single axis, pneumatic swing, friction stance phase control	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 343/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	L5824	Addition, endoskeletal knee-shin system, single axis, fluid swing phase control	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5826	Addition, endoskeletal knee-shin system, single axis, hydraulic swing phase control, with miniature high activity frame	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5828	Addition, endoskeletal knee-shin system, single axis, fluid swing and stance phase control	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5830	Addition, endoskeletal knee-shin system, single axis, pneumatic/swing phase control	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5840	Addition, endoskeletal knee/shin system, 4- bar linkage or multiaxial, pneumatic swing phase control	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5841	Addition, endoskeletal knee-shin system, polycentric, pneumatic swing, and stance phase control	04/01/2024			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5848	Addition to endoskeletal knee-shin system, fluid stance extension, dampening feature, with or without adjustability	02/01/2014			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, OHP, PEBB	L5856	Addition to lower extremity prosthesis, endoskeletal knee-shin system, microprocessor control feature, swing and stance	02/01/2014			Lower Limb Prosthesis (Company)
Medicare	L5856	Addition to lower extremity prosthesis, endoskeletal knee-shin system, microprocessor control feature, swing and stance	05/01/2011			Lower Limb Prosthesis (Medicare)
Commercial/ASO, OHP, PEBB	L5857	Addition to lower extremity prosthesis, endoskeletal knee-shin system,	02/01/2014			Lower Limb Prosthesis (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
		microprocessor control feature, swing phase only,				
Medicare	L5857	Addition to lower extremity prosthesis, endoskeletal knee-shin system, microprocessor control feature, swing phase only,	05/01/2011			Lower Limb Prosthesis (Medicare)
Commercial/ASO, OHP, PEBB	L5858	Addition to lower extremity prosthesis, endoskeletal knee shin system, microprocessor control feature, stance phase only	02/01/2014			Lower Limb Prosthesis (Company)
Medicare	L5858	Addition to lower extremity prosthesis, endoskeletal knee shin system, microprocessor control feature, stance phase only	05/01/2011			Lower Limb Prosthesis (Medicare)
Medicare	L5859	Knee-shin pro flex/ext cont	01/01/2013			Lower Limb Prosthesis (Medicare)
Commercial/ASO, OHP, PEBB	L5859	Knee-shin pro flex/ext cont	02/01/2014			Lower Limb Prosthesis (Company)
Commercial/ASO, Medicare, OHP, PEBB	L5926	Addition to lower extremity prosthesis, endoskeletal, knee disarticulation, above knee, hip disarticulation, positional rotation unit, any type	01/01/2024			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5930	Addition, endoskeletal system, high activity knee control frame	02/01/2014	02/01/2014		Lower Limb Prosthesis (Company)
Commercial/ASO, Medicare, OHP, PEBB	L5961	Endo poly hip, pneu/hyd/rot	03/01/2011			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5973	Endoskeletal ankle foot system, microprocessor controlled feature, dorsiflexion and/or plantar flexion control, includes power source	03/01/2017			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 345/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	L5980	All lower extremity prostheses, flex foot system	10/01/2020			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L5987	All lower extremity prosthesis, shank foot system with vertical loading pylon	10/01/2020			Lower Limb Prosthesis (Company); Lower Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6628	Upper extremity addition, quick disconnect hook adapter, otto bock or equal	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6629	Upper extremity addition, quick disconnect lamination collar with coupling piece, otto bock or equal	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6632	Upper extremity addition, latex suspension sleeve, each	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6680	Upper extremity addition, test socket, wrist disarticulation or below elbow	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6687	Upper extremity addition, frame type socket, below elbow or wrist disarticulation	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6715	Terminal device, multiple articulating digit, includes motor(s), initial issue or replacement	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6810	Addition to terminal device, precision pinch device	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6880	Electric hand, switch or myoelectric controlled, independently articulating digits, any grasp pattern or combination of grasp patterns, includes motor(s)	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 346/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	L6881	Automatic grasp feature, addition to upper limb electric prosthetic terminal device	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6882	Microprocessor control feature, addition to upper limb prosthetic terminal device	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6890	Addition to upper extremity prosthesis, glove for terminal device, any material, prefabricated, includes fitting and adjustment	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6925	Wrist disarticulation, external power, self- suspended inner socket, removable forearm shell, otto bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6935	Below elbow, external power, self-suspended inner socket, removable forearm shell, otto bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6945	Elbow disarticulation, external power, molded inner socket, removable humeral shell, outside locking hinges, forearm, otto bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6955	Above elbow, external power, molded inner socket, removable humeral shell, internal locking elbow, forearm, otto bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	L6965	Shoulder disarticulation, external power, molded inner socket, removable shoulder shell, shoulder bulkhead, humeral section, mechanical elbow, forearm, otto bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L6975	Interscapular-thoracic, external power, molded inner socket, removable shoulder shell, shoulder bulkhead, humeral section, mechanical elbow, forearm, otto bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L7007	Electric hand, switch or myoelectric controlled, adult	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L7008	Electric hand, switch or myoelectric, controlled, pediatric	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L7009	Electric hand, switch or myoelectric, controlled, pediatric	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L7045	Electric hook, switch or myoelectric controlled, pediatric	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L7180	Electronic elbow, microprocessor sequential control of elbow and terminal device	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L7181	Electronic elbow, microprocessor simultaneous control of elbow and terminal device	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 348/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	L7190	Electronic elbow, adolescent, variety village or equal, myoelectronically controlled	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L7191	Electronic elbow, child, variety village or equal, myoelectronically controlled	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L7368	Lithium ion battery charger, replacement only	01/01/2015	01/31/2021		Lower Limb Prosthesis (Company)
Commercial/ASO, Medicare, OHP, PEBB	L7400	Addition to upper extremity prosthesis, below elbow/wrist disarticulation, ultralight material (titanium, carbon fiber or equal)	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L7403	Addition to upper extremity prosthesis, below elbow/wrist disarticulation, acrylic material	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8465	Prosthetic shrinker, upper limb, each	01/01/2015			Myoelectric Upper Limb Prosthesis (Company); Myoelectric Upper Limb Prosthesis (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8600	Implantable breast prosthesis, silicone or equal	01/01/2018	12/31/2022		Gender Affirming Surgical Interventions (Company)
Commercial/ASO, Medicare, OHP, PEBB	L8603	Injectable bulking agent, collagen implant, urinary tract, 2.5 ml syringe, includes shipping and necessary supplies	07/01/2019			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8604	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, urinary tract, 1 ml, includes shipping and necessary supplies	07/01/2019			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, OHP, PEBB	L8605	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml, includes shipping and necessary supplies	08/01/2015	03/31/2016		Drug: Solesta (Dextranomer in Stabilized Sodium Hyaluronate) for Fecal Incontinence



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	L8606	Injectable bulking agent, synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies	07/01/2019			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8614	Cochlear device, includes all internal and external components	05/01/2010			Cochlear Implants and Auditory Brainstem Implants (Company); Cochlear Implants and Auditory Brainstem Implants (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8615	Headset/headpiece for use with cochlear implant device, replacement	05/01/2010			Cochlear Implants and Auditory Brainstem Implants (Company); Cochlear Implants and Auditory Brainstem Implants (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8616	Microphone for use with cochlear implant device, replacement	05/01/2010			Cochlear Implants and Auditory Brainstem Implants (Company); Cochlear Implants and Auditory Brainstem Implants (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8617	Transmitting coil for use with cochlear implant device, replacement	05/01/2010			Cochlear Implants and Auditory Brainstem Implants (Company); Cochlear Implants and Auditory Brainstem Implants (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8618	Transmitter cable for use with cochlear implant device, replacement	05/01/2010			Bone-Anchored Hearing Aids (Medicare); Cochlear Implants and Auditory Brainstem Implants (Company); Cochlear Implants and Auditory Brainstem Implants (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8619	Cochlear implant, external speech processor and controller, integrated system, replacement	05/01/2010			Cochlear Implants and Auditory Brainstem Implants (Company); Cochlear Implants and Auditory Brainstem Implants (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8621	Zinc air battery for use w/ cochlear implant device, replacement, each	05/01/2010	06/30/2017		Cochlear Implants and Auditory Brainstem Implants (Company)
Commercial/ASO, Medicare, OHP, PEBB	L8622	Alkaline battery for use w/ cochlear implant device, any size, replacement	05/01/2010	06/30/2017		Cochlear Implants and Auditory Brainstem Implants (Company)
Commercial/ASO, Medicare, OHP, PEBB	L8627	Cochlear implant, external speech processor, component, replacement	01/01/2010			Cochlear Implants and Auditory Brainstem Implants (Company); Cochlear Implants and Auditory Brainstem Implants (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	L8628	Cochlear implant, external controller component, replacement	05/01/2010			Cochlear Implants and Auditory Brainstem Implants (Company); Cochlear Implants and Auditory Brainstem Implants (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8629	Transmitting coil and cable, integrated, for use with cochlear implant device, replacement	01/01/2010			Cochlear Implants and Auditory Brainstem Implants (Company); Cochlear Implants and Auditory Brainstem Implants (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8678	Electrical stimulator supplies (external) for use with implantable neurostimulator, per month	04/01/2023			Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company)
Commercial/ASO, Medicare, OHP, PEBB	L8679	Implantable neurostimulator, pulse generator, any type	01/01/2014			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Fecal Incontinence Treatments (Company); Fecal Incontinence Treatments (Medicare); Gastric Electrical Stimulation (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Medicare); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, OHP, PEBB	L8680	Implantable neurostimulator electrode, each	07/01/2010			Electrical Stimulation: Non-Covered Therapies (Company); Fecal Incontinence Treatments (Company); Gastric Electrical Stimulation (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Vagus Nerve Stimulation (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	L8680	Implantable neurostimulator electrode, each	07/01/2010	08/31/2022		Electrical Stimulation and Electromagnetic Therapies (Medicare); Fecal Incontinence Treatments (Medicare); Gastric Electrical Stimulation (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8681	Pt prgrm for implt neurostim	07/01/2010			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	L8682	Implt neurostim radiofq rec	07/01/2010			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	L8683	Radiofq trsmtr for implt neu	07/01/2010			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation and Electromagnetic Therapies (Medicare); Electrical Stimulation: Non-Covered Therapies (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare); Vagus Nerve Stimulation (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	L8684	Radiofrequency transmitter (external) for use with implantable sacral root neurostimulator receiver for bowel and bladder management, replacement	03/01/2016			Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, OHP, PEBB	L8685	Implt nrostm pls gen sng rec	07/01/2010			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation: Non-Covered Therapies (Company); Fecal Incontinence Treatments (Company); Gastric Electrical Stimulation (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Vagus Nerve Stimulation (Company)
Medicare	L8685	Implt nrostm pls gen sng rec	07/01/2010	08/31/2022		Electrical Stimulation and Electromagnetic Therapies (Medicare); Fecal Incontinence Treatments (Medicare); Gastric Electrical Stimulation (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, OHP, PEBB	L8686	Implt nrostm pls gen sng non	07/01/2010			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation: Non-Covered Therapies (Company); Fecal Incontinence Treatments (Company); Gastric Electrical Stimulation (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Vagus Nerve Stimulation (Company)
Medicare	L8686	Implt nrostm pls gen sng non	07/01/2010	08/31/2022		Electrical Stimulation and Electromagnetic Therapies (Medicare); Fecal Incontinence Treatments (Medicare); Gastric Electrical Stimulation (Company); Urinary Incontinence Treatments (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension	07/01/2010			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation: Non-Covered Therapies (Company); Fecal Incontinence Treatments (Company); Gastric Electrical Stimulation (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Vagus Nerve Stimulation (Company)
Medicare	L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension	07/01/2010	08/31/2022		Electrical Stimulation and Electromagnetic Therapies (Medicare); Fecal Incontinence Treatments (Medicare); Gastric Electrical Stimulation (Company); Urinary Incontinence Treatments (Medicare)
Commercial/ASO, OHP, PEBB	L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension	07/01/2010			Deep Brain and Responsive Cortical Stimulation (Company); Electrical Stimulation: Non-Covered Therapies (Company); Fecal Incontinence Treatments (Company); Gastric Electrical Stimulation (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Vagus Nerve Stimulation (Company)
Medicare	L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension	07/01/2010	09/01/2022		Electrical Stimulation and Electromagnetic Therapies (Medicare); Fecal Incontinence Treatments (Medicare); Gastric Electrical Stimulation (Company); Urinary Incontinence Treatments (Medicare)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	L8689	External recharging system	07/01/2010			Electrical Stimulation: Non-Covered Therapies (Company); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Vagus Nerve Stimulation (Company); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Medicare	L8689	External recharging system	01/01/2020			Electrical Stimulation and Electromagnetic Therapies (Medicare); Urinary Incontinence Treatments (Medicare); Vagus Nerve Stimulation (Medicare Only) ARCHIVED 9/1/22
Commercial/ASO, Medicare, OHP, PEBB	L8690	Auditory osseointegrated device, includes all internal and external components	11/01/2023			Bone-Anchored Hearing Aids (Company); Bone-Anchored Hearing Aids (Medicare)
Commercial/ASO, OHP, PEBB	L8692	Auditory osseointegrated device, external sound processor, used without osseointegration, body worn, includes headband or other means of external attachment	11/01/2023			Bone-Anchored Hearing Aids (Company)
Commercial/ASO, Medicare, OHP, PEBB	L8694	Auditory osseointegrated device, transducer/actuator, replacement only, each	01/01/2018	06/30/2023		Cochlear Implants and Auditory Brainstem Implants (Company); Cochlear Implants and Auditory Brainstem Implants (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	L8695	External recharg sys extern	07/01/2010			Electrical Stimulation and Electromagnetic Therapies (Medicare); Implantable Spinal Cord and Dorsal Root Ganglion Stimulation (Company); Urinary Incontinence Treatments (Company); Urinary Incontinence Treatments (Medicare)
Medicare	M0300	IV chelation therapy (chemical endarterectomy)	12/01/2014	11/30/2017		Chelation Therapy for Non-Overload Conditions (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q0478	Power adapter, combo vad	03/01/2011	04/30/2022		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 355/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	Q0479	Power module combo vad, rep	03/01/2011	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	Q0480	Driver pneumatic vad, rep	05/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	Q0481	Microprcsr cu elec vad, rep	05/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	Q0482	Microprcsr cu combo vad, rep	05/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	Q0483	Monitor elec vad, rep	05/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	Q0484	Monitor elec or comb vad rep	05/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	Q0485	Monitor cable elec vad, rep	05/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	Q0486	Mon cable elec/pneum vad rep	05/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	Q0488	Pwr pack base elec vad, rep	05/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	Q0489	Pwr pck base combo vad, rep	05/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 356/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	Q0490	EMR pwr source elec vad, rep	05/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	Q0491	EMR pwr source combo vad rep	05/01/2010	12/31/2016		Cardiac: Ventricular Assist Devices (VAD/LVAD) and Artificial Heart (BIVAD) ARCHIVED 3/1/2022
Commercial/ASO, Medicare, OHP, PEBB	Q0507	Misc supply or accessory for use with an external ventricular assist device	07/01/2013	05/01/2022		
Commercial/ASO, Medicare, OHP, PEBB	Q0508	Miscellaneous supply or accessory for use with an implanted ventricular assist device	01/01/2015	05/01/2022		
Commercial/ASO, Medicare, OHP, PEBB	Q0509	Misc supply or accessory for use with any implanted ventricular assist device for which pymt was not made under Medicare Part A	07/01/2013	05/01/2022		
Medicare	Q2026	Radiesse Injection	06/01/2015			Cosmetic and Reconstructive Surgery (Medicare)
Commercial/ASO, OHP, PEBB	Q2026	Injection, radiesse, 0.1 ml	07/01/2023			Cosmetic and Reconstructive Surgery (Company)
Medicare	Q2028	Sculptra Injection	06/01/2015			Cosmetic and Reconstructive Surgery (Medicare)
Commercial/ASO, OHP, PEBB	Q2028	Injection, sculptra, 0.5 mg	07/01/2023			Cosmetic and Reconstructive Surgery (Company)
Commercial/ASO, Medicare, OHP, PEBB	Q2041	Axicabtagene Ciloleucel, up to 200 million autologous Anti-CD19 CAR T Cells, Including leukapheresis and dose preparation procedures, per infusion	04/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Yescarta®	T-Cell Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	01/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Kymriah®	T-Cell Therapy - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	Q2043	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP- GM-CSF, including leukapheresis and all other preparatory procedures, per infusion	07/01/2011		Commercial/ASO,Medicare,OHP,PEBB - Provenge®	Provenge <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q2053	Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	04/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Tecartus	T-Cell Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q2054	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	10/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Breyanzi	T-Cell Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q2055	Idecabtagene vicleucel, up to 460 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	01/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Abecma®	T-Cell Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q2056	Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	10/01/2022		Commercial/ASO,Medicare,OHP,PEBB - Carvykti	T-Cell Therapy - Pharmacy Policy
Medicare	Q3001	Brachytherapy Radioelements	01/01/2022			Liver Tumor Treatment (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4074	lloprost non-comp unit dose	01/01/2010		Commercial/ASO,Medicare,OHP,PEBB - Ventavis®	Pulmonary Arterial Hypertension - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q4101	Skin substitute, Apligraf, per square centimeter	04/01/2009		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 358/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	Q4102	Skin substitute, Oasis Wound Matrix, per square centimeter	04/01/2009		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, OHP, PEBB	Q4104	Skin substitute, Integra Bilayer Matrix Wound Dressing (BMWD), per square centimeter	07/01/2009		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company)
Medicare	Q4104	Skin substitute, Integra Bilayer Matrix Wound Dressing (BMWD), per square centimeter	06/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4105	Skin substitute, Integra Dermal Regeneration Template (DRT), per square centimeter	07/01/2009		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4106	Skin substitute, Dermagraft, per square centimeter	04/01/2009		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4107	Skin substitute, Graftjacket, per square centimeter	09/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, OHP, PEBB	Q4108	Skin substitute, Integra Matrix, per square centimeter	07/01/2009		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company)
Medicare	Q4108	Skin substitute, Integra Matrix, per square centimeter	06/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4110	Skin substitute, Primatrix, per square centimeter	09/01/2011	05/31/2018		Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4114	Integra flowable wound matrix, injectable, 1 cc	07/01/2009	05/31/2018		Skin and Tissue Substitutes (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	Q4116	Alloderm skin sub	10/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company)
Medicare	Q4116	Alloderm skin sub	10/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Medicare)
Medicare	Q4117	Hyalomatrix	03/01/2011	04/29/2015		Skin and Tissue Substitutes (Company)
Commercial/ASO, Medicare, OHP, PEBB	Q4118	Matristem micromatrix	03/01/2011	05/31/2018		Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Medicare	Q4118	Matristem micromatrix	03/01/2011	04/29/2015		Skin and Tissue Substitutes (Company)
Commercial/ASO, OHP, PEBB	Q4119	Matristem wound matrix	03/01/2011	12/31/2016		Skin and Tissue Substitutes (Company)
Medicare	Q4119	Matristem wound matrix	03/01/2011	04/29/2015		Skin and Tissue Substitutes (Company)
Commercial/ASO, Medicare, OHP, PEBB	Q4121	Theraskin	03/01/2011		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, OHP, PEBB	Q4122	Dermacell, per square centimeter	10/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company)
Medicare	Q4122	Dermacell, per square centimeter	10/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Medicare	Q4123	Alloskin rt, per square centimeter	01/01/2012	04/29/2015		Skin and Tissue Substitutes (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	Q4124	Oasis ultra tri-layer wound matrix, per square centimeter	01/01/2012		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4128	Flex hd, or allopatch hd, per square centimeter	01/01/2016		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Breast Surgery: Reduction Mammoplasty, Reconstructive Surgery, and Implant Management (Company); Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, OHP, PEBB	Q4129	Unite biomatrix, per square centimeter	01/01/2012	12/31/2016		Skin and Tissue Substitutes (Company)
Medicare	Q4129	unite biomatrix, per sq cm	01/01/2012	04/29/2015		Skin and Tissue Substitutes (Company)
Commercial/ASO, Medicare, OHP, PEBB	Q4131	Epifix	01/01/2013			Skin and Tissue Substitutes (Company)
Commercial/ASO, OHP, PEBB	Q4132	Grafix core	01/01/2013		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company)
Medicare	Q4132	Graix core	06/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, OHP, PEBB	Q4133	Grafix prime	01/01/2013		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company)
Medicare	Q4133	Grafix prime	06/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, OHP, PEBB	Q4134	hMatrix	01/01/2013	05/31/2018		Skin and Tissue Substitutes (Company)



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Medicare	Q4134	hMatrix	01/01/2013	04/29/2015		Skin and Tissue Substitutes (Company)
Commercial/ASO, OHP, PEBB	Q4135	Mediskin	01/01/2013	05/31/2018		Skin and Tissue Substitutes (Company)
Medicare	Q4135	Mediskin	01/01/2013	04/29/2015		Skin and Tissue Substitutes (Company)
Medicare	Q4136	EZderm	01/01/2013	04/29/2015		Skin and Tissue Substitutes (Company)
Commercial/ASO, Medicare, OHP, PEBB	Q4151	Amnioband or guardian, per square centimeter	03/01/2022		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4166	Cytal, per square centimeter	01/01/2017	05/31/2018		Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4167	Truskin, per square centimeter	01/01/2017	05/31/2018		Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4168	Amnioband, 1 mg	01/01/2017	05/31/2018		Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4169	Artacent wound, per square centimeter	01/01/2017	05/31/2018		Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4170	Cygnus, per square centimeter	01/01/2017	05/31/2018		Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4173	Palingen or palingen xplus, per square centimeter	01/01/2017	05/31/2018		Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4174	Palingen or promatrx, 0.36 mg per 0.25 cc	01/01/2017	05/31/2018		Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4175	Miroderm, per square centimeter	01/01/2017	05/31/2018		Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 362/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	Q4182	Transcyte, per square centimeter	06/01/2018		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4186	Epifix, per square centimeter	01/01/2019		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4205	Membrane graft or membrane wrap, per square centimeter	10/01/2019		This code does not require PA for the following diagnoses: F64.0, F64.1, F64.8 and F64.9	Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Commercial/ASO, OHP, PEBB	Q4206	Fluid flow or fluid GF, 1 cc	10/01/2019	06/30/2021		Skin and Tissue Substitutes (Company); Stem Cell Therapy for Orthopedic Applications (Company)
Medicare	Q4206	Fluid flow or fluid GF, 1 cc	10/01/2019	06/30/2021		Skin and Tissue Substitutes (Medicare); Stem Cell Therapy for Orthopedic Applications (Medicare)
Medicare	Q4251	Vim, per square centimeter	10/01/2021	02/28/2023		Skin and Tissue Substitutes (Medicare)
Medicare	Q4252	Vendaje, per square centimeter	10/01/2021	02/28/2023		Skin and Tissue Substitutes (Medicare)
Medicare	Q4253	Zenith amniotic membrane, per square centimeter	10/01/2021	02/28/2023		Skin and Tissue Substitutes (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	Q4304	Grafix plus, per square centimeter	01/01/2024			Skin and Tissue Substitutes (Company); Skin and Tissue Substitutes (Medicare)
Medicare, OHP	Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	04/01/2018		Medicare,OHP - Inflectra®	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, PEBB	Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	04/01/2018		Commercial/ASO,PEBB - Inflectra®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medically Infused Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy
Medicare, OHP	Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	04/01/2018		Medicare,OHP - Renflexis®	Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Commercial/ASO, PEBB	Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	04/01/2018		Commercial/ASO,PEBB - Renflexis®	Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medically Infused Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5106	Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units	07/01/2018		Commercial/ASO,Medicare,OHP,PEBB - Retacrit®	Aranesp <sup>®</sup> , Epogen <sup>®</sup> , Procrit <sup>®</sup> , Retacrit <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	01/01/2019			Injectable ANTI-Cancer Medications - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5109	Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg	01/01/2019			New Drug/Indication Awaiting P&T Review - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5112	Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg	07/01/2019			Injectable ANTI-Cancer Medications - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5113	Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg	07/01/2019			Injectable ANTI-Cancer Medications - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5114	Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg	07/01/2019			Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 364/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5115	Injection, rituximab-abbs, biosimilar, 10 mg	07/01/2019		Commercial/ASO,Medicare,OHP,PEBB - Truxima®	Medicare Part B Step Therapy - Pharmacy Policy; Rituximab - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5116	Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg	07/01/2020		Commercial/ASO,Medicare,OHP,PEBB -	Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5117	Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg	10/01/2019			Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5118	Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg	07/01/2020			Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	07/01/2020			Medicare Part B Step Therapy - Pharmacy Policy; Rituximab - Pharmacy Policy
Commercial/ASO, PEBB	Q5121	Injection, infliximab-axxq, biosimilar, (avsola), 10 mg	07/01/2020			Infusion Therapy Site of Care -Commercial- Pharmacy Policy; Medically Infused Therapeutic Immunomodulators(TIMs) (Commercial) - Pharmacy Policy
Medicare, OHP	Q5121	Injection, infliximab-axxq, biosimilar, (avsola), 10 mg	07/01/2020			Medically Infused Therapeutic Immunomodulators (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy; Therapeutic Immunomodulators(TIMs) (Medicaid) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	07/01/2021			Medicare Part B Step Therapy - Pharmacy Policy; Rituximab - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 365/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	01/01/2023			Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy; Medicare Part B Step Therapy - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	04/01/2023	08/01/2023		Ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitors - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	Q5129	Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg	04/01/2023			Injectable ANTI-Cancer Medications - Pharmacy Policy; Injectable ANTI-Cancer Medications (Medicare Part B) - Pharmacy Policy
Medicare	Q9980	hyaluronan or derivative, for intra-articular injection, 1 mg (use this code for GenVisc)	01/01/2016	12/31/2016		Viscosupplementation (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	S0013	Esketamine, nasal spray, 1 mg	01/01/2021		Commercial/ASO,Medicare,OHP,PEBB - Spravato®	SPRAVATO <sup>®</sup> - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	S0122	Injection, Menotropins, 75 lu	09/01/2003		Commercial/ASO,Medicare,OHP,PEBB - Menopur®	Infertility and Related Medications - Pharmacy Policy
Commercial/ASO, OHP, PEBB	S0189	Testosterone pellet. 75 mg	10/01/2015		Commercial/ASO,OHP,PEBB - See J3490 for Medicare	Hormone Replacement Therapy - Pharmacy Policy
Commercial/ASO, Medicare, PEBB	S0317	disease management program; per diem	01/01/2015	12/31/2017		Pain Management: Interdisciplinary Pain Management Program
Commercial/ASO, Medicare, OHP, PEBB	S1030	Continuous noninvasive glucose monitoring device, purchase (for physician interpretation of data, use cpt code)	09/01/2017	05/31/2023		Advanced Diabetes Management Technology (Company); Advanced Diabetes Management Technology (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	S1031	Continuous noninvasive glucose monitoring device, rental, including sensor, sensor replacement, and download to monitor (for physician interpretation of data, use cpt code)	09/01/2017	05/31/2023		Advanced Diabetes Management Technology (Company); Advanced Diabetes Management Technology (Medicare)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	S1034	Artificial pancreas device system (e.g., low glucose suspend (lgs) feature) including continuous glucose monitor, blood glucose device, insulin pump and computer algorithm that communicates with all of the devices	11/01/2017	01/31/2021		Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (All Lines of Business Except Medicare) Archived 2/1/2021
Commercial/ASO, OHP, PEBB	S1035	Sensor; invasive (e.g., subcutaneous), disposable, for use with artificial pancreas device system	11/01/2017	01/31/2021		Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (All Lines of Business Except Medicare) Archived 2/1/2021
Commercial/ASO, OHP, PEBB	S1036	Transmitter; external, for use with artificial pancreas device system	11/01/2017	01/31/2021		Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (All Lines of Business Except Medicare) Archived 2/1/2021
Commercial/ASO, OHP, PEBB	S1037	Receiver (monitor); external, for use with artificial pancreas device system	11/01/2017	01/31/2021		Diabetes: Integrated Insulin Infusion and Glucose Monitoring Systems (All Lines of Business Except Medicare) Archived 2/1/2021
Commercial/ASO, Medicare, OHP, PEBB	S1040	Cranial Remodeling Orthosis, Rigid W/Soft Interface Material	08/01/2014	03/31/2017		Helmet Therapy for Cranial Remodeling
Commercial/ASO, Medicare, OHP, PEBB	S2112	Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)	04/01/2019			Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Company); Autologous Chondrocyte Implantation (ACI) for Cartilaginous Defects of the Knee (Medicare)
Commercial/ASO, OHP, PEBB	S2202	Echosclerotherapy	01/01/2018	02/29/2024		Varicose Veins (Company)
Medicare	S2235	Implantation of auditory brain stem implant	10/01/2017	07/31/2022		Cochlear Implants and Auditory Brainstem Implants (Medicare)
Commercial/ASO, OHP, PEBB	S2235	Implantation of auditory brain stem implant	10/01/2017	06/30/2023		Cochlear Implants and Auditory Brainstem Implants (Company)
Commercial/ASO, Medicare, OHP, PEBB	S2340	Chemodenervation Of Abductor	09/01/2012			Botulinum Therapies (Company)

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, Medicare, OHP, PEBB	S2341	Chemodenervation of adductor muscle(s) of vocal cord	09/01/2012			Botulinum Therapies (Company)
Medicare	S2348	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar	01/01/2022	12/31/2022		Spinal Fusion and Decompression Procedures (Company); Spinal Fusion and Decompression Procedures (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	S3854	Gene expression profiling panel for use in the management of breast cancer treatment	03/01/2018	06/30/2023		Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Company); Genetic Testing: Gene Expression Profile Testing for Breast Cancer (Medicare)
Commercial/ASO, OHP, PEBB	S3870	Comparative genomic hybridization (cgh) microarray testing for developmental delay, autism spectrum disorder and/or intellectual disability	07/01/2018			Genetic and Molecular Testing (Company); Non-Covered Genetic Panel Tests (Company)
Medicare	S3870	Comparative genomic hybridization (cgh) microarray testing for developmental delay, autism spectrum disorder and/or intellectual disability	07/01/2018	12/31/2021		Genetic and Molecular Testing (Medicare)
Commercial/ASO, Medicare, OHP, PEBB	S8030	Scleral application of tantalum ring(s) for localization of lesions for proton beam therapy	05/01/2019	10/31/2021		Proton Beam Radiation Therapy (Company)
Commercial/ASO, Medicare, OHP, PEBB	S8030	Scleral application of tantalum ring(s) for localization of lesions for proton beam therapy	11/01/2021	08/31/2022	This code will pay if billed with diagnosis code C61. Prior Authorization required for all other diagnosis codes.	Proton Beam Radiation Therapy (Medicare)
Medicare	S8032	Low-dose Computed Tomography For Lung Cancer Screening	01/01/2015	01/01/2016	Commercial/ASO,Medicare,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology
Commercial/ASO, OHP, PEBB	S8032	Low-dose Computed Tomography For Lung Cancer Screening	01/01/2015	09/30/2016	Commercial/ASO,PEBB - Carelon prior authorization required	General Requirements - High Tech Diagnostic Imaging: MRI, MRA, SPECT, CT, CTA, PET, Nuclear Cardiology



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, OHP, PEBB	S9364	Home infusion therapy, total parenteral nutrition (TPN); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem	01/01/2013			Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, OHP, PEBB	S9365	Home infusion therapy, total parenteral nutrition (TPN); 1 liter per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem	01/01/2013			Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, OHP, PEBB	S9366	Home infusion therapy, total parenteral nutrition (TPN); more than 1 liter but no more than 2 liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem	01/01/2013			Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy
Commercial/ASO, OHP, PEBB	S9368	Home infusion therapy, total parenteral nutrition (TPN); more than 3 liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem	01/01/2013			Total Parenteral Nutrition (TPN) (Commercial) (Medicaid) - Pharmacy Policy; Total Parenteral Nutrition (TPN) (Medicare Part B) - Pharmacy Policy

\*Prior authorization is not a guarantee of payment. Benefits are based on eligibility at the time of service and are subject to applicable contract terms.

03/29/2024 369/370



Combined PA List	Code	Code Description	Prior Authorization Effective Date	Prior Authorization Termination Date	Combined Additional Notes	Medical Policy Name: Policy
Commercial/ASO, PEBB	S9432	Medical foods for non-inborn errors of metabolism	10/01/2021		Commercial/ASO,PEBB -	Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	S9433	Medical food nutritionally complete, administered orally, providing 100% of nutritional intake	11/01/2019			Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	S9434	Modified solid food supplements for inborn errors of metabolism	11/01/2019			Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	S9435	Medical foods for inborn errors of metabolism	01/01/2013			Medical Nutrition (Commercial) - Pharmacy Policy; Medical Nutrition (Medicaid) - Pharmacy Policy ; Medical Nutrition (Medicare Part B) - Pharmacy Policy
Commercial/ASO, Medicare, OHP, PEBB	S9472	Cardiac rehabilitation program, non-physician provider, per diem	10/01/2008	05/31/2015		